relevancy	row	span1	span2
0.9999753	0	[ said needle extending from a distal end of an inner needle of said needle which has an open distal end and a flat distal end. ]	[ A single needle needle that comprises an integral needle which has multiple portions thereof; ]
0.9973361	1	[ collecting a liquid, said liquid comprising a liquid pharmaceutical product and a liquid agent; and ]	[ A method of delivering an in vivo antimicrobial composition from an in vitro system to an in vivo tissue, the method comprising the steps of: ]
0.99998343	2	[ contacting the liquid pharmaceutical product with the in vivo system with an in vivo antimicrobial composition, wherein the liquid composition is not substantially hydrogenated ethanol, wherein the in vivo system is in a biological sample, and ]	[ collecting a liquid, said liquid comprising a liquid pharmaceutical product and a liquid agent; and ]
0.9999924	3	[ wherein said liquid compositions are substantially completely saturated with a composition of the same name as the liquid pharmaceutical product and the in vivo system in such a way that the antimicrobial composition does not have a pH that is less than approximately 9.5. ]	[ contacting the liquid pharmaceutical product with the in vivo system with an in vivo antimicrobial composition, wherein the liquid composition is not substantially hydrogenated ethanol, wherein the in vivo system is in a biological sample, and ]
0.99998975	4	[ all the amino acid residues of a protein comprising the first or second protein-binding domain protein encoded by an amino acid sequence of SEQ ID NO: ]	[ A method of preventing a protein or protein binding site in an antigen-binding domain of an antibody, comprising contacting the antibody with an anti-amino acid fragment of one or more amino acids comprising the first or second amino acid atposition to an antigen-binding domain thereof, wherein the antibody binds antigen-binding domain proteins comprising the epitope NSC2A6E, antigen-binding domain amino acids having the amino acid sequence below the first or second atposition, and ]
0.984162	5	[ 1. ]	[ all the amino acid residues of a protein comprising the first or second protein-binding domain protein encoded by an amino acid sequence of SEQ ID NO: ]
0.99087733	6	[ wherein R1: ]	[ A method of manufacturing a compound of the formula (II): ]
0.0501537	7	[ N1; ]	[ wherein R1: ]
0.9781066	8	[ R2: ]	[ N1; ]
0.011176993	9	[ H2; ]	[ R2: ]
0.9930194	10	[ R6: ]	[ H2; ]
0.9913464	11	[ OR2C1H3, ]	[ R6: ]
0.99999213	12	[ OR3C1H2, ]	[ OR2C1H3, ]
0.999992	13	[ H3C1H2, or ]	[ OR3C1H2, ]
0.99999094	14	[ H3C1H2CO2C2H2, ]	[ H3C1H2, or ]
0.23498648	15	[ wherein R2, R6 and R10 are each independently a metal; and ]	[ H3C1H2CO2C2H2, ]
0.0020050749	16	[ R1 is selected from the group consisting of C1-C30 alkyl, C1-C30 alkenyl, C1-C30 alkynyl, C1-C30 alkylene, C1-C30 aspartyl, C1-C30 phenyl, C1-C30 propyl, C1-C30 dioxolinyl, C1-C30 dioxolinylalkyl, C1-C30 dimethylalkyl, C1-C30 dioxolinylalkylamino, C1-C30 dioxolinyl alkoxy, C1-C30 dioxolinyl alkoxyalkyl, C1-C30 dioxolinyl cyano, C1-C30 dioxolinyl alkoxycarbonyl, C1-C30 dioxolinyl carbonylalkyl, C1 to C30 alkyl, or C1-C30 aralkyl, or C1 to CO2R2; ]	[ wherein R2, R6 and R10 are each independently a metal; and ]
0.0014391134	17	[ wherein R5 and R6 are each independently a metal. ]	[ R1 is selected from the group consisting of C1-C30 alkyl, C1-C30 alkenyl, C1-C30 alkynyl, C1-C30 alkylene, C1-C30 aspartyl, C1-C30 phenyl, C1-C30 propyl, C1-C30 dioxolinyl, C1-C30 dioxolinylalkyl, C1-C30 dimethylalkyl, C1-C30 dioxolinylalkylamino, C1-C30 dioxolinyl alkoxy, C1-C30 dioxolinyl alkoxyalkyl, C1-C30 dioxolinyl cyano, C1-C30 dioxolinyl alkoxycarbonyl, C1-C30 dioxolinyl carbonylalkyl, C1 to C30 alkyl, or C1-C30 aralkyl, or C1 to CO2R2; ]
0.9999906	18	[ b. a front cavity defining an opening on at least a portion of said front surface adjacent to said edge and extending through an interior edge of the golf club head; ]	[ A golf club head comprisinga. a cavity defining a shaft surface, an edge and a plurality of fasteners that are connected to and define a cavity area; ]
0.99998546	19	[ c. a back cavity configured to surround said cavity area at an end of said back cavity; ]	[ b. a front cavity defining an opening on at least a portion of said front surface adjacent to said edge and extending through an interior edge of the golf club head; ]
0.99999213	20	[ d. a side cavity formed at a longitudinal location between said opening on said front surface and said cavity area adjacent said end; ]	[ c. a back cavity configured to surround said cavity area at an end of said back cavity; ]
0.99999213	21	[ d. a center region surrounding the openings and defining a center line running longitudinal and outwardly from said opening on said front surface and the cavity; ]	[ d. a side cavity formed at a longitudinal location between said opening on said front surface and said cavity area adjacent said end; ]
0.9999912	22	[ e. a plurality of fasteners located in said opening on said front surface. ]	[ d. a center region surrounding the openings and defining a center line running longitudinal and outwardly from said opening on said front surface and the cavity; ]
0.9986292	23	[ 1) at least one domain having at least 90% identity to SEQ ID NO: ]	[ An isolated antibody or fragment thereof, wherein the antibody or fragment thereof binds to CD23 wherein the antibody or fragment thereof comprises: ]
0.9999924	24	[ 1; or 2) at least one domain having at least 45% identity to SEQ ID NO: ]	[ 1) at least one domain having at least 90% identity to SEQ ID NO: ]
0.99646795	25	[ 1 and which is a functional domain of the CD23. ]	[ 1; or 2) at least one domain having at least 45% identity to SEQ ID NO: ]
0.99999225	26	[ manufacturing an initial two-dimensional (2D) material package, comprising a plurality of different size packages; ]	[ A method of manufacturing a plurality of different sized pieces of footwear, including boot pieces, in a two-dimensional (2D) material format, comprising: ]
0.9999924	27	[ preparing first and second moldable layers of material on the initial 2D material package for a first molding application; ]	[ manufacturing an initial two-dimensional (2D) material package, comprising a plurality of different size packages; ]
0.9999924	28	[ preparing a second moldable layer of material; ]	[ preparing first and second moldable layers of material on the initial 2D material package for a first molding application; ]
0.9999924	29	[ preparing a surface layer of material on the second moldable layer; ]	[ preparing a second moldable layer of material; ]
0.99999225	30	[ cutting down the interior surfaces of the second moldablelayer and the surface layer during molding; and ]	[ preparing a surface layer of material on the second moldable layer; ]
0.9999924	31	[ molding the surface layer and first moldable layer onto the interior surfaces of the first moldablelayer and the interior surfaces of the second moldablelayer. ]	[ cutting down the interior surfaces of the second moldablelayer and the surface layer during molding; and ]
0.999992	32	[ a. injecting a compound into the oophorectal tract to form a metastase comprising at least one compound selected from the group consisting of, ]	[ A method for treating an angiographic lesion on an anatomy of an oophorectal tract in a subject comprising: ]
0.99356985	33	[ (i) a compound having 1 to 20 carbon atoms that is isolated from a pharmaceutical composition comprising a therapeutically active agent, and ]	[ a. injecting a compound into the oophorectal tract to form a metastase comprising at least one compound selected from the group consisting of, ]
0.9998536	34	[ (ii) a compound having 5 to 99 carbon atoms that at least partially is a hydroxyl group, ]	[ (i) a compound having 1 to 20 carbon atoms that is isolated from a pharmaceutical composition comprising a therapeutically active agent, and ]
0.9974228	35	[ b. administering to the subject a salt, powder or emulsion of a pharmaceutically acceptable salt, powder or emulsion, wherein the selected compound comprises a hydroxyl group, and ]	[ (ii) a compound having 5 to 99 carbon atoms that at least partially is a hydroxyl group, ]
0.99976486	36	[ c. treating an end site of the metastase in the oophorectal tract. ]	[ b. administering to the subject a salt, powder or emulsion of a pharmaceutically acceptable salt, powder or emulsion, wherein the selected compound comprises a hydroxyl group, and ]
0.99785966	37	[ a stent forming part having a proximal end and a distal end; ]	[ A multi-tiered prosthesis assembly including: ]
0.9975007	38	[ a proximal body and a first section disposed over at least a portion of said proximal body. ]	[ a stent forming part having a proximal end and a distal end; ]
0.008344608	39	[ the method comprising: ]	[ A method for providing non-immunostable coverage of a human skin, wherein said human skin is not a body tissue; ]
0.026818966	40	[ providing a first device that: ]	[ the method comprising: ]
0.024450025	41	[ has a first surface and a second surface, ]	[ providing a first device that: ]
0.99998045	42	[ said first surface and second surface defined by a cross-section and an axis on the first surface and extending from an outer edge of said first surface to a periphery of said first surface, and ]	[ has a first surface and a second surface, ]
0.9999876	43	[ said first and second surfaces forming an inner surface, each of said first surface and said second surface being made of a substantially rigid material, wherein said perimeter of said first surface is not defined by outer peripheral elements, each of said first surface and said second surface being formed by at least a portion of said perimeter of said first surface defining a body surface; ]	[ said first surface and second surface defined by a cross-section and an axis on the first surface and extending from an outer edge of said first surface to a periphery of said first surface, and ]
0.02843835	44	[ providing a second device that: ]	[ said first and second surfaces forming an inner surface, each of said first surface and said second surface being made of a substantially rigid material, wherein said perimeter of said first surface is not defined by outer peripheral elements, each of said first surface and said second surface being formed by at least a portion of said perimeter of said first surface defining a body surface; ]
0.012196408	45	[ has a first surface and a second surface, ]	[ providing a second device that: ]
0.9999715	46	[ said first surface and said second surface defined by a cross-section and an axis on the first surface. ]	[ has a first surface and a second surface, ]
0.999992	47	[ (a) providing a server processing program associated with said game server; ]	[ A method to optimize for optimal execution of game server processing, comprising: ]
0.99999213	48	[ (b) storing the game server processing program to memory at a first time; ]	[ (a) providing a server processing program associated with said game server; ]
0.9999013	49	[ (c) receiving a game data input from said gaming device, a game data output from said gaming device, and ]	[ (b) storing the game server processing program to memory at a first time; ]
0.99999225	50	[ a game data execution data from said gaming device, said game data execution data including a plurality of game data; ]	[ (c) receiving a game data input from said gaming device, a game data output from said gaming device, and ]
0.9999919	51	[ (d) in response to said game data input and at least a portion of said game data output being received from said gaming device, accessing memory of said server processing program in memory; and ]	[ a game data execution data from said gaming device, said game data execution data including a plurality of game data; ]
0.99999034	52	[ (e) in response to said data execution data being stored in a second memory location for a second time, accessing said second location in memory in response to said data execution data being stored in said second memory location. ]	[ (d) in response to said game data input and at least a portion of said game data output being received from said gaming device, accessing memory of said server processing program in memory; and ]
0.99999166	53	[ (a) providing a food product to be prepared; ]	[ A method for preparing and serving a food product comprising the steps of: ]
0.99999106	54	[ (b) preparing the food product by removing at least a portion of the food product from a liquid solution and mixing the liquid solution with starch; ]	[ (a) providing a food product to be prepared; ]
0.999992	55	[ (c) heating the liquid solution by heating the material with heat; ]	[ (b) preparing the food product by removing at least a portion of the food product from a liquid solution and mixing the liquid solution with starch; ]
0.99998975	56	[ (d) heating the material with heat to a temperature of about 20&#xb0; C. to about 50&#xb0; C. to permit the heated material to absorb the starch into the starch; and ]	[ (c) heating the liquid solution by heating the material with heat; ]
0.9999924	57	[ (e) heating the material with heat to a temperature of about 90&#xb0; C. to heat the material to a temperature of about 120&#xb0; C. in order to combine the heated material and the heated starch to form a mixture at a temperature of about 70&#xb0; C. to about 80&#xb0; C. to create a product. ]	[ (d) heating the material with heat to a temperature of about 20&#xb0; C. to about 50&#xb0; C. to permit the heated material to absorb the starch into the starch; and ]
0.9994448	58	[ a base having a back surface and spaced apart sidewalls in an interior configuration, the sidewalls formed with a first edge, the sidewalls being configured so as to support an upper limb of the patient while minimizing strain on the upper limb; ]	[ A medical support for a patient, comprising: ]
0.9978867	59	[ a first end; and ]	[ a base having a back surface and spaced apart sidewalls in an interior configuration, the sidewalls formed with a first edge, the sidewalls being configured so as to support an upper limb of the patient while minimizing strain on the upper limb; ]
0.99998844	60	[ a second end; ]	[ a first end; and ]
0.99968743	61	[ wherein the first and second ends of the base have two sides, each side substantially parallel to a longitudinal axis of the base and defining a pair of opposite first and second axial openings, a bottom edge thereof in a substantially vertical direction of the base, and ]	[ a second end; ]
0.9999733	62	[ a bottom edge of the base disposed about the back surface of the base opposite the bottom edge of each of the sidewalls. ]	[ wherein the first and second ends of the base have two sides, each side substantially parallel to a longitudinal axis of the base and defining a pair of opposite first and second axial openings, a bottom edge thereof in a substantially vertical direction of the base, and ]
0.98335797	63	[ detecting the presence of a substance in the blood of a patient; ]	[ A method comprising: ]
0.9999918	64	[ measuring a quantity of the substance in the blood based on a measurement performed at a measuring device; and ]	[ detecting the presence of a substance in the blood of a patient; ]
0.9999902	65	[ displaying a report in response to determining that the substance is detected in the measured quantity. ]	[ measuring a quantity of the substance in the blood based on a measurement performed at a measuring device; and ]
0.9999894	66	[ a proximate delivery element (1) for delivering the agent to the object; ]	[ A treatment apparatus for delivering an agent to an object wherein the treatment apparatus comprises: ]
0.99999225	67	[ a proximate targeting device (2) for providing information regarding an operation to the proximate delivery element (1) to identify an operative operation for administering to the object by the treatment appliance; ]	[ a proximate delivery element (1) for delivering the agent to the object; ]
0.9999912	68	[ at least one control means (3) for controlling the proximate targeting means (2); and ]	[ a proximate targeting device (2) for providing information regarding an operation to the proximate delivery element (1) to identify an operative operation for administering to the object by the treatment appliance; ]
0.99955875	69	[ an object detecting device (4) for detecting at least one condition associated with the object and for transmitting that information to at least a first server (16) and at least a second server (8) respectively, respectively. ]	[ at least one control means (3) for controlling the proximate targeting means (2); and ]
0.99999213	70	[ a second structure that comprises a second wall in a second configuration different from the first configuration, wherein the second wall comprises a first surface and a first side, the first side opening of the second structure and the second side opening of the second structure having different sizes, wherein the second wall comprises a second surface that has a smaller first size than the first surface and a larger second size than a first size of the first surface or a second size of the first surface or a wall portion thereof that encloses the first structure, wherein the first and second walls further comprise a third wall configured to couple the first structure to or attach the foot to or attach the foot to a foot of the user, and ]	[ An apparatus comprising: <|span|>a first structure that comprises a first wall in a first configuration, a first top-side surface of the first structure comprising a first side, a second top-side surface of the first structure comprising a second side, a first side opening of the first structure and a second side opening of the first structure for coupling a foot to or attaching an individual foot to a foot of a user, and ]
0.99999213	71	[ the third wall further comprises a fourth wall that couples the first and second wall into four sides, wherein the fourth wall has a fourth edge defined between the fourth and first surface in the first configuration and an end portion defining an exterior surface of the first exterior surface wherein the third arrangement and the two additional side structures are arranged in a second configuration different than the first configuration of the apparatus. ]	[ a second structure that comprises a second wall in a second configuration different from the first configuration, wherein the second wall comprises a first surface and a first side, the first side opening of the second structure and the second side opening of the second structure having different sizes, wherein the second wall comprises a second surface that has a smaller first size than the first surface and a larger second size than a first size of the first surface or a second size of the first surface or a wall portion thereof that encloses the first structure, wherein the first and second walls further comprise a third wall configured to couple the first structure to or attach the foot to or attach the foot to a foot of the user, and ]
0.9833966	72	[ a first end support with a plurality of openings spaced apart; ]	[ A surgical instrument comprising: ]
0.9999881	73	[ a second end support having a plurality of opposing openings with opposed ends, each of the first and second ends supports a user's hand and a user's hand support is located at a first end of the arm in contact with a patient's body, the first and second ends are fixed with respect to each other and are removably mounted to a support structure so that the second end of the arm can be extended in a first direction and a second direction; ]	[ a first end support with a plurality of openings spaced apart; ]
0.99976426	74	[ a patient interface member configured to be connected to a patient's hand for moving the body in and out of a surgical device; ]	[ a second end support having a plurality of opposing openings with opposed ends, each of the first and second ends supports a user's hand and a user's hand support is located at a first end of the arm in contact with a patient's body, the first and second ends are fixed with respect to each other and are removably mounted to a support structure so that the second end of the arm can be extended in a first direction and a second direction; ]
0.025157783	75	[ a first attachment member secured to the first end support using first and second fasteners with the first attachment member including a first end attachment member with a first end of the attachment member and a second end attachment member with a second end of the attachment member, ]	[ a patient interface member configured to be connected to a patient's hand for moving the body in and out of a surgical device; ]
0.99999	76	[ a flexible support having a first side and a second side, the first side receiving each one of the first and second fasteners and being attached to the first end support to define the first and second openings, ]	[ a first attachment member secured to the first end support using first and second fasteners with the first attachment member including a first end attachment member with a first end of the attachment member and a second end attachment member with a second end of the attachment member, ]
0.99967766	77	[ wherein the first end support has a proximal end portion, the second end support has a distal end portion attached to the proximal end portion, each of the mounting holes is located at the distal end portion. ]	[ a flexible support having a first side and a second side, the first side receiving each one of the first and second fasteners and being attached to the first end support to define the first and second openings, ]
0.99980026	78	[ constructing a three-dimensional geometry of at least two portions of a building having two or more levels of a ceiling or walls, the at least two portions having the geometry; ]	[ A method for creating or reconstructing a multi-level system comprising: ]
0.99999225	79	[ constructing a three-dimensional geometry of at the level of walls or ceiling wherein the three-dimensional geometry includes a portion of the building having a plurality of adjacent floor levels and the plurality of adjacent floor levels are all arranged orthogonal from each other, ]	[ constructing a three-dimensional geometry of at least two portions of a building having two or more levels of a ceiling or walls, the at least two portions having the geometry; ]
0.9999919	80	[ defining one or more elevations of the floor levels; ]	[ constructing a three-dimensional geometry of at the level of walls or ceiling wherein the three-dimensional geometry includes a portion of the building having a plurality of adjacent floor levels and the plurality of adjacent floor levels are all arranged orthogonal from each other, ]
0.9999912	81	[ maintaining the three-dimensional geometry by means of at least one of projecting or projecting-side structures, which are movable towards one floor level of the building using movable elements of the two or more level of the floor areas such that the multi-level geometry forms a four-level space, where each of the floor levels has its own raised level or raised level elevation, ]	[ defining one or more elevations of the floor levels; ]
0.9999914	82	[ defining at least one vertical floor elevation; and ]	[ maintaining the three-dimensional geometry by means of at least one of projecting or projecting-side structures, which are movable towards one floor level of the building using movable elements of the two or more level of the floor areas such that the multi-level geometry forms a four-level space, where each of the floor levels has its own raised level or raised level elevation, ]
0.99994123	83	[ creating a three-dimensional geometry of more than one floor level such that the at least one floor level is in the geometry, ]	[ defining at least one vertical floor elevation; and ]
0.99999213	84	[ wherein the two or more level of the first floor, one floor level and two levels of the second floor are located within the four-level space of the floor levels. ]	[ creating a three-dimensional geometry of more than one floor level such that the at least one floor level is in the geometry, ]
0.99996495	85	[ first administering to said patient an effective dose of a therapeutic agent and optionally in combination with pharmaceutically acceptable pharmaceutically acceptable carrier material wherein said pharmaceutically acceptable drug has a solubility in a subject at least about 0.5%. ]	[ A method of treating a patient characterized in that said method comprises administering a therapeutic agent selected from the group consisting of a benzodiazepine, a depressant, an aminoacidase, a peptide, an anion or a complex of an ion and an anion to said patient in a pharmaceutically acceptable form including: ]
0.99889696	86	[ 6. ]	[ A method of treating acute heart failure comprising administering an effective amount of L-Glutamine (GL) to a subject afflicted with heart failure, said GL comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence represented by SEQ ID NO: ]
0.9980299	87	[ a) forming a three-dimensional (3D) molded mold in a molding compound; ]	[ A method for producing liquid prosthesis tissues, comprising the steps of: ]
0.9999924	88	[ b) coating the mold in the molding compound a first layer of 3D mold material, wherein the molding compound is chosen from at least three different types of molding compounds; and ]	[ a) forming a three-dimensional (3D) molded mold in a molding compound; ]
0.99999225	89	[ c) exposing the molded mold on the 3D mold to a first material, wherein the first material is an elastomeric material, an impregnated material, or a material from a mixture of the types of molding compounds, and ]	[ b) coating the mold in the molding compound a first layer of 3D mold material, wherein the molding compound is chosen from at least three different types of molding compounds; and ]
0.99999225	90	[ then the 3D mold of the molding compound is deposited on the molding material exposed by step b); ]	[ c) exposing the molded mold on the 3D mold to a first material, wherein the first material is an elastomeric material, an impregnated material, or a material from a mixture of the types of molding compounds, and ]
0.99999225	91	[ d) placing the molded mold containing the first material on the 3D mold, wherein the mold formed on the molding material exposed by step c) is located in the 3D mold, ]	[ then the 3D mold of the molding compound is deposited on the molding material exposed by step b); ]
0.99999225	92	[ wherein the mold formed on the mold material exposed by step c) is a shape that is non-rotatable; ]	[ d) placing the molded mold containing the first material on the 3D mold, wherein the mold formed on the molding material exposed by step c) is located in the 3D mold, ]
0.9999825	93	[ e) removing the mold when the molding compound has been cured; and ]	[ wherein the mold formed on the mold material exposed by step c) is a shape that is non-rotatable; ]
0.99999213	94	[ f) removing the mold after cleaning the mold formed by step e); ]	[ e) removing the mold when the molding compound has been cured; and ]
0.9827418	95	[ wherein the liquid prosthesis tissues are produced. ]	[ f) removing the mold after cleaning the mold formed by step e); ]
0.99951875	96	[ providing a blood sample, ]	[ A method for diagnosing multiple sclerosis in an individual comprising: ]
0.99998856	97	[ storing the blood sample in a storage device, and ]	[ providing a blood sample, ]
0.99999046	98	[ measuring physiological parameters of the blood sample; ]	[ storing the blood sample in a storage device, and ]
0.9999269	99	[ determining the presence or absence of multiple sclerosis in the individual if the at least two measurement characteristics occur at the same time when the measurement parameters are measured in the same sequence. ]	[ measuring physiological parameters of the blood sample; ]
0.99963474	100	[ providing a delivery device comprising a first delivery device to be worn by the subject, a second delivery device with an adjustable length, and ]	[ A method for increasing blood pressure in a subject, comprising: ]
0.9999906	101	[ a third delivery device in fluid communication with the second delivery device, the same delivery device being coupled to at least at least one blood vessel and the delivery device being coupled to the second delivery device and to the third delivery device for fluid communication between delivery device and vessel; ]	[ providing a delivery device comprising a first delivery device to be worn by the subject, a second delivery device with an adjustable length, and ]
0.003529001	102	[ providing a plurality of devices configured to be worn on the subject in a selected order, the plurality of devices being selected from a group consisting of: ]	[ a third delivery device in fluid communication with the second delivery device, the same delivery device being coupled to at least at least one blood vessel and the delivery device being coupled to the second delivery device and to the third delivery device for fluid communication between delivery device and vessel; ]
0.9930311	103	[ (a) a first delivery device, (b) a second delivery device, (c) or (d) a third delivery device; ]	[ providing a plurality of devices configured to be worn on the subject in a selected order, the plurality of devices being selected from a group consisting of: ]
0.9999908	104	[ selecting a second delivery device with an adjustable length, ]	[ (a) a first delivery device, (b) a second delivery device, (c) or (d) a third delivery device; ]
0.99999225	105	[ wherein the adjustable length of the second delivery device is adjustable from a first position to a third position; and ]	[ selecting a second delivery device with an adjustable length, ]
0.0021001727	106	[ wherein all the plurality of devices in the group are simultaneously worn on the subject by said subject. ]	[ wherein the adjustable length of the second delivery device is adjustable from a first position to a third position; and ]
0.000532585	107	[ a first carrier; ]	[ A composition comprising: ]
0.99309075	108	[ a first surfactant; and ]	[ a first carrier; ]
0.010505906	109	[ a second carrier, wherein the second carrier comprises a monophosphate compound that is a polyphosphate, ]	[ a first surfactant; and ]
0.99998343	110	[ wherein the first compound is a polyphosphate; ]	[ a second carrier, wherein the second carrier comprises a monophosphate compound that is a polyphosphate, ]
0.99885607	111	[ the first surfactant is an active ingredient of an agricultural product; ]	[ wherein the first compound is a polyphosphate; ]
0.9936627	112	[ the first carrier comprises a polymeric matrix; and, ]	[ the first surfactant is an active ingredient of an agricultural product; ]
0.9999912	113	[ the first carrier and the second carrier are in liquid form. ]	[ the first carrier comprises a polymeric matrix; and, ]
0.99980885	114	[ a first electrode for delivering a first signal at an electrostatic current intensity to the body of a patient and a second electrode for delivering a second signal at a lower current intensity than the first signal to provide electric field stimulation to the body of the patient while simultaneously transmitting the electric field to the body of the patient by electrically coupling the first and second electrodes; and ]	[ An apparatus for inserting an implantable medical device (IMD) into a body of a patient, the IMD comprising: ]
0.9998343	115	[ an implantable medical device-related component within the IMD in communication with the first and second electrodes of the IMD for: ]	[ a first electrode for delivering a first signal at an electrostatic current intensity to the body of a patient and a second electrode for delivering a second signal at a lower current intensity than the first signal to provide electric field stimulation to the body of the patient while simultaneously transmitting the electric field to the body of the patient by electrically coupling the first and second electrodes; and ]
0.9996724	116	[ creating an electrical field from at least one of the first signal and the second signal via communication between the first electrode and the second electrode, ]	[ an implantable medical device-related component within the IMD in communication with the first and second electrodes of the IMD for: ]
0.9999914	117	[ applying the applied electrical field to the body of the patient when the first signal and the second signal are received by the second electrode and applying the applied electrical field to other parts of the body of the patient to provide additional electric field stimulation to the body of the patient while simultaneously transmitting the electric field to the other parts of the body of the patient. ]	[ creating an electrical field from at least one of the first signal and the second signal via communication between the first electrode and the second electrode, ]
0.99999213	118	[ at least a portion of the battery wall extending through the IMD. ]	[ An implantable medical device (IMD), wherein the IMD comprises a battery for conducting power to the IMD, at least some of the battery comprising a battery wall, and ]
0.9999652	119	[ a system for supplying a drug to a patient; ]	[ A nonrecombining drug delivery system, comprising: ]
0.99725926	120	[ a dispensing chamber; ]	[ a system for supplying a drug to a patient; ]
0.9999198	121	[ a dispensing mechanism operable to dispense delivery material at a dispensing tip of said system; ]	[ a dispensing chamber; ]
0.9999896	122	[ a cartridge for selectively receiving the delivery material; and ]	[ a dispensing mechanism operable to dispense delivery material at a dispensing tip of said system; ]
0.9997224	123	[ a mechanism having an actuator for moving the patient from a supine position to an upright position when said cartridge is within said dispensing chamber. ]	[ a cartridge for selectively receiving the delivery material; and ]
0.9903804	124	[ a first reservoir; and ]	[ A system for producing a therapeutic dose comprising: ]
0.9999789	125	[ a second reservoir, wherein during a first reservoir feeding cycle, a first part of the second reservoir is discharged through a first path into the first pathway and a second part of the second reservoir is discharged through a second path into the second pathway, the first path and the second path being adapted to provide a therapeutic dose of therapeutic substance to a patient. ]	[ a first reservoir; and ]
0.9999906	126	[ delivering a water supply to the irrigation device; and ]	[ A method of controlling an irrigation device for irrigation to a crop plant for crop irrigation, said method comprising the steps of: ]
0.99999225	127	[ removing a water supply from the irrigation device, and ]	[ delivering a water supply to the irrigation device; and ]
0.99999213	128	[ controlling delivery of the remaining water to the irrigation device. ]	[ removing a water supply from the irrigation device, and ]
0.9889107	129	[ a first end and a second end; ]	[ A dental prosthesis for cutting and forming a tooth's surface, said prosthesis comprising: ]
0.9998746	130	[ the first and second ends of said prosthesis being integrally formed such that when the one end of the prosthesis is in a closed state, the prosthesis projects from the first end to a second end, and ]	[ a first end and a second end; ]
0.99999225	131	[ when the one end of the prosthesis is in an open position, the prosthesis is in a closed position; ]	[ the first and second ends of said prosthesis being integrally formed such that when the one end of the prosthesis is in a closed state, the prosthesis projects from the first end to a second end, and ]
0.9798338	132	[ a first clamp and a secondary clamp; ]	[ when the one end of the prosthesis is in an open position, the prosthesis is in a closed position; ]
0.99999225	133	[ the first clamp having an opening and the secondary clamp having an opening; ]	[ a first clamp and a secondary clamp; ]
0.99999225	134	[ an outer surface of the first clamp being in contact with the outer surface of the secondary clamp; and ]	[ the first clamp having an opening and the secondary clamp having an opening; ]
0.9999815	135	[ wherein the opening of the first clamp is sized to permit a cutting device to enter the first clamp and an opening of the second clamp is sized to permit a cutting device to enter the second clamp. ]	[ an outer surface of the first clamp being in contact with the outer surface of the secondary clamp; and ]
0.9968797	136	[ introducing one or more organic materials of general biocompatibility with a plant; and ]	[ A method for producing a bioactive compound, comprising: ]
0.99998915	137	[ introducing a plurality of organic fibers comprising a broad variety of the respective types of natural fibers of natural fibers and which are available to the plant during harvest, ]	[ introducing one or more organic materials of general biocompatibility with a plant; and ]
0.99999225	138	[ wherein said organic fibers are introduced into the plant before the respective natural fibers, and ]	[ introducing a plurality of organic fibers comprising a broad variety of the respective types of natural fibers of natural fibers and which are available to the plant during harvest, ]
0.9999876	139	[ wherein when one or more organic materials of general biocompatibility are incorporated into a plant, the general biocompatibility of the general biocompatibility is enhanced in that said organic materials of general biocompatibility have a biocompatible chemical structure, ]	[ wherein said organic fibers are introduced into the plant before the respective natural fibers, and ]
0.99999225	140	[ whereinthe natural fibers of the natural fibers have in a general biocompatibility with the plant a molecular structure which prevents an inaccession or the loss of biocompatible chemical structure over time. ]	[ wherein when one or more organic materials of general biocompatibility are incorporated into a plant, the general biocompatibility of the general biocompatibility is enhanced in that said organic materials of general biocompatibility have a biocompatible chemical structure, ]
0.99891055	141	[ a) injecting a humanized drug consisting of the cysteine residue sequence comprising: ]	[ A method for treating a tumor, comprising: ]
0.99996233	142	[ (a) a cysteine residue at position 32 of SEQ ID NO: 4 in the amino acid sequence of SEQ ID NO: 4; ]	[ a) injecting a humanized drug consisting of the cysteine residue sequence comprising: ]
0.9999919	143	[ (b) a cysteine residue at position 16 of SEQ ID NO: 4 in the amino acid sequence of SEQ ID NO: 4, wherein amino acid residues 16 and 22 of SEQ ID NO: 4 at position 32 and 16 are replaced by amino acid residues 24, 16, and ]	[ (a) a cysteine residue at position 32 of SEQ ID NO: 4 in the amino acid sequence of SEQ ID NO: 4; ]
0.9999908	144	[ 22 of SEQ ID NO: 4, wherein there are no residues 24, 16, and ]	[ (b) a cysteine residue at position 16 of SEQ ID NO: 4 in the amino acid sequence of SEQ ID NO: 4, wherein amino acid residues 16 and 22 of SEQ ID NO: 4 at position 32 and 16 are replaced by amino acid residues 24, 16, and ]
0.999984	145	[ 22 of SEQ ID NO: 4 in or around the nucleotide at position 32; ]	[ 22 of SEQ ID NO: 4, wherein there are no residues 24, 16, and ]
2.9742634e-05	146	[ (c) a substituent selected from the group consisting of an alkyl, an alkyl-alkyl, an alkoxy, a benzyl, and ]	[ 22 of SEQ ID NO: 4 in or around the nucleotide at position 32; ]
0.99943596	147	[ a heteroalkoxy; and ]	[ (c) a substituent selected from the group consisting of an alkyl, an alkyl-alkyl, an alkoxy, a benzyl, and ]
0.99372804	148	[ (d) a pharmaceutically acceptable carrier; ]	[ a heteroalkoxy; and ]
0.99692625	149	[ b) administering a drug comprising a therapeutically effective amount of an antibody directed to the cysteine residue of part or all of SEQ ID NO: 4 or SEQ ID NO: 4-8 for the treatment of an immune rejection disorder, wherein the immune rejection disorder comprises an IHV, a B2E2+ cell, a CD3b cell , or an antigen-binding fragment of at least one of the groups; and ]	[ (d) a pharmaceutically acceptable carrier; ]
0.9999876	150	[ i. wherein said administration of said drug comprises an immune rejection therapy. ]	[ b) administering a drug comprising a therapeutically effective amount of an antibody directed to the cysteine residue of part or all of SEQ ID NO: 4 or SEQ ID NO: 4-8 for the treatment of an immune rejection disorder, wherein the immune rejection disorder comprises an IHV, a B2E2+ cell, a CD3b cell , or an antigen-binding fragment of at least one of the groups; and ]
0.99910283	151	[ means for placing a patient in a first manner; ]	[ A medical imaging device comprising: ]
0.99999225	152	[ means for fixing the patient in a second manner; ]	[ means for placing a patient in a first manner; ]
0.99992645	153	[ means for providing a target location for a surgical instrument, the surgical instrument defined as: ]	[ means for fixing the patient in a second manner; ]
0.9991424	154	[ wherein said support means is shaped as one for insertion into a first end site and a second end site; and ]	[ means for providing a target location for a surgical instrument, the surgical instrument defined as: ]
0.99991655	155	[ wherein said two sites are opposed, and ]	[ wherein said support means is shaped as one for insertion into a first end site and a second end site; and ]
0.0059741368	156	[ said support means is configured such that the means for fixing is mounted on a wall of said support means, said means for fixing being configured to secure a position of the surgical instrument on said support means such that at least a portion of a user is prevented from sliding off the support means when said surgical instrument is secured to said support means, ]	[ wherein said two sites are opposed, and ]
0.99999106	157	[ wherein said means for fixation is configured for: ]	[ said support means is configured such that the means for fixing is mounted on a wall of said support means, said means for fixing being configured to secure a position of the surgical instrument on said support means such that at least a portion of a user is prevented from sliding off the support means when said surgical instrument is secured to said support means, ]
0.9985487	158	[ establishing a fixation point for a distal section of the surgical instrument and having a surface extending therefrom and including a plurality of sharp edges; ]	[ wherein said means for fixation is configured for: ]
0.9999894	159	[ fixing a medical device to at least one of said sharp edges; ]	[ establishing a fixation point for a distal section of the surgical instrument and having a surface extending therefrom and including a plurality of sharp edges; ]
0.99999225	160	[ positioning said fixation point for the surgical instrument on at least one of said sharp edges based on a medical device image; and ]	[ fixing a medical device to at least one of said sharp edges; ]
0.99999225	161	[ positioning at least a portion of said attachment mechanism for placing the surgical instrument in the first place relative to at least one of said sharp edges, wherein said at least one of said sharp edges is disposed in a position on said fixation point that is substantially perpendicular to a distal plane of the distal section of the surgical instrument. ]	[ positioning said fixation point for the surgical instrument on at least one of said sharp edges based on a medical device image; and ]
0.9837915	162	[ a body including a rotatable rotor; ]	[ A machine in a vacuum cleaner having a shaft; comprising: ]
0.99899846	163	[ an actuator connected to the shaft; ]	[ a body including a rotatable rotor; ]
0.99987006	164	[ a controller coupled to the actuator; and ]	[ an actuator connected to the shaft; ]
0.9849814	165	[ at least one motor including: ]	[ a controller coupled to the actuator; and ]
0.99903905	166	[ a first motor having a bearing disposed adjacent a first rotor tip; ]	[ at least one motor including: ]
0.999992	167	[ a second motor having a rotor tip disposed on the motor; ]	[ a first motor having a bearing disposed adjacent a first rotor tip; ]
0.9999913	168	[ a third motor having a first roller tip and a second roller tip disposed on the first roller tip, respectively; ]	[ a second motor having a rotor tip disposed on the motor; ]
0.99999094	169	[ wherein the first motor and the second motor are rotatable relative to the fourth motor, and ]	[ a third motor having a first roller tip and a second roller tip disposed on the first roller tip, respectively; ]
0.99999094	170	[ the third motor is attached to the second rotor tip. ]	[ wherein the first motor and the second motor are rotatable relative to the fourth motor, and ]
0.9999918	171	[ proximate to a center of said rear face, a toe portion and a heel portion, an inner surface opposite said proximal and distal face adapted to receive at least a portion of the outer surface of the club head, said upper face including an inner surface having a portion extending along a longitudinal axis and adapted to receive said proximal and distal faces, at least one outer part protruding radially outwardly from said inner surface to be disposed between said inner surface and said outer part, and ]	[ A golf club head comprising a proximal and distal face, a rear face proximate to, and ]
0.99999213	172	[ at least one elongate connecting element extending generally outwardly from said inner surface and adapted to have a proximal end proximate said central face and a distal end proximate said proximal face, said inner surface extending generally outwardly and substantially flat toward said distal end when said golf club head is in a non-rotating position, said extension of said connection element is configured to move from a first configuration to a second configuration, said second configuration being closer to a closed position than the first configuration, said inner surface generally being oriented toward said proximal face in said first configuration. ]	[ proximate to a center of said rear face, a toe portion and a heel portion, an inner surface opposite said proximal and distal face adapted to receive at least a portion of the outer surface of the club head, said upper face including an inner surface having a portion extending along a longitudinal axis and adapted to receive said proximal and distal faces, at least one outer part protruding radially outwardly from said inner surface to be disposed between said inner surface and said outer part, and ]
0.9996123	173	[ a) an amino acid sequence having the amino acid sequence of SEQ ID NO: 27; and ]	[ A method for treating a patient of an in vivo imaging apparatus, the method comprising administering to the patient a first anti-neoplastic drug therapy comprising at least one anti-neoplastic drug that inhibits the interaction between one or more receptor proteins and an apoptotic receptor, wherein the at least one anti-neoplastic drug comprises an anti-neoplastic drug having at least one of the following amino acid substitutions: ]
0.9999914	174	[ b) an amino acid sequence having the amino acid sequence of SEQ ID NO: 27&#xb0; ]	[ a) an amino acid sequence having the amino acid sequence of SEQ ID NO: 27; and ]
0.99995744	175	[ (SEQ ID NO: 52) where each of SEQ ID NO: 27 and SEQ ID NO: 52 is the same amino acid sequence as a first anti-neoplastic drug. ]	[ b) an amino acid sequence having the amino acid sequence of SEQ ID NO: 27&#xb0; ]
0.99997914	176	[ illuminating the target with at least one laser beam, and ]	[ A method for applying a surface treatment to the surface of a target in the body of a patient, comprising the steps of: ]
0.99998796	177	[ applying a light treatment to the surface of the target; ]	[ illuminating the target with at least one laser beam, and ]
0.999323	178	[ using the illuminating light to emit an optical waveform at a first frequency; ]	[ applying a light treatment to the surface of the target; ]
0.9999914	179	[ using the light treatment to output a second frequency; ]	[ using the illuminating light to emit an optical waveform at a first frequency; ]
0.99123985	180	[ projecting an object against the surface of the target; and ]	[ using the light treatment to output a second frequency; ]
0.9999908	181	[ applying a surface treatment to the surfaces of the object and the target, ]	[ projecting an object against the surface of the target; and ]
0.017494766	182	[ wherein the second frequency is different from the first frequency, and ]	[ applying a surface treatment to the surfaces of the object and the target, ]
0.8758347	183	[ wherein the surface treatment comprises: changing a first surface frequency by an amount that is less than a second surface frequency for the target surface, ]	[ wherein the second frequency is different from the first frequency, and ]
0.9994248	184	[ wherein the transition frequency on the target corresponds to the transition frequency on the object, and ]	[ wherein the surface treatment comprises: changing a first surface frequency by an amount that is less than a second surface frequency for the target surface, ]
0.0023034776	185	[ wherein at least one of the light treatment phase and the surface treatment phase is substantially the same. ]	[ wherein the transition frequency on the target corresponds to the transition frequency on the object, and ]
0.99966323	186	[ an elongate member wherein a first end of said elongate member is located on a side of a patient's palate and has a proximal end and a distal end; ]	[ A device for removing teeth from a patient, the device comprising: ]
0.99998057	187	[ a tooth retrieval member for receiving a tooth for removal, wherein the tooth retrieval member has a second end generally parallel to a proximal end of said elongate member, the dental implant being attached to a portion of the tooth retrieval member; ]	[ an elongate member wherein a first end of said elongate member is located on a side of a patient's palate and has a proximal end and a distal end; ]
0.9999919	188	[ an elastic member in contact with the tooth retrieval member that is elongated through a distal end of said elongate member to allow free movement of the tooth retrieval member relative to said elongate member; and ]	[ a tooth retrieval member for receiving a tooth for removal, wherein the tooth retrieval member has a second end generally parallel to a proximal end of said elongate member, the dental implant being attached to a portion of the tooth retrieval member; ]
0.99998915	189	[ a locking device having a first end facing said first end of the elastic member and the locking device having a second end generally parallel to an outward movement of the dental implant in the distal end of the elastic member, wherein: ]	[ an elastic member in contact with the tooth retrieval member that is elongated through a distal end of said elongate member to allow free movement of the tooth retrieval member relative to said elongate member; and ]
0.99999213	190	[ after an initial movement of said dental implant relative to the locking device, the locking device is locked in response to the tooth removal by the patient. ]	[ a locking device having a first end facing said first end of the elastic member and the locking device having a second end generally parallel to an outward movement of the dental implant in the distal end of the elastic member, wherein: ]
0.99489427	191	[ a) a plurality of transversal cannula segments; ]	[ A surgical apparatus comprising: ]
0.9999894	192	[ b) two or more electrodes placed within the cannula segments, respectively, wherein each electrode is configured to interact with a different portion of a vessel, wherein each tissue segment, when stimulated by the conductive interconnections, expands or contracts relative to each other; and ]	[ a) a plurality of transversal cannula segments; ]
0.99999166	193	[ c) a sensor for detecting and/or outputting tissue segments and a control device adapted to move the transversal cannula segments in accordance with tissue segments, the control device further comprising: ]	[ b) two or more electrodes placed within the cannula segments, respectively, wherein each electrode is configured to interact with a different portion of a vessel, wherein each tissue segment, when stimulated by the conductive interconnections, expands or contracts relative to each other; and ]
0.99979764	194	[ i) a controller which operates in response to input from the sensor; ]	[ c) a sensor for detecting and/or outputting tissue segments and a control device adapted to move the transversal cannula segments in accordance with tissue segments, the control device further comprising: ]
0.99965274	195	[ ii) a controller unit configured to move the transversal cannula segments; and ]	[ i) a controller which operates in response to input from the sensor; ]
0.99998915	196	[ iii) a plurality of electrodes, wherein each electrode is configured to interact with the respective tissue segment independently, wherein the controller unit comprises: ]	[ ii) a controller unit configured to move the transversal cannula segments; and ]
0.99986815	197	[ i) an initial input unit in electrical communication with the controller; ]	[ iii) a plurality of electrodes, wherein each electrode is configured to interact with the respective tissue segment independently, wherein the controller unit comprises: ]
0.99999225	198	[ ii) an initial output unit in electrical communication with the controller; and ]	[ i) an initial input unit in electrical communication with the controller; ]
0.9999919	199	[ iii) a storage unit in electrical communication with the controller unit; ]	[ ii) an initial output unit in electrical communication with the controller; and ]
0.9999697	200	[ when the control device is in an active state, said controller unit is configured to cause said sensor from said storage unit to produce a first signal outputted by said controller unit and to cause said controller unit from said storage unit to generate a second signal outputted by said controller unit in order to move said transversal cannula segments relative to one another; ]	[ iii) a storage unit in electrical communication with the controller unit; ]
0.9999919	201	[ i) the first signal outputs signals indicative of movement of the transversal cannula segments when in a static state between said electrodes; and ]	[ when the control device is in an active state, said controller unit is configured to cause said sensor from said storage unit to produce a first signal outputted by said controller unit and to cause said controller unit from said storage unit to generate a second signal outputted by said controller unit in order to move said transversal cannula segments relative to one another; ]
0.99993443	202	[ ii) said controller unit is configured to cause said final output unit to output a frequency change signal according to the frequency change of the first signal. ]	[ i) the first signal outputs signals indicative of movement of the transversal cannula segments when in a static state between said electrodes; and ]
0.99997675	203	[ (a) contacting the tumor with a therapeutically effective amount of a medicament, the Medicament comprising an antigen that has been modified to selectively bind to one or more proteins of the antigen, wherein the antigen comprises one or more of SEQ ID NOs: 2, 8, or 9 that is different from SEQ ID NOs: 2, 3 or 4 that has been expressed by the corresponding one of SEQ ID NOs: 1, 2 or 4 that is different from SEQ ID NOs: 1, 2 or 4 that has been expressed by the corresponding one of SEQ ID NOs: 1 or 2; and ]	[ A method for detecting a presence of a tumor in a target tissue of cancerous tissue, wherein the method comprises: ]
0.99991906	204	[ (b) producing an antibody that reacts with to activate apoptosis in the target tissue. ]	[ (a) contacting the tumor with a therapeutically effective amount of a medicament, the Medicament comprising an antigen that has been modified to selectively bind to one or more proteins of the antigen, wherein the antigen comprises one or more of SEQ ID NOs: 2, 8, or 9 that is different from SEQ ID NOs: 2, 3 or 4 that has been expressed by the corresponding one of SEQ ID NOs: 1, 2 or 4 that is different from SEQ ID NOs: 1, 2 or 4 that has been expressed by the corresponding one of SEQ ID NOs: 1 or 2; and ]
0.9999888	205	[ administering a cancer responsive drug to the mammal to treat the cancer. ]	[ A method of treating a drug-resistant cancer in a mammal having a breast cancer, comprising: ]
0.0033376238	206	[ an elongated frame having a longitudinal axis, including: ]	[ A portable portable system comprising: ]
0.9868896	207	[ an upper side and a lower side; ]	[ an elongated frame having a longitudinal axis, including: ]
0.99978656	208	[ a cover attached to the lower side of the elongated frame and formed of a non-transitory material; ]	[ an upper side and a lower side; ]
0.9999912	209	[ a head positioned relative an exterior of the elongated frame, the head attached to the upper side of the frame such that when the mouth of a portable portable System is opened in one direction, the head lies flush with an opposite exterior of the elongated frame; and ]	[ a cover attached to the lower side of the elongated frame and formed of a non-transitory material; ]
0.99998987	210	[ a controller operatively associated with the elongated frame and coupled to the cover for controlling a fluid flow from the head; ]	[ a head positioned relative an exterior of the elongated frame, the head attached to the upper side of the frame such that when the mouth of a portable portable System is opened in one direction, the head lies flush with an opposite exterior of the elongated frame; and ]
0.9999758	211	[ wherein the controller is configured to control a fluid flow of liquid from the head until the battery or battery pack is fully discharged, when the controller is configured to control a current to the controller, and ]	[ a controller operatively associated with the elongated frame and coupled to the cover for controlling a fluid flow from the head; ]
0.9999913	212	[ when the controller is configured to control a voltage to the controller. ]	[ wherein the controller is configured to control a fluid flow of liquid from the head until the battery or battery pack is fully discharged, when the controller is configured to control a current to the controller, and ]
0.9998925	213	[ providing an animal with a non-transportable pharmaceutical carrier which includes at least one drug delivery device for delivering at least one drug to the animal, the non-transportable pharmaceutical carrier including a first side and a second side, the first side adapted to be received in a first delivery cavity of the animal and the second side adapted to be received in a second delivery cavity of the animal, wherein the drug delivery device is provided in the first transmission cavity of the animal; and ]	[ A method of treating an animal comprising at least one step of: ]
0.99999225	214	[ feeding an isolated human carrier comprising a first human drug to the animal and comprising a second drug delivery device, wherein the patient receives said isolated human carrier in the second delivery cavity of the animal, and ]	[ providing an animal with a non-transportable pharmaceutical carrier which includes at least one drug delivery device for delivering at least one drug to the animal, the non-transportable pharmaceutical carrier including a first side and a second side, the first side adapted to be received in a first delivery cavity of the animal and the second side adapted to be received in a second delivery cavity of the animal, wherein the drug delivery device is provided in the first transmission cavity of the animal; and ]
0.99999225	215	[ wherein the isolated human carrier is able to remain in the second delivery cavity longer than a non-transportable oral human pharmacokinetic device. ]	[ feeding an isolated human carrier comprising a first human drug to the animal and comprising a second drug delivery device, wherein the patient receives said isolated human carrier in the second delivery cavity of the animal, and ]
0.9868361	216	[ a control unit, and ]	[ A game, comprising: ]
0.9899278	217	[ an operator; ]	[ a control unit, and ]
0.9764213	218	[ a system for controlling the game having: ]	[ an operator; ]
0.13527675	219	[ an image sensor to determine, by sensor fusion means, a position of the image sensor; ]	[ a system for controlling the game having: ]
0.99999225	220	[ a position processor for receiving, by processor fusion means, an input that is the position of the image sensor as measured by the image sensor, wherein processor fusion means is associated with the image sensor, the position processor being connected by a connection device for transmitting the position of the image sensor to a game controller; and ]	[ an image sensor to determine, by sensor fusion means, a position of the image sensor; ]
0.99999213	221	[ an action processor associated with the image sensor, responsive to the input obtained by the position processor, a first sequence of steps to determine a first command for moving the operator from a location in the game space to a location in a non-game space (2). ]	[ a position processor for receiving, by processor fusion means, an input that is the position of the image sensor as measured by the image sensor, wherein processor fusion means is associated with the image sensor, the position processor being connected by a connection device for transmitting the position of the image sensor to a game controller; and ]
0.99999166	222	[ the medical implant including a casing to be mounted on a medical element; ]	[ A method of manufacturing a medical implant with a medical implant interface in a medical implant manufacturing machine, the method comprising: ]
0.9999738	223	[ a control module in communication with the casing; and ]	[ the medical implant including a casing to be mounted on a medical element; ]
0.99998	224	[ a controller that is implanted in the casing and that communicates with the controller by wiring a data processor to the controller, the data processor being in communication with the medical implant interface, ]	[ a control module in communication with the casing; and ]
0.9999896	225	[ wherein the data processor receives data from the control module to provide a first selection from a second selection list of medical implants as an input; and ]	[ a controller that is implanted in the casing and that communicates with the controller by wiring a data processor to the controller, the data processor being in communication with the medical implant interface, ]
0.99999225	226	[ that selects a second selection from the first selection list of medical implants based upon the selected second selection, whereinthe control module is configured to operate a medical implant design program in which at least one of the first selection and the second selection are selected to communicate via the casing and the control module to the casing. ]	[ wherein the data processor receives data from the control module to provide a first selection from a second selection list of medical implants as an input; and ]
0.999522	227	[ a pharmaceutically acceptable polymeric composition having a surface area of about 250 gb; ]	[ A method for treating a patient having a medical condition, comprising administering to said patient an effective amount of a composition comprising: ]
0.99732447	228	[ a therapeutic agent; ]	[ a pharmaceutically acceptable polymeric composition having a surface area of about 250 gb; ]
0.9999876	229	[ wherein the therapeutic agent is at least one of a peptide having a amino acid sequence of SEQ ID NO: ]	[ a therapeutic agent; ]
0.009660672	230	[ 2 or a lipophilic molecule having a protein containing at least 25% by weight of the polymeric composition; ]	[ wherein the therapeutic agent is at least one of a peptide having a amino acid sequence of SEQ ID NO: ]
0.00054702995	231	[ wherein said formulation is dispensed through a syringe via the pharmaceutical delivery means; and ]	[ 2 or a lipophilic molecule having a protein containing at least 25% by weight of the polymeric composition; ]
0.9996648	232	[ wherein the drug is administered to the patient for administration to said patient. ]	[ wherein said formulation is dispensed through a syringe via the pharmaceutical delivery means; and ]
0.9992299	233	[ 1 or SEQ ID NO: ]	[ A method for controlling expression of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9995889	234	[ 4 that comprises substitution at position 16 of amino acids 1-22 of SEQ ID No: ]	[ 1 or SEQ ID NO: ]
0.9999554	235	[ 1 with an amino acid 15-20 of SEQ ID NO: ]	[ 4 that comprises substitution at position 16 of amino acids 1-22 of SEQ ID No: ]
0.99997795	236	[ 2 or a amino acid 1-3 of SEQ ID NO: ]	[ 1 with an amino acid 15-20 of SEQ ID NO: ]
0.9993624	237	[ 4. ]	[ 2 or a amino acid 1-3 of SEQ ID NO: ]
0.99999154	238	[ providing a sample comprising the isolated tissue sample; ]	[ A method for detecting a concentration of an analyte in an isolated tissue sample comprising: ]
0.999992	239	[ exposing the isolated tissue sample for at least one time to at least one solvent; determining the time at which the at least one solvent is exposed; and ]	[ providing a sample comprising the isolated tissue sample; ]
0.99999213	240	[ detecting, via a microfluidic device, a concentration of at least one analyte in the isolated tissue sample, wherein detected analyte is a concentration from 0.005 mM to 20.6 mM. ]	[ exposing the isolated tissue sample for at least one time to at least one solvent; determining the time at which the at least one solvent is exposed; and ]
0.99914825	241	[ removing a first polymer and a second polymer from a non-absorbable resin medium; ]	[ A method for manufacturing a prosthetic implant from a polymer and a substrate, the method comprising: ]
0.99999225	242	[ melting the first polymer and/or the second polymer to obtain a melt coating for the non-absorbable resin medium; ]	[ removing a first polymer and a second polymer from a non-absorbable resin medium; ]
0.9999919	243	[ depositing the melt coating onto the substrate; ]	[ melting the first polymer and/or the second polymer to obtain a melt coating for the non-absorbable resin medium; ]
0.99999213	244	[ cooling the melt coating to at least about 5&#xb0; C. to melt the melt coating; and ]	[ depositing the melt coating onto the substrate; ]
0.01205864	245	[ forming the non-absorbable resin with the polymer and/or the substrate as a first portion of the implant, and ]	[ cooling the melt coating to at least about 5&#xb0; C. to melt the melt coating; and ]
0.99999225	246	[ forming the implant with the portion of the substrate as a second portion of the implant. ]	[ forming the non-absorbable resin with the polymer and/or the substrate as a first portion of the implant, and ]
0.011747313	247	[ at least one scanning surface having a shape and a dimension from which a magnetic field is generating; ]	[ A method for generating a multidimensional projection of a surface, the method consisting essentially of: ]
0.9999894	248	[ an imaging device having a projection surface for determining an image from the scanning surface and projecting the image thereon, the image projecting from the projection surface to an image surface in the surrounding atmosphere; ]	[ at least one scanning surface having a shape and a dimension from which a magnetic field is generating; ]
0.9999919	249	[ an imaging device having a projection surface for determining an image of said image surface from a reference image thereon, the image being projected by said imaging device to the surface at an image projection of the surface of the projection surface, said image projection having a range of image dimensions relative to at least one scan line; and ]	[ an imaging device having a projection surface for determining an image from the scanning surface and projecting the image thereon, the image projecting from the projection surface to an image surface in the surrounding atmosphere; ]
0.99999213	250	[ at least one detector for detecting the image projection of the projection surface based on the range of image dimensions of the projection surface. ]	[ an imaging device having a projection surface for determining an image of said image surface from a reference image thereon, the image being projected by said imaging device to the surface at an image projection of the surface of the projection surface, said image projection having a range of image dimensions relative to at least one scan line; and ]
0.99995303	251	[ a plunger, in operative communication with a plunger shaft, for plunger movement and for receiving an injection drug; ]	[ An injection-drug dispensing apparatus comprising: ]
0.99998593	252	[ a plunger shaft, and ]	[ a plunger, in operative communication with a plunger shaft, for plunger movement and for receiving an injection drug; ]
0.99997795	253	[ a plunger tip mounted to the plunger shaft and receiving and guiding from said plunger shaft an injection drug through said plunger tip; ]	[ a plunger shaft, and ]
0.99998856	254	[ a piston, in operative communication with said plunger shaft, for piston displacement of said plunger shaft; and ]	[ a plunger tip mounted to the plunger shaft and receiving and guiding from said plunger shaft an injection drug through said plunger tip; ]
0.9999906	255	[ a drive motor, in operative communication with said drive shaft, for moving said piston and a control unit, for controlling the delivery of said injection drug to a patient and for a control of movement of a first end end of a needle along a delivery direction, and ]	[ a piston, in operative communication with said plunger shaft, for piston displacement of said plunger shaft; and ]
0.99999046	256	[ a second end end of the needle along a direction toward a central portion of the patient to permit and adjust movement of the needle toward the central portion. ]	[ a drive motor, in operative communication with said drive shaft, for moving said piston and a control unit, for controlling the delivery of said injection drug to a patient and for a control of movement of a first end end of a needle along a delivery direction, and ]
0.9997025	257	[ containing an active substance for activating a therapeutic agent contained therein, said method comprising the steps of: ]	[ A method for providing a therapeutic composition in the form of a capsule having an expandable outer shell, a lumen in the shell extending from the outer shell to the interior of the shell, and ]
0.99903345	258	[ (a) providing a capsule configured to provide a fluid reservoir; ]	[ containing an active substance for activating a therapeutic agent contained therein, said method comprising the steps of: ]
0.99997747	259	[ (b) applying the capsule to the interior interior of the shell of the expandable outer shell in a form comprising first and second openings, respectively; ]	[ (a) providing a capsule configured to provide a fluid reservoir; ]
0.9999924	260	[ (c) allowing liquid to enter at the first entrance into the expandable outer shell in a fashion to form a solid volume in the first opening, and ]	[ (b) applying the capsule to the interior interior of the shell of the expandable outer shell in a form comprising first and second openings, respectively; ]
0.99999225	261	[ to form a solid volume in the second opening of the expandable outer shell in an exterior aspect of the expandable outer shell; ]	[ (c) allowing liquid to enter at the first entrance into the expandable outer shell in a fashion to form a solid volume in the first opening, and ]
0.99999225	262	[ (d) allowing a substantially uniform volume of liquid to flow into the first opening of the expandable outer shell in a form of a solid volume in the expandable outer shell that expands after the liquid has passed into the first entrance; and ]	[ to form a solid volume in the second opening of the expandable outer shell in an exterior aspect of the expandable outer shell; ]
0.9999919	263	[ (e) permitting a substantially uniform volume of liquid to flow into the second opening of the expandable outer shell in a manner to produce expanding material in the expandable outer shell such that said expanding material in the expandable outer shell is capable of penetrating a barrier; and ]	[ (d) allowing a substantially uniform volume of liquid to flow into the first opening of the expandable outer shell in a form of a solid volume in the expandable outer shell that expands after the liquid has passed into the first entrance; and ]
0.0031384216	264	[ (f) providing a composition that does not contain said active substance in the form of a capsule. ]	[ (e) permitting a substantially uniform volume of liquid to flow into the second opening of the expandable outer shell in a manner to produce expanding material in the expandable outer shell such that said expanding material in the expandable outer shell is capable of penetrating a barrier; and ]
0.9987832	265	[ 1 to about 1: ]	[ A method of treating a patient in need of treatment by administering a compound of Formula I by administering a pharmaceutically acceptable salt, buffer, a non-ionic hydrophilic polypeptide and/or a polypeptide comprising amino acid substitutions and an amino acid-binding sequence, wherein said compound is present in a ratio from about 1: ]
0.9944905	266	[ 100, wherein said compound is represented by a first color or by a color that is similar to the first color and represents a concentration of said compound which is less than about 40 mM in a subject. ]	[ 1 to about 1: ]
0.9996687	267	[ a tubular container body; ]	[ A biopsy container comprising: ]
0.99382955	268	[ an end of a distal distal end, the distal distal end defining an opening having a thickness adapted to receive a finger, a portion of the distal distal end and a portion of the distal distal end being formed in a generally flat, generally hollow cylindrical shape having a diameter of the distal distal end and a thickness of the bottom thereof which is substantially equal to its height; and ]	[ a tubular container body; ]
0.9999912	269	[ a locking mechanism on the bottom, the locking mechanism adapted to be slidably slidably movable under an impact by a finger of a hand of a user, such that the locking mechanism closes the opening to prevent access to the distal distal end. ]	[ an end of a distal distal end, the distal distal end defining an opening having a thickness adapted to receive a finger, a portion of the distal distal end and a portion of the distal distal end being formed in a generally flat, generally hollow cylindrical shape having a diameter of the distal distal end and a thickness of the bottom thereof which is substantially equal to its height; and ]
0.9999213	270	[ a base comprising an upper surface, a lower surface and a substantially transverse upper surface side, the upper surface being substantially perpendicular to the skin surface, the lower surface side including a top surface and a bottom surface, the base including an upper surface, an operating control module mounted within said upper surface of the base and including: ]	[ An ultrasound transducer adapted to provide ultrasonic communication between an ultrasound probe and a skin surface and an operating control device operable to control its operation, the operating control device being arranged to use the ultrasound transducer in response to an input signal from the ultrasound probe, such that an output of the ultrasound transducer is controlled so as to generate an ultrasound signal when the operation is performed, then wherein said operating control device comprises: ]
0.9995912	271	[ a first control element configured to receive input signals from either the operating control device or the ultrasound transducer, and ]	[ a base comprising an upper surface, a lower surface and a substantially transverse upper surface side, the upper surface being substantially perpendicular to the skin surface, the lower surface side including a top surface and a bottom surface, the base including an upper surface, an operating control module mounted within said upper surface of the base and including: ]
0.99999	272	[ a second control element configured to control the operation of the operating control device, the first control element including a lower surface located adjacent the user's face and a first end of a wire provided thereon, the second control element including a vertical cross-section; ]	[ a first control element configured to receive input signals from either the operating control device or the ultrasound transducer, and ]
0.9999864	273	[ one or more control elements configured to be slidably coupled to both the upper and lower surfaces to respectively permit operation through the user's skin or skin surface so that a plurality of respective positions of the one or more control elements are accommodated; and ]	[ a second control element configured to control the operation of the operating control device, the first control element including a lower surface located adjacent the user's face and a first end of a wire provided thereon, the second control element including a vertical cross-section; ]
0.9999894	274	[ at least one button configured to generate an input signal to the operating control device, so as to cause the control elements to act as a first set of the plurality of control elements in turn. ]	[ one or more control elements configured to be slidably coupled to both the upper and lower surfaces to respectively permit operation through the user's skin or skin surface so that a plurality of respective positions of the one or more control elements are accommodated; and ]
0.9981717	275	[ a container having a body portion having a surface facing in a direction, at least partially parallel to the direction, and ]	[ A system to detect a type of a body fluid and the type of a foodstuff, the system comprising: ]
0.9999894	276	[ having a plurality of side openings therein configured for receiving an interior portion of a foodstuff which comes into contact with said body portion, and ]	[ a container having a body portion having a surface facing in a direction, at least partially parallel to the direction, and ]
0.99954	277	[ having a first terminal portion coupled to said surface of said container; ]	[ having a plurality of side openings therein configured for receiving an interior portion of a foodstuff which comes into contact with said body portion, and ]
0.9999188	278	[ an identification sensor having a first terminal region and a second terminal region, the first and second terminals adjacent a plane which faces the first terminals, the first terminal region configured to face the surface of said container after said container has been disposed around the foodstuff; and ]	[ having a first terminal portion coupled to said surface of said container; ]
0.99999213	279	[ a device coupled to the identification sensor and connected to the second terminal region of the identification sensor to measure the surface of said interior portion of the container when viewed in the direction, the first terminal region configured to receive a first portion of a body part of a person. ]	[ an identification sensor having a first terminal region and a second terminal region, the first and second terminals adjacent a plane which faces the first terminals, the first terminal region configured to face the surface of said container after said container has been disposed around the foodstuff; and ]
0.99869126	280	[ creating a body portion having a main body surface and an outer surface; ]	[ A method for manufacturing a medical device, comprising the steps of: ]
0.9999913	281	[ embedding a first polymeric layer in the main body surface, wherein the first polymeric layer comprises a first polymer and is selected from the group consisting of ethylene glycol, and ]	[ creating a body portion having a main body surface and an outer surface; ]
0.990283	282	[ a silicone, and ]	[ embedding a first polymeric layer in the main body surface, wherein the first polymeric layer comprises a first polymer and is selected from the group consisting of ethylene glycol, and ]
0.99490154	283	[ wherein the first polymeric layer is in a first, polytetrafluoromethyl ester mixture; ]	[ a silicone, and ]
0.010848371	284	[ wherein the outer surface of the body portion is fabricated of a non-ionic material; and ]	[ wherein the first polymeric layer is in a first, polytetrafluoromethyl ester mixture; ]
0.99992526	285	[ forming a first layer having a main surface in the main body surface by applying a first layer to the first polymeric layer and a second layer having a main surface, the first layer having a central location and a peripheral location, in contact with the main body surface, on one of the first polymeric layer and the second layer, wherein the first and second layers are bonded together by bonding a polymer in the first layer for the one of the first polymer and the second polymer to the second layer, wherein the non-ionic material of the first polymer and the second polymer are separate. ]	[ wherein the outer surface of the body portion is fabricated of a non-ionic material; and ]
0.99994135	286	[ a catheter body; ]	[ A catheter comprising: ]
0.99997807	287	[ a tubular member comprising a first elongated inner surface on an outer surface of the tubular part, the inner surface being fixedly formed with a first material, the opening on the first outer surface of the tubular member comprising a first aperture, wherein if the catheter body is held with a first hand, each of two fingers of the first hand has two distinct fingers; and ]	[ a catheter body; ]
0.99999225	288	[ a pair of flexible, non-woven flexible strings, wherein each of the flexible flexible strings is shaped and dimensioned to fit the second elongated inner surface of the tubular member when the catheter body is held with a first hand, the flexure of the flexible strings having a degree of freedom greater than the degree of freedom of the inner surface of the tubular member. ]	[ a tubular member comprising a first elongated inner surface on an outer surface of the tubular part, the inner surface being fixedly formed with a first material, the opening on the first outer surface of the tubular member comprising a first aperture, wherein if the catheter body is held with a first hand, each of two fingers of the first hand has two distinct fingers; and ]
0.9998312	289	[ hydroxylated polyglycolin; ]	[ An anti-malarial agent, comprising: ]
0.9999919	290	[ a pharmaceutically acceptable salt of the hydroxylated polyglycolin; and ]	[ hydroxylated polyglycolin; ]
0.99999213	291	[ an aqueous solution of the hydroxylated polyglycolin. ]	[ a pharmaceutically acceptable salt of the hydroxylated polyglycolin; and ]
0.99376655	292	[ an acid solution, the solution being at a pH greater than 6.0; ]	[ A method for preparing a beverage comprising a process of: ]
0.992512	293	[ one or more solubilizers wherein the one or more solubilizers are selected from the group consisting of water, alcohols, and ]	[ an acid solution, the solution being at a pH greater than 6.0; ]
0.0010349369	294	[ a salt thereof; and ]	[ one or more solubilizers wherein the one or more solubilizers are selected from the group consisting of water, alcohols, and ]
0.020188097	295	[ a solution comprising a solvent that is solubilized at low pH by the the acid solution or solubilized at a pH greater than 7.6 by the one or more solubilizers. ]	[ a salt thereof; and ]
0.9968802	296	[ generating pressure pulses from a generator which includes a plurality of pressure devices including a gas discharge apparatus configured so as to output a plurality of gas discharge pulses; and ]	[ A method for applying a pressure over a target area, the method comprising: ]
0.9999883	297	[ applying a pressure over the target area of the target area based on a difference between the generated pressure pulses and a pre-defined application pressure corresponding to the pre-defined application pressure, wherein the pre-defined application pressure is greater than the target area's applicational pressure, ]	[ generating pressure pulses from a generator which includes a plurality of pressure devices including a gas discharge apparatus configured so as to output a plurality of gas discharge pulses; and ]
0.99999225	298	[ wherein the pre-defined application pressure is applied to the target area by means of an input device of at least one of a fluid handling and a fluid flow device. ]	[ applying a pressure over the target area of the target area based on a difference between the generated pressure pulses and a pre-defined application pressure corresponding to the pre-defined application pressure, wherein the pre-defined application pressure is greater than the target area's applicational pressure, ]
0.99910164	299	[ operating a transducer unit comprising a transmission axis to produce echo signals to be transmitted through time through a human body by a moving body in response to a signal to be received from said transducer unit; and ]	[ A method for performing a magnetic resonance imaging procedure comprising: ]
0.9999919	300	[ generating an image of the moving body by generating a light signal at said transmitting axis. ]	[ operating a transducer unit comprising a transmission axis to produce echo signals to be transmitted through time through a human body by a moving body in response to a signal to be received from said transducer unit; and ]
0.00036873284	301	[ a. determining an internal temperature of a first storage layer formed by a water-soluble polymer; ]	[ A process for the production of an oil-transmitting and/or bioactive composition, comprising: ]
0.999992	302	[ b. exposing a first material to the internal temperature to make the first material available to a polypropylene resin comprising a polysiloxane and a hydroxyl group in the hydroxyl group, wherein the polymer has the internal temperature of the first storage layer at least partially decreased to the internal temperature and wherein the first material comprises: an oil-transmitting and/or bioactive component; a bioactive substance; and ]	[ a. determining an internal temperature of a first storage layer formed by a water-soluble polymer; ]
0.99853826	303	[ a hydrocarbon residue, ]	[ b. exposing a first material to the internal temperature to make the first material available to a polypropylene resin comprising a polysiloxane and a hydroxyl group in the hydroxyl group, wherein the polymer has the internal temperature of the first storage layer at least partially decreased to the internal temperature and wherein the first material comprises: an oil-transmitting and/or bioactive component; a bioactive substance; and ]
0.9943773	304	[ wherein each of said oil-transmitting and/or bioactive components forms a region at least partially separated by a thickness of less than 50 microns and further wherein each of said oil-transmitting and/or bioactive components occurs within a layer that is not a layer formed under said first layer formed by the water-soluble polymer. ]	[ a hydrocarbon residue, ]
0.9995384	305	[ which comprises at least one of amino acids 679 to 918 of SEQ ID NO: ]	[ An isolated polypeptide comprising or a fragment thereof having at least 95% sequence identity as shown in SEQ ID NO: 4 (PTR: 13): ]
0.9995291	306	[ 4, whereinsaid polypeptide comprises a plurality of SEQ ID No. 1 to 9, wherein said polypeptide of SEQ ID NO: ]	[ which comprises at least one of amino acids 679 to 918 of SEQ ID NO: ]
0.9915324	307	[ 4 encodes PTC1, and ]	[ 4, whereinsaid polypeptide comprises a plurality of SEQ ID No. 1 to 9, wherein said polypeptide of SEQ ID NO: ]
0.99334925	308	[ wherein said polypeptide of SEQ ID NO: ]	[ 4 encodes PTC1, and ]
0.99978834	309	[ 4 is an H3 protein comprising amino acid residues 12 to 17 of SEQ ID No: ]	[ wherein said polypeptide of SEQ ID NO: ]
0.9995327	310	[ 4. ]	[ 4 is an H3 protein comprising amino acid residues 12 to 17 of SEQ ID No: ]
0.9999919	311	[ the M/Tp1 and/or M/Tp2 fusion proteins comprise the N-terminal domain of an H&#x2b2 wherein the N-terminal domain of the N-terminal domain of the M/Tp1 fusion protein is orthogonal to the N-terminal domain of the M/Tp2 fusion protein; and ]	[ A method of treating a chronic myocardial infarction comprising administering to a mammal or animal a therapeutically effective amount in vivo to a microalbumin/microtubule-targeting protein 1 (M/Tp1)/microtubule-targeting protein 2 (M/Tp2) fusion protein complex, wherein the microalbumin/microtubule-targeting protein 1 (M/Tp1)/microtubule-targeting protein 2 (M/Tp2) fusion protein complex comprises at least three fusion protein complexes that are mutually orthogonal, wherein: ]
0.99999225	312	[ the M/Tp1 fusion protein complex is one of said N-terminal domains having said N-terminal domain in an orthogonal relationship with the N-terminal domain of the N-terminal domain of the M/Tp2 fusion protein; and ]	[ the M/Tp1 and/or M/Tp2 fusion proteins comprise the N-terminal domain of an H&#x2b2 wherein the N-terminal domain of the N-terminal domain of the M/Tp1 fusion protein is orthogonal to the N-terminal domain of the M/Tp2 fusion protein; and ]
0.999992	313	[ wherein the M/Tp1 fusion proteins include the N-terminal domain of the M/Tp1 fusion protein is the H&#x2b2. ]	[ the M/Tp1 fusion protein complex is one of said N-terminal domains having said N-terminal domain in an orthogonal relationship with the N-terminal domain of the N-terminal domain of the M/Tp2 fusion protein; and ]
0.98585725	314	[ a plurality of support members spaced in a substantially parallel direction generally orthogonal to a longitudinal axis, each of the support members having a first end and a second end; at least one of said plurality of support members, with an outwardly protrudes forming a longitudinal axis, having the first end of said plurality of support members substantially parallel to the same longitudinal axis as at least one other of the plurality of support members, to form a first transverse link; a first cross-sectional area surrounding said first cross-sectional area being aligned to define at least partially the longitudinal axis, wherein at least one of one of said first support member and the one of said first transverse link has a first position along the longitudinal axis, the first position further including a first edge relative to the first transverse link, the first edge located along the entire length of the at least one of said plurality of support member; and ]	[ A device comprising: ]
0.9999914	315	[ at least one of said support members comprising a longitudinal axis which extends a distance away from one or more of said first support member and the one of said first transverse link toward a second distance away from said at least one of said plurality of support members. ]	[ a plurality of support members spaced in a substantially parallel direction generally orthogonal to a longitudinal axis, each of the support members having a first end and a second end; at least one of said plurality of support members, with an outwardly protrudes forming a longitudinal axis, having the first end of said plurality of support members substantially parallel to the same longitudinal axis as at least one other of the plurality of support members, to form a first transverse link; a first cross-sectional area surrounding said first cross-sectional area being aligned to define at least partially the longitudinal axis, wherein at least one of one of said first support member and the one of said first transverse link has a first position along the longitudinal axis, the first position further including a first edge relative to the first transverse link, the first edge located along the entire length of the at least one of said plurality of support member; and ]
0.99994326	316	[ delivering a cardiac stimulus to the heart; and ]	[ A non-invasive method for controlling a cardiac rhythm comprising: ]
0.99999213	317	[ receiving information from a monitoring unit, wherein the information is indicative of a target heart rate, wherein during the delivery of the cardiac stimulus the heart rate is electronically controlled, ]	[ delivering a cardiac stimulus to the heart; and ]
0.999992	318	[ wherein the monitoring unit is configured to monitor an internal electrical signal at the heart to provide information indicative of at least one target heart rate during the delivery of the cardiac stimulus to the heart, and ]	[ receiving information from a monitoring unit, wherein the information is indicative of a target heart rate, wherein during the delivery of the cardiac stimulus the heart rate is electronically controlled, ]
0.99999154	319	[ wherein the indication of the target heart rate is based on an interaction between the target heart rate and a current heart rate. ]	[ wherein the monitoring unit is configured to monitor an internal electrical signal at the heart to provide information indicative of at least one target heart rate during the delivery of the cardiac stimulus to the heart, and ]
0.9964238	320	[ a first portion comprising at least one of a first wall, a first surface, and ]	[ A device for positioning at least one prosthesis in a proximal portion of an implantable medical device, the prosthesis positioned within a cavity comprising a central core and a distal periphery, wherein the central core and a portion of the distal periphery have a surface, the device comprising: ]
0.9999907	321	[ a first surface side face, the first portion being disposed between and spaced away from at least one of the surface side face, the first wall and the first surface, wherein each of the first and second portions provides an insertion plane, and ]	[ a first portion comprising at least one of a first wall, a first surface, and ]
0.99929714	322	[ wherein the insertable device comprises at least one of a first, a second, and ]	[ a first surface side face, the first portion being disposed between and spaced away from at least one of the surface side face, the first wall and the first surface, wherein each of the first and second portions provides an insertion plane, and ]
0.9988865	323	[ a third implantable bone. ]	[ wherein the insertable device comprises at least one of a first, a second, and ]
0.9970415	324	[ acquiring imaging data from multiple imaging scans of a subject; ]	[ A method for controlling or diagnosing a disease or disorder in a subject in need thereof, the method comprising: ]
0.999992	325	[ calculating two-dimensional volume displacement of the imaging data; ]	[ acquiring imaging data from multiple imaging scans of a subject; ]
0.9999484	326	[ dividing the two-dimensionality of a plurality of imaging scans into multiple different time-domain segments with different time-domain sampling patterns; ]	[ calculating two-dimensional volume displacement of the imaging data; ]
0.99999225	327	[ combining the two-dimensional displacement of the imaging data into a three-dimensional volume displacement curve based on the different time-domain sampling patterns; ]	[ dividing the two-dimensionality of a plurality of imaging scans into multiple different time-domain segments with different time-domain sampling patterns; ]
0.99999225	328	[ determining a baseline volume displacement for multiple different time-domain segments based on the three-dimensional volume displacement curve; and ]	[ combining the two-dimensional displacement of the imaging data into a three-dimensional volume displacement curve based on the different time-domain sampling patterns; ]
0.99999225	329	[ presenting the three-dimensional volume displacement curve to a patient, including determining the two-dimensionality with respect to the baseline volume displacement. ]	[ determining a baseline volume displacement for multiple different time-domain segments based on the three-dimensional volume displacement curve; and ]
0.9996768	330	[ a plurality of game terminals, each game terminal having a plurality of game terminals; ]	[ A gaming board having an outer surface, the gaming board comprising: ]
0.9942497	331	[ a plurality of light emitting diodes (LEDs), each light emitting diode and having a plurality of LED lines coupled to one another; ]	[ a plurality of game terminals, each game terminal having a plurality of game terminals; ]
0.9998054	332	[ a game controller operatively coupled to said plurality of game terminals, further operably coupled to the plurality of light emitting diodes for controlling operation of said plurality of game terminals, said game controller havinga clock signal output; ]	[ a plurality of light emitting diodes (LEDs), each light emitting diode and having a plurality of LED lines coupled to one another; ]
0.9998803	333	[ a set signal output; and ]	[ a game controller operatively coupled to said plurality of game terminals, further operably coupled to the plurality of light emitting diodes for controlling operation of said plurality of game terminals, said game controller havinga clock signal output; ]
0.99999154	334	[ a set value output, wherein each of said set signal outputs is programmed for output and is based on the clock signal output. ]	[ a set signal output; and ]
0.9999914	335	[ M or more to a population subject to the spinal cord infarction, wherein: ]	[ A method for treating a spinal cord infarction comprising administering an antigen-binding protein at a dose in the range of 25-50 &#x3bc; ]
0.9918333	336	[ said antigen-binding protein comprises a C8 promoter and an H1 promoter, and ]	[ M or more to a population subject to the spinal cord infarction, wherein: ]
0.9999559	337	[ an H1 polypeptide is selected from the group consisting of: ]	[ said antigen-binding protein comprises a C8 promoter and an H1 promoter, and ]
0.9988951	338	[ (a) the amino acid sequence of sequence SEQ ID NO: 2; ]	[ an H1 polypeptide is selected from the group consisting of: ]
0.9999869	339	[ (b) sequence SEQ ID NO: 6; ]	[ (a) the amino acid sequence of sequence SEQ ID NO: 2; ]
0.9999912	340	[ (c) sequence SEQ ID NO: 7; ]	[ (b) sequence SEQ ID NO: 6; ]
0.9999912	341	[ (d) sequence SEQ ID NO: 8; ]	[ (c) sequence SEQ ID NO: 7; ]
0.99999154	342	[ (f) sequence SEQ ID NO: 9; or(g) sequence SEQ ID NO: 10; ]	[ (d) sequence SEQ ID NO: 8; ]
0.99905914	343	[ wherein the dose of the antigen-binding protein is selected to have the effect of protecting the population from spinal cord injury. ]	[ (f) sequence SEQ ID NO: 9; or(g) sequence SEQ ID NO: 10; ]
0.9982255	344	[ an animal; ]	[ A system for preventing and treating a disease progression in a mammal, comprising: ]
0.99991393	345	[ a treatment system for administering a treatment to the mammal at a first site in the animal, the treatment system comprising: ]	[ an animal; ]
0.9999471	346	[ a first implant suitable for insertion into said mammal; ]	[ a treatment system for administering a treatment to the mammal at a first site in the animal, the treatment system comprising: ]
0.99994874	347	[ a sensor adapted to detect the presence of a first drug in the mammal; ]	[ a first implant suitable for insertion into said mammal; ]
0.9999889	348	[ a user interface allowing the mammal to activate the first implant with an actuation of the user interface; ]	[ a sensor adapted to detect the presence of a first drug in the mammal; ]
0.99998224	349	[ a communication system configured to wirelessly communicate data of patient performance of a treatment process for an animal that is administered at the first site with said first implant and to wirelessly communicate data of a target animal that is operated on for the treatment by the mammal and not operated on; and ]	[ a user interface allowing the mammal to activate the first implant with an actuation of the user interface; ]
0.9999919	350	[ a user interface control for monitoring performance of the mammal at the first site, the control comprising: ]	[ a communication system configured to wirelessly communicate data of patient performance of a treatment process for an animal that is administered at the first site with said first implant and to wirelessly communicate data of a target animal that is operated on for the treatment by the mammal and not operated on; and ]
0.9999906	351	[ display information to indicate whether the mammal has executed the operation to remove a target element that is not part of said treatment; ]	[ a user interface control for monitoring performance of the mammal at the first site, the control comprising: ]
0.99999225	352	[ display information associated with the animal when the mammal has completed the operation to remove the target element; ]	[ display information to indicate whether the mammal has executed the operation to remove a target element that is not part of said treatment; ]
0.9999924	353	[ display information to indicate if the mammal has performed a treatment based on a success of the operation, the target element remaining during the actuation of said needle, and ]	[ display information associated with the animal when the mammal has completed the operation to remove the target element; ]
0.99953747	354	[ an operation result for the selected target animal; and ]	[ display information to indicate if the mammal has performed a treatment based on a success of the operation, the target element remaining during the actuation of said needle, and ]
0.99689615	355	[ display information indicative, at the time of the first implant selection, of whether the mammal has executed one or more treatment protocols; and ]	[ an operation result for the selected target animal; and ]
6.595087e-05	356	[ wherein said needle comprises: ]	[ display information indicative, at the time of the first implant selection, of whether the mammal has executed one or more treatment protocols; and ]
0.9999894	357	[ an elongate member extending to at least one of first and second corners of said needle; and ]	[ wherein said needle comprises: ]
0.0112044355	358	[ a body having at least 2 edges, ]	[ an elongate member extending to at least one of first and second corners of said needle; and ]
0.008143221	359	[ wherein the first and second corners of the needle have no longitudinal axis. ]	[ a body having at least 2 edges, ]
0.99999106	360	[ (a) establishing the in vitro sperm culture with a donor sperm sample within a lumen of the body of the donor sperm sample; ]	[ A method for the production of human embryos from an in vitro sperm culture comprising the steps of: ]
0.99999213	361	[ (b) providing an in vitro sperm culture-type sample, the samples being derived from at least one donor sperm; and ]	[ (a) establishing the in vitro sperm culture with a donor sperm sample within a lumen of the body of the donor sperm sample; ]
0.99999225	362	[ (c) delivering the in vitro sperm culture-type sample to a cell expressing the human embryonic stem-cell (HSEC)-like gene, wherein the HSEC-like gene is expressed in the lumen of the donor sperm sample. ]	[ (b) providing an in vitro sperm culture-type sample, the samples being derived from at least one donor sperm; and ]
0.9999907	363	[ a first playing player character and first playing game; ]	[ A non-transitory computer readable storage medium that stores computer program instructions that when executed by a computer, when the computer is operated, cause a device that is used for performing a game that is operable as a plurality of playing modes, including a gaming room for performing an action, to cause a first plurality of player characters in accordance with a plurality of playing modes in which the plurality of playing modes are played each as a predetermined player character, the playing modes comprising: ]
0.99999213	364	[ a second player character and second playing game, wherein each first playing game is an act of playing such a first playing game; ]	[ a first playing player character and first playing game; ]
0.9999894	365	[ a plurality of playing characters that are not playable by the first playing player character; and ]	[ a second player character and second playing game, wherein each first playing game is an act of playing such a first playing game; ]
0.99998987	366	[ a predetermined number of rules, that at least a portion of which is provided in a play command that includes, in the play command, a predetermined player character, and ]	[ a plurality of playing characters that are not playable by the first playing player character; and ]
0.99999225	367	[ the plurality of playing modes includes a play command that includes at least a portion of the play command that is contained in the predetermined player character and that, is executable to cause the predetermined player character to perform the predetermined playing mode. ]	[ a predetermined number of rules, that at least a portion of which is provided in a play command that includes, in the play command, a predetermined player character, and ]
0.008317276	368	[ accessing an image of an object to determine a color of said object; ]	[ A method for controlling multiple channels, said method comprising: ]
0.98607916	369	[ performing a plurality of steps of the following types of steps: ]	[ accessing an image of an object to determine a color of said object; ]
0.9947491	370	[ (a) generating at least one color of a portion of said object based on position of an image of a portion of said object in relation to the image of the portion of said object; ]	[ performing a plurality of steps of the following types of steps: ]
0.999972	371	[ (b) determining a phase in response to said image; ]	[ (a) generating at least one color of a portion of said object based on position of an image of a portion of said object in relation to the image of the portion of said object; ]
0.99999094	372	[ (c) measuring an amount of said color based on said phase; and, ]	[ (b) determining a phase in response to said image; ]
0.9999776	373	[ (d) correcting said portion having said color and displaying an image based on said correction of said portion having said portion having said color for said object; and ]	[ (c) measuring an amount of said color based on said phase; and, ]
0.99998057	374	[ controlling multiple channels including (c) and (d) and having three different color types based on said control. ]	[ (d) correcting said portion having said color and displaying an image based on said correction of said portion having said portion having said color for said object; and ]
0.99994683	375	[ selecting a subject representative of the disorder; ]	[ A method of treating a disorder having at least one of a pathological, degenerative and metabolic or respiratory disease associated therewith, comprising: ]
0.9942669	376	[ administering to said subject a therapeutically effective amount of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ]	[ selecting a subject representative of the disorder; ]
0.9996582	377	[ 2, SEQ ID NO: ]	[ administering to said subject a therapeutically effective amount of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.99999	378	[ 4, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.99951947	379	[ 5, and ]	[ 4, SEQ ID NO: ]
0.9990879	380	[ SEQ ID NO: ]	[ 5, and ]
0.9997087	381	[ 6. ]	[ SEQ ID NO: ]
0.99999225	382	[ a composition comprising a water-soluble carrier and an anti-inflammatory agent, wherein said anti-inflammatory agent is selected from the group consisting of: ]	[ A composition comprising a water-soluble carrier and an anti-inflammatory agent, and ]
0.0010187024	383	[ a) a monoclonal antibody designed to bind to a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, ]	[ a composition comprising a water-soluble carrier and an anti-inflammatory agent, wherein said anti-inflammatory agent is selected from the group consisting of: ]
0.99999225	384	[ b) a monoclonal antibody designed to bind to a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, ]	[ a) a monoclonal antibody designed to bind to a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, ]
0.9999906	385	[ c) the polypeptide comprising the amino acid sequence; and ]	[ b) a monoclonal antibody designed to bind to a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, ]
0.9993243	386	[ d) an anti-inflammatory agent. ]	[ c) the polypeptide comprising the amino acid sequence; and ]
0.9998246	387	[ providing a medical device, or a part thereof, including a plurality of diagnostic sensors, wherein each of said plurality of diagnostic sensors can detect an internal disorder of a person in the medical device or a medical device, and ]	[ A method of enhancing a process for cleaning a medical device from an exterior of a medical device, said medical device comprising a patient monitoring area, said method comprising the steps of: ]
0.99999046	388	[ transmit data relating to the internal disorder to a central database; ]	[ providing a medical device, or a part thereof, including a plurality of diagnostic sensors, wherein each of said plurality of diagnostic sensors can detect an internal disorder of a person in the medical device or a medical device, and ]
0.99998105	389	[ identifying at least one diagnostic sensor for acquiring data from the central database; ]	[ transmit data relating to the internal disorder to a central database; ]
0.9999924	390	[ sending the data comprising the identifying information of said at least one diagnostic sensor to a remote processing center or an external computer computer; ]	[ identifying at least one diagnostic sensor for acquiring data from the central database; ]
0.99999213	391	[ generating a diagnostic report from data relating to the internal disorder transmitted to the central database when an event associated with the location of the at least one diagnostic sensor is identified; and ]	[ sending the data comprising the identifying information of said at least one diagnostic sensor to a remote processing center or an external computer computer; ]
0.99998975	392	[ analyzing the data of the diagnostic report to identify at least one method comprising monitoring symptoms, symptoms related to a patient specific condition of the patient in the medical device, and ]	[ generating a diagnostic report from data relating to the internal disorder transmitted to the central database when an event associated with the location of the at least one diagnostic sensor is identified; and ]
0.99464285	393	[ identifying and selecting one or more diagnostic factors suitable for use in detecting said internal disorder. ]	[ analyzing the data of the diagnostic report to identify at least one method comprising monitoring symptoms, symptoms related to a patient specific condition of the patient in the medical device, and ]
0.99728847	394	[ an antigen generating device which generates an antigen; and ]	[ A system for the treatment of cancer or cancer related disease in a host, comprising: ]
0.99996984	395	[ a host cell culture receiving device which receives and transmits at least a portion of the antigen in response to a host cell reaction, wherein a portion of the host cell culture receiving device has a cell response indicator which measures the number of cells in the host cell culture receiving the portion of the host cell culture which has a cell response indicative of an effective level of cell proliferation, wherein the effective level of cell proliferation is measured during a first time period, wherein the at least a portion of the host cell culture receiving the portion of the host cell culture which has a cell response indicative of a growth factor responsive to an antigen is not measured during the second time period; and ]	[ an antigen generating device which generates an antigen; and ]
0.9999832	396	[ a system for detecting the growth factor responsive to the antigen, the first time period, and ]	[ a host cell culture receiving device which receives and transmits at least a portion of the antigen in response to a host cell reaction, wherein a portion of the host cell culture receiving device has a cell response indicator which measures the number of cells in the host cell culture receiving the portion of the host cell culture which has a cell response indicative of an effective level of cell proliferation, wherein the effective level of cell proliferation is measured during a first time period, wherein the at least a portion of the host cell culture receiving the portion of the host cell culture which has a cell response indicative of a growth factor responsive to an antigen is not measured during the second time period; and ]
0.99998605	397	[ the second time period. ]	[ a system for detecting the growth factor responsive to the antigen, the first time period, and ]
0.99997807	398	[ said distal end portion of said flexible material comprising a substantially cylindrical wall at said intermediate portion and having an intermediate end portion including a rigid portion extending axially along said distal end portion, wherein (i) said middle portion includes a substantially cylindrical wall at said intermediate portion and extending away from said elongate shaft into said elongate shaft's end, (ii) said distal end portion is disposed between said middle portion, said middle portion defining a distance from the distal end portion distal portion of said flange, and ]	[ A catheter having an inner tube and a flexible catheter arm with a proximal end to the tube and a distal end to an implantable member, said catheter arm having a longitudinal axis, a longitudinal axis length and a longitudinal axis radius of curvature, said elongate shaft having a proximal end portion configured to be disposed within said tube, said distal end portion defining an intermediate portion extending along said longitudinal axis length and axially opposite to said tube axis, said elongate shaft having a proximal end portion of a flexible material positioned for insertion through said tube's end surface, and ]
0.99999225	399	[ (iii) said intermediate portion is configured for insertion into a patient's urethra orifice; wherein said proximal end portion defines a hollow space between said distal end portion of said flexible material and the elongate shaft's proximal end portion; and ]	[ said distal end portion of said flexible material comprising a substantially cylindrical wall at said intermediate portion and having an intermediate end portion including a rigid portion extending axially along said distal end portion, wherein (i) said middle portion includes a substantially cylindrical wall at said intermediate portion and extending away from said elongate shaft into said elongate shaft's end, (ii) said distal end portion is disposed between said middle portion, said middle portion defining a distance from the distal end portion distal portion of said flange, and ]
0.99997973	400	[ wherein said distal end portion does not extend within said truncated tube for insertion of said implantable member. ]	[ (iii) said intermediate portion is configured for insertion into a patient's urethra orifice; wherein said proximal end portion defines a hollow space between said distal end portion of said flexible material and the elongate shaft's proximal end portion; and ]
0.9999912	401	[ a generally concave curved portion having a base, and ]	[ Surgical instrument configured to be slid within an eye, said surgical instrument comprising: a generally concave curved portion having a top surface and a bottom surface; and ]
0.99998975	402	[ a slot of a size; a threaded tube extending from said bottom surface opposite said top surface of said curved portion; and ]	[ a generally concave curved portion having a base, and ]
0.9999914	403	[ a generally elongate sleeve extending from said base of said curved portion; ]	[ a slot of a size; a threaded tube extending from said bottom surface opposite said top surface of said curved portion; and ]
0.999941	404	[ said sleeve being elongate and comprising at least two first opposing ends disposed on sides of said socket, and ]	[ a generally elongate sleeve extending from said base of said curved portion; ]
0.9999924	405	[ means for securing said at least two first opposing ends in said slot of said sleeve and securing said socket to a member or support structure such that said socket can be slid into said eye. ]	[ said sleeve being elongate and comprising at least two first opposing ends disposed on sides of said socket, and ]
0.9931166	406	[ a housing; ]	[ An apparatus for operating a portable electronic device with a user, comprising: ]
0.9996971	407	[ a user interface disposed with the housing in a first position; ]	[ a housing; ]
0.9999782	408	[ display information at a first position of the user interface; ]	[ a user interface disposed with the housing in a first position; ]
0.99998987	409	[ user feedback means disposed with the housing in a second position, wherein the user feedback means sends output data to the display information when the user selects a user selection on the user interface, and ]	[ display information at a first position of the user interface; ]
0.9999889	410	[ output data is responsive to user input; and ]	[ user feedback means disposed with the housing in a second position, wherein the user feedback means sends output data to the display information when the user selects a user selection on the user interface, and ]
0.9999918	411	[ communication means disposed with the housing in a third position, wherein when the user input is received by a first input and the input includes a gesture, the user feedback means is responsive to the user input and produces output data indicative of the gesture, and ]	[ output data is responsive to user input; and ]
0.99999225	412	[ when the user has selected a second position and input is received by a second input in response to the gesture by a user, the user feedback is responsive on the user interface to the user selection by the first input and to the selected second position, and ]	[ communication means disposed with the housing in a third position, wherein when the user input is received by a first input and the input includes a gesture, the user feedback means is responsive to the user input and produces output data indicative of the gesture, and ]
0.99999225	413	[ after the second user input, then the user feedback is responsive on the user interface to the gesture by the second user input. ]	[ when the user has selected a second position and input is received by a second input in response to the gesture by a user, the user feedback is responsive on the user interface to the user selection by the first input and to the selected second position, and ]
0.08691233	414	[ a compound having the structure: X(R)r1&#x2014; ]	[ A therapeutic pharmaceutical composition comprising: ]
0.9772046	415	[ &#x2003; ]	[ a compound having the structure: X(R)r1&#x2014; ]
0.0050825393	416	[ SO2; ]	[ &#x2003; ]
0.98319685	417	[ wherein R is an independently selected aryl group which is optionally substituted by one or more hydroxyl groups which form a hydroxyl group, or a hydrolysis group or an hydrogen atom, said hydroxyl group being an anhydro group (H), ]	[ SO2; ]
0.99186486	418	[ m is an integer of from 0 and 1. ]	[ wherein R is an independently selected aryl group which is optionally substituted by one or more hydroxyl groups which form a hydroxyl group, or a hydrolysis group or an hydrogen atom, said hydroxyl group being an anhydro group (H), ]
0.99999213	419	[ reacting said aqueous-fluorescent composition with an aqueous solution of at least one monovalent oligomer comprising the first amino acid sequence of Formula (I): ]	[ A method of preparing an aqueous-fluorescent composition comprising: ]
0.9809161	420	[ wherein N is an integer from 1 to 8; ]	[ reacting said aqueous-fluorescent composition with an aqueous solution of at least one monovalent oligomer comprising the first amino acid sequence of Formula (I): ]
0.9999603	421	[ R1 is an integer from 1 to 9; ]	[ wherein N is an integer from 1 to 8; ]
0.99995077	422	[ R2 has an integer from 1 to 4; ]	[ R1 is an integer from 1 to 9; ]
0.99990356	423	[ R3 is an integer from 1 to 8; and, ]	[ R2 has an integer from 1 to 4; ]
0.99997425	424	[ Q is an integer from 5 to 7. ]	[ R3 is an integer from 1 to 8; and, ]
0.99919945	425	[ administering to a subject in need thereof the amino acid sequence of a nucleic acid molecule represented by SEQ ID NO: 6; and ]	[ A method for the treatment of a tumor, comprising: ]
0.99541205	426	[ measuring the effectiveness of said treatment. ]	[ administering to a subject in need thereof the amino acid sequence of a nucleic acid molecule represented by SEQ ID NO: 6; and ]
0.002575472	427	[ a substrate; and ]	[ One or more imaging devices comprising: ]
0.9994135	428	[ a first antenna arranged on the substrate and connected to the substrate, the first antenna comprising: ]	[ a substrate; and ]
0.001604106	429	[ circuitry for controlling at least one of operation and illumination to at least some of the imaging device; ]	[ a first antenna arranged on the substrate and connected to the substrate, the first antenna comprising: ]
0.9999919	430	[ at least one optical fiber arranged on the at least one optical fiber and to which at least a portion of light emitted from the imaging device passes during operation; and ]	[ circuitry for controlling at least one of operation and illumination to at least some of the imaging device; ]
0.9999924	431	[ at least one transducer arranged on the at least one transducer and to which at least a portion of light transmitted from the imaging device passes during operation; ]	[ at least one optical fiber arranged on the at least one optical fiber and to which at least a portion of light emitted from the imaging device passes during operation; and ]
0.9997912	432	[ wherein the circuitry controls operation and illumination to the at least one portion of the light that passes through the at least one fiber, the circuitry also controls illumination to the at least one portion of the light that passes through the at least one fiber, ]	[ at least one transducer arranged on the at least one transducer and to which at least a portion of light transmitted from the imaging device passes during operation; ]
0.9999924	433	[ wherein a power signal generated by a power source is modulated to transmit the voltage on the at least one radiation source and a low-wavelength radiation beam that reaches the portion of the light that passes through the at least one fiber is modulated to send the voltage off the at least one fiber and an emission radiation beam that reaches the portion of the light that passes through the at least one fiber is modulated to transmit the voltage on the at least one radiation source at a wavelength such that a volume of a region of the region of the beam that flows with the light in the portion of the light that passes through the at least one fiber reaches a predetermined size. ]	[ wherein the circuitry controls operation and illumination to the at least one portion of the light that passes through the at least one fiber, the circuitry also controls illumination to the at least one portion of the light that passes through the at least one fiber, ]
0.9852013	434	[ wherein: ]	[ A method for reducing the incidence of respiratory depression in a person who is at risk for developing such respiratory depression or for developing the onset of respiratory depression in a medical patient comprising administering a compound having the structure: ]
0.9920014	435	[ N represents two alkyls; ]	[ wherein: ]
0.99983525	436	[ R1 represents an unsubstituted hydro group; ]	[ N represents two alkyls; ]
0.99997985	437	[ R2 represents an alkyl; ]	[ R1 represents an unsubstituted hydro group; ]
0.99998665	438	[ R3 represents an alkenyl; ]	[ R2 represents an alkyl; ]
0.99925834	439	[ a hydrazine residue may optionally optionally form a phenyl or dibenzo ring with respect to an alkenyl; and ]	[ R3 represents an alkenyl; ]
0.99999154	440	[ the phenyl or dibenzo ring may optionally form a C1-C4-alkyl group with a substituted C1 to C4 alkyl group; whereby R3 may optionally form a pharmaceutically acceptable salt thereof. ]	[ a hydrazine residue may optionally optionally form a phenyl or dibenzo ring with respect to an alkenyl; and ]
0.9999877	441	[ wherein a nucleic acid encoding said polypeptide comprises SEQ ID NO. 1. ]	[ A method of preparing an isolated polypeptide from a cationic protein, wherein said protein has been selected from the group consisting of mycadillus and epidermal growth factor(EGF) and comprises about 50 amino acids or less, ]
0.9999826	442	[ each of said five cards includes at least one player-selected winning combination among a plurality of winning combinations; ]	[ A game of chance board game, comprising an initial set of five randomly generated poker chips positioned opposite said initial set of five randomly generated poker chips, wherein: ]
0.9999912	443	[ each card of said initial set of five cards having a predetermined rank and class; ]	[ each of said five cards includes at least one player-selected winning combination among a plurality of winning combinations; ]
0.9999924	444	[ each card of said initial set of five cards being used for at least one of a first round of cards, a first pair of cards, and ]	[ each card of said initial set of five cards having a predetermined rank and class; ]
0.9999908	445	[ a second pair of cards; ]	[ each card of said initial set of five cards being used for at least one of a first round of cards, a first pair of cards, and ]
0.9999889	446	[ each card of said initial set of five cards including a characteristic represented by an image displayed on said second pair of cards; ]	[ a second pair of cards; ]
0.99999094	447	[ each of said five cards and each of said five cards being generated by a computer; ]	[ each card of said initial set of five cards including a characteristic represented by an image displayed on said second pair of cards; ]
0.99999094	448	[ players of said initial set of five cards playing on said initial set of five cards with said respective cards; and ]	[ each of said five cards and each of said five cards being generated by a computer; ]
0.9999913	449	[ said initial set being randomly generated while said first, second, and ]	[ players of said initial set of five cards playing on said initial set of five cards with said respective cards; and ]
0.9939161	450	[ third pairs of cards are selected; ]	[ said initial set being randomly generated while said first, second, and ]
0.99998975	451	[ wherein the first pair of cards is placed with a first card of said five cards; and ]	[ third pairs of cards are selected; ]
0.9999902	452	[ wherein the first card is a first card of said one card from the initial set of five of said five randomly generated card including all of the cards which in said first card represents a common starting card; ]	[ wherein the first pair of cards is placed with a first card of said five cards; and ]
0.999992	453	[ wherein each of said 5 cards includes a characteristic represented by an image displayed on a second pair of cards; and ]	[ wherein the first card is a first card of said one card from the initial set of five of said five randomly generated card including all of the cards which in said first card represents a common starting card; ]
0.99999225	454	[ each of said 5 cards also includes a characteristic represented by an image appearing on a third pair of cards; ]	[ wherein each of said 5 cards includes a characteristic represented by an image displayed on a second pair of cards; and ]
0.9999883	455	[ wherein each of said five player-selected winning combinations has a respective number of winning combinations, and ]	[ each of said 5 cards also includes a characteristic represented by an image appearing on a third pair of cards; ]
0.99999225	456	[ each card including said characteristic is played for a corresponding winning combination during a corresponding predetermined time period. ]	[ wherein each of said five player-selected winning combinations has a respective number of winning combinations, and ]
0.9999918	457	[ measuring a concentration of blood in a sample contained within at least one of an oral cavity or nasal cavity of a person, wherein measuring the concentration of blood indicates that the person is a carrier and does not further indicate that the person is a subject of a drug; ]	[ A method for determining whether a person is a carrier or an object of a drug of composition, comprising: ]
0.99999225	458	[ determining whether the concentration of blood in the sample is within a concentration range that would be considered a level of a drug and whether this level is less than a level of a drug required for treating a risk to cardiovascular health; and ]	[ measuring a concentration of blood in a sample contained within at least one of an oral cavity or nasal cavity of a person, wherein measuring the concentration of blood indicates that the person is a carrier and does not further indicate that the person is a subject of a drug; ]
0.99999213	459	[ providing therapeutic medicine for administering to an afflicted person at a time when a level of the drug of composition is lower than the level of the drug required for treating a risk to cardiovascular health. ]	[ determining whether the concentration of blood in the sample is within a concentration range that would be considered a level of a drug and whether this level is less than a level of a drug required for treating a risk to cardiovascular health; and ]
0.99986255	460	[ a first liquid controller, the first liquid controller configured to control a supply and/or discharge associated liquid to be supplied/disposed, the first liquid controller configured to measure quantities associated with an individual user of the liquid selected from the group consisting of ethanol, ethanol in combination with water and water in combination with ethanol, which includes ethanol used to produce a beverage, and ]	[ Apparatus for managing a liquid, comprising: ]
0.0013545466	461	[ a liquid having a viscosity (v) of 25% to 70% by weight; and ]	[ a first liquid controller, the first liquid controller configured to control a supply and/or discharge associated liquid to be supplied/disposed, the first liquid controller configured to measure quantities associated with an individual user of the liquid selected from the group consisting of ethanol, ethanol in combination with water and water in combination with ethanol, which includes ethanol used to produce a beverage, and ]
0.9954308	462	[ a second liquid controller, the second liquid controller configured to control a volume of water to be delivered or dispensed to the individual user and to control the supply or discharge of the liquid, a volume of alcohol in combination with a temperature of at least 100&#xb0; C., and ]	[ a liquid having a viscosity (v) of 25% to 70% by weight; and ]
0.9999777	463	[ another liquid, the liquid containing alcohol and/or other liquids wherein the liquid containing alcohol is selected from the group consisting of alcoholic alcohol, acetoneic alcohol, glycerineic alcohol, sugarcaneic alcohol, phenylethylamineic alcohol, pyrazoleic alcohol, and ]	[ a second liquid controller, the second liquid controller configured to control a volume of water to be delivered or dispensed to the individual user and to control the supply or discharge of the liquid, a volume of alcohol in combination with a temperature of at least 100&#xb0; C., and ]
0.023324557	464	[ bromine. ]	[ another liquid, the liquid containing alcohol and/or other liquids wherein the liquid containing alcohol is selected from the group consisting of alcoholic alcohol, acetoneic alcohol, glycerineic alcohol, sugarcaneic alcohol, phenylethylamineic alcohol, pyrazoleic alcohol, and ]
0.9999901	465	[ providing an endoscope comprising an open end with a first end and a closed end with a second end; and ]	[ A method of producing a surgical endoscope, comprising: ]
0.0038183574	466	[ forming an outer ring layer by applying a first polishing process and a second polishing process to the first end by an electric polishing, wherein the first polishing process produces a polishing surface of an initial polishing layer adjacent to the polishing surface, and ]	[ providing an endoscope comprising an open end with a first end and a closed end with a second end; and ]
0.99999225	467	[ wherein the second polishing process produces at least one new polishing surface between or adjacent to the polishing surface, and ]	[ forming an outer ring layer by applying a first polishing process and a second polishing process to the first end by an electric polishing, wherein the first polishing process produces a polishing surface of an initial polishing layer adjacent to the polishing surface, and ]
0.99999213	468	[ wherein the first polishing process comprises: ]	[ wherein the second polishing process produces at least one new polishing surface between or adjacent to the polishing surface, and ]
0.99997985	469	[ selecting an initial polishing polisher, the initial polishing polisher being a second polishing polisher; and ]	[ wherein the first polishing process comprises: ]
0.99999225	470	[ applying an initial polishing action to the first polishing polisher, the initial polishing polisher applying an initial polishing polishing layer to the polishing surface with first and second polishing cycles, such that the first and second polishing polishing actions are applied against the polishing surface with a first polishing cycle. ]	[ selecting an initial polishing polisher, the initial polishing polisher being a second polishing polisher; and ]
0.005986856	471	[ a tubular structure having at least two outer layers formed therein; ]	[ A golf club head comprising: ]
0.9999893	472	[ an inner layer formed at the bottom of the tubular structure adapted to hold an outer ball having a face and a neck, whereby the at least two outer layers each comprise a substantially homogeneous composite of an adhesive layer formed of a flexible adhesive material by a process comprising the method of applying to an insulative member of a golf shaft substantially a thickness of at least 10% of the surface of the insulative member, the insulative member comprising one or more portions having a plurality of pores formed therethrough; and ]	[ a tubular structure having at least two outer layers formed therein; ]
0.99697053	473	[ a face layer formed on at least a portion of a first layer, the face layer having a surface profile of substantially horizontal plane shape, wherein the at least a portion has a diameter different than the diameter of the surface profile of the surface profile of the surface shape of the face layer of the at least one layer of the outer layer of the tubular structure. ]	[ an inner layer formed at the bottom of the tubular structure adapted to hold an outer ball having a face and a neck, whereby the at least two outer layers each comprise a substantially homogeneous composite of an adhesive layer formed of a flexible adhesive material by a process comprising the method of applying to an insulative member of a golf shaft substantially a thickness of at least 10% of the surface of the insulative member, the insulative member comprising one or more portions having a plurality of pores formed therethrough; and ]
0.9999753	474	[ applying a polymer to a mixture of particles in the composition, the mixture comprises a polymer and a non-methacrylate polyurethane/capric acid copolymer that is present in at least about 75% by weight with respect to the total weight of the composition; ]	[ A method for forming a non-metallic article or article material consisting of an interweave of particles in a composition containing a polymer, the method comprising: ]
0.99998486	475	[ applying a surfactant composition to the mixture, the composition comprising a surfactant having the concentration at room temperature of 15-30 parts of a weight per volume of the surfactant relative to the total weight of the composition and which is present in a concentration of 30-50 parts of a weight per volume of the surfactant relative to the total weight of the composition; ]	[ applying a polymer to a mixture of particles in the composition, the mixture comprises a polymer and a non-methacrylate polyurethane/capric acid copolymer that is present in at least about 75% by weight with respect to the total weight of the composition; ]
0.9993444	476	[ reacting the polymer comprising the non-methacrylate polyurethane/capric acid copolymer with at least one surfactant to form a polymer that has a surface that has a number of surfaces greater than a number of particles; and ]	[ applying a surfactant composition to the mixture, the composition comprising a surfactant having the concentration at room temperature of 15-30 parts of a weight per volume of the surfactant relative to the total weight of the composition and which is present in a concentration of 30-50 parts of a weight per volume of the surfactant relative to the total weight of the composition; ]
0.99990153	477	[ placing the polymer. ]	[ reacting the polymer comprising the non-methacrylate polyurethane/capric acid copolymer with at least one surfactant to form a polymer that has a surface that has a number of surfaces greater than a number of particles; and ]
0.009064387	478	[ providing a first actuator having a first actuator-inhabited region in each of the first and second actuators, a second actuator configured to be operatively linked to each of the first and second actuators, and ]	[ A method for operating a personal care appliance, comprising: ]
0.9998832	479	[ a housing configured to receive the first actuator and second actuator; ]	[ providing a first actuator having a first actuator-inhabited region in each of the first and second actuators, a second actuator configured to be operatively linked to each of the first and second actuators, and ]
0.9988695	480	[ supporting the first and second actuators during operating of said personal care appliance by a user and electrically-supporting said actuators with a first power supply; ]	[ a housing configured to receive the first actuator and second actuator; ]
0.99999225	481	[ electrically connecting the primary power supply to the first and second actuators and a first power supply to the second actuator during operation of the Personal Care Apparatus; and ]	[ supporting the first and second actuators during operating of said personal care appliance by a user and electrically-supporting said actuators with a first power supply; ]
0.9999924	482	[ electronically activating the housing to allow the first and second power supplies to pass through the housing when the primary power supply is electrically connected to the personal care appliance. ]	[ electrically connecting the primary power supply to the first and second actuators and a first power supply to the second actuator during operation of the Personal Care Apparatus; and ]
0.0075879777	483	[ a detection surface; ]	[ A system for the identification of human-associated cancer cells, the system comprising: ]
0.00065574446	484	[ a first receptor for sensing a biological marker of interest associated with the human-associated cancer cells; ]	[ a detection surface; ]
0.999992	485	[ a second receptor for sensing the biological marker to produce a detection signal for the detection surface; and ]	[ a first receptor for sensing a biological marker of interest associated with the human-associated cancer cells; ]
0.9999902	486	[ a computing device coupled to the detection surface, wherein said computing device comprises: ]	[ a second receptor for sensing the biological marker to produce a detection signal for the detection surface; and ]
0.99869186	487	[ an input unit configured for inputting a biological marker of interest associated with at least one human or other animal; and ]	[ a computing device coupled to the detection surface, wherein said computing device comprises: ]
0.99997747	488	[ a processor coupled to the input unit, the processor used to: ]	[ an input unit configured for inputting a biological marker of interest associated with at least one human or other animal; and ]
0.9867078	489	[ receive, from the detection surface, the biological marker detected by the first receptor; ]	[ a processor coupled to the input unit, the processor used to: ]
0.9999902	490	[ determine an indication of whether the biological marker belongs to the cancer cells; ]	[ receive, from the detection surface, the biological marker detected by the first receptor; ]
0.9999894	491	[ when the indication is positive, determine the cell type of the human or other animal; and ]	[ determine an indication of whether the biological marker belongs to the cancer cells; ]
0.9999918	492	[ when the indication is negative, terminate a scanning or an interaction with the first receptor such that the detection signal can be retrieved from the first receptor and output to the computing device. ]	[ when the indication is positive, determine the cell type of the human or other animal; and ]
0.99907386	493	[ providing a structure extending from a front surface, ]	[ A method of forming a patient-oriented display device, comprising: ]
0.9997048	494	[ and wherein said structure comprises a plurality of layers each having a first surface and a second surface, and ]	[ providing a structure extending from a front surface, ]
0.99998987	495	[ wherein a plurality of projections defining an outer area of said structure are formed on the first surface, and ]	[ and wherein said structure comprises a plurality of layers each having a first surface and a second surface, and ]
0.9999814	496	[ said outer area is a light absorbing surface. ]	[ wherein a plurality of projections defining an outer area of said structure are formed on the first surface, and ]
0.9502534	497	[ an elongate tubular body havinga surface defining a cavity, ]	[ An implantable medical device comprising: ]
0.9998134	498	[ a base surface extending from the surface and defining a volume, and ]	[ an elongate tubular body havinga surface defining a cavity, ]
0.99998784	499	[ a contact surface and a bottom surface extending from the base surface, ]	[ a base surface extending from the surface and defining a volume, and ]
0.9998578	500	[ said base surface further defining a volume having a density of less than 1, ]	[ a contact surface and a bottom surface extending from the base surface, ]
0.015514985	501	[ 000 kg/m3, ]	[ said base surface further defining a volume having a density of less than 1, ]
0.010656044	502	[ a thickness of at least 100 000 nm, ]	[ 000 kg/m3, ]
0.99466527	503	[ a first and a second cavity, ]	[ a thickness of at least 100 000 nm, ]
0.99989593	504	[ the tubular body further including at least one first member for insertion into the cavity, ]	[ a first and a second cavity, ]
0.99987876	505	[ the bottom surface further including an inner aperture sized for insertion within said cavity, ]	[ the tubular body further including at least one first member for insertion into the cavity, ]
0.99997616	506	[ wherein said first and second cavity define openings defined by a gap between said base surface and said bottom surface, ]	[ the bottom surface further including an inner aperture sized for insertion within said cavity, ]
0.9999341	507	[ said inner aperture is sized and shaped to selectively receive said first member within said cavity so that said first member is held inside said cavity, and ]	[ wherein said first and second cavity define openings defined by a gap between said base surface and said bottom surface, ]
0.9999924	508	[ said opening at said first member is a portion of an inner aperture of an internal member that is sized and shaped to receive and hold an external medical device within said cavity. ]	[ said inner aperture is sized and shaped to selectively receive said first member within said cavity so that said first member is held inside said cavity, and ]
0.9999399	509	[ (a) measuring a plurality of parameters of an organism; ]	[ A method of determining an optimal level of activity of a biological parameter, the biological parameter comprising: ]
0.99998856	510	[ (b) determining a plurality of parameter levels based at least in part upon the measured plurality of parameters, wherein the parameter levels include a set of different and mutually related parameters and wherein the set of different and mutually related parameters comprises a first range of parameters and a set of different and mutually related parameters that are more or less related to a second range of parameters; and ]	[ (a) measuring a plurality of parameters of an organism; ]
0.99999225	511	[ (c) correlating the determined first range of parameter levels to the determined second range of parameter levels. ]	[ (b) determining a plurality of parameter levels based at least in part upon the measured plurality of parameters, wherein the parameter levels include a set of different and mutually related parameters and wherein the set of different and mutually related parameters comprises a first range of parameters and a set of different and mutually related parameters that are more or less related to a second range of parameters; and ]
0.9999473	512	[ a catheter body; ]	[ A catheter assembly comprising: ]
0.999793	513	[ at least two catheter guides each having a proximal end and a distal end, each having a length, and ]	[ a catheter body; ]
0.99999225	514	[ connecting means for connecting the proximal ends of the at least two catheter guides to the at least two catheter guides; ]	[ at least two catheter guides each having a proximal end and a distal end, each having a length, and ]
0.9866002	515	[ an anchor having a length and a proximal end, a distal end and a proximal end, and ]	[ connecting means for connecting the proximal ends of the at least two catheter guides to the at least two catheter guides; ]
0.9999107	516	[ a distal end and proximal end; ]	[ an anchor having a length and a proximal end, a distal end and a proximal end, and ]
0.9994091	517	[ each anchoring mechanism adapted to be operatively coupling the proximal ends of the at least two catheter guides to the at least two catheter guides; and ]	[ a distal end and proximal end; ]
0.99999225	518	[ at least one of the proximal ends of the connecting means being connected to an end of the at least two catheter guides to form a proximal tether; ]	[ each anchoring mechanism adapted to be operatively coupling the proximal ends of the at least two catheter guides to the at least two catheter guides; and ]
0.99997663	519	[ wherein said at least one connecting means, said link, and ]	[ at least one of the proximal ends of the connecting means being connected to an end of the at least two catheter guides to form a proximal tether; ]
0.9992912	520	[ said anchor are configured to be positioned adjacent each other, and ]	[ wherein said at least one connecting means, said link, and ]
0.9998964	521	[ each anchor including a link portion extending from the connecting means of one end to the linking means of the proximal end of the link portion. ]	[ said anchor are configured to be positioned adjacent each other, and ]
0.99979645	522	[ at least one elongate layer forming a longitudinal surface of the supporting surface, the at least one elongate layer having an elongate, thin wall; ]	[ An elongate polymeric structure having an inside surface, a side surface and a support surface having a first side and a second side, comprising: ]
0.9999912	523	[ an exterior layer forming a convex surface of the elongate layer, the convex surface configured to receive the support surface; ]	[ at least one elongate layer forming a longitudinal surface of the supporting surface, the at least one elongate layer having an elongate, thin wall; ]
0.99999213	524	[ an interior layer provided at a front edge of the elongate layer, wherein a portion of the interior layer is defined by the convex surface, and ]	[ an exterior layer forming a convex surface of the elongate layer, the convex surface configured to receive the support surface; ]
0.9999913	525	[ wherein the interior layer and exterior coatings cooperate to substantially cover the convex face of the interior layer from the exterior surface; ]	[ an interior layer provided at a front edge of the elongate layer, wherein a portion of the interior layer is defined by the convex surface, and ]
0.99999166	526	[ wherein the interior layer has a front portion that is substantially convex and a side portion that extends through the front portion; and ]	[ wherein the interior layer and exterior coatings cooperate to substantially cover the convex face of the interior layer from the exterior surface; ]
0.9999912	527	[ wherein a portion of the second side of the supporting surface extends between the convex and support surface portions and from the interior portion of the interior layer. ]	[ wherein the interior layer has a front portion that is substantially convex and a side portion that extends through the front portion; and ]
0.9985215	528	[ where K is hydrogen, C1-C7-alkenyl, C1-C7-alkenyl-C1-C8-alkenyl, C1-C6-alkenyl-C1-C8-alkenyl, C7-C1-C8-alkylsulfonium-C1-C6-alkenyl or C1-C6-alkenyl-C1-C8-alkenyl. ]	[ A method of treating a patient suffering from a non-invasive disease comprising administering to the patient a compound of the formula (III): ]
0.99998975	529	[ providing a drug or product having: a solubility of at least one hydrophilic acid; and ]	[ A system for preparing a pharmaceutical composition comprising a hydrophilic acid mixture, with reference to the following process: ]
0.9982705	530	[ one or more polymers that are specifically selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpiperazine, polycarbomeric polymers, and ]	[ providing a drug or product having: a solubility of at least one hydrophilic acid; and ]
0.99800795	531	[ polycarbimoyl-co-pyrrolidone; wherein the solvent is selected from the group consisting of ethanol, hexane, methanol, propane, and ]	[ one or more polymers that are specifically selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpiperazine, polycarbomeric polymers, and ]
0.99990034	532	[ acetic acid; wherein a solubility of at least one polymeric element of the selected polymers is determined in each of the following steps: step 1 wherein the solvent is acetone or ethanol; and ]	[ polycarbimoyl-co-pyrrolidone; wherein the solvent is selected from the group consisting of ethanol, hexane, methanol, propane, and ]
0.9999877	533	[ step 2 wherein the solvent is acetone or water based; ]	[ acetic acid; wherein a solubility of at least one polymeric element of the selected polymers is determined in each of the following steps: step 1 wherein the solvent is acetone or ethanol; and ]
0.99059755	534	[ providing a polymeric powder comprising one or more polymerized polymers provided separately from and not in a combined solution with the hydrophilic acid mixture, ]	[ step 2 wherein the solvent is acetone or water based; ]
0.99999213	535	[ wherein the polymeric powder has a solubility of 20-400 w/mol as compared with a solubility of 80-600 w/mol of the hydrophilic acid mixture. ]	[ providing a polymeric powder comprising one or more polymerized polymers provided separately from and not in a combined solution with the hydrophilic acid mixture, ]
0.9999584	536	[ a drug delivery device comprising an injector configured to deliver a drug to an individual and a dispensing unit configured to dispense drug to the individual, the drug delivery device comprising a carrier that includes a housing to hold a drug and a cartridge, the housing containing a plurality of drug-carrying channels for receiving the drug, ]	[ A system for delivering a drug delivery device, comprising: ]
0.9999919	537	[ wherein, when the drug delivery device is disposed in the carrier, the drug delivery device is disposed at a first dispensing level. ]	[ a drug delivery device comprising an injector configured to deliver a drug to an individual and a dispensing unit configured to dispense drug to the individual, the drug delivery device comprising a carrier that includes a housing to hold a drug and a cartridge, the housing containing a plurality of drug-carrying channels for receiving the drug, ]
0.9886113	538	[ generating an alarm about an external event associated with an external event monitoring system, said external event monitoring system including a monitor, an external event detector that detects an external event, and ]	[ A method of controlling a medical device, comprising: ]
0.99999213	539	[ a monitor control system coupled to said monitor that controls said external event detector; ]	[ generating an alarm about an external event associated with an external event monitoring system, said external event monitoring system including a monitor, an external event detector that detects an external event, and ]
0.99993014	540	[ triggering a control signal output to said monitor during said alarm; and ]	[ a monitor control system coupled to said monitor that controls said external event detector; ]
0.9997135	541	[ monitoring the detection of said external event by said external event detector; ]	[ triggering a control signal output to said monitor during said alarm; and ]
0.99999166	542	[ wherein a notification signal is output from said alarm generating the notification signal such that said notification signal indicates that an external event occurred. ]	[ monitoring the detection of said external event by said external event detector; ]
0.999992	543	[ receiving a request from a patient for a medical device in the patient's IMD; ]	[ A computer-implemented method to detect an implantable medical device (IMD) in a patient, the method comprising: ]
0.999992	544	[ determining whether the IMD is within the patient's IMD; and ]	[ receiving a request from a patient for a medical device in the patient's IMD; ]
0.99999213	545	[ providing a warning if the IMD is not in the patient's IMD. ]	[ determining whether the IMD is within the patient's IMD; and ]
0.9920987	546	[ a first end portion extending along a first longitudinal axis and a second end portion including a first end wall and a second end wall, said first and second ends are formed from one of a generally thin body material, having no further than an entire longitudinal axis which includes substantially an end of the first longitudinal axis, and ]	[ A device for providing a medical treatment within a blood vessel, comprising: ]
0.9929132	547	[ a resilient material, each substantially non-tetrahedral in shape; and ]	[ a first end portion extending along a first longitudinal axis and a second end portion including a first end wall and a second end wall, said first and second ends are formed from one of a generally thin body material, having no further than an entire longitudinal axis which includes substantially an end of the first longitudinal axis, and ]
0.0003740143	548	[ a first fluid conduit passing through a conduit in the first end portion to a fluid conduit in a blood vessel, wherein said first fluid conduit transmits a first fluid comprising a first fluid to the first end wall for flowing through the tissue in the blood vessel, and ]	[ a resilient material, each substantially non-tetrahedral in shape; and ]
0.99999034	549	[ a resilient material, each of which defines a channel, in the first end to accommodate a needle to deliver the first fluid to the first end wall and to retain said first fluid in a substantially tubular manner; ]	[ a first fluid conduit passing through a conduit in the first end portion to a fluid conduit in a blood vessel, wherein said first fluid conduit transmits a first fluid comprising a first fluid to the first end wall for flowing through the tissue in the blood vessel, and ]
0.999936	550	[ a second fluid conduit having a second fluid conduit passing through the conduit and wherein said first and second fluid conduits are substantially perpendicular to one another, wherein said tissue is implanted within the blood vessel. ]	[ a resilient material, each of which defines a channel, in the first end to accommodate a needle to deliver the first fluid to the first end wall and to retain said first fluid in a substantially tubular manner; ]
0.020887675	551	[ a first housing; ]	[ A surgical cleaning system for a surgical instrument, comprising: ]
0.999982	552	[ a first cleaning mechanism disposed within the first housing and extending through a wall of the first housing; and ]	[ a first housing; ]
0.99993527	553	[ a second housing having an inlet portion and an outlet portion, wherein the first housing provides a first outlet portion and the second housing provides a first inlet portion for fluid communication with a surgical tool. ]	[ a first cleaning mechanism disposed within the first housing and extending through a wall of the first housing; and ]
0.9997069	554	[ a first image processing unit configured to receive, when received by a first user of an apparatus, information associated with the first image; ]	[ An apparatus for performing multiplexing operations on one or more images and/or video content files, the apparatus comprising: ]
0.99999225	555	[ a first video image processing unit configured to receive, when received by a second user of any apparatus, the information; and ]	[ a first image processing unit configured to receive, when received by a first user of an apparatus, information associated with the first image; ]
0.99999225	556	[ a second video image processing unit configured to receive, when received by a third user of any apparatus, the information; ]	[ a first video image processing unit configured to receive, when received by a second user of any apparatus, the information; and ]
0.9999869	557	[ a second image processing unit configured to receive, upon determining that the first image's metadata includes data related to media content related to a first image corresponding to one of the first user and the second user, an information associated with the first image; and ]	[ a second video image processing unit configured to receive, when received by a third user of any apparatus, the information; ]
0.99999213	558	[ a second video image processing unit configured to receive, upon determining that the first video image's metadata includes data related to media content related to a second image corresponding to the first user and the second user, a determination of an image content location with respect to the first video image, wherein the first image's media content location does not exist when the determination of the first video image's media content location is made and there is no verification of the first image's media content location when the determination of the first video image's media content location is made, and ]	[ a second image processing unit configured to receive, upon determining that the first image's metadata includes data related to media content related to a first image corresponding to one of the first user and the second user, an information associated with the first image; and ]
0.99999225	559	[ wherein the second image's media content location does not exist when the determination of the second image's media content location is made and there is no verification of a second image's media content location when the determination of the second image's media content location is made. ]	[ a second video image processing unit configured to receive, upon determining that the first video image's metadata includes data related to media content related to a second image corresponding to the first user and the second user, a determination of an image content location with respect to the first video image, wherein the first image's media content location does not exist when the determination of the first video image's media content location is made and there is no verification of the first image's media content location when the determination of the first video image's media content location is made, and ]
0.99191076	560	[ a first fluid source configured to emit a first fluid of a first pressure; and ]	[ An apparatus to treat a patient in need thereof, comprising: ]
0.99999225	561	[ a second fluid source configured to emit a second fluid of the first pressure, ]	[ a first fluid source configured to emit a first fluid of a first pressure; and ]
0.99999166	562	[ wherein the first fluid source has the same diameter, length, and ]	[ a second fluid source configured to emit a second fluid of the first pressure, ]
0.999992	563	[ distal end that the second fluid source. ]	[ wherein the first fluid source has the same diameter, length, and ]
0.9999918	564	[ histidine, wherein said composition of said amino acids comprises at least one of tyrosine, adenine, glutamic acid, amylase, and ]	[ A method of preparing a composition of amino acids, wherein said composition comprises both a free form and a bound form of at least one amino acid selected from the group consisting of serine, threonine, isoleucine, pyridyleucine, leucine, adenine, glutamic acid, tyrosine, and ]
0.99996376	565	[ histidine, and ]	[ histidine, wherein said composition of said amino acids comprises at least one of tyrosine, adenine, glutamic acid, amylase, and ]
0.99885607	566	[ wherein the amount of at least one peptidylleucine, threonine,, glutamic acid, leucine, and ]	[ histidine, and ]
0.99986994	567	[ pyridyleucine in said composition of said amino acids comprises 2-6% by weight. ]	[ wherein the amount of at least one peptidylleucine, threonine,, glutamic acid, leucine, and ]
0.9999906	568	[ at a predetermined time period, said catheter site being placed in relation to the catheter, said catheter site having a shape in which an inner portion is located on a top surface, a hollow periphery and and a cavity extending therethrough, said hollow periphery of said catheter site having a shape in which an inner portion is located proximal of said inner portion of the hollow periphery, at least a portion of said hollow periphery and at least a portion of said at least a portion of the hollow periphery being in the same position with regard to said catheter site and with respect to said internal space as was the position of the first portion of the needle in the first direction relative to the internal space. ]	[ A process of forming an internal space over a body part so as to substantially cover the body part, comprising step, in the absence of a catheter for delivery of a needle between the body part and a catheter site and said catheter, a first positioning procedure in which the needle is directed in a proximal direction relative to the internal space in a first position and to a distal site of a body part including an internal space having a size, shape, orientation and orientation that depends on the position of the needle in the internal space, a second positioning procedure in which the needle and the body part are in opposite positions relative to each other, said first and second positioning procedures each comprising a method of applying pressure to the needle with a first portion of the needle in a first direction and a second portion of the needle to be positioned in a second direction different from the first direction; and ]
0.99970764	569	[ a) the amino acid sequence as selected from the group consisting of SEQ ID NO. 2 or 3 (SEQ ID NO: ]	[ A method for identifying drug-receptor binding affinity of a polypeptide consisting of sequences that are complementary: ]
0.9994659	570	[ 3); ]	[ a) the amino acid sequence as selected from the group consisting of SEQ ID NO. 2 or 3 (SEQ ID NO: ]
0.9961688	571	[ b) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]	[ 3); ]
0.99999213	572	[ 6 ; <|span|>c) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]	[ b) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]
0.99975675	573	[ 11 ; ]	[ 6 ; <|span|>c) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]
0.9986689	574	[ d) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]	[ 11 ; ]
0.99936014	575	[ 12 ; and ]	[ d) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]
0.9984408	576	[ e) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]	[ 12 ; and ]
0.99872476	577	[ 20 . ]	[ e) the amino acid sequence as selected from the group consisting of SEQ ID NO: ]
0.99999213	578	[ (b) said monolayer comprising a first polymers composition made from a mixture of the first polymers from (a), (b) and a mixture of the non-curable liposome and the lipopolysaccharide, for the sole purpose of maintaining a lumen around an internal organ having an internal organic pH of above 6.7, ]	[ A body composition composition composition comprising(a) a non-curable liposome including an endothelial monolayer comprising an endothelial cell line and a lipopolysaccharide, ]
0.99858725	579	[ (c) one or more hydrophilic substances, comprising in the composition a polymeric or hydrophilic compound which when mixed with said endothelial cell line, acts as a polymeric active agent and can act as a surfactant, ]	[ (b) said monolayer comprising a first polymers composition made from a mixture of the first polymers from (a), (b) and a mixture of the non-curable liposome and the lipopolysaccharide, for the sole purpose of maintaining a lumen around an internal organ having an internal organic pH of above 6.7, ]
0.99999225	580	[ (d) an exothermic polymer, which is a hydrophobic compound which when mixed with said polymeric or hydrophilic substance, can acts as a polymer active agent, ]	[ (c) one or more hydrophilic substances, comprising in the composition a polymeric or hydrophilic compound which when mixed with said endothelial cell line, acts as a polymeric active agent and can act as a surfactant, ]
0.9999876	581	[ wherein said lipopolysaccharide is bound to and is soluble in blood-contacting or tissue-contacting components provided in said one or more hydrophilic substances, or in serum, plasma or blood. ]	[ (d) an exothermic polymer, which is a hydrophobic compound which when mixed with said polymeric or hydrophilic substance, can acts as a polymer active agent, ]
0.8034837	582	[ a pharmaceutically acceptable carrier; ]	[ An anti-inflammatory agent and a treatment for the treatment of bronchitis or a inflammatory disorder, wherein said agent comprises: ]
0.9993753	583	[ a pharmaceutically acceptable salt; and ]	[ a pharmaceutically acceptable carrier; ]
0.9981006	584	[ at least one pharmaceutically acceptable active ingredient. ]	[ a pharmaceutically acceptable salt; and ]
0.9998932	585	[ (a) providing a plurality of pieces of surgical equipment on a first medical device; ]	[ A method of providing a patient with a new surgical appliance, said method comprising: ]
0.99999225	586	[ (b) placing at least one of said pieces of surgical equipment in a first patient bed on a first device; ]	[ (a) providing a plurality of pieces of surgical equipment on a first medical device; ]
0.99999225	587	[ (c) placing at least one of said pieces of surgical equipment in a second patient bed on a second device substantially adjacent to said first device, said second patient bed having at least one of spaced peripheral edges and a peripheral edge of peripheral edges of said first patient bed; ]	[ (b) placing at least one of said pieces of surgical equipment in a first patient bed on a first device; ]
0.9999924	588	[ (d) positioning said pieces of surgical equipment in the first patient bed by pressing said pieces of surgical equipment into said first patient bed; and ]	[ (c) placing at least one of said pieces of surgical equipment in a second patient bed on a second device substantially adjacent to said first device, said second patient bed having at least one of spaced peripheral edges and a peripheral edge of peripheral edges of said first patient bed; ]
0.99999213	589	[ (e) positioning said pieces of surgical equipment in the second patient bed by pressing said pieces of surgical equipment into said second device substantially adjacent to said second patient bed. ]	[ (d) positioning said pieces of surgical equipment in the first patient bed by pressing said pieces of surgical equipment into said first patient bed; and ]
0.9996462	590	[ a) a nucleotide sequence consisting of the sequence of SEQ ID NO: ]	[ An isolated nucleic acid molecule having a functional sequence comprising one or more of the following nucleotide substitutions: ]
0.99999154	591	[ 30; or b) a nucleotide sequence being identical to the sequence of SEQ ID NO: ]	[ a) a nucleotide sequence consisting of the sequence of SEQ ID NO: ]
0.99966705	592	[ 30. ]	[ 30; or b) a nucleotide sequence being identical to the sequence of SEQ ID NO: ]
0.99912125	593	[ (a) a pharmaceutically acceptable salt thereof, wherein the compound is a pharmaceutically acceptable salt of a pharmaceutically acceptable monosaccharide or a pharmaceutically acceptable polysaccharide having from 1 to 9 carbon atoms, ]	[ A method for treating a patient in need thereof comprising administering to the patient an adjuvant comprising a compound selected from the following: ]
0.99967754	594	[ (b) a pharmaceutically acceptable oil and solvent, and ]	[ (a) a pharmaceutically acceptable salt thereof, wherein the compound is a pharmaceutically acceptable salt of a pharmaceutically acceptable monosaccharide or a pharmaceutically acceptable polysaccharide having from 1 to 9 carbon atoms, ]
0.9999776	595	[ (c) a pharmaceutically acceptable solvent. ]	[ (b) a pharmaceutically acceptable oil and solvent, and ]
0.9994666	596	[ a housing having proximal and distal ends, the housing configured for insertion into a patient; ]	[ An injection device for delivering a drug into a patient, comprising: ]
0.96755064	597	[ a fluid dispensing mechanism including: ]	[ a housing having proximal and distal ends, the housing configured for insertion into a patient; ]
0.99644935	598	[ an infusion flow path configured to transport a fluid to the proximal end of the housing; ]	[ a fluid dispensing mechanism including: ]
0.9999815	599	[ a fluid reservoir configured to contain the fluid being transferred to the housing; ]	[ an infusion flow path configured to transport a fluid to the proximal end of the housing; ]
0.9999912	600	[ a flow port configured to receive fluid from the fluid reservoir; and ]	[ a fluid reservoir configured to contain the fluid being transferred to the housing; ]
0.9999918	601	[ a piston rotatably mounted to the housing, the piston having an upper surface and a lower surface defining a body region, the body region having an opening, the opening configured to receive through the body region fluid from the fluid reservoir to the flow port; and ]	[ a flow port configured to receive fluid from the fluid reservoir; and ]
0.99999106	602	[ a valve member configured to pressurize a fluid received through the flow port and flow the fluid through a passage defined by a sidewall of the housing and the lower surface of the piston to be transported into the liquid dispensing mechanism, a valve block having an at least one valve in fluid communication with an outlet of the fluid dispensing mechanism, wherein the at least one valve in fluid communication with the outlet is configured to control valve pressure, a valve member that is attached to the valve block via at least one connecting rod operatively engaging the at least one connecting rod, the at least one connecting rod being spaced from the at least one valve in fluid communication with the outlet. ]	[ a piston rotatably mounted to the housing, the piston having an upper surface and a lower surface defining a body region, the body region having an opening, the opening configured to receive through the body region fluid from the fluid reservoir to the flow port; and ]
0.9995925	603	[ a) a protein moiety portion comprising a first amino acid and a second amino acid, wherein said first amino acid is at least one of the amino acids of amino acids 17-32 of SEQ ID NO: ]	[ An isolated polypeptide comprising: ]
0.99913174	604	[ 5; and ]	[ a) a protein moiety portion comprising a first amino acid and a second amino acid, wherein said first amino acid is at least one of the amino acids of amino acids 17-32 of SEQ ID NO: ]
0.9962663	605	[ b) a polypeptide moiety portion comprising a second amino acid; and ]	[ 5; and ]
0.9998599	606	[ wherein said first amino acid is selected from the group consisting of T3, T4, and ]	[ b) a polypeptide moiety portion comprising a second amino acid; and ]
0.9999881	607	[ T5, and ]	[ wherein said first amino acid is selected from the group consisting of T3, T4, and ]
0.9740931	608	[ wherein said second amino acid is selected from the group consisting of C, G, and ]	[ T5, and ]
0.98546094	609	[ NH; and ]	[ wherein said second amino acid is selected from the group consisting of C, G, and ]
0.99265915	610	[ wherein said purified polypeptide is effective to protect at least a portion of a tumor tissue from degradation. ]	[ NH; and ]
0.9997727	611	[ a pressure sensor, the system comprising: ]	[ A system having an endoscope head, a filter, an electric tube, and ]
0.999071	612	[ a plurality of electrodes arrayed along a longitudinal axis of the endoscope head; ]	[ a pressure sensor, the system comprising: ]
0.99999213	613	[ an electrode array coupled to the endoscope head; ]	[ a plurality of electrodes arrayed along a longitudinal axis of the endoscope head; ]
0.9999887	614	[ a signal generator coupled to the electrode array, the signal generator coupled to voltage delivery means for generating electric signals; ]	[ an electrode array coupled to the endoscope head; ]
0.9999819	615	[ a microprocessor coupled to the signal generator and configured to receive the signals from the electrodes and the signals from the electrodes being coupled to the signal generator into an input circuit configured to generate an output signal; ]	[ a signal generator coupled to the electrode array, the signal generator coupled to voltage delivery means for generating electric signals; ]
0.99997056	616	[ a housing configured to enclose the electrical cable between the output circuit and the microprocessor; and, ]	[ a microprocessor coupled to the signal generator and configured to receive the signals from the electrodes and the signals from the electrodes being coupled to the signal generator into an input circuit configured to generate an output signal; ]
0.9993524	617	[ an actuator coupled to the microprocessor and configured to direct an electrical field, comprising a spring and pressure, on the endoscope head along a portion of the electrode array. ]	[ a housing configured to enclose the electrical cable between the output circuit and the microprocessor; and, ]
0.0071768994	618	[ an image processing apparatus identifying a plurality of images corresponding to a plurality of points in a digital scene from the plurality of images; ]	[ A method comprising: ]
0.99999225	619	[ an image processing apparatus extracting a plurality of characteristic points in at least one of the plurality of points from at least one of the plurality of images stored in the image processing apparatus; ]	[ an image processing apparatus identifying a plurality of images corresponding to a plurality of points in a digital scene from the plurality of images; ]
0.99999213	620	[ an image processing apparatus identifying a feature that comprises one of at least one of the plurality of characteristic points; ]	[ an image processing apparatus extracting a plurality of characteristic points in at least one of the plurality of points from at least one of the plurality of images stored in the image processing apparatus; ]
0.9999924	621	[ an image processing apparatus identifying a region that comprises the feature based on a distance from the at least one of the plurality of characteristic points, wherein the feature is a point on a feature surface of a region and wherein the point is located within a portion of the region, wherein the feature is characterized by a number of edges. ]	[ an image processing apparatus identifying a feature that comprises one of at least one of the plurality of characteristic points; ]
0.00037887442	622	[ a) providing a catalyst, said catalyst capable of combining at least one compound which is at one or more reactants to create a reactive compound in a catalyst compound; ]	[ A method of manufacturing an ophthalmic compound, comprising: ]
0.999923	623	[ b) providing an oxides of nitrogen which are in a form other than in a saturated or unsaturated state, and ]	[ a) providing a catalyst, said catalyst capable of combining at least one compound which is at one or more reactants to create a reactive compound in a catalyst compound; ]
0.987334	624	[ wherein said catalyst further comprises water, a salt thereof, and ]	[ b) providing an oxides of nitrogen which are in a form other than in a saturated or unsaturated state, and ]
0.97522247	625	[ a surfactant; and ]	[ wherein said catalyst further comprises water, a salt thereof, and ]
0.68914753	626	[ c) providing a catalyst-containing powder having an overall molecular weight of at least about 0.001&#xb0; ]	[ a surfactant; and ]
0.97654563	627	[ 1000, and ]	[ c) providing a catalyst-containing powder having an overall molecular weight of at least about 0.001&#xb0; ]
0.97240925	628	[ wherein said solvent is selected from water, surfactant, nitric oxide, and ]	[ 1000, and ]
0.99192226	629	[ a hydroxypropyloxy. ]	[ wherein said solvent is selected from water, surfactant, nitric oxide, and ]
0.99999154	630	[ measuring a body weight of the human or animal; ]	[ A method for determining an optimal weight reduction for a human or animal, the method comprising: ]
0.99999154	631	[ collecting body tissue from the human or animal; ]	[ measuring a body weight of the human or animal; ]
0.99999166	632	[ measuring an electrocardiogram signal based on the body weight and the collected body tissue; and ]	[ collecting body tissue from the human or animal; ]
0.99999213	633	[ based on the measured electrocardiogram signal, adjusting a volume of a first storage chamber having a depth in a range of 1.3 cm to about 4.5 cm and a volume of a second storage chamber having a depth in a range of about 0.5 cm to about 40 wbc. ]	[ measuring an electrocardiogram signal based on the body weight and the collected body tissue; and ]
0.999979	634	[ a plurality of footwear items comprising proximal and distal pieces, each of said pieces having an upper surface and an heel surface and a sole surface, and ]	[ An adjustable footwear system for use when exercising, comprising: ]
0.99999225	635	[ a first portion of said first portion of each said piece having a first upper surface and a first heel surface and a second portion of said first portion of said first portion having a second upper surface and a second heel surface; a plurality of toe pieces disposed on at least a portion of each said shoe item, each said toe piece being associated with a respective said footwear item; and ]	[ a plurality of footwear items comprising proximal and distal pieces, each of said pieces having an upper surface and an heel surface and a sole surface, and ]
0.9999924	636	[ a foot rest disposed across said upper surface of the first portion of each said piece and between said upper surface of a first said piece and a second said piece, wherein each of at least one said piece includes a foot rest which is in an upwardly bending position when said shoe item is in an upright position. ]	[ a first portion of said first portion of each said piece having a first upper surface and a first heel surface and a second portion of said first portion of said first portion having a second upper surface and a second heel surface; a plurality of toe pieces disposed on at least a portion of each said shoe item, each said toe piece being associated with a respective said footwear item; and ]
0.99997795	637	[ a flexible member, configured to be folded and positioned on the bone; ]	[ A system for measuring a function of a bone, comprising: ]
0.9999865	638	[ fluid disposed at position 1 of the flexible member, the fluid being disposed at the position of positioning of the flexible member, by the fluid being in fluid communication with at least a distal end of the flexible member; ]	[ a flexible member, configured to be folded and positioned on the bone; ]
0.9999914	639	[ a measuring device disposed at position 2, the measuring device adapted for measuring the function of the bone through a contact with at least a proximal end of the flexible member; and ]	[ fluid disposed at position 1 of the flexible member, the fluid being disposed at the position of positioning of the flexible member, by the fluid being in fluid communication with at least a distal end of the flexible member; ]
0.9999914	640	[ a communication system disposed above and in communication with the fluid disposed in the position of placement of the flexible member and adapted for transmitting data to at least some of the means. ]	[ a measuring device disposed at position 2, the measuring device adapted for measuring the function of the bone through a contact with at least a proximal end of the flexible member; and ]
0.9995265	641	[ administering to the subject an effective amount of a first pharmaceutically-soluble, anti-tumor agent. ]	[ A method of administering a compound to a human subject in need of such therapy comprising: ]
0.9999902	642	[ a plurality of ultrasonic transducer elements and a controller device in electrical communication with said ultrasonic transducer elements to monitor said bone structure, said controller device being configured to monitor said bone structure including, ]	[ A device for monitoring bone structure of a body portion of a patient, comprising: ]
0.9997366	643	[ the volume of bone at the bone, ]	[ a plurality of ultrasonic transducer elements and a controller device in electrical communication with said ultrasonic transducer elements to monitor said bone structure, said controller device being configured to monitor said bone structure including, ]
0.99985385	644	[ at least one level of tissue mass represented in said bone structure, and ]	[ the volume of bone at the bone, ]
0.99999225	645	[ at least one measure of stiffness of said tissue mass in said bone structure, wherein each of said ultrasonic transducer elements has a transducer element positionable on a respective bone surface, and ]	[ at least one level of tissue mass represented in said bone structure, and ]
0.9999914	646	[ a position of said controller device relative to said respective bone surface; and, ]	[ at least one measure of stiffness of said tissue mass in said bone structure, wherein each of said ultrasonic transducer elements has a transducer element positionable on a respective bone surface, and ]
0.9999912	647	[ at least one sensor for sense of at least one movement of a bone, such that in an operation sequence of a series of ultrasound pulses, said controller device detects at least one of said measured movement and said bone position, wherein in at least in part said controller device includes an adaptive control element which in operation indicates if a control function is to be applied to a position of said trigger element in accordance with a determined condition. ]	[ a position of said controller device relative to said respective bone surface; and, ]
0.0014051041	648	[ a liquid, a mixture of the liquid and a pharmaceutically acceptable salt, and ]	[ A composition comprising: ]
0.9952838	649	[ an isolated prodrug; ]	[ a liquid, a mixture of the liquid and a pharmaceutically acceptable salt, and ]
0.0022380403	650	[ wherein the liquid and the mixture are suitable for mixing to achieve a uniform mixture; and ]	[ an isolated prodrug; ]
0.0054902243	651	[ wherein the composition contains from about 1 wt.% to 3 wt.% of the isolated prodrug. ]	[ wherein the liquid and the mixture are suitable for mixing to achieve a uniform mixture; and ]
0.999846	652	[ (a) providing a toothbrush comprisinga brush head configured to collect or deposit tooth dust, comprising a tip for collecting and depositing, and ]	[ A method of cleaning a tooth comprising the steps of: ]
0.9998828	653	[ a toothbrush tip configured to contact a surface of a tooth surface, wherein a tip of the brush head is configured to contact a surface that is above a first part of a tongue, wherein the surface is adjacent to a first portion of a oral cavity, wherein the first surface is adjacent to the lower surface of the tongue, and ]	[ (a) providing a toothbrush comprisinga brush head configured to collect or deposit tooth dust, comprising a tip for collecting and depositing, and ]
0.99999213	654	[ wherein both the tip and the oral cavity is located within a first portion of the tongue, wherein a portion of the tooth surface adjacent to the second portion of the tongue is disposed above at least a portion of the first portion of the tongue and wherein the dental surfaces are located beneath at least part of the second portion of the tongue; ]	[ a toothbrush tip configured to contact a surface of a tooth surface, wherein a tip of the brush head is configured to contact a surface that is above a first part of a tongue, wherein the surface is adjacent to a first portion of a oral cavity, wherein the first surface is adjacent to the lower surface of the tongue, and ]
0.99993825	655	[ (b) inserting the brush head into the oral cavity; ]	[ wherein both the tip and the oral cavity is located within a first portion of the tongue, wherein a portion of the tooth surface adjacent to the second portion of the tongue is disposed above at least a portion of the first portion of the tongue and wherein the dental surfaces are located beneath at least part of the second portion of the tongue; ]
0.99990106	656	[ (c) removing a toothbrush dust sample from the toothbrush; and ]	[ (b) inserting the brush head into the oral cavity; ]
0.9999924	657	[ (d) removing the toothbrush dust sample from the second portion of the tongue when the brush is disposed over the lip of the tongue while there remains the surface of the first portion of the tongue as the only surface between the brush and the oral cavity. ]	[ (c) removing a toothbrush dust sample from the toothbrush; and ]
0.99976224	658	[ (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1. ]	[ An in vitro assay for a polypeptide which binds to human T cells, comprising: ]
0.9999893	659	[ injecting a first dose of a first composition into an interior of a lesion tissue to treat said lesion, the method comprising providing a first therapeutic agent; ]	[ A method for treating a lesion, the method comprising: ]
0.9999914	660	[ placing an interstitial fluid within the lesion tissue to the interior of the lesion tissue; ]	[ injecting a first dose of a first composition into an interior of a lesion tissue to treat said lesion, the method comprising providing a first therapeutic agent; ]
0.9999707	661	[ passing the first dose of the first composition through an interstitial fluid; and ]	[ placing an interstitial fluid within the lesion tissue to the interior of the lesion tissue; ]
0.997703	662	[ treating said lesion tissue with the first therapeutic agent. ]	[ passing the first dose of the first composition through an interstitial fluid; and ]
0.99999166	663	[ wherein a single or multiple antimicrobial or anti-adhesive polymer components are present in a solution. ]	[ A method of using a surgical instrument for a patient for the prevention of disease or disorder by introducing in said device an antimicrobial or anti-adhesive polymer into a target tissue, wherein the antimicrobial or anti-adhesive polymer binds to a tissue-specific antibody and inhibits the binding of the IgG or IgM or IgD to the protein, wherein the antimicrobial or anti-adhesive polymer comprises an antimicrobial or anti-adhesive polymer matrix component at least one of a monolithic or a multidomeric polymer matrix component, and ]
0.9999473	664	[ a gaming apparatus for conducting a multidigit plurality of multidigital games; ]	[ A multi-functional gaming machine comprising: ]
0.99999213	665	[ a gaming controller operatively coupled with the gaming apparatus, wherein the gaming controller receives a set of instruction requests from a player and generates commands responsive to the set of instruction requests to execute a combination of at least one operation to perform an operation for the multidigit plurality of games, and ]	[ a gaming apparatus for conducting a multidigit plurality of multidigital games; ]
0.9999918	666	[ wherein the combination of at least one operation is based on a set of one or more other operations; and ]	[ a gaming controller operatively coupled with the gaming apparatus, wherein the gaming controller receives a set of instruction requests from a player and generates commands responsive to the set of instruction requests to execute a combination of at least one operation to perform an operation for the multidigit plurality of games, and ]
0.00029185408	667	[ a display device operatively coupled to the gaming controller, ]	[ wherein the combination of at least one operation is based on a set of one or more other operations; and ]
0.004541242	668	[ which comprises: ]	[ a display device operatively coupled to the gaming controller, ]
0.000592867	669	[ one or more gaming terminals operatively coupled to the gaming apparatus; ]	[ which comprises: ]
0.99996305	670	[ a plurality of gaming cards, each of which defines a gaming condition, each of the plurality of gaming cards having a unique code, wherein the unique code is uniquely associated with one of the multi-dimensional operations, wherein it is possible for the code to change, and ]	[ one or more gaming terminals operatively coupled to the gaming apparatus; ]
0.999992	671	[ wherein the unique code generates one or more special conditions associated with a particular multiplayer game when the particular multiplayer game is played by any one person; ]	[ a plurality of gaming cards, each of which defines a gaming condition, each of the plurality of gaming cards having a unique code, wherein the unique code is uniquely associated with one of the multi-dimensional operations, wherein it is possible for the code to change, and ]
0.99999225	672	[ wherein and wherein the one or more gaming terminals is operated by a player that is capable of receiving the particular multiplayer game at or on a gaming terminal of each of the plurality of gaming terminals and to use the particular multiplayer game in accordance with a game program generated within and executed by the specific multiplayer game on the gaming terminal of each of the plurality of gaming terminals; and ]	[ wherein the unique code generates one or more special conditions associated with a particular multiplayer game when the particular multiplayer game is played by any one person; ]
0.99999225	673	[ wherein each of the different gaming terminals is an output device for simultaneously displaying on at least one of a display portion and a play portion, two distinct play conditions associated with the specific multiplayer game. ]	[ wherein and wherein the one or more gaming terminals is operated by a player that is capable of receiving the particular multiplayer game at or on a gaming terminal of each of the plurality of gaming terminals and to use the particular multiplayer game in accordance with a game program generated within and executed by the specific multiplayer game on the gaming terminal of each of the plurality of gaming terminals; and ]
0.9999914	674	[ the nucleic acid also comprises a nucleic acid encoding at least one of the polypeptide, an amino acid selected from the group consisting of the amino acid sequence of the selected polypeptide, and ]	[ A method of increasing resistance to a selected polypeptide in a human or animal organism, said method comprising administering an effective amount of a nucleic acid encoding the selected polypeptide to the selected subject in a formulation having the polypeptide, wherein the administered dose of said nucleic acid is effective to increase the ability of a human or animal to resist the selected polypeptide to enhance the protective activity of a portion of polypeptide, said nucleic acid being in the form of a base-pregnated molecule that comprises 2 or more nucleotides joined to form a first sequence of the selected polypeptide that is complementary to that in the selected nucleic acid from which the first sequence was extracted, and ]
0.9996619	675	[ amino acids selected from the group consisting of the amino acid sequence of the HLA-DR1 receptor, the HLA-DR3 receptor, the HLA-DR4 receptor, the HLA-DRD1 receptor, the HLA-DRD2 receptor, the HLA-DRD3 receptor, the HLA-DRD4 receptor, and ]	[ the nucleic acid also comprises a nucleic acid encoding at least one of the polypeptide, an amino acid selected from the group consisting of the amino acid sequence of the selected polypeptide, and ]
0.9999919	676	[ the HLA-DRD5 receptor. ]	[ amino acids selected from the group consisting of the amino acid sequence of the HLA-DR1 receptor, the HLA-DR3 receptor, the HLA-DR4 receptor, the HLA-DRD1 receptor, the HLA-DRD2 receptor, the HLA-DRD3 receptor, the HLA-DRD4 receptor, and ]
0.058145627	677	[ the method comprising: ]	[ A method of treating a wound, wherein said wound is located in a subject; ]
0.9877038	678	[ selecting a plurality of blood types to have a predetermined level of vascular permeability and having substantially free of vascular permeability, having an average of the first blood type versus the second blood type, in a blood sample of the wound; ]	[ the method comprising: ]
0.99999225	679	[ measuring the level of arteriolistin in the the blood sample for both the first blood type and the second blood type, at the same time; and ]	[ selecting a plurality of blood types to have a predetermined level of vascular permeability and having substantially free of vascular permeability, having an average of the first blood type versus the second blood type, in a blood sample of the wound; ]
0.99998546	680	[ identifying a first tissue area in the subject at or below a first predetermined threshold of blood vessel permeability, wherein said first tissue is selected between the first blood type and the second blood type; ]	[ measuring the level of arteriolistin in the the blood sample for both the first blood type and the second blood type, at the same time; and ]
0.9998123	681	[ applying to the subject an amount of an agent selected from the group consisting of, at least one of anticonvulsants or anticoagulants. ]	[ identifying a first tissue area in the subject at or below a first predetermined threshold of blood vessel permeability, wherein said first tissue is selected between the first blood type and the second blood type; ]
0.9999913	682	[ comprising at least one element extending through a second hole, the prosthesis is removably coupled to the prosthesis shaft portion, and ]	[ A prosthesis adapted to be implanted inside a prosthesis shaft, the prosthesis having a first end and a second end disposed adjacent between two of a pair of first and second opposing ends of a prosthesis body, the first end and the second end being separate and apart from one another, the prosthesis having a first support layer and a second support layer, each of the first and second opposing ends of the prosthesis having a first opposing member defined therein and the same defining the first opposing member and the first opposing member also defining a second opposing member defined therein, the first and second opposing members adapted to extend through a first hole and a second hole defined in the prosthesis body and extending between two substantially opposing surfaces defined by the first opposing members, the base of the second opposing member of the first opposing member being adapted to rest against or substantially rest against one of the opposing surfaces defined in the prosthesis body and having a portion of the second opposing member defining the same surface and the second opposite member of the second opposing member extending proximate the second opposing member, the prosthesis further comprising a prosthesis shaft portion adapted to be inserted directly through a passage connecting the one opposing surface of the first opposing member of the second opposing member of first opposing member; and ]
0.99999213	683	[ the first and second opposing members are removably coupled to the prosthesis shaft. ]	[ comprising at least one element extending through a second hole, the prosthesis is removably coupled to the prosthesis shaft portion, and ]
0.99927026	684	[ a handle portion; ]	[ A surgical tool comprising: ]
0.9999914	685	[ a plurality of teeth extending radially outwardly from the handle portion; ]	[ a handle portion; ]
0.99999166	686	[ a pair of teeth extending upwardly from the handle portion in a first direction; and ]	[ a plurality of teeth extending radially outwardly from the handle portion; ]
0.99999166	687	[ a pair of teeth extending inwardly from the handle portion in a second direction, each of the teeth including a pair of teeth opposite the other tooth and having a first end and a second end, from which is distal through which is in the first direction. ]	[ a pair of teeth extending upwardly from the handle portion in a first direction; and ]
0.999982	688	[ a) inserting the stent into the cavity, wherein the cavity is a bore; ]	[ A method of applying a lumen in a stent into a cavity, comprising: ]
0.9999856	689	[ b) cutting the bore in a first direction to a second direction; ]	[ a) inserting the stent into the cavity, wherein the cavity is a bore; ]
0.99999225	690	[ c) cutting the second direction in a third direction so that a portion of said bore intersects the cavity; ]	[ b) cutting the bore in a first direction to a second direction; ]
0.99995494	691	[ d) cutting a top surface of the cavity with a first tool to permit the passage of a lumen under the top surface into the cavity, the first tool configured to engage with a first surface of the lumen, and ]	[ c) cutting the second direction in a third direction so that a portion of said bore intersects the cavity; ]
0.9999912	692	[ the second tool configured to engage with a second surface of the lumen; ]	[ d) cutting a top surface of the cavity with a first tool to permit the passage of a lumen under the top surface into the cavity, the first tool configured to engage with a first surface of the lumen, and ]
0.9990876	693	[ e) advancing the lumen into the cavity at a first level of the bore in a first direction and advancing the lumen into the cavity at a second level of the bore in the second direction, wherein an axis of the first and second levels have opposite ends; ]	[ the second tool configured to engage with a second surface of the lumen; ]
0.9999684	694	[ f) pushing the first tool away from the top surface of the cavity so that the first surface is below a surface of the cavity; and ]	[ e) advancing the lumen into the cavity at a first level of the bore in a first direction and advancing the lumen into the cavity at a second level of the bore in the second direction, wherein an axis of the first and second levels have opposite ends; ]
0.9999862	695	[ g) re-entering the cavity at a second level of the bore in a third direction different than the first level, wherein the second level is a height level higher than the first level. ]	[ f) pushing the first tool away from the top surface of the cavity so that the first surface is below a surface of the cavity; and ]
0.9986773	696	[ R5 is the same as R1, or a substituent not specified. ]	[ A method of making a compound of formula IwhereinR1R2= R3 and R4 are independently hydrogen, alkyl, alkenyl, alkynyl, benzyl, alkylene, alkenon, or alkynocycloalkyl; and ]
0.9992841	697	[ obtaining first data regarding the level of inflammatory bowel disease (IBD) protein in biological tissue of a subject; ]	[ A method of treating a disease comprising: ]
0.99999225	698	[ measuring the content of inflammatory bowel disease (IBD) protein in the biological tissue of the subject; and ]	[ obtaining first data regarding the level of inflammatory bowel disease (IBD) protein in biological tissue of a subject; ]
0.9999924	699	[ assessing the level of inflammatory bowel disease (IBD) protein in each of the first data that indicate a level of inflammatory bowel disease (IBD) protein in biological tissue of the subject compared to a baseline level of said inflammatory bowel disease (IBD) protein in biopsy tissue. ]	[ measuring the content of inflammatory bowel disease (IBD) protein in the biological tissue of the subject; and ]
0.9999919	700	[ a fiber antenna having an antenna structure and configured to receive an in-scan ultrasound signal from the ultrasound transducer and that transmits light to a detector structure via a waveform sensor that detects light that has been transmitted through the fiber antenna; ]	[ An ultrasound transducer apparatus comprising: ]
0.9998822	701	[ a fiber antenna housing having a tubular inner frame that includes an upper, lower and inner core with both the lower and inner core extending outwardly from the frame; and ]	[ a fiber antenna having an antenna structure and configured to receive an in-scan ultrasound signal from the ultrasound transducer and that transmits light to a detector structure via a waveform sensor that detects light that has been transmitted through the fiber antenna; ]
0.99999034	702	[ a fiber antenna antenna frame coupled to the fiber antenna housing, the fiber antenna antennas comprising a plurality of fiber coils positioned inside the fiber antenna housing. ]	[ a fiber antenna housing having a tubular inner frame that includes an upper, lower and inner core with both the lower and inner core extending outwardly from the frame; and ]
0.9975249	703	[ an electrocardiograph ( ECG ). ]	[ A method of providing a device that measures and displays physiological parameters of a person in need of an intervention, the method comprising: ]
0.15457518	704	[ an inner surface having a plurality of spaced-apart elements; ]	[ An instrument for a surgical procedure comprising: ]
0.012142364	705	[ a plurality of elongate-to-spined guides including a plurality of first sections of a flexible metal band and at least one second section of the metal band, wherein the first section of the flexible metal band includes a first elongate-to-spined guide surface and the second section of the metal band including a second elongate-to-spined guide surface; ]	[ an inner surface having a plurality of spaced-apart elements; ]
0.9866224	706	[ an extension member extending into the inner surface between at least one of its ends and the plurality of spaced-apart elements and being flexible; ]	[ a plurality of elongate-to-spined guides including a plurality of first sections of a flexible metal band and at least one second section of the metal band, wherein the first section of the flexible metal band includes a first elongate-to-spined guide surface and the second section of the metal band including a second elongate-to-spined guide surface; ]
0.9898072	707	[ a pair of end portions provided on the elongate-to-spined guides for supporting and retracting the end portions; ]	[ an extension member extending into the inner surface between at least one of its ends and the plurality of spaced-apart elements and being flexible; ]
0.99999225	708	[ a portion of the elongate-to-spined guides extending towards the end portions and extending into or towards the extension members, the portion of the elongate-to-spined guides also including a second, non-spaced-apart section of the metal band extending from the elongate-to-spined guides toward the extension member; and ]	[ a pair of end portions provided on the elongate-to-spined guides for supporting and retracting the end portions; ]
0.99999213	709	[ an anchor being provided on a portion of the elongate-to-spined guides extending between the second and non-spaced-apart sections of the metal band. ]	[ a portion of the elongate-to-spined guides extending towards the end portions and extending into or towards the extension members, the portion of the elongate-to-spined guides also including a second, non-spaced-apart section of the metal band extending from the elongate-to-spined guides toward the extension member; and ]
0.99985754	710	[ receiving, by a processor, a user request for access to a game object; ]	[ A method for operating a gaming machine for use in a game, comprising: ]
0.99999213	711	[ processing, by the processor, the user request to determine whether the game object has been previously accessed by a user by determining whether any user-created games within the game object has been previously modified to provide a level of functionality in the user that has been previously added by the user, and ]	[ receiving, by a processor, a user request for access to a game object; ]
0.9999924	712	[ if the gaming machine's functionality is enhanced in a user-created game, storing user action data associated with the user. ]	[ processing, by the processor, the user request to determine whether the game object has been previously accessed by a user by determining whether any user-created games within the game object has been previously modified to provide a level of functionality in the user that has been previously added by the user, and ]
0.9946345	713	[ a solvent with a non-volatile structure for the preparation of a hydrophilic material; ]	[ A method of preparing a topical formulation comprising: ]
0.9968086	714	[ a polymerizable substrate comprising a first polymerizable component, a second polymerizable component and a solvent; ]	[ a solvent with a non-volatile structure for the preparation of a hydrophilic material; ]
0.99999213	715	[ a non-polar carrier configured to support the solvent in an environment having a first pH and wherein the first polymerizable component is an organic solvent and the second polymerizable component is an organic solvent; and ]	[ a polymerizable substrate comprising a first polymerizable component, a second polymerizable component and a solvent; ]
0.9840895	716	[ wherein the substrate is a composition of an aromatic organic polyurethane base and a water-soluble component that forms on the surface of the substrate, in solution when the composition is heated to a temperature above 500 and 500&#xb1; F., ]	[ a non-polar carrier configured to support the solvent in an environment having a first pH and wherein the first polymerizable component is an organic solvent and the second polymerizable component is an organic solvent; and ]
0.9970085	717	[ the organic solvent being chosen from poly(vinylpyridinesulfonate) resin and binder, and ]	[ wherein the substrate is a composition of an aromatic organic polyurethane base and a water-soluble component that forms on the surface of the substrate, in solution when the composition is heated to a temperature above 500 and 500&#xb1; F., ]
0.99980503	718	[ the solvent chosen from a hydrophilic solvent, or a hydrophilic ester. ]	[ the organic solvent being chosen from poly(vinylpyridinesulfonate) resin and binder, and ]
0.9990501	719	[ 32. ]	[ A method of treating a wound in an individual, the method comprising providing a therapeutic agent comprising a first polypeptide of SEQ ID NO: ]
0.9999918	720	[ attaching the medicament dispensing system to a dispensing end portion of and releasably engageable with a dispensing end of a distal end of a pharmaceutical unit, the medicament dispensing system comprising an outer, nonwoven, flexible tubing and a distal terminal portion, the distal terminal portion comprising a first end portion connected to the outer, nonwoven, flexible tubing and a second end portion connected to a first end of a distal sleeve portion, ]	[ A method of dispensing a pharmaceutical unit from a dispersion container of a medicament dispensing system, the method comprising: ]
0.9999924	721	[ the medicine dispersion container including a distal port for receiving at least one pharmaceutical unit of the dispensing system therein and a distal port proximate the outer, nonwoven, flexible tubing of the dispensing system, ]	[ attaching the medicament dispensing system to a dispensing end portion of and releasably engageable with a dispensing end of a distal end of a pharmaceutical unit, the medicament dispensing system comprising an outer, nonwoven, flexible tubing and a distal terminal portion, the distal terminal portion comprising a first end portion connected to the outer, nonwoven, flexible tubing and a second end portion connected to a first end of a distal sleeve portion, ]
0.99999225	722	[ the distal port of the pharmaceutical unit being formed of a material with a generally straight configuration with a maximum length, at least once the distal port of the pharmaceutical unit extends from a distal end portion of the outer fluid fluid fluid barrier of the dispensing system to the distal port of the pharmaceutical unit, and ]	[ the medicine dispersion container including a distal port for receiving at least one pharmaceutical unit of the dispensing system therein and a distal port proximate the outer, nonwoven, flexible tubing of the dispensing system, ]
0.9999895	723	[ at least one distal valve defining a port having a radius of curvature greater than 4 nanometers, wherein the medicine dispensing system has a diameter of between 0.1 and 0.30 microns in an extent extending across an average of a length and the average width of the medical fluid interface of the medicament dispensing system. ]	[ the distal port of the pharmaceutical unit being formed of a material with a generally straight configuration with a maximum length, at least once the distal port of the pharmaceutical unit extends from a distal end portion of the outer fluid fluid fluid barrier of the dispensing system to the distal port of the pharmaceutical unit, and ]
0.99999166	724	[ in a first control module configured to measure an axon of at least one electrode of a catheter, receiving a signal indicative of a difference in the axonal flux, wherein the signal is indicative of the axon being displaced relative to a common electrode contact; ]	[ A method for controlling a catheter of a device comprising two or more electrodes with a common electrode contact having an adjacent electrode contact, comprising: ]
0.99999225	725	[ in a second control module configured to measure an axon of at least one other electrode of the catheter, receiving an indication of an axonal flux that was absent in an axon from said first controller module from which a signal from an adjacent control module was received, and ]	[ in a first control module configured to measure an axon of at least one electrode of a catheter, receiving a signal indicative of a difference in the axonal flux, wherein the signal is indicative of the axon being displaced relative to a common electrode contact; ]
0.9999924	726	[ said signal is indicative of an axonal flux that was present in said first controller module; the distance between adjacent electrodes as compared to each other being measured; and ]	[ in a second control module configured to measure an axon of at least one other electrode of the catheter, receiving an indication of an axonal flux that was absent in an axon from said first controller module from which a signal from an adjacent control module was received, and ]
0.9999924	727	[ determining whether the axon measured by the first controller module is greater than the axon measured by the second controller module by calculating a difference between the axonal flux from said first controller module and the axonal flux from said second controller module; ]	[ said signal is indicative of an axonal flux that was present in said first controller module; the distance between adjacent electrodes as compared to each other being measured; and ]
0.99469984	728	[ if the difference is greater than a first threshold value, controlling the catheter to be in a first closed state; and ]	[ determining whether the axon measured by the first controller module is greater than the axon measured by the second controller module by calculating a difference between the axonal flux from said first controller module and the axonal flux from said second controller module; ]
0.99999225	729	[ if the difference is different than the first threshold value, changing the first closed state to a second closed state; and ]	[ if the difference is greater than a first threshold value, controlling the catheter to be in a first closed state; and ]
0.99547714	730	[ in a data processing system that is configured to determine the axon from the axon measured by the first control module. ]	[ if the difference is different than the first threshold value, changing the first closed state to a second closed state; and ]
0.99998856	731	[ accessing a cardiac surgery procedure information storage device and storing a patient information list, wherein the patient information list includes instructions which comprise: ]	[ A method for performing cardiac surgery, comprising: ]
0.9999614	732	[ receiving, from a user, a patient parameter which is used for performing the surgical procedure; ]	[ accessing a cardiac surgery procedure information storage device and storing a patient information list, wherein the patient information list includes instructions which comprise: ]
0.9997162	733	[ retrieving a medical parameter from a data recording portion of a medical device; ]	[ receiving, from a user, a patient parameter which is used for performing the surgical procedure; ]
0.99651295	734	[ determining a patient preference of the user; ]	[ retrieving a medical parameter from a data recording portion of a medical device; ]
0.99991536	735	[ obtaining, in response to the patient preference, at least part of the medical parameters and patient parameters which are known by the cardiac surgery procedure and associated with a patient, wherein the medical parameters and patient parameters are stored in the patient information list; ]	[ determining a patient preference of the user; ]
0.9999914	736	[ determining an anatomical parameter which is associated with a device for performing the surgical procedure; ]	[ obtaining, in response to the patient preference, at least part of the medical parameters and patient parameters which are known by the cardiac surgery procedure and associated with a patient, wherein the medical parameters and patient parameters are stored in the patient information list; ]
0.9999869	737	[ obtaining, in response to the at least part of the medical parameters and patient parameters, at least part of the medical parameters and the anatomical parameter from a patient; and ]	[ determining an anatomical parameter which is associated with a device for performing the surgical procedure; ]
0.99999225	738	[ storing the obtained at least part of the medical parameters and the obtained at least part of the medical parameters, and ]	[ obtaining, in response to the at least part of the medical parameters and patient parameters, at least part of the medical parameters and the anatomical parameter from a patient; and ]
0.99999225	739	[ storing the stored obtained at least part of the medical parameters and the obtained at least part of the medical parameters, as part of the patient information list. ]	[ storing the obtained at least part of the medical parameters and the obtained at least part of the medical parameters, and ]
0.9990388	740	[ a first cover coupled to the bottom of the vehicle having an open top in communication with an air duct of the vehicle, and ]	[ In a vehicle for carrying one or more passengers, a bed assembly, which comprises: ]
0.9983267	741	[ at least one end thereof connected to a front seat, and ]	[ a first cover coupled to the bottom of the vehicle having an open top in communication with an air duct of the vehicle, and ]
0.9992986	742	[ at least one end having a bed cover extending along a length of said at least one end of said at least one end of said first cover; ]	[ at least one end thereof connected to a front seat, and ]
0.9998361	743	[ a second cover having an open top in communication with an air duct of the vehicle, and ]	[ at least one end having a bed cover extending along a length of said at least one end of said at least one end of said first cover; ]
0.9999833	744	[ at least one end thereof connecting to a rear seat of the vehicle, the second cover being configured to accommodate at least two seats of the one or more passengers; ]	[ a second cover having an open top in communication with an air duct of the vehicle, and ]
0.9999807	745	[ a head rest, at least partially attached to the first cover for at least partially seating a user thereon; ]	[ at least one end thereof connecting to a rear seat of the vehicle, the second cover being configured to accommodate at least two seats of the one or more passengers; ]
0.9999608	746	[ means for guiding said head rest through the air duct; and ]	[ a head rest, at least partially attached to the first cover for at least partially seating a user thereon; ]
0.9999908	747	[ a cover fastened to said cover, the cover coupled to said cover by means for permitting said cover to be driven in a driving direction for the use of said passengers, wherein the mechanism for allowing said head rest and for guiding said head rest is generally substantially the same as from a front end of said second cover to an end of said head rest; ]	[ means for guiding said head rest through the air duct; and ]
0.99999154	748	[ wherein by driving said head rest and said cover in said driving direction, and ]	[ a cover fastened to said cover, the cover coupled to said cover by means for permitting said cover to be driven in a driving direction for the use of said passengers, wherein the mechanism for allowing said head rest and for guiding said head rest is generally substantially the same as from a front end of said second cover to an end of said head rest; ]
0.9999919	749	[ the occupant's head rests on said heads of the two seats of the vehicles so arranged at said front and rear ends and said cover for guiding said head rest does not obstruct the driver's vision. ]	[ wherein by driving said head rest and said cover in said driving direction, and ]
0.9999914	750	[ displaying three ultrasound image modes; ]	[ A method for generating an ultrasound image to detect an object, in need thereof including: ]
0.99946624	751	[ generating a plurality of ultrasonic beams into a probe; ]	[ displaying three ultrasound image modes; ]
0.99977607	752	[ processing the three ultrasound image modes to generate an associated ultrasound image; ]	[ generating a plurality of ultrasonic beams into a probe; ]
0.9999919	753	[ generating an ultrasound echo image from the ultrasound image; and ]	[ processing the three ultrasound image modes to generate an associated ultrasound image; ]
0.99999213	754	[ providing an ultrasound echo signal. ]	[ generating an ultrasound echo image from the ultrasound image; and ]
0.9998895	755	[ preparing a medium comprising a cancer cell; and ]	[ A method for inhibiting the growth of a cancer cell comprising: ]
0.9992711	756	[ administering to a cancer cell of the cancer cell an effective amount of a composition comprising an effective amount of peptides comprising: ]	[ preparing a medium comprising a cancer cell; and ]
0.9984433	757	[ (a) a sequence having at least 95% identity to the sequence of SEQ ID NO: ]	[ administering to a cancer cell of the cancer cell an effective amount of a composition comprising an effective amount of peptides comprising: ]
0.9999548	758	[ 2, wherein said peptides comprise a peptide sequence having the sequence of the polypeptide having SEQ ID NO: ]	[ (a) a sequence having at least 95% identity to the sequence of SEQ ID NO: ]
0.9960962	759	[ 2 and (b) a peptide composition comprising a composition of at least about 75% by weight of pectin. ]	[ 2, wherein said peptides comprise a peptide sequence having the sequence of the polypeptide having SEQ ID NO: ]
0.99994445	760	[ a toy body having an interior and a peripheral surface; ]	[ A toy comprising: ]
0.99999166	761	[ a plurality of plastic sheets disposed along one side of said interior of said toy body; ]	[ a toy body having an interior and a peripheral surface; ]
0.99999106	762	[ a flexible member disposed laterally adjacent said peripheral surface, said flexible member connected to said surface of said toy body, said flexible member having a first end portion coupled to said interior of said toy body and a second end portion coupled to said peripheral surface, said first end portion and said second end portion defining a substantially straight shaft extending between said first and second ends adjacent said peripheral surface; ]	[ a plurality of plastic sheets disposed along one side of said interior of said toy body; ]
0.9999881	763	[ wherein said shaft of said flexible member comprises a flexible cross-section and wherein said flexible member includes an anchor part. ]	[ a flexible member disposed laterally adjacent said peripheral surface, said flexible member connected to said surface of said toy body, said flexible member having a first end portion coupled to said interior of said toy body and a second end portion coupled to said peripheral surface, said first end portion and said second end portion defining a substantially straight shaft extending between said first and second ends adjacent said peripheral surface; ]
0.9935415	764	[ or a pharmaceutically acceptable salt thereof. ]	[ A method of treating an acute pancreatitis comprising administering to a member of a group comprising an active agent and a compound having at least 90% identity to an active agent of formula (I): ]
0.9802367	765	[ a plurality of frame members configured to receive pixels; ]	[ An image processing apparatus comprising: ]
0.9991774	766	[ at least one light generating element configured to generate light from the selected frames to be processed; ]	[ a plurality of frame members configured to receive pixels; ]
0.9980191	767	[ a switching power management element configured to switch at least a portion of each of the plurality of frame members in a state of state switching with respect to an output state of the switchable frame members; ]	[ at least one light generating element configured to generate light from the selected frames to be processed; ]
0.99999225	768	[ an operation mode selector configured to select a single processing mode if the switchable frame members, in the state of state switching with respect to the output state, yield data which is not usable in the output state; ]	[ a switching power management element configured to switch at least a portion of each of the plurality of frame members in a state of state switching with respect to an output state of the switchable frame members; ]
0.9999875	769	[ an output control circuit configured to store, on a main circuit, a selection signal which specifies whether a first selection signal is to be switched by the operation mode selector or a second selection signal is to be switched by the operation mode selector; and ]	[ an operation mode selector configured to select a single processing mode if the switchable frame members, in the state of state switching with respect to the output state, yield data which is not usable in the output state; ]
0.9999918	770	[ a time and a switch time control circuit configured to select the processing mode to be executed according to the selection signal, wherein a time when a time of operation is to be set is selected when the switching power management element moves from the first selection signal to the second selection signal and a time of operation is to be set when a first control signal is output and a second control signal is output. ]	[ an output control circuit configured to store, on a main circuit, a selection signal which specifies whether a first selection signal is to be switched by the operation mode selector or a second selection signal is to be switched by the operation mode selector; and ]
0.9999621	771	[ a cover having an interior, wherein the cover is in contact with the wearer's body as the wearable device is worn; ]	[ A portable, wearable device for a wearer, comprising: ]
0.99996257	772	[ a first user interface unit, the exterior of the cover being at least partially exposed to at least partially via the exterior interior of the cover to display a first device having a display screen; ]	[ a cover having an interior, wherein the cover is in contact with the wearer's body as the wearable device is worn; ]
0.99999225	773	[ a second user interface unit, the exterior of the cover being at least partially covered over by the first user interface unit to display a second device having a display screen; ]	[ a first user interface unit, the exterior of the cover being at least partially exposed to at least partially via the exterior interior of the cover to display a first device having a display screen; ]
0.9999887	774	[ a display screen mounted in proximity to the face of the wearer via a surface of the user interface unit; wherein the first user interface unit, second user interface unit, and ]	[ a second user interface unit, the exterior of the cover being at least partially covered over by the first user interface unit to display a second device having a display screen; ]
0.9999697	775	[ display screen are responsive to movement of the wearable device relative to the skin and the display screen is responsive to movement of the wearable device relative to the wearer's body, whereby movement of the wearable device relative to the wearer's body indicates whether the wearable device is worn. ]	[ a display screen mounted in proximity to the face of the wearer via a surface of the user interface unit; wherein the first user interface unit, second user interface unit, and ]
0.9995912	776	[ an elongate cannula having a distal end and a proximal end and extending around a circumferential longitudinal axis of the cannula, the elongate cannula comprising a proximal end with a closed first tubular end, an enlarged enlarged first tubular end, and ]	[ A catheter comprising: ]
0.9999919	777	[ a closed second tubular end extending along an expanded longitudinal axis, the enlarged enlarged first tubular end including a proximal portion having a distal end therethrough and a distal portion with a proximal end extending to substantially complete the enlarged enlarged first tubular end with a closed first cavity, the closed second tubular end having a proximal portion extending along the expanded longitudinal axis, the closed second tubular end with a closed first opening for passing into or from a second portion of the expanded longitudinal axis; and ]	[ an elongate cannula having a distal end and a proximal end and extending around a circumferential longitudinal axis of the cannula, the elongate cannula comprising a proximal end with a closed first tubular end, an enlarged enlarged first tubular end, and ]
0.9999896	778	[ an elongate member disposed on or in the closed second tubular end of the cannula. ]	[ a closed second tubular end extending along an expanded longitudinal axis, the enlarged enlarged first tubular end including a proximal portion having a distal end therethrough and a distal portion with a proximal end extending to substantially complete the enlarged enlarged first tubular end with a closed first cavity, the closed second tubular end having a proximal portion extending along the expanded longitudinal axis, the closed second tubular end with a closed first opening for passing into or from a second portion of the expanded longitudinal axis; and ]
0.9999062	779	[ a center portion including a base having a center portion surface that is joined to a second portion at a location within a golf ball, the second portion having an outer surface and an inner surface that is spaced from the outer surface of the first portion and is parallel to a centerline of the second portion in a vertical direction from the first portion; ]	[ A golf golf club head comprising: ]
0.99999106	780	[ a forward face including a pair of outer face edge portions, each of the pair of edge portions having a top end and an opposite bottom end, the top end of each edge portion receiving the inner surface of the base when the first portion is joined to the center portion; and ]	[ a center portion including a base having a center portion surface that is joined to a second portion at a location within a golf ball, the second portion having an outer surface and an inner surface that is spaced from the outer surface of the first portion and is parallel to a centerline of the second portion in a vertical direction from the first portion; ]
0.99999213	781	[ a back face having two edge portions, each edge portion having a top end and a bottom end, the back face facing the first portion which contacts the base portion that receives the first portion when the second portion is joined to the center portion. ]	[ a forward face including a pair of outer face edge portions, each of the pair of edge portions having a top end and an opposite bottom end, the top end of each edge portion receiving the inner surface of the base when the first portion is joined to the center portion; and ]
0.01387112	782	[ a housing; ]	[ A medical treatment apparatus for treating an anatomical region, comprising: ]
0.9992009	783	[ a plurality of apertures therein for receiving fluid from the anatomical region through the housing; and ]	[ a housing; ]
0.99998605	784	[ an apparatus body disposed in the housing and coupled to the plurality of apertures; ]	[ a plurality of apertures therein for receiving fluid from the anatomical region through the housing; and ]
0.99991107	785	[ wherein the apertures comprise at least one channel; and ]	[ an apparatus body disposed in the housing and coupled to the plurality of apertures; ]
0.9999676	786	[ wherein a distal end of the apparatus body is adapted to be in contact with the apertures through the apertures. ]	[ wherein the apertures comprise at least one channel; and ]
0.9997178	787	[ 2, wherein said at least one compound comprises either an at least one amino acid substitution, a substituted amino acid substitution or both, and ]	[ A method of treating a patient with an autoimmune disorder, comprising administering to the patient an effective amount of at least two compounds of SEQ ID NO: ]
0.99671066	788	[ one or more of the compounds is one of an anti-inflammatory agent, a therapeutically beneficial agent, or a neuroenhancing agent. ]	[ 2, wherein said at least one compound comprises either an at least one amino acid substitution, a substituted amino acid substitution or both, and ]
0.99993515	789	[ (a) adding an immunogenic composition to the tumor tissue of the cancer cell; and ]	[ A method of enhancing an antibody bound under or to the surface of one or more cell epitopes of a cancer cell, said method comprising: ]
0.999992	790	[ (b) administering a therapeutically effective amount of the immunogenic composition to the cancer cell. ]	[ (a) adding an immunogenic composition to the tumor tissue of the cancer cell; and ]
0.99788	791	[ a plurality of electrodes; ]	[ An implantable medical device comprising a plurality of interconnection channels, each interconnection channel having a plurality of trans-connection points and each each of the plurality of interconnection devices comprising: ]
0.9972746	792	[ a plurality of transistors; ]	[ a plurality of electrodes; ]
0.008708247	793	[ a control module; and ]	[ a plurality of transistors; ]
0.996689	794	[ a memory having a plurality of control instructions; ]	[ a control module; and ]
0.00023355946	795	[ wherein an electrode of a first interconnection channel of the plurality of interconnection devices is electrically connected to a trans-connection point of a trans-connection coil of a second interconnection channel of the plurality of interconnection devices; and ]	[ a memory having a plurality of control instructions; ]
0.00043561833	796	[ wherein the control module is connected to a switch that can be manually depressed to open and close the switch; and ]	[ wherein an electrode of a first interconnection channel of the plurality of interconnection devices is electrically connected to a trans-connection point of a trans-connection coil of a second interconnection channel of the plurality of interconnection devices; and ]
1.843999e-05	797	[ wherein at least one of the plurality of electrodes of the first interconnection channel is directly charged to an external electrode, with a charge applied from the external electrode into the conductive path of the internal electrode within the plurality of trans-connection channels of the plurality of interconnection devices. ]	[ wherein the control module is connected to a switch that can be manually depressed to open and close the switch; and ]
0.99811804	798	[ a valve tube having a longitudinal axis, an inner wall, an outer wall, a second wall extending from the outer wall and being in fluid communication with the inner wall, and ]	[ An implantable heart valve comprising: ]
0.9999912	799	[ a tubular wall extending from the inner wall to the outer wall, wherein the outer wall is defined by a second wall that is substantially non-circular and is in fluid communication with the inner wall and the second wall extends generally inward from the inner wall, and ]	[ a valve tube having a longitudinal axis, an inner wall, an outer wall, a second wall extending from the outer wall and being in fluid communication with the inner wall, and ]
0.99959487	800	[ wherein said second wall has a length greater than the longitudinal axis and the end of said second wall is defined by a channel; and ]	[ a tubular wall extending from the inner wall to the outer wall, wherein the outer wall is defined by a second wall that is substantially non-circular and is in fluid communication with the inner wall and the second wall extends generally inward from the inner wall, and ]
0.008364423	801	[ a tubular portion surrounding the valve tube having an inner surface, an outer surface, and ]	[ wherein said second wall has a length greater than the longitudinal axis and the end of said second wall is defined by a channel; and ]
0.020586325	802	[ a channel for allowing fluid communication with said second wall of said second wall. ]	[ a tubular portion surrounding the valve tube having an inner surface, an outer surface, and ]
0.9999876	803	[ imaging a first section of the structure; ]	[ A method of creating a virtual image of a structure, the method comprising: ]
0.00065346225	804	[ collecting a first data collection set representing an array of information; ]	[ imaging a first section of the structure; ]
0.99999213	805	[ storing the collected first data collection set in a storage device; ]	[ collecting a first data collection set representing an array of information; ]
0.9999924	806	[ analyzing a first pixel in the first data collection set with a processor; and ]	[ storing the collected first data collection set in a storage device; ]
0.9999907	807	[ producing an output data set from the analysis. ]	[ analyzing a first pixel in the first data collection set with a processor; and ]
0.99998987	808	[ wherein the antibody or antigen-presenting cells are antigenically purified from human cells, and ]	[ A method of treating a patient suffering from or requiring cardiac surgery, comprising administering an endogenous antibody or antigen-presenting cell (APC) to the patient, wherein the antibody or antigen-presenting cell is a cell that specifically binds to B-cell epitopes comprising the HLA-DQ2 domain, HLA-DR3 domain, HLA-DR4 domain, or HLA-DR5 domain, or is in any combination thereof, wherein the humanized antibody or antigen-presenting cell selected from the group consisting of R-FvR6, G-FgR7 and R-L5; ]
0.99977356	809	[ the patient has a normal or abnormal HLA-DR2 or HLA-DR3, normal or abnormal HLA-DR3A/D or normal or abnormal HLA-DQ1 or HLA-DR2 regions comprising the HLA-DQ1 and HLA-DQ2 regions respectively. ]	[ wherein the antibody or antigen-presenting cells are antigenically purified from human cells, and ]
0.98997986	810	[ a power source; and ]	[ An apparatus for a vacuum cleaner for disposing and collecting waste matter consisting essentially of a vacuum system, containing a vacuum compressor and at least one suction conduit disposed along a direction of the vacuum system and for allowing a vacuum to enter in the suction conduit and for moving an object therebetween via the suction conduit, the apparatus comprising: ]
0.9339236	811	[ a vacuum compressor for moving the object according to an action of electricity, wherein a vacuum is exerted on the suction conduit, from a vacuum source along a direction of the vacuum system, which is determined according to a formula A= &#x2014; ]	[ a power source; and ]
0.0026847674	812	[ 1&#x2550; ]	[ a vacuum compressor for moving the object according to an action of electricity, wherein a vacuum is exerted on the suction conduit, from a vacuum source along a direction of the vacuum system, which is determined according to a formula A= &#x2014; ]
0.0129670175	813	[ 1+1a&#x2462; ]	[ 1&#x2550; ]
0.010151271	814	[ N&#x2014; ]	[ 1+1a&#x2462; ]
0.016692013	815	[ (1)wherein a vacuum force F is multiplied by a quantity in a first dimension and a suction pressure P &#x2014; ]	[ N&#x2014; ]
0.99999154	816	[ A is a first vacuum pressure pressure corresponding to the vacuum force, wherein the first vacuum pressure pressure is the suction pressure associated with the vacuum compressor. ]	[ (1)wherein a vacuum force F is multiplied by a quantity in a first dimension and a suction pressure P &#x2014; ]
0.9998933	817	[ (a) providing at least one drug delivery route in a patient, the at least one drug delivery route including at least one drug delivery route, ]	[ A method of delivering a drug to a subject, comprising: ]
0.99999154	818	[ (a.a) administering the drug to the subject via the drug delivery route to deliver the drug to the subject; ]	[ (a) providing at least one drug delivery route in a patient, the at least one drug delivery route including at least one drug delivery route, ]
0.9999913	819	[ (a.b) after delivery of the drug, identifying drug metabolites in the subjects blood; and ]	[ (a.a) administering the drug to the subject via the drug delivery route to deliver the drug to the subject; ]
0.9999728	820	[ (b) providing a drug-induced immune response to the subject. ]	[ (a.b) after delivery of the drug, identifying drug metabolites in the subjects blood; and ]
0.9999918	821	[ providing a flexible substrate to be placed on said skin area, ]	[ A self cleaning method to be used as an agent for cleaning a skin area comprising the steps of: ]
0.9999771	822	[ filling the flexible substrate with water containing at least one of an effective amount of at least one agent. ]	[ providing a flexible substrate to be placed on said skin area, ]
0.0007224087	823	[ a) a first housing, wherein said first housing has a first opening; and ]	[ An electrosurgical sterilization device comprising: ]
0.999992	824	[ b) a second housing, wherein said second housing has a second opening and an intermediate part, wherein said intermediate part extends therethrough; ]	[ a) a first housing, wherein said first housing has a first opening; and ]
0.9999914	825	[ wherein an end of said second housing is removably affixed to said first housing. ]	[ b) a second housing, wherein said second housing has a second opening and an intermediate part, wherein said intermediate part extends therethrough; ]
0.99981135	826	[ a bone structure, the bone structure comprising an intervertebral space, wherein the segmenting of the bone structure into an upper and lower portion comprises two main regions, the first region comprising at least one of a medial section and a lateral section; ]	[ An intervertebral implant that provides stimulation to a vertebral region, the implant comprising: ]
0.9998857	827	[ a first electrode disposed between a first region of the intervertebral space and a first region of the intervertebral space adjacent to one of the regions; ]	[ a bone structure, the bone structure comprising an intervertebral space, wherein the segmenting of the bone structure into an upper and lower portion comprises two main regions, the first region comprising at least one of a medial section and a lateral section; ]
0.99999225	828	[ a second electrode disposed between a first region of the intervertebral space and a second region of the intervertebral space adjacent to the first region; ]	[ a first electrode disposed between a first region of the intervertebral space and a first region of the intervertebral space adjacent to one of the regions; ]
0.99999	829	[ a support structure, the support structure being located adjacent the intervertebral space between the first and second regions so as to extend between the first and second regions, the support structure being formed of a first rigid and a second rigid material wherein the first rigid material extends between the first and second regions; and ]	[ a second electrode disposed between a first region of the intervertebral space and a second region of the intervertebral space adjacent to the first region; ]
0.99999154	830	[ wherein the second rigid material is different from the second rigid material. ]	[ a support structure, the support structure being located adjacent the intervertebral space between the first and second regions so as to extend between the first and second regions, the support structure being formed of a first rigid and a second rigid material wherein the first rigid material extends between the first and second regions; and ]
0.9994624	831	[ providing one or more transducers to a patient and including a device comprising: ]	[ A method of delivering a medical device into a body of a patient comprising the steps of: ]
0.9945878	832	[ in electrical communication for providing electrical power; and ]	[ providing one or more transducers to a patient and including a device comprising: ]
0.99039817	833	[ a first channel being provided in an outer edge of the device, the second channel being located proximate to a second channel having an inner surface to be in contact with a tissue; ]	[ in electrical communication for providing electrical power; and ]
0.0047749705	834	[ providing one or more transducer wires or a single device including two or more transducer wires to an external device disposed on the subject of the patient; and ]	[ a first channel being provided in an outer edge of the device, the second channel being located proximate to a second channel having an inner surface to be in contact with a tissue; ]
0.996906	835	[ providing at least one signal port with an electronic output, ]	[ providing one or more transducer wires or a single device including two or more transducer wires to an external device disposed on the subject of the patient; and ]
0.9999912	836	[ operating the device to deliver a medical device through the signal port to the body of the patient. ]	[ providing at least one signal port with an electronic output, ]
0.99998593	837	[ a signal carrier arranged to contact and provide an electrical signal to at least one nerve being received by the spinal cord catheter, the signal carrier comprising a transmitter that transmits an ultrasound waveform to electrically stimulate the at least one nerve; and ]	[ A device operably connected to the spinal cord of a patient, the device comprising a spinal cord catheter and a flexible cord having a cross section and an elongate length, wherein the elongate length is at least 1,2, 3 or 4 times the cross section of a human cell; and ]
0.99999046	838	[ an output device connected to the transmitter and configured to emit an ultrasound waveform and to sense and to produce electrical signals. ]	[ a signal carrier arranged to contact and provide an electrical signal to at least one nerve being received by the spinal cord catheter, the signal carrier comprising a transmitter that transmits an ultrasound waveform to electrically stimulate the at least one nerve; and ]
0.9999808	839	[ a lumen formed over an outer surface of the stent; and ]	[ A stent comprising: ]
0.9998103	840	[ an adhesive having a solid core material and a viscosity effective to bond the solid core material to the outer surface of the foam stent, wherein the solid core material is in an open-cell configuration and the viscosity has a weight ratio between 90% or greater and less than 40% by weight, wherein the solid core material has a density of at least 1.5 g/cm2 and the viscosity has a coefficient of friction which is greater than 25 at about 1 m/s. ]	[ a lumen formed over an outer surface of the stent; and ]
0.99955827	841	[ a support unit configured to be affixed to a patient, wherein the support unit includes a longitudinal axis that is generally perpendicular to the longitudinal axis of the support unit, wherein a plurality of light source elements positioned along the longitudinal axis of the support unit are adjustable substantially from a first position, wherein a first light source is positioned proximate to the longitudinal axis of the support unit, to a second position, wherein the light source is positioned at one end of the longitudinal axis of the support unit, and ]	[ An apparatus for monitoring a patient, the apparatus comprising: ]
0.99999154	842	[ where the first position and the second position are relative to the longitudinal axis of the support unit; ]	[ a support unit configured to be affixed to a patient, wherein the support unit includes a longitudinal axis that is generally perpendicular to the longitudinal axis of the support unit, wherein a plurality of light source elements positioned along the longitudinal axis of the support unit are adjustable substantially from a first position, wherein a first light source is positioned proximate to the longitudinal axis of the support unit, to a second position, wherein the light source is positioned at one end of the longitudinal axis of the support unit, and ]
0.9999888	843	[ a plurality of sensors and electrodes located at respective proximal ends of the longitudinal axis of the support unit, wherein the plurality of sensors and electrodes each is configured to be positioned substantially parallel with the longitudinal axis of the support unit and, when the support unit is not affixed to the patient, which configuration is aligned with a center of gravity of the patient; ]	[ where the first position and the second position are relative to the longitudinal axis of the support unit; ]
0.9999852	844	[ a controller including at least one command processor configured to be electrically coupled to a plurality of sensors to receive a signal corresponding to a function to be monitored in response to a command to operate the operation of the support unit of the apparatus, wherein the at least one command processor provides a plurality of signals representative of the function to be monitored. ]	[ a plurality of sensors and electrodes located at respective proximal ends of the longitudinal axis of the support unit, wherein the plurality of sensors and electrodes each is configured to be positioned substantially parallel with the longitudinal axis of the support unit and, when the support unit is not affixed to the patient, which configuration is aligned with a center of gravity of the patient; ]
0.9993197	845	[ a compound of formula (I) wherein R1, R2 and R4 are each independently and independently selected from the group consisting of hydrogen, CH2, C(H)CH3, CO, N(H)H, N(SCH2)C(CH2)CH30, OH, NR3, CH(NH)2, C1-10alkyl, CO, O2-10alkoxy, OH, C1-9alkoxy, C1-2alkoxy, CO, NH5-O, NH4-O, OC2-2-2-3alkyl, CN, CH(O2)C1-3alkyl, NCO1, CH(O2)C1-3alkyl, NR3, n-methoxy, OH, CO2-3, CO3-1, NR5-O, N(CH2)2, CH3, CO, N(O)NH2, CR, NH or CO2-NH. ]	[ A method of treating a condition in a mammal, including treating the condition by contacting the condition with a therapeutically effective amount of a compound, wherein said compound comprises a salt or salt product selected from the group consisting of: ]
0.006934992	846	[ a) a container and two fluid carriers, each having a distal end and a proximal end and a fluid conduit between a proximal end of the container and a distal end of the container, the conduit being configured to receive a fluid; ]	[ A drug delivery apparatus comprising: ]
0.9998411	847	[ b) a plurality of transducers between the transducers of the transgenerator; ]	[ a) a container and two fluid carriers, each having a distal end and a proximal end and a fluid conduit between a proximal end of the container and a distal end of the container, the conduit being configured to receive a fluid; ]
0.9997868	848	[ c) a pump operable to pump the fluid from the fluid transducer to a fluid transport reservoir and within the transfer fluid receptacle of the fluid carrier. ]	[ b) a plurality of transducers between the transducers of the transgenerator; ]
0.9948978	849	[ a housing; ]	[ An electronic device comprising: ]
0.9726303	850	[ a first power source; ]	[ a housing; ]
0.9999913	851	[ a second power source; ]	[ a first power source; ]
0.984781	852	[ a power-off device that generates sufficient power to power the electronic device; and ]	[ a second power source; ]
0.99996996	853	[ a battery, wherein the power-off device is configured to be placed in contact with first and second ends of a flexible sheet having first and second faces, wherein the first and second faces provide a contact surface, and ]	[ a power-off device that generates sufficient power to power the electronic device; and ]
0.9999919	854	[ wherein, when in a first position, the first side of the flexible sheet contacts the first power source when the first and second faces are on the flexible sheet and when in a second position, the first face contacts the second side of the flexible sheet when the flexible sheet is in contact with said first and second faces; ]	[ a battery, wherein the power-off device is configured to be placed in contact with first and second ends of a flexible sheet having first and second faces, wherein the first and second faces provide a contact surface, and ]
0.99999225	855	[ wherein when in a first actuation position, the first side of the flexible sheet is positioned between the first power source and said power-off device, and ]	[ wherein, when in a first position, the first side of the flexible sheet contacts the first power source when the first and second faces are on the flexible sheet and when in a second position, the first face contacts the second side of the flexible sheet when the flexible sheet is in contact with said first and second faces; ]
0.99999213	856	[ when in a second actuation position, the first side of the flexible sheet is positioned between the first power source and the second power source. ]	[ wherein when in a first actuation position, the first side of the flexible sheet is positioned between the first power source and said power-off device, and ]
0.9999443	857	[ wherein the therapeutic amount is not more than 2.75 &#x3bc; ]	[ A method of treating or preventing neurodegeneration in a mammal, comprising administering to the mammal a therapeutic amount of a pharmaceutical composition, wherein the pharmaceutical composition is the same at a concentration of 50 mg/cm3 or greater than the concentration of 50 mg/cm3, and ]
0.01266817	858	[ m. ]	[ wherein the therapeutic amount is not more than 2.75 &#x3bc; ]
0.998919	859	[ introducing the sample through a single-phase infusion tube to a blood stem cell in the lumen of the infusion tube such that the infusion tube extends through a peripheral wall of the infusion tube and exits the blood stem cell, ]	[ A method of detecting an immune response, comprising: ]
0.99999225	860	[ detecting a change in size of the peripheral wall of the infusion tube based upon the size of the infusion tube; ]	[ introducing the sample through a single-phase infusion tube to a blood stem cell in the lumen of the infusion tube such that the infusion tube extends through a peripheral wall of the infusion tube and exits the blood stem cell, ]
0.99999213	861	[ measuring the size of the peripheral wall after the infusion tube exits the blood stem cell, ]	[ detecting a change in size of the peripheral wall of the infusion tube based upon the size of the infusion tube; ]
0.99999213	862	[ determining if a change in the size of the peripheral wall within a period of less than 48 hours following the infusion tube exiting the blood stem cell indicates that the immune response may be indicative, and ]	[ measuring the size of the peripheral wall after the infusion tube exits the blood stem cell, ]
0.99999225	863	[ if the size of the peripheral wall is not determined within the period of less than 48 hours, further testing if the immune response may be indicative, and ]	[ determining if a change in the size of the peripheral wall within a period of less than 48 hours following the infusion tube exiting the blood stem cell indicates that the immune response may be indicative, and ]
0.99999225	864	[ if the immune response is not determined then determining an immune response level within the blood stem cell. ]	[ if the size of the peripheral wall is not determined within the period of less than 48 hours, further testing if the immune response may be indicative, and ]
0.9999919	865	[ (a) administering to the blood sample a therapeutic agent which enhances the ability of the blood sample to absorb the therapeutic agent, ]	[ A method of enhancing the absorption of a therapeutic agent in a blood sample from a subject in need thereof comprising the steps of: ]
0.9999883	866	[ (b) detecting a change in permeability of the blood sample from a first value to a second value in a time interval, the change being greater than about 1 min, such that the permeability of the blood sample is increased when the change is greater than about 1 min than when the change is less than about 1 minute; ]	[ (a) administering to the blood sample a therapeutic agent which enhances the ability of the blood sample to absorb the therapeutic agent, ]
0.9999924	867	[ (c) analyzing the change in permeability detected in step (b) relative to the first value to determine whether the change in a time interval is indicative of an increase in the ability of the blood sample to absorb the therapeutic agent. ]	[ (b) detecting a change in permeability of the blood sample from a first value to a second value in a time interval, the change being greater than about 1 min, such that the permeability of the blood sample is increased when the change is greater than about 1 min than when the change is less than about 1 minute; ]
0.9999908	868	[ delivering a delivery device into the patient to deliver a therapeutically effective amount of a medicine or a therapeutically effective amount of a composition into the patient; ]	[ A method for delivering a medicine into a patient during said patient being a patient of a device, the method comprising: ]
0.99999094	869	[ receiving, using the device, a diagnosis of a patient having a condition which includes a blood vessel disease, wherein the diagnosis indicates that said delivery device is a therapeutically effective delivery device and that said delivery device is delivered into the patient by a user; ]	[ delivering a delivery device into the patient to deliver a therapeutically effective amount of a medicine or a therapeutically effective amount of a composition into the patient; ]
0.99999154	870	[ determining that the delivery device is a device which is not being used; ]	[ receiving, using the device, a diagnosis of a patient having a condition which includes a blood vessel disease, wherein the diagnosis indicates that said delivery device is a therapeutically effective delivery device and that said delivery device is delivered into the patient by a user; ]
0.9986957	871	[ deactivating the device by at least one of a user who initiates the deactivation from the device and the device; ]	[ determining that the delivery device is a device which is not being used; ]
0.89848095	872	[ delivering the medicine to the vessel; ]	[ deactivating the device by at least one of a user who initiates the deactivation from the device and the device; ]
0.9999862	873	[ removing the device from the vessel; ]	[ delivering the medicine to the vessel; ]
0.9998704	874	[ determining that the delivery device or the device is in a range where it is not being used; and ]	[ removing the device from the vessel; ]
0.99965715	875	[ removing the device from the vessel; ]	[ determining that the delivery device or the device is in a range where it is not being used; and ]
0.0026911264	876	[ wherein the patient is at the patient's treatment center and a patient in the patient's care is at the patient's treatment center. ]	[ removing the device from the vessel; ]
0.99927706	877	[ selecting a sample for processing; ]	[ A method for the processing of a blood sample from a patient, comprising the steps of: ]
0.99998784	878	[ mixing the sample using a first extraction process to isolate the first portion of the blood sample to be processed; ]	[ selecting a sample for processing; ]
0.9999924	879	[ mixing a second extraction process with the first extraction process to extract a second portion of the sample; ]	[ mixing the sample using a first extraction process to isolate the first portion of the blood sample to be processed; ]
0.99998295	880	[ separating the second portion from the first portion; ]	[ mixing a second extraction process with the first extraction process to extract a second portion of the sample; ]
0.9999726	881	[ determining whether a first property of the first portion indicates that the blood sample is less than a predetermined condition at a threshold level; and ]	[ separating the second portion from the first portion; ]
0.99999225	882	[ selecting a second processing step based on a determination that the first property of the first portion indicates that the blood sample is less than the predetermined condition at the threshold level. ]	[ determining whether a first property of the first portion indicates that the blood sample is less than a predetermined condition at a threshold level; and ]
0.9987174	883	[ a flexible flexible device having a proximal end, ]	[ An implantable medical device that is adapted to be inserted into a body, the device comprisingan implantable medical lead with an elongated housing, ]
0.9997402	884	[ a first conductive electrode attached to the connector portion of the elongated housing and located adjacent the proximal end of the elongated housing, ]	[ a flexible flexible device having a proximal end, ]
0.99999225	885	[ a second conductive electrode attached to the connector portion of the elongated housing and located adjacent the proximal end of the elongated housing, ]	[ a first conductive electrode attached to the connector portion of the elongated housing and located adjacent the proximal end of the elongated housing, ]
0.99879515	886	[ a first electrode to be electrically coupled to the implantable medical lead, and ]	[ a second conductive electrode attached to the connector portion of the elongated housing and located adjacent the proximal end of the elongated housing, ]
0.9999888	887	[ a second electrode to be electrically coupled to the second conductive electrode, ]	[ a first electrode to be electrically coupled to the implantable medical lead, and ]
0.9999894	888	[ wherein each of the first and second contacts is electrically coupled to the second electrode to be electrically coupled to the implantable medical lead, and ]	[ a second electrode to be electrically coupled to the second conductive electrode, ]
0.99995875	889	[ wherein the coil and the coils of the first and second electrodes are electrically connected together. ]	[ wherein each of the first and second contacts is electrically coupled to the second electrode to be electrically coupled to the implantable medical lead, and ]
0.99998975	890	[ analyzing a first patient's cardiac activity; ]	[ A computer-implemented method for identifying a group of patients having a first characteristic that is indicative of a risk of cardiac arrhythmia, such method comprising the steps of: ]
0.9999924	891	[ identifying a second patient with a risk of cardiac arrhythmia that is different from the first patient's cardiac activity; and ]	[ analyzing a first patient's cardiac activity; ]
0.9999924	892	[ identifying a first characteristic that indicates the degree to which a risk of cardiac arrhythmia is common to the first patient and the first characteristic of the second patient, wherein the first characteristic of the first patient is different from the second characteristic of the second patient and wherein the risk of cardiac arrhythmia in the first patient is different from the risk of cardiac arrhythmia in the second patient. ]	[ identifying a second patient with a risk of cardiac arrhythmia that is different from the first patient's cardiac activity; and ]
0.9925539	893	[ (i) a biodegradable, deformable, rigid body in a body-shaped configuration having a center of curvature; ]	[ An implantable implant for a spinal implant, comprising: ]
0.9998331	894	[ (ii) at least one distal end portion of at least one surface of at least one implantable surface, wherein the proximal end portion comprises at least one resilient material in the form of a hollow tube and a cylindrical shape; ]	[ (i) a biodegradable, deformable, rigid body in a body-shaped configuration having a center of curvature; ]
0.99999166	895	[ (iii) at least one connector on at least one of the at least one surface and the hollow tube; and ]	[ (ii) at least one distal end portion of at least one surface of at least one implantable surface, wherein the proximal end portion comprises at least one resilient material in the form of a hollow tube and a cylindrical shape; ]
0.9999907	896	[ (iv) at least one connector end portion on the cylindrical shape of the at least one surface, wherein the at least one connector end portion is configured to receive a portion of a vertebral spine. ]	[ (iii) at least one connector on at least one of the at least one surface and the hollow tube; and ]
0.9999174	897	[ a catheter body adapted to be placed on a catheter arm; and ]	[ A catheter comprising: ]
0.99999213	898	[ a catheter arm, the catheter body, and ]	[ a catheter body adapted to be placed on a catheter arm; and ]
0.9999906	899	[ the catheter arm configured to interlock and permit fluid flow therethrough between the catheter arm and the catheter body of a first length and a second length, said second length of the catheter extending through at least one of a first end of each of the catheter arms and at a second end of each of the catheter arms, wherein the first end of each of the first length of the catheter ends at a first port of fluid delivery means connected to the first length, and ]	[ a catheter arm, the catheter body, and ]
0.99998975	900	[ a second end of each of the first length of the catheter ends at a second port of fluid delivery means connected to a second length, each of the port of fluid delivery means in fluid communication with at least one of said first port of fluid delivery means for allowing the fluid flow through the at least one of the first port of fluid delivery means to the at least one of said first length of the catheter. ]	[ the catheter arm configured to interlock and permit fluid flow therethrough between the catheter arm and the catheter body of a first length and a second length, said second length of the catheter extending through at least one of a first end of each of the catheter arms and at a second end of each of the catheter arms, wherein the first end of each of the first length of the catheter ends at a first port of fluid delivery means connected to the first length, and ]
0.99784636	901	[ (a) acquiring a plurality of images on a display device by performing a plurality of scanning motions on the display device; ]	[ A computer-implemented method for creating a graphical display object, the method comprising: ]
0.9998573	902	[ (b) calculating a first plurality of attributes of the one or more images from the plurality of images, and ]	[ (a) acquiring a plurality of images on a display device by performing a plurality of scanning motions on the display device; ]
0.99999225	903	[ storing the first plurality of attributes when comparing two different images that contain similar images; ]	[ (b) calculating a first plurality of attributes of the one or more images from the plurality of images, and ]
0.99999046	904	[ (c) calculating a second plurality of attributes of the one or more images from the plurality of images, and ]	[ storing the first plurality of attributes when comparing two different images that contain similar images; ]
0.99999213	905	[ storing the second plurality of attributes when comparing two different images that contain similar images; and ]	[ (c) calculating a second plurality of attributes of the one or more images from the plurality of images, and ]
0.011558596	906	[ (d) generating a graphical display object by performing a graphical display operation on the graphical display object. ]	[ storing the second plurality of attributes when comparing two different images that contain similar images; and ]
0.9999919	907	[ wherein at least a portion of the exterior surface of the golf ball is coated with said conductive materials which conduct in air from the lower end to the bottom of the golf ball; ]	[ A golf ball having a surface configured to be played golf-like from the upper end to the bottom of the ball, the ball having an external diameter of less than 5 microns, ]
0.99998915	908	[ wherein the ball is coated with a conductive pattern which comprisesa plurality of alternating strips of conductive material; and ]	[ wherein at least a portion of the exterior surface of the golf ball is coated with said conductive materials which conduct in air from the lower end to the bottom of the golf ball; ]
0.999959	909	[ a surface which substantially covers the alternating conductive sheets, and ]	[ wherein the ball is coated with a conductive pattern which comprisesa plurality of alternating strips of conductive material; and ]
0.99564666	910	[ which is provided with a plurality of grooves arranged in a generally arcuate shape between said patterns of conductive material. ]	[ a surface which substantially covers the alternating conductive sheets, and ]
0.9999907	911	[ wherein the ratio of said number of radical groups between the 6 to 36 atoms is as follows: ]	[ A composition for producing a non-contoured hair shaft, said composition comprising a formula for producing a non-contoured hair shaft, which formula comprises a number of radicals or a group of radicals of said formula which together represents a radical from each of 6 to 36 atoms, and ]
0.008804141	912	[ A1 1.3-7.1 &#x3bc; ]	[ wherein the ratio of said number of radical groups between the 6 to 36 atoms is as follows: ]
0.9999906	913	[ 1&#x3bc; &#x3bc; 3.0, a2 1.6-7.3 &#x3bc; ]	[ A1 1.3-7.1 &#x3bc; ]
0.99996626	914	[ 1&#x3bc; &#x3bc; 3.9, a3 1.6-7.4 &#x3bc; ]	[ 1&#x3bc; &#x3bc; 3.0, a2 1.6-7.3 &#x3bc; ]
0.99990034	915	[ 1&#x3bc; &#x3bc; 7.0, x4=1-3, ]	[ 1&#x3bc; &#x3bc; 3.9, a3 1.6-7.4 &#x3bc; ]
0.9999877	916	[ x5=1-3, and ]	[ 1&#x3bc; &#x3bc; 7.0, x4=1-3, ]
0.9992519	917	[ m(x)0=(1-x)2 or m(2x )4=(1-x2)2&#x2212; ]	[ x5=1-3, and ]
0.97011214	918	[ 1. ]	[ m(x)0=(1-x)2 or m(2x )4=(1-x2)2&#x2212; ]
0.999992	919	[ the D3-D5 chain consisting of 3 to 4 amino acids of the diterpentan moiety; and ]	[ A pharmaceutical composition comprising one or more monomers including(a) diterpenes that specifically interact with a polyethylene glycol monomer including a diterpentan moiety, wherein the D3-D5 cyclic diterpentan moiety of the diterpentan moiety comprises: ]
0.99940586	920	[ an amino terminal residue which is at least 3 amino acids away from the amino terminus of the C1-C6 chain of the polyethylene glycol monomer in the polyethylene glycol. ]	[ the D3-D5 chain consisting of 3 to 4 amino acids of the diterpentan moiety; and ]
0.0007816346	921	[ a material that is resistant to corrosion and that can be exposed to at least a portion of a material composition; ]	[ A method for manufacturing a liquid comprising: ]
0.99917173	922	[ a coating portion that is substantially all of the material material and is the material; and ]	[ a material that is resistant to corrosion and that can be exposed to at least a portion of a material composition; ]
0.0008908928	923	[ a barrier assembly including: ]	[ a coating portion that is substantially all of the material material and is the material; and ]
0.99769753	924	[ an opening that is at least partially closed; ]	[ a barrier assembly including: ]
0.99996793	925	[ an upper surface that is substantially planar, substantially rigid and substantially perpendicular to the upper surface at a generally vertical distance from an upper point of the opening; ]	[ an opening that is at least partially closed; ]
0.9999906	926	[ a barrier surface that has a width that is larger than the width of the upper surface; and ]	[ an upper surface that is substantially planar, substantially rigid and substantially perpendicular to the upper surface at a generally vertical distance from an upper point of the opening; ]
0.9999912	927	[ an elastomer having at least one bond or bond-receiving part extending between the upper surface and outer surface of the barrier surface; ]	[ a barrier surface that has a width that is larger than the width of the upper surface; and ]
0.9999883	928	[ wherein the barrier surface has a substantially smooth, non-scattered surface layer that is not scattered upon contact with contact surface and that forms an open space to be exposed to the material composition; and ]	[ an elastomer having at least one bond or bond-receiving part extending between the upper surface and outer surface of the barrier surface; ]
0.99999166	929	[ wherein the wall thickness of the material composition has an equal weight to the width of the upper surface. ]	[ wherein the barrier surface has a substantially smooth, non-scattered surface layer that is not scattered upon contact with contact surface and that forms an open space to be exposed to the material composition; and ]
0.9958003	930	[ first producing a substrate by mixing a hydroxypropylcellulose with a polymer mixture comprising 1, ]	[ A method of producing a composite polyolefin with a thickness of at least 80% by weight, comprising: ]
0.9989506	931	[ 3-dimethylcyclopropylmethylcellulose and 10-diphexysiloxysiloxane; wherein the 2, ]	[ first producing a substrate by mixing a hydroxypropylcellulose with a polymer mixture comprising 1, ]
0.99999225	932	[ 3-dimethylcyclopropylmethylcellulose and the 10-diphexysiloxysiloxane have a weight ratio of less than 10: ]	[ 3-dimethylcyclopropylmethylcellulose and 10-diphexysiloxysiloxane; wherein the 2, ]
0.97981274	933	[ 1. ]	[ 3-dimethylcyclopropylmethylcellulose and the 10-diphexysiloxysiloxane have a weight ratio of less than 10: ]
0.00017965212	934	[ a) at least one complementarity determinant comprising a first GAG and a second GAG, wherein the first GAG is bound to the first GAG by both hydrogen binding or polypeptide bonds, wherein the second GAG provides aminoacylglycolic acid moieties, and ]	[ An isolated monoclonal antibody specifically specifically directed against IL-8, wherein the monoclonal antibody comprises a monoclonal chain length of at least 16 kDa and comprising: ]
0.99999166	935	[ the first and second GAG are respectively present in a homogeneous structure; and ]	[ a) at least one complementarity determinant comprising a first GAG and a second GAG, wherein the first GAG is bound to the first GAG by both hydrogen binding or polypeptide bonds, wherein the second GAG provides aminoacylglycolic acid moieties, and ]
0.9999765	936	[ b) one, or more, complementarity determining regions that are bound to the bound GAG. ]	[ the first and second GAG are respectively present in a homogeneous structure; and ]
0.99999	937	[ positioning a pair of elongated arms proximate to the body and distal to an upper torso; ]	[ A method of providing support for an upper torso, said method comprising: ]
0.9999746	938	[ defining an arcuate path from the arms; ]	[ positioning a pair of elongated arms proximate to the body and distal to an upper torso; ]
0.999992	939	[ securing the arms at a first point to the arcuate path, the arms proximate to the arcuate path, thereby providing a support base for a respective arm within the arcuate path, the support base having proximal ends; and ]	[ defining an arcuate path from the arms; ]
0.9999733	940	[ adjusting in a first axis position of the arms, the first axis including a central axis, and ]	[ securing the arms at a first point to the arcuate path, the arms proximate to the arcuate path, thereby providing a support base for a respective arm within the arcuate path, the support base having proximal ends; and ]
0.9998853	941	[ a second axis, ]	[ adjusting in a first axis position of the arms, the first axis including a central axis, and ]
0.99997866	942	[ wherein the first axis position substantially aligns with a distal point of each arm and the second axis position substantially aligns with the distal point of each arm, ]	[ a second axis, ]
0.9999913	943	[ wherein the first axis positions the arms proximate to a respective position where a proximal portion of the arms is proximate to the chest of the respective torso and away from the shoulder blades of the respective body, and ]	[ wherein the first axis position substantially aligns with a distal point of each arm and the second axis position substantially aligns with the distal point of each arm, ]
0.99997175	944	[ a distal point of each of the arms is less than the distal range of the arms, ]	[ wherein the first axis positions the arms proximate to a respective position where a proximal portion of the arms is proximate to the chest of the respective torso and away from the shoulder blades of the respective body, and ]
0.9999918	945	[ wherein the arms are positioned at a position near the distal point of each arm. ]	[ a distal point of each of the arms is less than the distal range of the arms, ]
0.99995136	946	[ identifying, by a processor, a plurality of hybrid transgenic DNA constructs comprising a plurality of genes containing a promoter, wherein the plurality of gene segments are selected from the group consisting of, ]	[ A method for controlling a plurality of transgenic strains each of which contains at least one promoter, the method comprising: ]
0.99257386	947	[ (i) a plurality of progeny, and ]	[ identifying, by a processor, a plurality of hybrid transgenic DNA constructs comprising a plurality of genes containing a promoter, wherein the plurality of gene segments are selected from the group consisting of, ]
0.9999281	948	[ (ii) a plurality of chimeric transgenic DNA constructs, wherein a chimeric progeny of the plurality of gene segments has a gene comprising a first target gene and a gene comprising a second target gene, wherein the DNA constructs from each of the plurality of gene segments have at least one of: a DNA region containing the first target gene and the second target gene; and, and ]	[ (i) a plurality of progeny, and ]
0.99999225	949	[ wherein each of the first target gene and the second target gene is expressed by at least one of the DNA constructs from the plurality of gene segments. ]	[ (ii) a plurality of chimeric transgenic DNA constructs, wherein a chimeric progeny of the plurality of gene segments has a gene comprising a first target gene and a gene comprising a second target gene, wherein the DNA constructs from each of the plurality of gene segments have at least one of: a DNA region containing the first target gene and the second target gene; and, and ]
0.00011587614	950	[ at least a first layer for preparing a bioplastic material, said first layer including a first material; ]	[ A device for treating a patient for a degenerative disease, comprising: ]
0.99999225	951	[ at least a second layer for providing surface and structure of the bioplastic material at a first volume, and ]	[ at least a first layer for preparing a bioplastic material, said first layer including a first material; ]
0.99999225	952	[ at least a third layer for providing surface and structure of the bioplastic material at a second volume; and ]	[ at least a second layer for providing surface and structure of the bioplastic material at a first volume, and ]
0.9999924	953	[ a support for supporting the at least first layer and the at least second layer, said support being in a second volume different than the first volume in which said second layer and said first layer are disposed, wherein said support is adapted to support the surfaces and structure of the bioplastic material in the second volume. ]	[ at least a third layer for providing surface and structure of the bioplastic material at a second volume; and ]
0.9990522	954	[ a power supply unit for supplying a plurality of electrically conductive electrical wires to a current source; ]	[ An apparatus for providing electrical power to a power source, the apparatus comprising: ]
0.99999213	955	[ a current detecting unit for detecting an individual current flowing from a central conductor of the plurality of electrically conductive electrical wires; ]	[ a power supply unit for supplying a plurality of electrically conductive electrical wires to a current source; ]
0.99999225	956	[ an output detecting unit for detecting output of the output detecting unit from the central conductor of the plurality of electrically conductive electrical wires; ]	[ a current detecting unit for detecting an individual current flowing from a central conductor of the plurality of electrically conductive electrical wires; ]
0.99918884	957	[ a receiving module for receiving an output signal from the current source; and ]	[ an output detecting unit for detecting output of the output detecting unit from the central conductor of the plurality of electrically conductive electrical wires; ]
0.9999443	958	[ a control unit for controlling the electrical power flowing through the power supply unit from the current source to the current detecting unit. ]	[ a receiving module for receiving an output signal from the current source; and ]
0.9999912	959	[ an edge surface defining a perimeter and having a first portion for receiving an elongate piece of material, a second portion defining a longitudinal axis for receiving a support device, and ]	[ A flexible device having a front edge, an interior wall, a lateral edge defining a longitudinal axis for receiving a connector, a lateral border defining an open slot for holding a strap, and ]
0.99998343	960	[ a third portion of surface for receiving a first side portion of a wrist of a person; ]	[ an edge surface defining a perimeter and having a first portion for receiving an elongate piece of material, a second portion defining a longitudinal axis for receiving a support device, and ]
0.99931777	961	[ wherein the interior walls are sized for positioning the flexible device on an area between the outer surface of the side portions, wherein the second portion of face region is smaller than the second portion of exterior surface and the lateral border has a larger diameter than that of the interior wall. ]	[ a third portion of surface for receiving a first side portion of a wrist of a person; ]
0.9982774	962	[ 2 in length. ]	[ An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: ]
0.982787	963	[ a) a non-conductive body having a substantially flat-shape and having a tip with a first end and a second end opposite to the first end, the substantially flat shape comprising a first hole, the substantially flat shape comprising a second hole and a hole defining an opening to receive a ball having an elongate diameter, said elongate diameter not less than about 40 mm; ]	[ A portable golf ball comprising: ]
0.9999845	964	[ b) a generally non-conductive material between the first and second holes; ]	[ a) a non-conductive body having a substantially flat-shape and having a tip with a first end and a second end opposite to the first end, the substantially flat shape comprising a first hole, the substantially flat shape comprising a second hole and a hole defining an opening to receive a ball having an elongate diameter, said elongate diameter not less than about 40 mm; ]
0.99982953	965	[ c) a substantially hollow housing having a diameter greater than about 1.5 mm; and ]	[ b) a generally non-conductive material between the first and second holes; ]
0.99997544	966	[ d) a non-conductive filler formed on a bottom portion of the housing such that at least a portion of the cushion material is provided by said housing, the filler in communication with the substantially hollow housing and at least the substantially hollow housing including a substantially cylindrical member having a first end and a second end. ]	[ c) a substantially hollow housing having a diameter greater than about 1.5 mm; and ]
0.98127675	967	[ a housing; ]	[ A device comprising: ]
0.99920684	968	[ a first and second side chamber provided in the housing and containing a storage chamber, each having an open end portion; ]	[ a housing; ]
0.9858483	969	[ a first flexible housing-cap, each housing-cap being coupled to the housing, and ]	[ a first and second side chamber provided in the housing and containing a storage chamber, each having an open end portion; ]
0.029009297	970	[ having a top surface and a bottom surface; and ]	[ a first flexible housing-cap, each housing-cap being coupled to the housing, and ]
0.022085372	971	[ a second flexible housing-cap, each housing-cap being coupled to the first flexible housing-cap, and ]	[ having a top surface and a bottom surface; and ]
0.99999213	972	[ having a top surface and a bottom surface such that a first portion of a plurality of the first side chamber enclose a second portion of a plurality of the first side chamber, whereby said housing is configured to cover said first portion and an interior surface of said first flexible housing-cap when a portion of a second portion of the first side chamber is covered with said first flexible housing-cap such that an end portion of a portion of a base portion of the housing is located adjacent said second portion at the second portion of the first side chamber. ]	[ a second flexible housing-cap, each housing-cap being coupled to the first flexible housing-cap, and ]
0.99876726	973	[ receiving a blood sample from said patient; ]	[ A method of treating a patient suffering from a chronic kidney disease, comprising: ]
0.9999727	974	[ analyzing a sample from the patient, wherein a concentration of a substance of interest in said sample corresponding to a composition of the chronic kidney disease is higher than the concentration of said substance associated with the chronic kidney disease; ]	[ receiving a blood sample from said patient; ]
0.99999213	975	[ determining a ratio of said concentration of said substance of interest to the concentration of said substance associated with the chronic kidney disease, wherein said determining the ratio is performed in a patient-specific fashion; ]	[ analyzing a sample from the patient, wherein a concentration of a substance of interest in said sample corresponding to a composition of the chronic kidney disease is higher than the concentration of said substance associated with the chronic kidney disease; ]
0.99999213	976	[ determining a change of serum levels of said substance of interest to the serum levels associated with the chronic kidney disease, wherein said determining the change of the serum levels is performed in a patient-specific fashion; ]	[ determining a ratio of said concentration of said substance of interest to the concentration of said substance associated with the chronic kidney disease, wherein said determining the ratio is performed in a patient-specific fashion; ]
0.99999225	977	[ administering a therapeutically effective amount of a therapeutically effective amount of a substance of interest, wherein said administering at least one substance of interest is said substance of interest that is associated with the chronic kidney disease. ]	[ determining a change of serum levels of said substance of interest to the serum levels associated with the chronic kidney disease, wherein said determining the change of the serum levels is performed in a patient-specific fashion; ]
0.99946624	978	[ substantially free of structural defects; ]	[ A prosthesis comprising: ]
0.9999896	979	[ a flexible implant structure including first and second projections, wherein the first projection of the prosthesis is free of structural defects and wherein the second projection is substantially flexible, and ]	[ substantially free of structural defects; ]
0.9999876	980	[ is mounted on substantially an implant surface that is substantially transparent and at least partially devoid of structural defects; and ]	[ a flexible implant structure including first and second projections, wherein the first projection of the prosthesis is free of structural defects and wherein the second projection is substantially flexible, and ]
0.9970294	981	[ at least one member capable of movement between an adjustable position in relation to the first projection and a deformable position wherein the first and second projections of the prosthesis, in the deformable position, are generally parallel to and generally parallel to one another about a single plane. ]	[ is mounted on substantially an implant surface that is substantially transparent and at least partially devoid of structural defects; and ]
0.99945027	982	[ a) at least one agent that promotes a reduced level of expression of a target gene comprising a carbohydrate-derived type 4 &#x2003; ]	[ A method of treating obesity comprising administering to one or more humans comprising: ]
0.15777525	983	[ (D4&#x2003; ]	[ a) at least one agent that promotes a reduced level of expression of a target gene comprising a carbohydrate-derived type 4 &#x2003; ]
0.96310234	984	[ ) polypeptide; ]	[ (D4&#x2003; ]
0.9985329	985	[ b) at least 4 weeks of administration of a diet comprising at least one of sugar, starch, cereal grains, low-fat milk, soybean oil, corn oil, corn oil/seed oil or sugar/starch; ]	[ ) polypeptide; ]
0.9999908	986	[ c) at least 8 weeks of administration of a glucose, carbohydrate or amino acid replacement therapy; and ]	[ b) at least 4 weeks of administration of a diet comprising at least one of sugar, starch, cereal grains, low-fat milk, soybean oil, corn oil, corn oil/seed oil or sugar/starch; ]
0.9999914	987	[ d) at least 2 weeks of administration of a therapy comprising a mixture of: ]	[ c) at least 8 weeks of administration of a glucose, carbohydrate or amino acid replacement therapy; and ]
0.99983835	988	[ i) a substance that comprises a combination of at least one of a glucagon hormone agonist and a glucagon receptor agonist; and ]	[ d) at least 2 weeks of administration of a therapy comprising a mixture of: ]
0.99989474	989	[ ii) a composition that reduces activity of a phosphofructokinase in a subject in need thereof. ]	[ i) a substance that comprises a combination of at least one of a glucagon hormone agonist and a glucagon receptor agonist; and ]
0.04491239	990	[ a base; ]	[ A medical instrument, comprising: ]
0.9998323	991	[ at least one insertable part formed on said base; ]	[ a base; ]
0.99999225	992	[ first engagement mechanism coupled to said at least one insertable part and further comprising: ]	[ at least one insertable part formed on said base; ]
0.99995875	993	[ a first support structure coupled to said first support structure which is disposed on a first portion of said base, wherein said first support structure has at least one engagement system; and ]	[ first engagement mechanism coupled to said at least one insertable part and further comprising: ]
0.99999166	994	[ a second support structure coupled to said first support structure; ]	[ a first support structure coupled to said first support structure which is disposed on a first portion of said base, wherein said first support structure has at least one engagement system; and ]
0.97971845	995	[ a pivot element configured to pivot to provide a first contact with a first axis and the first contact including a first length and another first length less than said first length, a third length less than said first length, and ]	[ a second support structure coupled to said first support structure; ]
0.99998796	996	[ a fourth length different than said first length; and ]	[ a pivot element configured to pivot to provide a first contact with a first axis and the first contact including a first length and another first length less than said first length, a third length less than said first length, and ]
0.9818541	997	[ a drive system extending from said first support structure through to a pivot member configured for engagement with at least one of said first and second support structures. ]	[ a fourth length different than said first length; and ]
0.99994886	998	[ a memory medium storing a digital sound stream; ]	[ An electronic device for producing a sound output, comprising: ]
0.99999225	999	[ an output device for outputting the digital sound stream to a source; ]	[ a memory medium storing a digital sound stream; ]
0.99997103	1000	[ a control circuit for controlling an operation of the output device and causing the output device to output a signal corresponding to a command by one or more of a user, system, or machine, the control circuit including an input for receiving the command from the user, the input receiving a command associated with the command by the one or more of the user, system, or machine; and ]	[ an output device for outputting the digital sound stream to a source; ]
0.999992	1001	[ a processor for generating a sound output based on the output from the output device based on input from the user, system, or machine; ]	[ a control circuit for controlling an operation of the output device and causing the output device to output a signal corresponding to a command by one or more of a user, system, or machine, the control circuit including an input for receiving the command from the user, the input receiving a command associated with the command by the one or more of the user, system, or machine; and ]
0.99970466	1002	[ wherein the processor includes a display apparatus for displaying a visual user interface on which a user can interact with the input for receiving the command and determining at least one result of the command, the result and the determined at least one result in a manner that includes determining the user's attitude and reaction to the result; and ]	[ a processor for generating a sound output based on the output from the output device based on input from the user, system, or machine; ]
0.999972	1003	[ wherein the processor includes at least one voice input element for inputting by the user using the control circuit to determine at least one of a physiological status or a behavioral disposition of the individual from the indication on the display. ]	[ wherein the processor includes a display apparatus for displaying a visual user interface on which a user can interact with the input for receiving the command and determining at least one result of the command, the result and the determined at least one result in a manner that includes determining the user's attitude and reaction to the result; and ]
0.019904897	1004	[ a) separating a sample into an effective amount of water and acid-soluble materials; ]	[ A method of producing at least one compound, comprising the steps of: ]
0.99999225	1005	[ b) filtering the water and acid-soluble materials to remove acid-soluble material; and ]	[ a) separating a sample into an effective amount of water and acid-soluble materials; ]
0.99999213	1006	[ c) producing a solvent through a reaction of the water and acid-soluble materials; ]	[ b) filtering the water and acid-soluble materials to remove acid-soluble material; and ]
0.99999225	1007	[ wherein the water and acid-soluble materials are removed by introducing the solvent at a temperature below a desired threshold such that the acid-soluble materials, and ]	[ c) producing a solvent through a reaction of the water and acid-soluble materials; ]
0.9988708	1008	[ any remaining water, evaporate from each other via a single solvent-induced reaction. ]	[ wherein the water and acid-soluble materials are removed by introducing the solvent at a temperature below a desired threshold such that the acid-soluble materials, and ]
0.9999924	1009	[ wherein the first biological activity is a therapeutically effective amount and is within the range of from approximately 5% to 55% by weight of the pharmacologically acceptable carrier. ]	[ An apparatus for administering a pharmaceutical composition comprising a therapeutically effective amount of selected anti-viral agents having a first biological activity and a second biological activity, the pharmaceutical composition comprising a biological product and a pharmacologically acceptable carrier, wherein the first and second biological activities are different than the first biological activity, and ]
0.9999385	1010	[ identifying and treating a condition that causes a immune response in a patient; and ]	[ A method of treating an autoimmune disease, comprising: ]
0.99990034	1011	[ administering to the patient an effective amount of a composition comprising an antibody that binds to the BV-LAP3 and BV-LEP motifs of HLA DQ2, HLA DQ6, HLA DQ9, HLA-A2 and HLA-A4. ]	[ identifying and treating a condition that causes a immune response in a patient; and ]
0.99999213	1012	[ a) delivering an inhibitor from a medication or formula to the infantile disorder; ]	[ A method of treating an infantile disorder that consists essentially of a deficiency of a key enzyme component, the infantile disorder comprising the steps of: ]
0.9999442	1013	[ b) providing an infusion from a supply line of a medicament dispenser; ]	[ a) delivering an inhibitor from a medication or formula to the infantile disorder; ]
0.99998665	1014	[ c) activating the inhibitor to increase the concentration of a key component in the infusion; ]	[ b) providing an infusion from a supply line of a medicament dispenser; ]
0.9999914	1015	[ d) administering the infusion to the infantile disorder in a manner to enhance the response to the inhibitor; and ]	[ c) activating the inhibitor to increase the concentration of a key component in the infusion; ]
0.9999913	1016	[ e) stopping the administration upon a reduction in the concentration of the key component of the infusion. ]	[ d) administering the infusion to the infantile disorder in a manner to enhance the response to the inhibitor; and ]
0.99999094	1017	[ collecting data from a user with the imaging device to determine patient-specific characteristics of the user; ]	[ A method for determining a patient's health condition, using an imaging device, comprising: ]
0.9999826	1018	[ presenting the collected data to a data management system, wherein the collected data includes a plurality of user-defined symptoms and health conditions and a user profile of the user; ]	[ collecting data from a user with the imaging device to determine patient-specific characteristics of the user; ]
0.999992	1019	[ receiving patient data comprising patient-specific physiological activity indicative of health status of particular types of symptoms or health conditions of the user; ]	[ presenting the collected data to a data management system, wherein the collected data includes a plurality of user-defined symptoms and health conditions and a user profile of the user; ]
0.99999225	1020	[ combining with a controller, the collected collected data based on the user-defined symptoms or health conditions, the collection of the collected data, the determined patient-specific characteristics of the user, the collected data, and ]	[ receiving patient data comprising patient-specific physiological activity indicative of health status of particular types of symptoms or health conditions of the user; ]
0.999443	1021	[ other information to determine a medical parameter, and ]	[ combining with a controller, the collected collected data based on the user-defined symptoms or health conditions, the collection of the collected data, the determined patient-specific characteristics of the user, the collected data, and ]
0.99971575	1022	[ presenting the collected data for selection of a treatment; and ]	[ other information to determine a medical parameter, and ]
0.99991775	1023	[ displaying on a screen a graphical representation of the graphical representation and a medical diagnosis indication indicative of the medical parameter. ]	[ presenting the collected data for selection of a treatment; and ]
0.9998672	1024	[ (a) performing a first actuator-controlled cycle; ]	[ A method for controlling a movement of a first body member relative to the first body member when a first actuator is operative on the first body member, said method comprising: ]
0.99999225	1025	[ (b) performing a second actuator-controlled cycle; ]	[ (a) performing a first actuator-controlled cycle; ]
0.9999441	1026	[ (c) periodically repeating the steps (a) through (c) until a predetermined first value is achieved; and, ]	[ (b) performing a second actuator-controlled cycle; ]
0.99998975	1027	[ (d) repeating the steps (a) through (c) until at least one of the first body member having an initial position, a desired placement and an overall direction is moved in substantially a circular manner while in the circular manner; and ]	[ (c) periodically repeating the steps (a) through (c) until a predetermined first value is achieved; and, ]
0.99999213	1028	[ (e) executing a control method to adjust a predetermined position in the circular manner for determining whether or not to perform a second cycle when a substantially opposite value is achieved. ]	[ (d) repeating the steps (a) through (c) until at least one of the first body member having an initial position, a desired placement and an overall direction is moved in substantially a circular manner while in the circular manner; and ]
0.99936265	1029	[ a) inserting a biopsy needle into a biopsy site; ]	[ A method of increasing a number of fibroblasts within a skin tissue, the method comprising: ]
0.9999857	1030	[ b) inserting a first segment of muscle; ]	[ a) inserting a biopsy needle into a biopsy site; ]
0.9999658	1031	[ c) removing a portion of said first segment at a time when a first sample of tissue is aspirated into the biopsy site, wherein the portion of said first segment is removed from the biopsy site; and ]	[ b) inserting a first segment of muscle; ]
0.9999902	1032	[ d) replacing the portion of the first segment with a second segment having longer arm length, wherein said second segment is inserted into the bone, wherein the first segment is replaced with a third segment having longer arm length and said third segment is inserted into an inner membrane layer of a fibroblast in the bone upon the first segment being removed. ]	[ c) removing a portion of said first segment at a time when a first sample of tissue is aspirated into the biopsy site, wherein the portion of said first segment is removed from the biopsy site; and ]
0.9999908	1033	[ administering to a patient an agent, the agent including a peptide and a pharmaceutically acceptable carrier, wherein said pharmacaceutically acceptable carrier is capable of enhancing delivery of one or more therapeutic agents to the patient via the peptide, and ]	[ A method for enhancing delivery of therapeutic agents administered to a patient, comprising: ]
0.99985397	1034	[ wherein the peptide comprises at least 95% of identity to the amino acid sequence of SEQ ID NO: 28 and wherein the peptide is administered to the patient for at least one of an acute hepatitis C viral infection and an acute myocardial infarction; and ]	[ administering to a patient an agent, the agent including a peptide and a pharmaceutically acceptable carrier, wherein said pharmacaceutically acceptable carrier is capable of enhancing delivery of one or more therapeutic agents to the patient via the peptide, and ]
0.99887973	1035	[ enhancing delivery of the agent to the patient to facilitate therapy. ]	[ wherein the peptide comprises at least 95% of identity to the amino acid sequence of SEQ ID NO: 28 and wherein the peptide is administered to the patient for at least one of an acute hepatitis C viral infection and an acute myocardial infarction; and ]
0.99972016	1036	[ receiving at least one of at least two primary sources of medical signals; and ]	[ A method for producing an implantable medical device for implantation in a subject in a surgical procedure, comprising: ]
0.99999154	1037	[ analyzing the received medical signals to determine whether a surgical condition exists for the subject; ]	[ receiving at least one of at least two primary sources of medical signals; and ]
0.99999225	1038	[ transmitting to at least one of the primary sources of medical signals information relating to a surgical condition of the subject for which surgical procedure the implantable medical device is produced; and ]	[ analyzing the received medical signals to determine whether a surgical condition exists for the subject; ]
0.99999213	1039	[ determining from the information transmitted about the surgical condition that a surgical procedure is required to produce the surgical device, wherein processing of the information is provided by at least one processor, wherein said at least one processor is configured to process medical signals using at least one of a first type of processing, an analysis of at least one of a number of primary sources of medical signals for a primary source of the received medical signals, or a comparison of at least one of the primary sources of medical signals including different frequency ranges of the received medical signals, during a first processing or a second processing. ]	[ transmitting to at least one of the primary sources of medical signals information relating to a surgical condition of the subject for which surgical procedure the implantable medical device is produced; and ]
0.9999598	1040	[ administering to a subject in need of such treatment a humanized therapeutic agent that is effective for treating a disease that is associated with lipid peroxidation in the liver, wherein said humanized therapeutic agent is a humanized therapeutic agent that is in a composition suitable for administration to a subject in need of such treatment; and ]	[ A method of treating a liver injury, said method comprising: ]
0.999992	1041	[ administering such an agent in a therapeutic range that is effective for treating such liver injury. ]	[ administering to a subject in need of such treatment a humanized therapeutic agent that is effective for treating a disease that is associated with lipid peroxidation in the liver, wherein said humanized therapeutic agent is a humanized therapeutic agent that is in a composition suitable for administration to a subject in need of such treatment; and ]
0.99999166	1042	[ (i) incubating the anthrogenin with an antiproliferative agent to form an anthrogenin incubator that is capable of containing at least one anthrogenin in a media; ]	[ A method of preparing an anthrogenin in a biological medium, the anthrogenin comprising three or more serogins of amino acids 50-180 amino acids in length, the method comprising the steps of: ]
0.9999924	1043	[ (ii) delivering the anthrogenin incubator from the anthrogenin incubator to at least one aqueous solution; and ]	[ (i) incubating the anthrogenin with an antiproliferative agent to form an anthrogenin incubator that is capable of containing at least one anthrogenin in a media; ]
0.9999919	1044	[ (iii) contacting the at least one aqueous solution with the three or more serogins in their respective anthrogenin and incubating said three or more serogins of amino acids for a time sufficient to cause binding of said three or more serogins to said at least one aqueous solution and thereby thereby producing the three or more serogins, and ]	[ (ii) delivering the anthrogenin incubator from the anthrogenin incubator to at least one aqueous solution; and ]
0.99999225	1045	[ wherein said three or more serogins of amino acids of the three or more serogins are each of a serogin type including a glycerine or an acid. ]	[ (iii) contacting the at least one aqueous solution with the three or more serogins in their respective anthrogenin and incubating said three or more serogins of amino acids for a time sufficient to cause binding of said three or more serogins to said at least one aqueous solution and thereby thereby producing the three or more serogins, and ]
0.998963	1046	[ providing a bed; ]	[ A method of improving patient comfort and compliance with a procedure, the method comprising: ]
0.9999908	1047	[ providing a seat in an intermediate space between the bed and the seat; ]	[ providing a bed; ]
0.9998851	1048	[ providing a bed surface on said bed; ]	[ providing a seat in an intermediate space between the bed and the seat; ]
0.9995247	1049	[ placing at least one patient support (a) disposed along any edge of the bed; ]	[ providing a bed surface on said bed; ]
0.99999213	1050	[ positioning a medical bed on the bed surface on the patient support (a); ]	[ placing at least one patient support (a) disposed along any edge of the bed; ]
0.99999213	1051	[ positioning a patient support (b) in any position on the patient support (b); ]	[ positioning a medical bed on the bed surface on the patient support (a); ]
0.99999213	1052	[ placing an object (i) in the intermediate space when the bed surface is positioned on the patient support (a); ]	[ positioning a patient support (b) in any position on the patient support (b); ]
0.99999213	1053	[ applying a load onto said bed surface when the bed surface is disposed on the patient support (a); ]	[ placing an object (i) in the intermediate space when the bed surface is positioned on the patient support (a); ]
0.99998295	1054	[ providing a control system that controls the bed, the seat and the patient support; and ]	[ applying a load onto said bed surface when the bed surface is disposed on the patient support (a); ]
0.9999838	1055	[ placing an operating instrument (i) on at least one of the patient support (a) and (b), the head of which is mounted in the intermediate space when the bed surface is placed on the seat when the bed surface is placed on the patient support (a), by moving said device relative to the bed surface and the patient support (a) to perform a treatment or procedure. ]	[ providing a control system that controls the bed, the seat and the patient support; and ]
0.999992	1056	[ a drive mechanism mounted on the toy toy system; ]	[ A toy toy system, comprising: ]
0.99999046	1057	[ a controller mounted on the drive mechanism; and ]	[ a drive mechanism mounted on the toy toy system; ]
0.9999919	1058	[ a motor mounted on the drive mechanism; ]	[ a controller mounted on the drive mechanism; and ]
0.99998724	1059	[ wherein the drive mechanism has a first side with a spring engaged, and ]	[ a motor mounted on the drive mechanism; ]
0.99993944	1060	[ a second side with an arm portion; ]	[ wherein the drive mechanism has a first side with a spring engaged, and ]
0.9999919	1061	[ wherein the drive mechanism is capable of being moved along with a body in response to movement of the arm portion relative to the second side; ]	[ a second side with an arm portion; ]
0.9999838	1062	[ wherein the drive mechanism includes first and second motors, and ]	[ wherein the drive mechanism is capable of being moved along with a body in response to movement of the arm portion relative to the second side; ]
0.9999876	1063	[ a control system for controlling the arms, wherein the first motor is mounted on the first side of the drive mechanism, and ]	[ wherein the drive mechanism includes first and second motors, and ]
0.9999838	1064	[ the second motor is powered by the control system; ]	[ a control system for controlling the arms, wherein the first motor is mounted on the first side of the drive mechanism, and ]
0.9999683	1065	[ wherein the first motor in the drive mechanism is a motor that generates an output power corresponding to the power of the first motor on one side of the drive mechanism while the robot remains on the second side of the drive mechanism and the second motor is powered by the control system upon a first motion of the arm portion on the first side; ]	[ the second motor is powered by the control system; ]
0.99999225	1066	[ wherein the first motor in the drive mechanism is mounted to the drive mechanism such that the first motor is movable within a predetermined movement range on one side of the drive mechanism while the arm portion is motioned on to the first side; and ]	[ wherein the first motor in the drive mechanism is a motor that generates an output power corresponding to the power of the first motor on one side of the drive mechanism while the robot remains on the second side of the drive mechanism and the second motor is powered by the control system upon a first motion of the arm portion on the first side; ]
0.99999213	1067	[ wherein the controller is also mounted to the drive mechanism such that the controller controls the motor for the motor to be moved from the predetermined movement range to at least the predetermined range of movable movements, wherein the predetermined movement range corresponds to an upper portion of the arm portion. ]	[ wherein the first motor in the drive mechanism is mounted to the drive mechanism such that the first motor is movable within a predetermined movement range on one side of the drive mechanism while the arm portion is motioned on to the first side; and ]
0.9999013	1068	[ wherein R1 is a hydrogen atom, the amino acid sequence being selected from the group consisting of SEQ ID&#x2014; ]	[ A method of treating a patient having an infection comprising treating the infection with an ancillary antibody comprising the amino acid sequence shown below: ]
0.9996736	1069	[ 1 and SEQ ID&#x2014; ]	[ wherein R1 is a hydrogen atom, the amino acid sequence being selected from the group consisting of SEQ ID&#x2014; ]
0.99339724	1070	[ 30 wherein R11 does not occur at least one time, R12 does not occur at least one time, and ]	[ 1 and SEQ ID&#x2014; ]
0.012355798	1071	[ R12 is selected from the group consisting of the alkyl, hydroxyl, cyano, heteroalkyl, and ]	[ 30 wherein R11 does not occur at least one time, R12 does not occur at least one time, and ]
0.9851414	1072	[ C1 to C40; and ]	[ R12 is selected from the group consisting of the alkyl, hydroxyl, cyano, heteroalkyl, and ]
0.9997174	1073	[ wherein the compound H is C1 to C60 alkyl; ]	[ C1 to C40; and ]
1.2298222e-05	1074	[ wherein the ancillary antibody binds to the infection and comprises GCP or GCP/GCP; ]	[ wherein the compound H is C1 to C60 alkyl; ]
0.9999758	1075	[ wherein the infection consists of a pathogen; and ]	[ wherein the ancillary antibody binds to the infection and comprises GCP or GCP/GCP; ]
0.9996202	1076	[ wherein the ancillary antibody is selected from the group consisting of hCTP, hCTP, hCTP cDNA, CD4, CRP, CD1, FAP/FAP cDNA, FAP/FAP cDNA, CD40, CRP polypeptide, IL-11, LPS, CRP and F-actin, as well as combinations thereof. ]	[ wherein the infection consists of a pathogen; and ]
0.99999225	1077	[ filling the solid biochar structure with a liquid solution to form the biochar solid biochar structure, the step of filling comprises: ]	[ A method of forming a biochar structure comprising at least one of depositing a biochar mixture as biochar to form a solid biochar structure, filling a solid form of the biochar with a salt solution, and ]
0.99820304	1078	[ mixing a solution of a selected solute with a salt solution; ]	[ filling the solid biochar structure with a liquid solution to form the biochar solid biochar structure, the step of filling comprises: ]
0.9999924	1079	[ mixing a water solution with the solution of the selected solute; ]	[ mixing a solution of a selected solute with a salt solution; ]
0.99999225	1080	[ mixing a liquid solution with the solution of the selected solute; ]	[ mixing a water solution with the solution of the selected solute; ]
0.99916506	1081	[ adding a chemical reaction condition comprising the solvent, and ]	[ mixing a liquid solution with the solution of the selected solute; ]
0.9920105	1082	[ at least one of water, solvent or solvents to the solution of the selected solute; ]	[ adding a chemical reaction condition comprising the solvent, and ]
0.9930253	1083	[ allowing the chemical reaction to occur; and ]	[ at least one of water, solvent or solvents to the solution of the selected solute; ]
0.9923413	1084	[ curing the porous solite using the liquid solution. ]	[ allowing the chemical reaction to occur; and ]
0.9717852	1085	[ an apparatus housing; ]	[ An apparatus for providing a therapeutic dose of a therapeutically effective amount of sodium-potentiated anesthetic to a patient, comprising: ]
0.9885584	1086	[ a plurality of electrodes placed on the housing; ]	[ an apparatus housing; ]
0.99999106	1087	[ a control unit operatively connected to the plurality of electrodes; ]	[ a plurality of electrodes placed on the housing; ]
0.99673414	1088	[ a first electrode being positioned on the housing and connected to an electrical connector; and ]	[ a control unit operatively connected to the plurality of electrodes; ]
0.999992	1089	[ a second electrode being positioned on the housing and connected to at least one of a first and second electrodes; ]	[ a first electrode being positioned on the housing and connected to an electrical connector; and ]
0.9999887	1090	[ an electrical supply wire connected to the power supply, the electrical supply wire including an electric capacitor for supplying current to one or more of the first and second electrodes. ]	[ a second electrode being positioned on the housing and connected to at least one of a first and second electrodes; ]
0.009241252	1091	[ a) contacting one or more cells with a cell culture of an anionic monomer that differs from the a)-phenylmethacrylate monomer in both the form of a heterocyclic ring and any of the heterocyclic rings and wherein the biasing factor is selected from the group consisting of a 1, ]	[ A method of selectively increasing or decreasing the amount of a polypeptide comprising: ]
0.9936352	1092	[ 5-hydroxyethoxy-cyclohexahydro- and a 1-bicyclohexahydro-2-hydroxyethyl. ]	[ a) contacting one or more cells with a cell culture of an anionic monomer that differs from the a)-phenylmethacrylate monomer in both the form of a heterocyclic ring and any of the heterocyclic rings and wherein the biasing factor is selected from the group consisting of a 1, ]
0.99985576	1093	[ a support arm extending in a first direction toward a cavity of a tooth, the support arm comprising at least one tooth mount, the support arm comprising a longitudinal axis along which the support arm extends through and between at least two recesses, first and second ends of the plurality of recesses being at substantially 90&#xb0; to 100&#xb0; from the longitudinal axis, ]	[ A dental implant for positioning on a dental surface, the implant comprising: ]
0.99999046	1094	[ a base unit defining a longitudinal axis extending from the base unit and further defining the longitudinal axis, the longitudinal axis defining an opening wherein a pair of jaw extensions located in at least two different directions between the first and second ends of the recesses and extending in parallel and generally perpendicular to the longitudinal axis are coupled together and positioned relative to the longitudinal axis, ]	[ a support arm extending in a first direction toward a cavity of a tooth, the support arm comprising at least one tooth mount, the support arm comprising a longitudinal axis along which the support arm extends through and between at least two recesses, first and second ends of the plurality of recesses being at substantially 90&#xb0; to 100&#xb0; from the longitudinal axis, ]
0.9999881	1095	[ a plurality of bone screws connected to and coupled to opposite ends of the base unit, ]	[ a base unit defining a longitudinal axis extending from the base unit and further defining the longitudinal axis, the longitudinal axis defining an opening wherein a pair of jaw extensions located in at least two different directions between the first and second ends of the recesses and extending in parallel and generally perpendicular to the longitudinal axis are coupled together and positioned relative to the longitudinal axis, ]
0.9999906	1096	[ a bone screw having a proximal end and a distal end and being configured to couple to at least one bone of the tooth adjacent to and attached to the bone screw. ]	[ a plurality of bone screws connected to and coupled to opposite ends of the base unit, ]
0.9984609	1097	[ a central body having opposed first and second inner surfaces; ]	[ An intervertebral implant comprising: ]
0.9854366	1098	[ a tubular wall having a first circumferential surface to which a first portion of the implant is affixed and a second circumferential surface that is opposed to the first circumferential surface, the second circumferential surface having a longitudinal axis perpendicular to the first circumferential surface; ]	[ a central body having opposed first and second inner surfaces; ]
0.999838	1099	[ a first electrode attached to the first circumferential surface of the central body; and ]	[ a tubular wall having a first circumferential surface to which a first portion of the implant is affixed and a second circumferential surface that is opposed to the first circumferential surface, the second circumferential surface having a longitudinal axis perpendicular to the first circumferential surface; ]
0.99999225	1100	[ a second electrode attached to a circumferential surface of the central body, the first, second and 3.30 mm spacing between the first and second circumferential surfaces being greater than the 3.30 mm spacing between the first and second circumferential surfaces. ]	[ a first electrode attached to the first circumferential surface of the central body; and ]
0.95319515	1101	[ receiving an initial message as a first message from the player; ]	[ A method comprising: ]
0.999992	1102	[ determining if the initial message is an invalid initial message in response to a second message from the player including at least one of content and a number of characters that can be used to determine whether the initial message is a invalid initial message, wherein determining the second message comprises determining whether the second message contains content or the number of characters that can be used to determine whether the initial message is an invalid initial message; ]	[ receiving an initial message as a first message from the player; ]
0.9999924	1103	[ sending the second message at least partially in response to determining that the initial message can be determined to be invalid, wherein the sending of the second message includes, ]	[ determining if the initial message is an invalid initial message in response to a second message from the player including at least one of content and a number of characters that can be used to determine whether the initial message is a invalid initial message, wherein determining the second message comprises determining whether the second message contains content or the number of characters that can be used to determine whether the initial message is an invalid initial message; ]
0.999992	1104	[ receiving, at the player's device, a determination that the initial content of the second message includes the at least one of content and the number of characters that can be used to determine whether the initial message is a valid initial message, ]	[ sending the second message at least partially in response to determining that the initial message can be determined to be invalid, wherein the sending of the second message includes, ]
0.99999225	1105	[ communicating the determination to a control device in an association with the player, wherein the control device operates to apply a rules system to be used in handling the at least one of content and the number of characters that can be used to determine whether the initial message is a valid initial message; and ]	[ receiving, at the player's device, a determination that the initial content of the second message includes the at least one of content and the number of characters that can be used to determine whether the initial message is a valid initial message, ]
0.99999225	1106	[ processing to allow updating an item in a cache when the player's device determines the second message is a valid initial message. ]	[ communicating the determination to a control device in an association with the player, wherein the control device operates to apply a rules system to be used in handling the at least one of content and the number of characters that can be used to determine whether the initial message is a valid initial message; and ]
0.9997377	1107	[ a first support member extending from a first front end of the instrument; ]	[ An apparatus for use with a surgical instrument, the apparatus comprising: ]
0.999992	1108	[ a second support member extending from the first front end; and ]	[ a first support member extending from a first front end of the instrument; ]
0.9365774	1109	[ a first spring member configured to be disposed between and supported by a first arm and a first side of the instrument, the first support member supporting the first support member by way of a first pivot, the first spring member being disposed between and supporting the first arm by way of a second pivot, the second support member supporting by way of the first pivot at a first location between a first pivot edge and at least one pivot hole formed in the first support member, the first spring member being disposed between and supporting the first arm by way of a second pivot, the second support member supporting the second support member by way of the first pivot, the second spring member being disposed between and supporting the second arm by way of the first pivot, further wherein the second arm is disposed between and supporting by way of the first pivot. ]	[ a second support member extending from the first front end; and ]
0.9830276	1110	[ a light source; ]	[ A system for providing an external image on an external imaging system, the system including: ]
0.9952642	1111	[ an image capturing unit configured to cause an image to be captured by projecting light into an external image comprising a first portion and a second portion, the first portion being in an elongate shape and the second portion being in a cylindrical shape; ]	[ a light source; ]
0.9999881	1112	[ a first light path adapted to generate light on a first axis of the image captured by the image capturing unit from the light source; and ]	[ an image capturing unit configured to cause an image to be captured by projecting light into an external image comprising a first portion and a second portion, the first portion being in an elongate shape and the second portion being in a cylindrical shape; ]
0.99999225	1113	[ a second light path adapted to generate light on a second axis of the image captured by the image capturing unit from the image capturing unit, ]	[ a first light path adapted to generate light on a first axis of the image captured by the image capturing unit from the light source; and ]
0.999992	1114	[ wherein the first light path is connected to the image capturing unit by a first coupling path and is connected to the image capturing unit by a second coupling path, ]	[ a second light path adapted to generate light on a second axis of the image captured by the image capturing unit from the image capturing unit, ]
0.99999213	1115	[ wherein the first light path and the second light path are located in a predetermined space defined in the first portions of each of the first portion of the image and the second portion of the image of each of the first and second portions and respectively configured to correspond with the respective images of the first and second portions of the image, wherein the first and second coupling paths are located in parallel, ]	[ wherein the first light path is connected to the image capturing unit by a first coupling path and is connected to the image capturing unit by a second coupling path, ]
0.99999	1116	[ wherein the device is configured to generate an image on the external imaging system by scanning on the image capturing unit with the first and second light paths and receiving, on the external imaging system, a set of reference images of the imaging system. ]	[ wherein the first light path and the second light path are located in a predetermined space defined in the first portions of each of the first portion of the image and the second portion of the image of each of the first and second portions and respectively configured to correspond with the respective images of the first and second portions of the image, wherein the first and second coupling paths are located in parallel, ]
0.99999225	1117	[ transmitting the electrical activity level of the subject through an RFID network to an RFID receiver located at a position along the subject and including one or more processors; ]	[ A method for measuring an electrical activity level of a subject, comprising: ]
0.99999225	1118	[ measuring a signal for the time period from the reception of the RFID signal to measure the electrical activity level of the subject using the RFID receiver; and ]	[ transmitting the electrical activity level of the subject through an RFID network to an RFID receiver located at a position along the subject and including one or more processors; ]
0.9999924	1119	[ storing the electrical activity level of the subject to be measured as a value in a memory of the one or more processors. ]	[ measuring a signal for the time period from the reception of the RFID signal to measure the electrical activity level of the subject using the RFID receiver; and ]
1.8355528e-05	1120	[ (i) providing a plurality of grafts of the type generally characterized as monoclonal antibody or a chimeric form, said monoclonal antibody or chimeric form expressing a heavy chain lysine moiety which includes a residue from at least one amino acid position of SEQ ID NO: 1, wherein said a chimeric form expressed or capable of expressing at least one of said heavy chain lysine moieties of all at least a portion of said heavy chain lysine moiety being at least three amino acids from SEQ ID NO: 1; and ]	[ A method for treating an obstruction of a lumen proximal to a brain, comprising: ]
0.99999225	1121	[ (ii) preparing each graft with a drug that inhibits the binding of the heavy chain lysine moiety in the graft to said protein; ]	[ (i) providing a plurality of grafts of the type generally characterized as monoclonal antibody or a chimeric form, said monoclonal antibody or chimeric form expressing a heavy chain lysine moiety which includes a residue from at least one amino acid position of SEQ ID NO: 1, wherein said a chimeric form expressed or capable of expressing at least one of said heavy chain lysine moieties of all at least a portion of said heavy chain lysine moiety being at least three amino acids from SEQ ID NO: 1; and ]
0.99999225	1122	[ wherein said drug consists of a heavy chain lysine moiety or an extracellular region of said protein and wherein said graft comprises at least the entire body of said brain and said drug comprises no more than about 80% of said drug. ]	[ (ii) preparing each graft with a drug that inhibits the binding of the heavy chain lysine moiety in the graft to said protein; ]
0.9980489	1123	[ providing a blood culture medium comprising a nucleic acid encoding an envelope protein having a amino acid sequence selected from the group consisting of SEQ ID NO: 17, 17L, 19, and ]	[ A method of increasing the concentration of human CD20 cell CD8+ T cells in a non-human mammalian subject, said method comprising: ]
0.99961984	1124	[ 20, wherein said nucleic acid expresses a human CD20 cell-containing epitope (SEQ ID NO: 17) or a human CD20 cell-containing epitope(SEQ ID NO: 19) wherein said nucleic acid is present in a concentration not greater than 25% by weight, wherein said nucleic acid expresses at least one of the following proteins in a concentration not greater than 25% by weight: ]	[ providing a blood culture medium comprising a nucleic acid encoding an envelope protein having a amino acid sequence selected from the group consisting of SEQ ID NO: 17, 17L, 19, and ]
0.99990344	1125	[ SEQ ID NO: 19, SEQ ID NO: 20, SLC1R24, orSEQ ID NO: 25 ]	[ 20, wherein said nucleic acid expresses a human CD20 cell-containing epitope (SEQ ID NO: 17) or a human CD20 cell-containing epitope(SEQ ID NO: 19) wherein said nucleic acid is present in a concentration not greater than 25% by weight, wherein said nucleic acid expresses at least one of the following proteins in a concentration not greater than 25% by weight: ]
0.999566	1126	[ and expressing a human CD20 cell-free CD8+ lymphocyte glycoprotein (CGL). ]	[ SEQ ID NO: 19, SEQ ID NO: 20, SLC1R24, orSEQ ID NO: 25 ]
0.99981624	1127	[ an ultrasonic transducer body for generating ultrasonic waves having a transmission frequency; and ]	[ An ultrasound transducer apparatus comprising: ]
0.99999225	1128	[ an input control module for controlling output of ultrasound transmitted from the ultrasonic transducer body, the ultrasonic transducer body includinga base body having an elongate member, ]	[ an ultrasonic transducer body for generating ultrasonic waves having a transmission frequency; and ]
0.02628202	1129	[ a longitudinal axis defining a distal end, and ]	[ an input control module for controlling output of ultrasound transmitted from the ultrasonic transducer body, the ultrasonic transducer body includinga base body having an elongate member, ]
0.999992	1130	[ a longitudinal axis defining an inner surface of the distal end; ]	[ a longitudinal axis defining a distal end, and ]
0.999933	1131	[ a first and second distal end portions each defining an axis, and ]	[ a longitudinal axis defining an inner surface of the distal end; ]
0.99999154	1132	[ an outer surface of one of the first and second distal end portions adjacent the axis and defining a transverse area and an internal volume in proximity to the transverse area of the first and second distal end portions and extending into the inner surface of the distal end portion; and ]	[ a first and second distal end portions each defining an axis, and ]
0.9999902	1133	[ a control circuit for controlling the transmitted ultrasonic waves by applying a first transducer output of a first ultrasonic energy channel comprising a transmitter and a control channel associated with the first ultrasonic channel to the inner surface of the distal end portion and applying a second ultrasonic energy channel comprising a transmitter and a control channel associated with the second ultrasonic channel to the inner surface of the distal end portion, thereby creating a channel boundary. ]	[ an outer surface of one of the first and second distal end portions adjacent the axis and defining a transverse area and an internal volume in proximity to the transverse area of the first and second distal end portions and extending into the inner surface of the distal end portion; and ]
0.025025247	1134	[ a) providing a sensor having a substantially cylindrical shape; ]	[ A method comprising: ]
0.999964	1135	[ b) positioning the sensor at a location adjacent to an animal so as to generate a sensed signal which is transmitted through the animal; and ]	[ a) providing a sensor having a substantially cylindrical shape; ]
0.9999863	1136	[ c) determining a position of the cat in relation to the sensor. ]	[ b) positioning the sensor at a location adjacent to an animal so as to generate a sensed signal which is transmitted through the animal; and ]
0.9999201	1137	[ C12-C30-alkyl-carbaldehyde, wherein said compound is a cyclohexyl group having a molecular weight of 80-90% by weight than C12H of the N-terminus of the C12-C24-alkyl group. ]	[ A method of inhibiting inflammation in a subject, the method comprising administering to said subject at least one of an effective amount of a compound selected from the group consisting of C12-C24-alkyl-alkyl-cyclohexyl, C12-C25-alkyl-alkylpyridine, C12-C28-alkyl-cyanoreganol, and ]
0.99999225	1138	[ administering to said unassisted user, in an interactive state, a first medication therapy component comprising a first set of prescription instructions that includes instructions to treat a patient's disease in accordance with a medication regimen based on a prescribed dose of said first medication therapy component, and ]	[ A method of providing interactive entertainment to an unassisted user in accordance with a patient-specific medication therapy, comprising: ]
0.99999225	1139	[ an additional set of prescription instructions that further includes instructions to provide information to said patient regarding the patient's disease to control performance on the medication regimen; ]	[ administering to said unassisted user, in an interactive state, a first medication therapy component comprising a first set of prescription instructions that includes instructions to treat a patient's disease in accordance with a medication regimen based on a prescribed dose of said first medication therapy component, and ]
0.00036594184	1140	[ performing on said unassisted user in said interactive state an action to interact with a mobile environment; ]	[ an additional set of prescription instructions that further includes instructions to provide information to said patient regarding the patient's disease to control performance on the medication regimen; ]
0.99999225	1141	[ wherein said interactive game of interaction includes an environment that dynamically changes over time to interact with said unassisted user in the interactive state; and ]	[ performing on said unassisted user in said interactive state an action to interact with a mobile environment; ]
0.9999864	1142	[ wherein said action to interact occurs via an interactive means in the mobile environment; and ]	[ wherein said interactive game of interaction includes an environment that dynamically changes over time to interact with said unassisted user in the interactive state; and ]
0.9999801	1143	[ providing said interactive game of interaction to said unassisted user; ]	[ wherein said action to interact occurs via an interactive means in the mobile environment; and ]
0.99062073	1144	[ said second medication therapy component based essentially on the first set of prescription instructions and the additional set of prescription instructions, which does not include any prescription instructions that are not provided to be displayed on a screen of an authorized handheld device. ]	[ providing said interactive game of interaction to said unassisted user; ]
0.99948597	1145	[ a) a plurality of antibodies and antigenic fragments of each of the antibody and antigenic fragment of each of the antibodies, ]	[ A device for administering an immunoglobulin, the device comprising: ]
0.99946815	1146	[ wherein, in a first antibody, a polypeptide comprising the amino acid sequence encoded by SEQ ID NO. 2 and the fragment of immunoglobulin that is immunohistochemically linked to said plurality of anti- CD1 antibodies comprises a binding affinity for a CD25 T cell receptor, wherein said CD25 T cell receptor is a G-protein coupled receptor1. ]	[ a) a plurality of antibodies and antigenic fragments of each of the antibody and antigenic fragment of each of the antibodies, ]
0.99996877	1147	[ a tubular body connected to a main structure, said distal end of said tubular body providing access to said heart of said patient, said distal end of said tubular body having first and second ends, said first end including a first insertion portion, said main structure having a wall that comprises a top surface, the main structure having a second insertion portion, a top surface defined by a first region of said wall, said second insertion portion, said bottom surface of the wall, adjacent said top surface of said top surface defining a closed region, said first insertion portion forming a closed loop; ]	[ A catheter for inserting into a heart of a patient and for withdrawing from said patient, comprising: ]
0.99999225	1148	[ a lumen extending between said first insertion portion and said closed region of said main structure, said lumen having an opening that extends substantially adjacent the top surface of said main structure; ]	[ a tubular body connected to a main structure, said distal end of said tubular body providing access to said heart of said patient, said distal end of said tubular body having first and second ends, said first end including a first insertion portion, said main structure having a wall that comprises a top surface, the main structure having a second insertion portion, a top surface defined by a first region of said wall, said second insertion portion, said bottom surface of the wall, adjacent said top surface of said top surface defining a closed region, said first insertion portion forming a closed loop; ]
0.999984	1149	[ an extension mechanism mounted on said main structure; ]	[ a lumen extending between said first insertion portion and said closed region of said main structure, said lumen having an opening that extends substantially adjacent the top surface of said main structure; ]
0.99904555	1150	[ said extensions extending along a proximal length in a direction perpendicular to said first insertion portion; and ]	[ an extension mechanism mounted on said main structure; ]
0.9999906	1151	[ said retracting portion defined by a third insertion portion of said first extension and in an intermediate position relative to an end of said first extension, the third insertion portion extending beyond the opening and substantially perpendicular to said opening and the first extension and being movable substantially perpendicular to the first insertion portion, including said lumen being closed at a first proximal end and in a direction perpendicular to said first insertion portion. ]	[ said extensions extending along a proximal length in a direction perpendicular to said first insertion portion; and ]
0.9997452	1152	[ administering to the patient an effective amount of a pharmaceutical composition comprising a protease inhibitor and a pharmaceutical composition comprising a cytotoxic antibody which specifically binds to the extracellular domain of CD4 cells; and ]	[ A method of treating a patient suffering from a vascular disorder in which a distal end of the blood vessel is infected by blood viruses which penetrate the surface of the blood vessel, the blood viruses infecting an endothelial tumor in the patient, the method comprising: ]
0.9999924	1153	[ administering to the patient a cytotoxic antibody which specifically binds to the extracellular domain of CD3 cells. ]	[ administering to the patient an effective amount of a pharmaceutical composition comprising a protease inhibitor and a pharmaceutical composition comprising a cytotoxic antibody which specifically binds to the extracellular domain of CD4 cells; and ]
0.9992957	1154	[ a drive shaft; ]	[ A golf swing assembly, comprising: ]
0.9983614	1155	[ a shaft member; ]	[ a drive shaft; ]
0.9914936	1156	[ a first leg that is fixedly attached to the drive shaft and which extends along the drive shaft to a distal end of the drive shaft; ]	[ a shaft member; ]
0.99999225	1157	[ a second leg that is fixedly attached to the shaft and which extends along the shaft to a distal end of the shaft; and ]	[ a first leg that is fixedly attached to the drive shaft and which extends along the drive shaft to a distal end of the drive shaft; ]
0.99998164	1158	[ a support structure including at least two rigid members with each of the members configured to deform with respect to the shaft, the support structure being formed to support the drive shaft and the first and second leg in a flexed condition, ]	[ a second leg that is fixedly attached to the shaft and which extends along the shaft to a distal end of the shaft; and ]
0.99997723	1159	[ wherein each of the members of the support structural comprises a central frame which is fixedly attached to the shaft member and which allows the members to be supported in respective axial orientation with respect to the shaft and the central frame; and ]	[ a support structure including at least two rigid members with each of the members configured to deform with respect to the shaft, the support structure being formed to support the drive shaft and the first and second leg in a flexed condition, ]
0.9958223	1160	[ wherein the support structure includes at least one movable support element; ]	[ wherein each of the members of the support structural comprises a central frame which is fixedly attached to the shaft member and which allows the members to be supported in respective axial orientation with respect to the shaft and the central frame; and ]
0.99998844	1161	[ wherein the axial position of each of the members in the axial position of the support structure is independent of each other in at least a portion of the axial orientation of the support structure. ]	[ wherein the support structure includes at least one movable support element; ]
0.996997	1162	[ a) providing a first polymer comprising a monomeric amine group, an amine group with a high concentration of hydrogen peroxide or halogen peroxide and one or less poly(butylene) oxide groups; ]	[ A method for making a biodegradable gel polymer for use in products comprising the steps of: ]
0.99999213	1163	[ b) providing a second polymer comprising a monomeric amine group having a first cross-linker or a second cross-linker, wherein the first cross-linker is selected from an aryl group, a heteroaryl group, a phenyl group, a halogen group and one or more cycloalkyl groups and the second cross-linker is selected from an aralkyl group, a cycloalkyl group and an aralkyl-aryl group and wherein the polymer is a carrier of hydrophobicity; and ]	[ a) providing a first polymer comprising a monomeric amine group, an amine group with a high concentration of hydrogen peroxide or halogen peroxide and one or less poly(butylene) oxide groups; ]
0.99997056	1164	[ c) combining the first and second polymer to form a multi-part gel polymer having the following properties: ]	[ b) providing a second polymer comprising a monomeric amine group having a first cross-linker or a second cross-linker, wherein the first cross-linker is selected from an aryl group, a heteroaryl group, a phenyl group, a halogen group and one or more cycloalkyl groups and the second cross-linker is selected from an aralkyl group, a cycloalkyl group and an aralkyl-aryl group and wherein the polymer is a carrier of hydrophobicity; and ]
0.99935883	1165	[ A) a hydrophobic bond to hydrophobic surface; ]	[ c) combining the first and second polymer to form a multi-part gel polymer having the following properties: ]
0.9999379	1166	[ B) a hydrophobicity in water; and ]	[ A) a hydrophobic bond to hydrophobic surface; ]
0.99959964	1167	[ C) a light-transmitting strength of about 30% (wt/wt) of total weight. ]	[ B) a hydrophobicity in water; and ]
0.9874791	1168	[ identifying a first compound of formula (I) from at least one second compound of formula (I), wherein at least one property of the first and the second compound determines a first or second concentration of the first compound in an apparatus that is configured to be worn, wherein the first and the second compound are selected from the group consisting of a first organic compound, a second organic compound, and ]	[ A method comprising: ]
0.99997914	1169	[ a third organic compound; and ]	[ identifying a first compound of formula (I) from at least one second compound of formula (I), wherein at least one property of the first and the second compound determines a first or second concentration of the first compound in an apparatus that is configured to be worn, wherein the first and the second compound are selected from the group consisting of a first organic compound, a second organic compound, and ]
0.9891506	1170	[ contacting the first and second compounds with an analyte to measure the at least one property of the first and the second compounds for at least one of the first and the second compounds, wherein the method further comprises contacting the second and first compounds with the analyte at a rate sufficient to reduce the level, and <|span|>/or the rate, of the analyte in the second compound. ]	[ a third organic compound; and ]
0.9999467	1171	[ a toothbrush comprising an interior and an outer surface, wherein the toothbrush comprises a first inner member, one or more interior members, and ]	[ An electronic toothbrush assembly comprising: ]
0.9998215	1172	[ one or more external ends; ]	[ a toothbrush comprising an interior and an outer surface, wherein the toothbrush comprises a first inner member, one or more interior members, and ]
0.005196246	1173	[ a toothbrush support having a plurality of support members extending from the toothbrush supporting member; ]	[ one or more external ends; ]
0.99996865	1174	[ at least two of at least the plurality of support members extending within the interior of the interior; and ]	[ a toothbrush support having a plurality of support members extending from the toothbrush supporting member; ]
0.999992	1175	[ at least one of the plurality of support members being disposed within a cavity defined between said interior and the outer surface. ]	[ at least two of at least the plurality of support members extending within the interior of the interior; and ]
0.99998665	1176	[ a) determining at least one parameter and/or characteristic of body temperature of a patient, the at least one parameter comprising at least one of a concentration of arterioles and/or endothelial cells, and; ]	[ A method for monitoring body temperature, the method comprising: ]
0.99999213	1177	[ b) generating one or more digital signals indicative of the at least one parameter from a first digital signal which is measured or an analog sensor which is not measured and whose detection is indicative of the patient's physiological condition of an extent of arterioli and/or endothelial cell saturation; ]	[ a) determining at least one parameter and/or characteristic of body temperature of a patient, the at least one parameter comprising at least one of a concentration of arterioles and/or endothelial cells, and; ]
0.99999213	1178	[ wherein the one or more digital signals are stored and transmitted to a second digital signal which is determined via digital signal processing from one or more detected digital signals which are collected in response to a plurality of measurements on one or more subjects which are further correlated for the specific measurement of the second digital signal wherein one or more of the respective measurements includes the detection of at least one arterioli on a surface of the patient; and ]	[ b) generating one or more digital signals indicative of the at least one parameter from a first digital signal which is measured or an analog sensor which is not measured and whose detection is indicative of the patient's physiological condition of an extent of arterioli and/or endothelial cell saturation; ]
0.99999225	1179	[ wherein for each of said measurement of one or more subjects the first digital signal is generated from one of a plurality of signals generated by a single sensor coupled to a single sensor device and that the second digital signal is from one or more of a plurality of signals generated by a plurality of sensors coupled to multiple sensor devices. ]	[ wherein the one or more digital signals are stored and transmitted to a second digital signal which is determined via digital signal processing from one or more detected digital signals which are collected in response to a plurality of measurements on one or more subjects which are further correlated for the specific measurement of the second digital signal wherein one or more of the respective measurements includes the detection of at least one arterioli on a surface of the patient; and ]
0.9968054	1180	[ a central processing unit (CPU) configured to store instructions; and ]	[ A system for use with a game controller, comprising: ]
0.9998068	1181	[ at least one processor configured to transmit execution instructions to a game controller for executing the instructions stored on the CPU, wherein the at least one processor is an input device and means for receiving the instructions from the at least one CPU. ]	[ a central processing unit (CPU) configured to store instructions; and ]
0.9997634	1182	[ administering to a subject in need thereof and to a plurality of other subjects in need thereof, a therapeutically effective amount of an effective amount of glycoprotein. ]	[ A method for the treatment or prevention of diabetes comprising: ]
0.99973696	1183	[ a device for providing physical assistance to a person in need of such physical assistance such that physical assistance is provided to the person while at least one of a first and a second portion of the skin of the person is exposed by an exterior surface of the at least one of a first and a second portion of the skin being exposed to the external environment; and ]	[ A system for providing assistance to a person suffering from non-pharmaceutical symptoms, comprising: ]
0.99999225	1184	[ a device for preventing the physical assistance from being provided to the person during operation of the device to create an image by a processor of at least one of the exterior surface of the at least one of the first and second portion of the skin exposed to the external environment, the device comprising: ]	[ a device for providing physical assistance to a person in need of such physical assistance such that physical assistance is provided to the person while at least one of a first and a second portion of the skin of the person is exposed by an exterior surface of the at least one of a first and a second portion of the skin being exposed to the external environment; and ]
0.9999919	1185	[ an indicator portion including a first plurality of discrete sensors, wherein the first plurality of discrete sensors are provided directly with the device for providing physical assistance for any person suffering from non-pharmaceutical symptoms and wherein the indicator portion is configured to provide the physical assistance to the person during operation of the device; ]	[ a device for preventing the physical assistance from being provided to the person during operation of the device to create an image by a processor of at least one of the exterior surface of the at least one of the first and second portion of the skin exposed to the external environment, the device comprising: ]
0.99999213	1186	[ at least one first image portion provided to the at least one device of the device for providing the physical assistance to the person; and ]	[ an indicator portion including a first plurality of discrete sensors, wherein the first plurality of discrete sensors are provided directly with the device for providing physical assistance for any person suffering from non-pharmaceutical symptoms and wherein the indicator portion is configured to provide the physical assistance to the person during operation of the device; ]
0.99999225	1187	[ at least one second image portion provided to the at least one device of the device for providing the physical assistance to the person while the at least one physical assistance is being provided. ]	[ at least one first image portion provided to the at least one device of the device for providing the physical assistance to the person; and ]
0.9999888	1188	[ (a) determining a physiological signature from the entity; ]	[ A method for determining the location or proximity to a biological system of an entity having a physiological condition, comprising: ]
0.99999225	1189	[ (b) identifying a first set of attributes by examining an association element of the entity, the first set of attributes being associated with one of the physiological signatures of a first of a plurality of entities; ]	[ (a) determining a physiological signature from the entity; ]
0.99999213	1190	[ (c) identifying a second set of attributes by examining an association element of a second of a plurality of entities, the second set of attributes being associated with one of the physiological signatures of a second entity of the plurality of entities; and ]	[ (b) identifying a first set of attributes by examining an association element of the entity, the first set of attributes being associated with one of the physiological signatures of a first of a plurality of entities; ]
0.99999225	1191	[ (d) correlating the first set of attributes of the first entity with the second set of attributes of the second entity. ]	[ (c) identifying a second set of attributes by examining an association element of a second of a plurality of entities, the second set of attributes being associated with one of the physiological signatures of a second entity of the plurality of entities; and ]
0.00018609635	1192	[ a) a hollow housing with an end part; ]	[ A bioreactor for controlling a biopsy vessel; the bioreactor comprising: ]
0.9997063	1193	[ b) a bioreactor base comprising: ]	[ a) a hollow housing with an end part; ]
0.99998856	1194	[ i) a first bioreactor body attached to said hollow housing and having a first diameter; ]	[ b) a bioreactor base comprising: ]
0.999992	1195	[ ii) a second bioreactor body attached to said hollow housing; ]	[ i) a first bioreactor body attached to said hollow housing and having a first diameter; ]
0.99988544	1196	[ iii) a first fluid pump connected to a second fluid pump; ]	[ ii) a second bioreactor body attached to said hollow housing; ]
0.99999225	1197	[ iv) a third fluid pump connected to a first fluid pump; ]	[ iii) a first fluid pump connected to a second fluid pump; ]
0.99999225	1198	[ v) a second fluid pump connected to a second fluid pump; ]	[ iv) a third fluid pump connected to a first fluid pump; ]
0.99999225	1199	[ vi) a fourth fluid pump connected to a third fluid pump; ]	[ v) a second fluid pump connected to a second fluid pump; ]
0.99986565	1200	[ vii) a second fluid sensor mounted to said hollow housing and having a first height and a second height; and ]	[ vi) a fourth fluid pump connected to a third fluid pump; ]
0.999992	1201	[ viii) a biopsy sensor mounted to said hollow housing and having at least two sensors positioned in the cavity of the biopsy vessel when said hollow housing is coupled for monitoring the volume of the fluid. ]	[ vii) a second fluid sensor mounted to said hollow housing and having a first height and a second height; and ]
0.9920305	1202	[ a) identifying a plurality of body parts, said plurality of body parts comprising a first part and a second part, each part comprising a proximal end and a distal end, said first part and said second part comprising a central axis, each central axis being fixed in shape to a longitudinal axis of a second body part, the central axis being substantially perpendicular to said longitudinal axis, said first part and said second part containing a first fluid channel extending into said first part relative to the second part, said first fluid channel defining a fluid flow path for fluid flow through said first body part; ]	[ A method for measuring position of a body portion, comprising the steps of: ]
0.99999213	1203	[ b) sensing at or at a location along said central axis a velocity that defines a fluid movement within a first fluid channel of the proximal end of said first part, said at or at said location also detecting an interaction between a first fluid or a first fluid and a first fluid channel configured to receive the first fluid in said one or more first fluid sources; ]	[ a) identifying a plurality of body parts, said plurality of body parts comprising a first part and a second part, each part comprising a proximal end and a distal end, said first part and said second part comprising a central axis, each central axis being fixed in shape to a longitudinal axis of a second body part, the central axis being substantially perpendicular to said longitudinal axis, said first part and said second part containing a first fluid channel extending into said first part relative to the second part, said first fluid channel defining a fluid flow path for fluid flow through said first body part; ]
0.99999166	1204	[ c) in a response to said sensed at or at said detected movement, controlling a velocity of fluid in the fluid flow path of said first channel in response to said sensed at or at said location, and ]	[ b) sensing at or at a location along said central axis a velocity that defines a fluid movement within a first fluid channel of the proximal end of said first part, said at or at said location also detecting an interaction between a first fluid or a first fluid and a first fluid channel configured to receive the first fluid in said one or more first fluid sources; ]
0.99999225	1205	[ in response to the velocity of fluid in said fluid flow path falling below a predetermined threshold level of said velocity, and, thereby, to create an indication that the first fluid or the first fluid channel is empty. ]	[ c) in a response to said sensed at or at said detected movement, controlling a velocity of fluid in the fluid flow path of said first channel in response to said sensed at or at said location, and ]
0.99999213	1206	[ a liquid food product base having a first and second bottom of a liquid food product; ]	[ A liquid food product, comprising: ]
0.9999924	1207	[ at least one liquid food product liquid food product container having a first bottom; ]	[ a liquid food product base having a first and second bottom of a liquid food product; ]
0.9992243	1208	[ a bottom cap; and ]	[ at least one liquid food product liquid food product container having a first bottom; ]
0.9999883	1209	[ a latching mechanism for the bottom cap that defines an opening in a front of the bottom cap, wherein the opening is configured to define a lumen in a top portion of the base, in combination with the bottom cap having an upwardly facing upper lid. ]	[ a bottom cap; and ]
0.99995077	1210	[ providing a first piece of material to be tested, the first piece of test material being adapted to be placed on or adjacent to a test article, and ]	[ A method for measuring the strength of a structure to be tested, the assembly comprising a pair of opposing axial walls having a base portion and a distal end portion, the method comprising the steps of: ]
0.99995565	1211	[ to thereby define a first testing region that extends substantially perpendicular to the axial wall to be tested, and ]	[ providing a first piece of material to be tested, the first piece of test material being adapted to be placed on or adjacent to a test article, and ]
0.9999019	1212	[ a second piece of test material being adapted to be placed on or adjacent to the test article, and ]	[ to thereby define a first testing region that extends substantially perpendicular to the axial wall to be tested, and ]
0.9998179	1213	[ to thereby define a second testing region that is relatively greater than the first testing region; ]	[ a second piece of test material being adapted to be placed on or adjacent to the test article, and ]
0.9982834	1214	[ providing a pair of support bars having an outer surface that defines a longitudinal axis and extending generally perpendicularly to the outer surface thereof; ]	[ to thereby define a second testing region that is relatively greater than the first testing region; ]
0.0030764812	1215	[ providing a first testing article, the first testing article being provided to define and extend a first test region; ]	[ providing a pair of support bars having an outer surface that defines a longitudinal axis and extending generally perpendicularly to the outer surface thereof; ]
1.4631816e-05	1216	[ supporting the pair of support bars in a longitudinal direction at an inner end side of the axial wall; and ]	[ providing a first testing article, the first testing article being provided to define and extend a first test region; ]
0.99999225	1217	[ deploying, against a test surface of the axial wall, said pair of support bars in an axial direction relative to the axial wall; ]	[ supporting the pair of support bars in a longitudinal direction at an inner end side of the axial wall; and ]
0.99999225	1218	[ wherein each of the pair of support bars engages a first section of the inner surface of at least one of the axial walls by providing a tension relative to each of the pair of support bars that is equal to or greater than a first stiffness, wherein the first stiffness is an electrical resistance of the respective pair of support bars, wherein deploying a pair of support bars provides a first force against a first of the first testing regions within the axial wall, and ]	[ deploying, against a test surface of the axial wall, said pair of support bars in an axial direction relative to the axial wall; ]
0.999992	1219	[ wherein deploying the pair of support bars to a test area of a test specimen does not provide a second force against a second of the selected one of the axial walls. ]	[ wherein each of the pair of support bars engages a first section of the inner surface of at least one of the axial walls by providing a tension relative to each of the pair of support bars that is equal to or greater than a first stiffness, wherein the first stiffness is an electrical resistance of the respective pair of support bars, wherein deploying a pair of support bars provides a first force against a first of the first testing regions within the axial wall, and ]
0.9977507	1220	[ 4, and ]	[ A pharmaceutical composition comprising (a) a composition of an antibody having the sequence or ATCC number PTA-1198, which molecule binds the extracellular domain of VEGF as identified in SEQ ID NO: ]
0.9981969	1221	[ (b) an antibody consisting of the nucleic acid sequence set forth in SEQ ID NO: ]	[ 4, and ]
0.99918514	1222	[ 4. ]	[ (b) an antibody consisting of the nucleic acid sequence set forth in SEQ ID NO: ]
0.9757001	1223	[ 1) a cycloalkyl; 1) a hydroxyalkyl; 1) a nitrogen atoms atom; 2) a carbon atom atom; ]	[ A method of measuring an absorption by a compound of a chemical ion that is in the following order of molecular weight: ]
0.9999219	1224	[ 2) an oxygen atom; 3) an anion atom; ]	[ 1) a cycloalkyl; 1) a hydroxyalkyl; 1) a nitrogen atoms atom; 2) a carbon atom atom; ]
0.99998474	1225	[ 3) a quinone atom; ]	[ 2) an oxygen atom; 3) an anion atom; ]
0.9999639	1226	[ 4) an amphiphilic moiety; and ]	[ 3) a quinone atom; ]
0.9999894	1227	[ 4) an amphiphilic complex, and ]	[ 4) an amphiphilic moiety; and ]
0.9978429	1228	[ wherein said method comprises, from an initial state, introducing the compound into a living organism to a concentration that is between about 0.02 g/L and about 30 g/L, and ]	[ 4) an amphiphilic complex, and ]
0.9999796	1229	[ thereafter sampling the concentration to determine a concentration of the compound, ]	[ wherein said method comprises, from an initial state, introducing the compound into a living organism to a concentration that is between about 0.02 g/L and about 30 g/L, and ]
0.0036555575	1230	[ wherein said molecular weight of one or more of said amino acids is between about 3.2 and about 9.2. ]	[ thereafter sampling the concentration to determine a concentration of the compound, ]
0.999992	1231	[ (a) contacting the active agent substance with a compound to be active agented to provide effective interaction of the active agent to the pharmaceutical composition; and ]	[ A method for producing a pharmaceutical composition comprising an active agent as an active agent substance, the pharmaceutical composition comprising a pharmaceutically acceptable salt and, in a pharmaceutically acceptable container, a pharmaceutical composition carrier, the method comprising: ]
0.9999924	1232	[ (b) contacting a pharmaceutical composition containing the active agent substance with a pharmaceutically acceptable carrier to produce a non-active agented pharmaceutical composition, wherein the pharmaceutically acceptable carrier comprises a formulation formulation containing a pharmaceutically acceptable active agent, ]	[ (a) contacting the active agent substance with a compound to be active agented to provide effective interaction of the active agent to the pharmaceutical composition; and ]
0.9997459	1233	[ wherein the pharmaceutical preparation is a pharmaceutical composition. ]	[ (b) contacting a pharmaceutical composition containing the active agent substance with a pharmaceutically acceptable carrier to produce a non-active agented pharmaceutical composition, wherein the pharmaceutically acceptable carrier comprises a formulation formulation containing a pharmaceutically acceptable active agent, ]
0.9787596	1234	[ providing a non-tangible container comprising: ]	[ A method comprising: ]
0.99360424	1235	[ a top portion and a bottom portion, ]	[ providing a non-tangible container comprising: ]
0.9999795	1236	[ wherein the top portion including a first end, a second end and a front edge, ]	[ a top portion and a bottom portion, ]
0.99998033	1237	[ wherein the top portion comprises a first surface and a second surface, ]	[ wherein the top portion including a first end, a second end and a front edge, ]
0.9999883	1238	[ the bottom portion comprising at least a second surface and at least a back surface; and ]	[ wherein the top portion comprises a first surface and a second surface, ]
0.9999894	1239	[ wherein the first surface, the second surface and the back surface are adapted to support an implantable medical device, and ]	[ the bottom portion comprising at least a second surface and at least a back surface; and ]
0.9999809	1240	[ wherein at least one of the first and second surfaces is flexible; ]	[ wherein the first surface, the second surface and the back surface are adapted to support an implantable medical device, and ]
0.999985	1241	[ wherein extending the first and second surfaces further includes extending the top portion to have a front, back and a front end, with an inner surface comprising a bottom portion, an outer surface and a side end, and ]	[ wherein at least one of the first and second surfaces is flexible; ]
0.9999472	1242	[ at least one of the side end is adapted to support a top of the implantable medical device; and ]	[ wherein extending the first and second surfaces further includes extending the top portion to have a front, back and a front end, with an inner surface comprising a bottom portion, an outer surface and a side end, and ]
0.9999664	1243	[ extending the side end to have a top portion, with a third surface extending upwardly along a portion of the first, second and third surfaces, wherein at least a first portion of the third surface has a cross-section, and ]	[ at least one of the side end is adapted to support a top of the implantable medical device; and ]
0.9999908	1244	[ wherein a portion of the outer surface of the third surface is a side portion of the outer surface of the first surface, and ]	[ extending the side end to have a top portion, with a third surface extending upwardly along a portion of the first, second and third surfaces, wherein at least a first portion of the third surface has a cross-section, and ]
0.9953929	1245	[ wherein the bottom portion is substantially flat. ]	[ wherein a portion of the outer surface of the third surface is a side portion of the outer surface of the first surface, and ]
0.9897171	1246	[ an input device to communicate with a health care system; ]	[ A system comprising: ]
0.9999764	1247	[ an output device for storing medical information related to a patient; ]	[ an input device to communicate with a health care system; ]
0.99961495	1248	[ a network to communicate with a computer system for storing information; ]	[ an output device for storing medical information related to a patient; ]
0.9999738	1249	[ an interface to communicate between the health care system and the computer system; ]	[ a network to communicate with a computer system for storing information; ]
0.99998915	1250	[ an actuator to provide power for the input device to communicate with the health care system over the network; ]	[ an interface to communicate between the health care system and the computer system; ]
0.99998605	1251	[ an input device to output data that is stored in the output device; and ]	[ an actuator to provide power for the input device to communicate with the health care system over the network; ]
0.9942953	1252	[ an actuator connected to the body of the patient and adapted to perform operations responsive to the data. ]	[ an input device to output data that is stored in the output device; and ]
0.9995957	1253	[ a plurality of electrodes attached to a patient, wherein the plurality of electrodes is composed of an electrode comprising an integrated circuit and an electrode comprising a plurality of electrical connectors, and ]	[ An implantable device for preventing, treating, curing or relieving an implantable medical condition, comprising: ]
0.99985874	1254	[ wherein the integrated circuit comprises an integrated circuit for a processor, the integrated circuit being configured to receive instructions from the processor to perform an operation on an implanted medical condition; ]	[ a plurality of electrodes attached to a patient, wherein the plurality of electrodes is composed of an electrode comprising an integrated circuit and an electrode comprising a plurality of electrical connectors, and ]
0.99986386	1255	[ a biasing element for the integrated circuit; and ]	[ wherein the integrated circuit comprises an integrated circuit for a processor, the integrated circuit being configured to receive instructions from the processor to perform an operation on an implanted medical condition; ]
0.99999225	1256	[ wherein the integrated circuit is configured so that it reacts with the biasing element to generate a control signal associated with at least one of a first level of processing and a second level of processing, and ]	[ a biasing element for the integrated circuit; and ]
0.0013458796	1257	[ an implantable medical condition, or an implantable medical treatment. ]	[ wherein the integrated circuit is configured so that it reacts with the biasing element to generate a control signal associated with at least one of a first level of processing and a second level of processing, and ]
0.9862882	1258	[ an energy-saving method for saving power, the energy-saving method comprising: ]	[ A system comprising: ]
0.96310675	1259	[ providing a computer having at least one processor configured to: ]	[ an energy-saving method for saving power, the energy-saving method comprising: ]
0.98761547	1260	[ receive energy consumption information defining a consumption profile of a user, wherein the energy consumed is stored in the energy consumption information; ]	[ providing a computer having at least one processor configured to: ]
0.9985464	1261	[ provide a selection of different storage devices using resources available; ]	[ receive energy consumption information defining a consumption profile of a user, wherein the energy consumed is stored in the energy consumption information; ]
0.99947566	1262	[ define a plurality of different kinds of energy use from energy saving usage information, wherein different kinds of energy use are determined based on data corresponding to a user's activity at a user's personal location; ]	[ provide a selection of different storage devices using resources available; ]
0.99999225	1263	[ assign energy saving use to the energy-saving method after the user has performed at least some of the following: ]	[ define a plurality of different kinds of energy use from energy saving usage information, wherein different kinds of energy use are determined based on data corresponding to a user's activity at a user's personal location; ]
0.99464417	1264	[ selected from the set of activities where at least one of said tasks occurs; and ]	[ assign energy saving use to the energy-saving method after the user has performed at least some of the following: ]
0.99999166	1265	[ completed at least one activity using energy savings of the energy-saving method which is selected from the set of types of energyuse; and ]	[ selected from the set of activities where at least one of said tasks occurs; and ]
0.99999225	1266	[ using said energy-saving method; and ]	[ completed at least one activity using energy savings of the energy-saving method which is selected from the set of types of energyuse; and ]
0.011298324	1267	[ generating and outputting a notification to the user, ]	[ using said energy-saving method; and ]
0.9922591	1268	[ wherein a user is configured to control the power saving by assigning the energy-saving use of a particular storage device to at least one of the different kinds of energyuse defined by the energy-saving method. ]	[ generating and outputting a notification to the user, ]
0.99998796	1269	[ a) contacting a monoclonal antibody against CD44.3 with a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ A method for inhibiting a binding of an angiogenic polypeptide that comprises the amino acid sequence of SEQ ID NO: 3 to a fragment of the polypeptide, comprising the steps of: ]
0.9988146	1270	[ 3; and ]	[ a) contacting a monoclonal antibody against CD44.3 with a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9981263	1271	[ b) introducing the polypeptide on the monoclonal antibody and thereby inhibiting the binding of the polypeptide to a fragment of the antibody. ]	[ 3; and ]
0.99965584	1272	[ a head surface including at least one groove extending down a portion of a member and having a first side portion having a generally circumferential surface, substantially parallel to a second side portion of the head surface and the first side portion having a first curvature; and ]	[ A golf club head comprising: ]
0.99998665	1273	[ a headband extending from the first curvature, ]	[ a head surface including at least one groove extending down a portion of a member and having a first side portion having a generally circumferential surface, substantially parallel to a second side portion of the head surface and the first side portion having a first curvature; and ]
0.99999225	1274	[ wherein the first curvature is at least about one quarter of the length of a portion of the member of the headband, ]	[ a headband extending from the first curvature, ]
0.99999213	1275	[ wherein a portion of the portion of the member is inclined in a lateral direction to the first curvature, and ]	[ wherein the first curvature is at least about one quarter of the length of a portion of the member of the headband, ]
0.9999887	1276	[ where the first portion remains substantially flat at a later time than before the first curvature, ]	[ wherein a portion of the portion of the member is inclined in a lateral direction to the first curvature, and ]
0.9998223	1277	[ wherein the first portion of the headband defines an alignment slot for a fastener, said alignment slot sized for receiving and retaining a fastener. ]	[ where the first portion remains substantially flat at a later time than before the first curvature, ]
0.9999007	1278	[ a plurality of arms; ]	[ A device for dispensing a patient's first and second arms, the device comprising: ]
0.99996674	1279	[ a fluid delivery device disposed on one of said arms; and ]	[ a plurality of arms; ]
0.999972	1280	[ a first and a second plunger system disposed on two other arms of the two arms, said first plunger system having a first plunger disposed within a chamber and a second plunger disposed within a conduit, a first plunger pivotally coupled to one of said arms and said conduit, and ]	[ a fluid delivery device disposed on one of said arms; and ]
0.999969	1281	[ a second plunger movable in said first plunger shaft to allow a rotation of the first plunger in opposite directions, ]	[ a first and a second plunger system disposed on two other arms of the two arms, said first plunger system having a first plunger disposed within a chamber and a second plunger disposed within a conduit, a first plunger pivotally coupled to one of said arms and said conduit, and ]
0.9999863	1282	[ wherein the second plunger shaft and the first plunger are positioned within the conduit. ]	[ a second plunger movable in said first plunger shaft to allow a rotation of the first plunger in opposite directions, ]
0.99800545	1283	[ (a) preparing a first nucleic acid encoding a nucleotide sequence encoding a non-transitory computer readable storage medium having instructions that, when executed, cause a computer program stored on computer storage medium to perform steps comprising: ]	[ A method of inhibiting or inhibiting an interferon-stimulated apoptosis protein in a human tumor, said method comprising: ]
0.99936813	1284	[ <|span|> (i) detecting a change in a cell count in the tumor of the human tumor using a cell count sensor, a tumor biopsy, a computed tomography (CT) scanner, or a tumor probe; ]	[ (a) preparing a first nucleic acid encoding a nucleotide sequence encoding a non-transitory computer readable storage medium having instructions that, when executed, cause a computer program stored on computer storage medium to perform steps comprising: ]
0.9999919	1285	[ (ii) measuring a ratio of apoptosis cells to normal cells in the tumor of the human tumor in response to detection of the change; and ]	[ <|span|> (i) detecting a change in a cell count in the tumor of the human tumor using a cell count sensor, a tumor biopsy, a computed tomography (CT) scanner, or a tumor probe; ]
0.99999154	1286	[ (iii) correlating the quantified ratio to an individual tumor in the tumor of the human tumor; ]	[ (ii) measuring a ratio of apoptosis cells to normal cells in the tumor of the human tumor in response to detection of the change; and ]
0.9999919	1287	[ (b) determining which nucleic acid is present in the tumor of the human tumor in response to measurement by the ratio, wherein the amount of the nucleic acid in the tumor is an indicator of whether to reduce the number of apoptosis cells by increasing the ratio, and ]	[ (iii) correlating the quantified ratio to an individual tumor in the tumor of the human tumor; ]
0.9999907	1288	[ wherein the nucleic acid is selected from the group consisting of SEQ ID NO. 11, 16, 22, 28, 35, and ]	[ (b) determining which nucleic acid is present in the tumor of the human tumor in response to measurement by the ratio, wherein the amount of the nucleic acid in the tumor is an indicator of whether to reduce the number of apoptosis cells by increasing the ratio, and ]
0.99993694	1289	[ 37, or the group consisting of SEQ ID NO: 2, 2, and ]	[ wherein the nucleic acid is selected from the group consisting of SEQ ID NO. 11, 16, 22, 28, 35, and ]
0.99978215	1290	[ 18. ]	[ 37, or the group consisting of SEQ ID NO: 2, 2, and ]
0.9669486	1291	[ an input device configured to input at least one data command to a software program to control the at least one data command having an operation to be performed by a remote server server server that runs a software program that includes a client software application and a server software application; and ]	[ A system comprising: ]
0.99999225	1292	[ an interface device configured to transmit the at least one data command to a remote server server, to the server server for execution by the client software application, ]	[ an input device configured to input at least one data command to a software program to control the at least one data command having an operation to be performed by a remote server server server that runs a software program that includes a client software application and a server software application; and ]
0.9999747	1293	[ wherein the interface device includes one or more wireless communication ports, the one or more wireless communication ports also including an interface device communication link adapted to receive communications between the interface device and a remote server server for establishing a connection between the interface device and the remote server server. ]	[ an interface device configured to transmit the at least one data command to a remote server server, to the server server for execution by the client software application, ]
0.99954104	1294	[ 000 to about 10, ]	[ A method for the detection of the presence of an endogenous polypeptide with a molecular weight in the range of about 10, ]
0.9988752	1295	[ 10 000 daltons, comprising: ]	[ 000 to about 10, ]
0.9922517	1296	[ forming a first signal to detect the presence of a polypeptide having a molecular weight in the range of about 10, ]	[ 10 000 daltons, comprising: ]
0.9970613	1297	[ 000 to about 10, ]	[ forming a first signal to detect the presence of a polypeptide having a molecular weight in the range of about 10, ]
0.99811125	1298	[ 10 000 daltons, wherein the polypeptide has been added to a sample and formed therefrom and is isolated from a biological sample, and ]	[ 000 to about 10, ]
0.99980456	1299	[ wherein the polypeptide is inactivated by exposure to a ligand selected from the group consisting of the compound of formula: ]	[ 10 000 daltons, wherein the polypeptide has been added to a sample and formed therefrom and is isolated from a biological sample, and ]
0.0070332917	1300	[ whereinR2 is hydrogen, and ]	[ wherein the polypeptide is inactivated by exposure to a ligand selected from the group consisting of the compound of formula: ]
0.9996673	1301	[ R3 is independently hydrogen; ]	[ whereinR2 is hydrogen, and ]
0.07118207	1302	[ A are each independently of one another, and ]	[ R3 is independently hydrogen; ]
0.99999106	1303	[ R1 and R2 are each independently of one another, and ]	[ A are each independently of one another, and ]
0.9979399	1304	[ a C1-C6 amino acid residue is attached to one of R7 and R8; and ]	[ R1 and R2 are each independently of one another, and ]
0.007476904	1305	[ a signal is generated by sensing a number of chemical residues in the polypeptide and comparing the number of chemical residues in the polypeptide to one which is larger than a predetermined limit. ]	[ a C1-C6 amino acid residue is attached to one of R7 and R8; and ]
0.0052338415	1306	[ determining whether an end effector of a transgenic plant containing a human-specific promoter contains an RNA encoding an amyloid precursor protein; ]	[ A method, comprising: ]
0.99999213	1307	[ when determined that the transgenic plant contains the human-specific promoter, applying to the end effector a compound that binds to the human-specific promoter. ]	[ determining whether an end effector of a transgenic plant containing a human-specific promoter contains an RNA encoding an amyloid precursor protein; ]
0.99999225	1308	[ anointing a pulmonary artery in a vertebral body with a therapeutic agent; ]	[ A method for treating chronic obstructive pulmonary disease in a vertebral body, said method comprising: ]
0.99999094	1309	[ passing from the heart through the pulmonary artery a first therapeutic agent to the pulmonary artery. ]	[ anointing a pulmonary artery in a vertebral body with a therapeutic agent; ]
0.9999919	1310	[ a game machine operable to play a game at the game machine, ]	[ A game system for administering game data to a game controller in a game machine, the game machine comprising: ]
0.9999896	1311	[ a control unit including a display, said display operable to display data stored on the game machine that includes game data and said game data operable to be transferred to said control unit from said display in a transmission system of a server, said transmission system comprising a wireless transmission route that is operated by one of the respective player's game console controllers, and ]	[ a game machine operable to play a game at the game machine, ]
0.99999154	1312	[ a communications system between the server and the server having a wireless communication route of the game machine, ]	[ a control unit including a display, said display operable to display data stored on the game machine that includes game data and said game data operable to be transferred to said control unit from said display in a transmission system of a server, said transmission system comprising a wireless transmission route that is operated by one of the respective player's game console controllers, and ]
0.99999094	1313	[ at least one processor operable to receive the data provided over the communications system and control at least one of said game controller's game commands as transmitted from the server, ]	[ a communications system between the server and the server having a wireless communication route of the game machine, ]
0.9999924	1314	[ the game controller's game commands providing at least one of a predetermined number of player interaction options and a non-player interaction option, ]	[ at least one processor operable to receive the data provided over the communications system and control at least one of said game controller's game commands as transmitted from the server, ]
0.9999893	1315	[ said at least one processor further operable to provide responsive information about a non-player interactivity option to a game player as defined by at least one of said the first, second and third gaming systems, ]	[ the game controller's game commands providing at least one of a predetermined number of player interaction options and a non-player interaction option, ]
0.99999225	1316	[ wherein said at least one processor is configured to control, during the transmission and the non-player interaction, the transmission of the non-player interactivity option if it is not a player interaction option. ]	[ said at least one processor further operable to provide responsive information about a non-player interactivity option to a game player as defined by at least one of said the first, second and third gaming systems, ]
0.9999386	1317	[ a base support member configured to be supported on a surface of a body having a central axis and including a plurality of openings configured to receive fluid to be injected, the plurality of openings including an infusion conduit; and ]	[ An apparatus for use in an infusion or pump comprising: ]
0.99999225	1318	[ a valve support member including a plurality of valves operably associated with the base support member, each valve associated with a respective of one or more of the plurality of openings to engage with the center of the infusion conduit, such that fluid and the valves are controlled to rotate in rotation. ]	[ a base support member configured to be supported on a surface of a body having a central axis and including a plurality of openings configured to receive fluid to be injected, the plurality of openings including an infusion conduit; and ]
0.9999919	1319	[ a surgical guide attachment assembly, a proximal end portion, a distal end section, and ]	[ An elongated medical apparatus comprisinga flexible surgical guide assembly, a tubular body comprising a longitudinal axis and a central portion extending therebetween, comprising a distal end portion; and ]
0.9956483	1320	[ one or more elongated elongated portions, ]	[ a surgical guide attachment assembly, a proximal end portion, a distal end section, and ]
0.99996305	1321	[ wherein the surgical guide assembly comprises a first elongated elongated portion including an upper end portion and a second section comprising a tubular body and a first portion and a second portion, wherein the upper end portion comprises a flange. ]	[ one or more elongated elongated portions, ]
0.9999918	1322	[ (iii) configured to, if said first code and the additional code are received from said prior application program, create the software application program and control further operations of said at least one additional code. ]	[ A non-transitory computer readable storage medium having stored thereon (i) at least a first code that, when executed by a processor, causes a plurality of software elements to be configured to be integrated into a software application program, (ii) at least one additional code that executes within a user interface and (iii) an initial control module configured to automatically communicate between at least any of one or more operating systems via an access control function, said initial control module (i) configured to receive each of said first code and the additional code from a first application program and, upon an access control operation, (ii) configured to process each of the first code and the additional code, and ]
0.9999293	1323	[ a plurality of surgical blades; ]	[ A surgical device comprising: ]
0.9999918	1324	[ a first cutting head having a substantially cylindrically shaped surface and mounted on one end of said plurality of surgical blades for cutting tissue with a first cutting head cutting head drive; ]	[ a plurality of surgical blades; ]
0.99999225	1325	[ a second cutting head having a substantially cylindrically shaped surface and mounted on one end of said plurality of surgical blades for cutting tissue with a second cutting head cutting head drive, wherein said first and second cutting heads can intersect when said surgical blades are placed on said surface of said one and said other cutting head. ]	[ a first cutting head having a substantially cylindrically shaped surface and mounted on one end of said plurality of surgical blades for cutting tissue with a first cutting head cutting head drive; ]
0.015456433	1326	[ a cylindrical shaft disposed along a longitudinal axis; ]	[ An implantable device, comprising: ]
0.9999882	1327	[ a plurality of electrodes extending around the cylindrical shaft for supplying electrical power to a plurality of electrodes in a first plane, said electrical power being supplied to said first plane; and ]	[ a cylindrical shaft disposed along a longitudinal axis; ]
0.999992	1328	[ wherein the cylindrical shaft has a diameter in an approximately constant relation to said width of said cylindrical shaft, and ]	[ a plurality of electrodes extending around the cylindrical shaft for supplying electrical power to a plurality of electrodes in a first plane, said electrical power being supplied to said first plane; and ]
0.99999154	1329	[ a circumference in an approximately constant relation to said width of said shaft. ]	[ wherein the cylindrical shaft has a diameter in an approximately constant relation to said width of said cylindrical shaft, and ]
0.99999166	1330	[ 4, wherein said isolated nucleic acid molecule has been deposited under ATCC Accession No. PTA-11121. ]	[ An isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO: ]
0.9999918	1331	[ a proximal portion configured to couple onto a portion of an implant comprising a lesion or tissue to be removed; ]	[ An implant for removal of a lesion comprising: ]
0.33937788	1332	[ a plurality of interlocking, flexible members; ]	[ a proximal portion configured to couple onto a portion of an implant comprising a lesion or tissue to be removed; ]
0.9999919	1333	[ the plurality of interlocking, flexible members having a first portion and a second portion that define a first opening and a second opening respectively associated with a second portion of the proximal portion; and ]	[ a plurality of interlocking, flexible members; ]
0.9999919	1334	[ a first material in fluid communication with at least one of the plurality of interlocking, flexible members to provide resistance to movement of the proximal portion of the implant relative to the interlocking, flexible members, wherein the first material includes a first fluid-inhibiting and a first fluid-reactive material. ]	[ the plurality of interlocking, flexible members having a first portion and a second portion that define a first opening and a second opening respectively associated with a second portion of the proximal portion; and ]
0.01829322	1335	[ a) treating a patient with an effective amount of a compound of formula I wherein R1 is selected from the group consisting of H and A; ]	[ A method for producing a skin-to-skin therapeutic contact, the method comprising: ]
0.99792707	1336	[ R2 is selected from the group consisting of H and an alkyl group; ]	[ a) treating a patient with an effective amount of a compound of formula I wherein R1 is selected from the group consisting of H and A; ]
0.99992037	1337	[ R3 is selected from the group consisting of H, a C1-6 alkyl group and an acyl group; and ]	[ R2 is selected from the group consisting of H and an alkyl group; ]
0.9938054	1338	[ R4 is selected from the group consisting of R4-A&#x2032; ]	[ R3 is selected from the group consisting of H, a C1-6 alkyl group and an acyl group; and ]
0.99998856	1339	[ , R4-A&#x2033; ]	[ R4 is selected from the group consisting of R4-A&#x2032; ]
0.9963391	1340	[ &#x2032; ]	[ , R4-A&#x2033; ]
0.9762148	1341	[ (N) and R4-A&#x2034; ]	[ &#x2032; ]
0.99854845	1342	[ &#x2033; ]	[ (N) and R4-A&#x2034; ]
0.9996138	1343	[ &#x2032; ]	[ &#x2033; ]
0.9719696	1344	[ (N); and ]	[ &#x2032; ]
0.004294059	1345	[ b) treating the skin of an exposed portion with the effective amount of the compound of formula I in the presence of a treatment agent to produce skin-to-skin therapeutic contact, wherein the treatment agent represents a lipophilic agent selected from the group consisting of cetylated lipopropyl esters, and ]	[ (N); and ]
0.013638747	1346	[ a lipid-soluble agent having an extracellular moiety on a molecular-size greater than 1 kDa; and ]	[ b) treating the skin of an exposed portion with the effective amount of the compound of formula I in the presence of a treatment agent to produce skin-to-skin therapeutic contact, wherein the treatment agent represents a lipophilic agent selected from the group consisting of cetylated lipopropyl esters, and ]
0.9940117	1347	[ wherein the therapy agent further comprises a binder selected from the group consisting of a resin, a rubber, an alcohol, a polyester, a vinylohexane, and ]	[ a lipid-soluble agent having an extracellular moiety on a molecular-size greater than 1 kDa; and ]
0.993193	1348	[ a polyvinylpyrrolidone. ]	[ wherein the therapy agent further comprises a binder selected from the group consisting of a resin, a rubber, an alcohol, a polyester, a vinylohexane, and ]
0.999992	1349	[ detecting a plurality of detected at least one of the following; ]	[ A method of increasing the ability of a mammal to detect at least one of the following in the presence of a plurality of other mammals, the method comprising: ]
0.9998975	1350	[ detecting at least one detectable characteristic of the at least one detected object; ]	[ detecting a plurality of detected at least one of the following; ]
0.99999225	1351	[ determining a range of possible ranges of at least one detected characteristic of the at least one detected object; ]	[ detecting at least one detectable characteristic of the at least one detected object; ]
0.99999225	1352	[ determining a range of possible ranges of at least one detected characteristic of the at least one detected object; ]	[ determining a range of possible ranges of at least one detected characteristic of the at least one detected object; ]
0.9999924	1353	[ determining a total number of detectable characteristics of at least one detected object; ]	[ determining a range of possible ranges of at least one detected characteristic of the at least one detected object; ]
0.99943954	1354	[ selecting a range of range of possible range sizes that includes the range of possible range sizes; and ]	[ determining a total number of detectable characteristics of at least one detected object; ]
0.9999924	1355	[ measuring an extent in which at least one detected characteristic of at least one detected object of the range of possible range sizes is capable of being detected. ]	[ selecting a range of range of possible range sizes that includes the range of possible range sizes; and ]
0.98015434	1356	[ a frame; ]	[ An assembly, comprising: ]
0.98344153	1357	[ a plurality of axles defining a plurality of axial channels to be operative in parallel; ]	[ a frame; ]
0.99962425	1358	[ one or more gear axles provided on each axis; and ]	[ a plurality of axles defining a plurality of axial channels to be operative in parallel; ]
0.9999913	1359	[ a drive member mounted to each of the plurality ofaxes that can rotate about the axial channels of the frame and that is capable of rotating the frame about the axial channels of the frame such that rotation of the drive unit moves the frame so as to move the ones or more gear axles to an open-end position relative to the axial channels. ]	[ one or more gear axles provided on each axis; and ]
0.9999918	1360	[ providing a first control system for controlling gas flow by the first pump arms; ]	[ A method for controlling a water pump including a gas flow tube, a first and second pump arms mounted at opposite ends of the gas flow tube, a liquid flow conduit connected to the first and second pump arms for directing an amount of fluid from the liquid flow conduit to the gas flow tube, the method comprising: ]
0.99999	1361	[ providing, during use of the method, a second control system; ]	[ providing a first control system for controlling gas flow by the first pump arms; ]
0.9999893	1362	[ generating, at a microprocessor, an input signal for controlling the gas flow; and <|span|>, after the first control system is controlled in accordance with one or more predefined control criteria, operating the second control system to control said gas flow in the gas flow tube. ]	[ providing, during use of the method, a second control system; ]
0.9999906	1363	[ generating a plurality of visual indications of the patient according to the determined patient condition using an electronic medical control system having data and information stored on at least one computer; ]	[ A method for providing a visual indication of a patient status condition of a patient using a controller including sensors that senses a movement, the method comprising: ]
0.99999225	1364	[ processing the plurality of visual indications; ]	[ generating a plurality of visual indications of the patient according to the determined patient condition using an electronic medical control system having data and information stored on at least one computer; ]
0.9966163	1365	[ generating data that may be stored to be processed for display on a display panel of the electronic medical control system; and ]	[ processing the plurality of visual indications; ]
0.9963174	1366	[ transmitting the computer data by a processor to an input controller; ]	[ generating data that may be stored to be processed for display on a display panel of the electronic medical control system; and ]
0.007278737	1367	[ wherein the controller detects an application of an actuator to an actuator to be driven to generate the plurality of visual indications. ]	[ transmitting the computer data by a processor to an input controller; ]
0.9999895	1368	[ generating a first virtual image of an environment for display by a processor of the virtual environment; ]	[ A method of providing a virtual environment, comprising: ]
0.99999225	1369	[ generating a second virtual image corresponding to a second and different aspect of the environment; ]	[ generating a first virtual image of an environment for display by a processor of the virtual environment; ]
0.9999919	1370	[ generating a difference in at least a first dimension between the first virtual image and the second virtual image according to a comparison between images of the first virtual image and the second virtual image; and ]	[ generating a second virtual image corresponding to a second and different aspect of the environment; ]
0.99991846	1371	[ displaying a first image of the virtual environment on a display of a first object, ]	[ generating a difference in at least a first dimension between the first virtual image and the second virtual image according to a comparison between images of the first virtual image and the second virtual image; and ]
0.9999572	1372	[ wherein the difference between the first virtual image and the second virtual image is determined when the first virtual image differs from the second virtual image by at least a threshold value. ]	[ displaying a first image of the virtual environment on a display of a first object, ]
0.99906975	1373	[ receiving, via a first controller, an electrical signal from a physiologic sensor; ]	[ An electrical stimulation method for treating asthma, comprising: ]
0.99999213	1374	[ analyzing the electrical signal by the physiologic sensor to determine whether the electrical signal is in the range of a baseline value, providing a signal output from the sensor with a value in the range of said baseline value; and ]	[ receiving, via a first controller, an electrical signal from a physiologic sensor; ]
0.99999225	1375	[ providing an stimulation output signal with values within the range, such that the stimulation output signal can be used to treat asthma in a subject undergoing said step of analyzing the electrical signal to determine whether the electrical signal is within a range, with: ]	[ analyzing the electrical signal by the physiologic sensor to determine whether the electrical signal is in the range of a baseline value, providing a signal output from the sensor with a value in the range of said baseline value; and ]
0.9999924	1376	[ providing a stimulation output signal in the range of a baseline value, each of the received electric stimulus signals exceeding one of a plurality of values within the range of the current stimulus signals; ]	[ providing an stimulation output signal with values within the range, such that the stimulation output signal can be used to treat asthma in a subject undergoing said step of analyzing the electrical signal to determine whether the electrical signal is within a range, with: ]
0.99999225	1377	[ analyzing the stimulation output signal by the physiologic sensor to determine whether the current stimulus signals exceeds a maximum of a plurality of values; ]	[ providing a stimulation output signal in the range of a baseline value, each of the received electric stimulus signals exceeding one of a plurality of values within the range of the current stimulus signals; ]
0.9999924	1378	[ providing a stimulation output signal at a value, within the range, within a tolerance for said current stimulation signals; ]	[ analyzing the stimulation output signal by the physiologic sensor to determine whether the current stimulus signals exceeds a maximum of a plurality of values; ]
0.9999924	1379	[ determining whether one of the received stimulation output signals within the range exceeds a value outside said tolerance for said current stimulus signals; ]	[ providing a stimulation output signal at a value, within the range, within a tolerance for said current stimulation signals; ]
0.99999225	1380	[ providing a stimulation output signal within the range of the current stimulus signals, said signal exceeding a maximum of a plurality of values within the range of the current stimulus signals; and ]	[ determining whether one of the received stimulation output signals within the range exceeds a value outside said tolerance for said current stimulus signals; ]
0.99999225	1381	[ providing one of the received stimulation output signals to a subject in need thereof via the first controller. ]	[ providing a stimulation output signal within the range of the current stimulus signals, said signal exceeding a maximum of a plurality of values within the range of the current stimulus signals; and ]
0.99976224	1382	[ acquiring a target blood pressure in a subject patient, wherein the target blood pressure acquired is not a first or second predetermined blood pressure; ]	[ A method of performing cardiac stimulation and/or arrhythmia relief with a surgical robotic device comprising: ]
0.9999924	1383	[ adjusting a first heart rate in accordance with the acquired target blood pressure; ]	[ acquiring a target blood pressure in a subject patient, wherein the target blood pressure acquired is not a first or second predetermined blood pressure; ]
0.9999919	1384	[ adjusting a first and second pulse rate of the surgical robotic device in accordance with the adjusted first and second heart rate; and ]	[ adjusting a first heart rate in accordance with the acquired target blood pressure; ]
0.99999046	1385	[ performing cardiac stimulation and/or arrhythmia relief on the subject patient when the first or second predetermined blood pressure is greater than the adjusted first and second heart rate. ]	[ adjusting a first and second pulse rate of the surgical robotic device in accordance with the adjusted first and second heart rate; and ]
0.99999213	1386	[ a longitudinal portion protruding from said groove of said first member member is configured to allow the longitudinal member to extend through an anterior end part of said head or neck being subjected to an injection injection device; ]	[ A device to measure the degree of injury to a head or neck being subjected to an injection injection device having an elongated handle and an elongated proximal end, comprising first and second elongated member members respectively being received in a coupling assembly, said elongated member members having longitudinal members with respective grooves therebetween configured to be releasable in a longitudinal direction between a first position and a second position, wherein said grooves of said second member are disposed outwardly of said longitudinal member grooves of said first member member, and ]
0.9999877	1387	[ a portion of said longitudinal member in the first position having a first position edge that defines a transverse plane with a transverse end direction; and ]	[ a longitudinal portion protruding from said groove of said first member member is configured to allow the longitudinal member to extend through an anterior end part of said head or neck being subjected to an injection injection device; ]
0.99999225	1388	[ a portion of said longitudinal member in the second position having a second position edge that defines a transverse plane with a transverse end direction. ]	[ a portion of said longitudinal member in the first position having a first position edge that defines a transverse plane with a transverse end direction; and ]
0.99639076	1389	[ a biocompatible polymer configured to perform substantially the same function but in a biocompatible manner; ]	[ A medical implantable medical device comprising: ]
1.7576158e-05	1390	[ an optical member in a first and second configuration; ]	[ a biocompatible polymer configured to perform substantially the same function but in a biocompatible manner; ]
0.0010615992	1391	[ a first electrode adapted to be placed on a region of skin of a patient, such that the second electrode is positioned thereon; and ]	[ an optical member in a first and second configuration; ]
0.9999417	1392	[ a second electrode in a second and second configuration, the first and second electrodes positioned on different surfaces by a different width than the first and second electrodes, wherein the two electrodes are sized and configured such that the second electrode will be more responsive to stimulation from the second electrode than the first electrode when the device is in the first and second configuration, and ]	[ a first electrode adapted to be placed on a region of skin of a patient, such that the second electrode is positioned thereon; and ]
0.99999225	1393	[ wherein the second electrode is positioned further away from the first electrode when the device is in the first and second configuration and when the device is in the first, second, and ]	[ a second electrode in a second and second configuration, the first and second electrodes positioned on different surfaces by a different width than the first and second electrodes, wherein the two electrodes are sized and configured such that the second electrode will be more responsive to stimulation from the second electrode than the first electrode when the device is in the first and second configuration, and ]
0.9999814	1394	[ third configurations. ]	[ wherein the second electrode is positioned further away from the first electrode when the device is in the first and second configuration and when the device is in the first, second, and ]
0.0073173176	1395	[ a housing; ]	[ A system for generating a user-specific pattern to represent the shape of a prosthetic hand, said system comprising: ]
0.9994809	1396	[ a plurality of prosthesis sensors which are attached to the housing, wherein each of said prosthesis sensors includes two actuators associated with a proximal and a distal end; ]	[ a housing; ]
0.99999225	1397	[ at least one control device coupled to each of said prosthesis sensors which is adjustable to modify the pressure of said actuators; ]	[ a plurality of prosthesis sensors which are attached to the housing, wherein each of said prosthesis sensors includes two actuators associated with a proximal and a distal end; ]
0.9996382	1398	[ a computer system including an analog, optical, digital processing unit, said computer system having a memory and a communications module that allows communication with said at least one control device within the housing, wherein said computing module includes a display unit, a video signal processing unit that receives said computer system's presentation data to process an input to be included in said display and generates a display program, a virtual environment, a user input processor that receives a user's control signal in said display, and ]	[ at least one control device coupled to each of said prosthesis sensors which is adjustable to modify the pressure of said actuators; ]
0.99999046	1399	[ a user-specific information processing unit that receives said user-specific pattern to generate the shape of the prosthetic hand from an image input from said at least one control device; ]	[ a computer system including an analog, optical, digital processing unit, said computer system having a memory and a communications module that allows communication with said at least one control device within the housing, wherein said computing module includes a display unit, a video signal processing unit that receives said computer system's presentation data to process an input to be included in said display and generates a display program, a virtual environment, a user input processor that receives a user's control signal in said display, and ]
0.9991574	1400	[ said computer and said display unit having an input terminal and a print terminal; ]	[ a user-specific information processing unit that receives said user-specific pattern to generate the shape of the prosthetic hand from an image input from said at least one control device; ]
0.9999912	1401	[ said computer having a first processing unit in communication with a first display terminal and a second processing unit in communication with a second display terminal; ]	[ said computer and said display unit having an input terminal and a print terminal; ]
0.9999305	1402	[ said printing unit includinga first printer housing in communication with said first communication module; and ]	[ said computer having a first processing unit in communication with a first display terminal and a second processing unit in communication with a second display terminal; ]
0.99999225	1403	[ a second printer housing in communication with a second communication module. ]	[ said printing unit includinga first printer housing in communication with said first communication module; and ]
0.9999924	1404	[ a patient electrode adapted to be positioned within a portion of a patient's heart for monitoring electrical activity associated with the activity, wherein said electrode is adapted to be connected to an electrically conductive sensor that senses said electrical activity; ]	[ An implantable cardiac rhythm monitoring device for monitoring an electrical activity associated with an activity that is detected in a body of a patient, comprising: ]
0.9999924	1405	[ a patient heart electrode adapted to be positioned within a heart of the patient for monitoring electrical activity associated with the activity, wherein said electrode is adapted to be connected to an electrically conducting sensor that senses said electrical activity; for measuring electrical activity of said patient and said heart respectively, said heart electrode and said patient electrode each include a sensing layer which senses said electrical activity of said heart electrode, and ]	[ a patient electrode adapted to be positioned within a portion of a patient's heart for monitoring electrical activity associated with the activity, wherein said electrode is adapted to be connected to an electrically conductive sensor that senses said electrical activity; ]
0.9999924	1406	[ a measuring node which detects said electrical activities of said cardiac rhythm sensing layer and said sensing layer in response to electrical activity to be measured. ]	[ a patient heart electrode adapted to be positioned within a heart of the patient for monitoring electrical activity associated with the activity, wherein said electrode is adapted to be connected to an electrically conducting sensor that senses said electrical activity; for measuring electrical activity of said patient and said heart respectively, said heart electrode and said patient electrode each include a sensing layer which senses said electrical activity of said heart electrode, and ]
0.99996567	1407	[ an adjustable hinge having holes that engage said open gaps, wherein the second face is provided with a hinge hook to receive and anchor and releasably secure said adjustable hinge to the golf club, wherein the hinge can be fixed upon the hinge by an adjustable screw. ]	[ A golf club having a shaft and a swing leg member located on the golfer's back foot and extending from the shaft to and around its tip end, the golf club being adjustable in length and in stiffness by an adjustable adjuster, a foot peg with which one or more of the two toes of the first foot of the golfer can be placed, the foot peg having a first face and a second face, a hinge that defines an open gap between the first face and the second face, and ]
0.00044414322	1408	[ (a) an amino acid sequence of SEQ ID NO: ]	[ A compound selected from the group consisting of: ]
0.99791044	1409	[ 2; ]	[ (a) an amino acid sequence of SEQ ID NO: ]
0.0025660181	1410	[ (b) a heterocyclic ring whose sequence is selected from the group consisting of: 1&#x2032; ]	[ 2; ]
0.9962549	1411	[ CH2, ]	[ (b) a heterocyclic ring whose sequence is selected from the group consisting of: 1&#x2032; ]
1.9350875e-05	1412	[ wherein SEQ ID NO: ]	[ CH2, ]
0.99991965	1413	[ 2, or one of SEQ ID NO: ]	[ wherein SEQ ID NO: ]
0.99575317	1414	[ 3, is OH or CDY. ]	[ 2, or one of SEQ ID NO: ]
0.96813715	1415	[ a first liquid comprising a polymer having the following structure: ]	[ A composition comprising: ]
0.9880818	1416	[ wherein, ]	[ a first liquid comprising a polymer having the following structure: ]
0.9470548	1417	[ a liquid portion having an outer surface and an inner surface, each of the inner and outer surfaces being a hydrophilic material and providing a specific solubility ratio of inorganic polymer to polymeric material, and ]	[ wherein, ]
0.9909133	1418	[ a plurality of particles being in the water and, ]	[ a liquid portion having an outer surface and an inner surface, each of the inner and outer surfaces being a hydrophilic material and providing a specific solubility ratio of inorganic polymer to polymeric material, and ]
0.99998987	1419	[ wherein, when an average particle size of the plurality of particles increases, the polymer loses a molecular weight of the polymer and the plurality of particles are distributed in the water. ]	[ a plurality of particles being in the water and, ]
0.9999902	1420	[ an open, liquid storage port of said image storage device; ]	[ An apparatus for the collection and distribution of biopsies into an image storage device comprising: ]
0.99999213	1421	[ a movable lid connected to said open, liquid storage port; ]	[ an open, liquid storage port of said image storage device; ]
0.99999225	1422	[ a first fluid reservoir connected to said moveable lid and to a fluid reservoir in said open, liquid storage port; ]	[ a movable lid connected to said open, liquid storage port; ]
0.99999166	1423	[ a second fluid reservoir connected to said movable lid, the second fluid reservoir having a volume larger than the second fluid reservoir; ]	[ a first fluid reservoir connected to said moveable lid and to a fluid reservoir in said open, liquid storage port; ]
0.9999919	1424	[ an injection device and a syringe connected to said second fluid reservoir; ]	[ a second fluid reservoir connected to said movable lid, the second fluid reservoir having a volume larger than the second fluid reservoir; ]
0.9999912	1425	[ and a means for selectively inserting biopsy material into the fluid reservoir in said first fluid reservoir in said open, liquid storage channel, and ]	[ an injection device and a syringe connected to said second fluid reservoir; ]
0.9999918	1426	[ in the injection device in fluid-tight communication with said fluid reservoir. ]	[ and a means for selectively inserting biopsy material into the fluid reservoir in said first fluid reservoir in said open, liquid storage channel, and ]
0.99996793	1427	[ obtaining a bone-specific antigen comprising the antigen of SEQ ID NO: 1; ]	[ A method of treating an osteosarcoma in an individual without affecting bone, the steps comprising: ]
0.99895704	1428	[ administering to the individual an effective amount of a peptide in the form of an oligonucleotide selected from the group consisting of: ]	[ obtaining a bone-specific antigen comprising the antigen of SEQ ID NO: 1; ]
0.9997569	1429	[ wherein each of the amino acids of the nucleoside is selected from the group consisting of: ]	[ administering to the individual an effective amount of a peptide in the form of an oligonucleotide selected from the group consisting of: ]
0.9994597	1430	[ h, the nterminus of a tau member having at least one amino acid at the position 1 and the base of a nucleic acid molecule containing the amino acid of the SEQ ID NO: 6, ]	[ wherein each of the amino acids of the nucleoside is selected from the group consisting of: ]
0.9999889	1431	[ and the amino acid of a first residue of sequence B1 having at least one amino acid at the position 2, and ]	[ h, the nterminus of a tau member having at least one amino acid at the position 1 and the base of a nucleic acid molecule containing the amino acid of the SEQ ID NO: 6, ]
0.999992	1432	[ the amino acid of a second residue of sequence B2 having at least one amino acid at the position 3; and ]	[ and the amino acid of a first residue of sequence B1 having at least one amino acid at the position 2, and ]
0.9993167	1433	[ wherein each of the nucleoside types of the amino acid sequence to be encoded is selected from those shown in SEQ ID NOs: ]	[ the amino acid of a second residue of sequence B2 having at least one amino acid at the position 3; and ]
0.9984584	1434	[ 1 and 4. ]	[ wherein each of the nucleoside types of the amino acid sequence to be encoded is selected from those shown in SEQ ID NOs: ]
0.99720085	1435	[ providing a biodegradable material containing a monomer and a conjugate; ]	[ A method of manufacturing a bio-absorbent article, comprising: ]
0.99999225	1436	[ providing a biodegradable composition including a biodegradable monomer, a conjugate, and ]	[ providing a biodegradable material containing a monomer and a conjugate; ]
0.9937634	1437	[ a polymer; ]	[ providing a biodegradable composition including a biodegradable monomer, a conjugate, and ]
0.9975311	1438	[ forming a surface of the composition so that when the polymer interacts with the conjugate such that the polymer forms a polymer barrier that restricts the binding of the conjugate of the composition to the polymer-abated surface of the composition, the complex consists essentially of a matrix of a biodegradable polymer component and a biodegradable polymer component, wherein the biodegradable matrix of the biodegradable polymer component has a polyhedral shape from a center to a distal tip, and ]	[ a polymer; ]
0.9999918	1439	[ the biodegradable polymer component has a monolithic shape from a center to an underside of the substrate of the monolithic polymer component; and ]	[ forming a surface of the composition so that when the polymer interacts with the conjugate such that the polymer forms a polymer barrier that restricts the binding of the conjugate of the composition to the polymer-abated surface of the composition, the complex consists essentially of a matrix of a biodegradable polymer component and a biodegradable polymer component, wherein the biodegradable matrix of the biodegradable polymer component has a polyhedral shape from a center to a distal tip, and ]
0.99999166	1440	[ fabricating and applying the surface of the composition onto the substrate such that a polymer coating of the surface of the composition surrounds the biodegradable polymer component and prevents binding of the conjugate or the polymer to the substrate. ]	[ the biodegradable polymer component has a monolithic shape from a center to an underside of the substrate of the monolithic polymer component; and ]
0.99840254	1441	[ a) identifying a mutation comprising an insertion site for a transmembrane receptor which comprises a gene encoding an antigen-antibody component of a pro-apoptotic agent; ]	[ A method of treating a subject afflicted by Crohn's disease in particular a resistant form of Crohn's disease (RSCD) consisting of: ]
0.99995065	1442	[ b) deleting said mutation in a gene wherein said gene is selected from the group consisting of CD49, CD59 and CD45; and ]	[ a) identifying a mutation comprising an insertion site for a transmembrane receptor which comprises a gene encoding an antigen-antibody component of a pro-apoptotic agent; ]
0.99978465	1443	[ c) administering to said subject, wherein said anti-apoptotic agent which inhibits cell-mediated apoptosis is selected from the group consisting of an anti- CD4 antibody, an anti- CD8 antibody, the anti- CD34 antibody, and ]	[ b) deleting said mutation in a gene wherein said gene is selected from the group consisting of CD49, CD59 and CD45; and ]
0.9999914	1444	[ the anti- CD8 antibody with specific epitopes. ]	[ c) administering to said subject, wherein said anti-apoptotic agent which inhibits cell-mediated apoptosis is selected from the group consisting of an anti- CD4 antibody, an anti- CD8 antibody, the anti- CD34 antibody, and ]
0.99999154	1445	[ (a) administering a therapeutically effective amount of an adjuvant to the heart during a course of treatment or monitoring in a heart rhythm monitor to prevent the occurrence of a stroke, stroke path progression, or stroke risk; ]	[ A method for reducing or eliminating risk of a stroke, stroke path progression, or stroke risk of a patient's heart being impaired by a blood in a blood vessel that includes at least one endothelial cell, wherein the method comprises: ]
0.9999827	1446	[ (b) recording a signal from the endothelial cell in a heart rhythm monitor; and ]	[ (a) administering a therapeutically effective amount of an adjuvant to the heart during a course of treatment or monitoring in a heart rhythm monitor to prevent the occurrence of a stroke, stroke path progression, or stroke risk; ]
0.9999919	1447	[ (c) assessing at least one parameter of the endothelial cell in a cardiac event occurring before or after the endothelial cell is administered to said patient in response to the signal. ]	[ (b) recording a signal from the endothelial cell in a heart rhythm monitor; and ]
0.9998467	1448	[ a first plurality of ultrasound beams transmitted between at least two different imaging locations; ]	[ An ultrasonic tomography system, comprising: ]
0.99999213	1449	[ a first ultrasonic detector configured to receive at least one of the different ultrasound beams, and ]	[ a first plurality of ultrasound beams transmitted between at least two different imaging locations; ]
0.99999225	1450	[ set an ultrasonic energy for detecting one or more different kinds of ultrasound of the different types of ultrasound beams, wherein the first ultrasonic detector comprises a first waveguiding material and a first ultrasound detection element; and ]	[ a first ultrasonic detector configured to receive at least one of the different ultrasound beams, and ]
0.99999225	1451	[ a second ultrasonic detector configured to receive at least one of the different ultrasound beams, and ]	[ set an ultrasonic energy for detecting one or more different kinds of ultrasound of the different types of ultrasound beams, wherein the first ultrasonic detector comprises a first waveguiding material and a first ultrasound detection element; and ]
0.99999225	1452	[ set an ultrasonic energy for detecting the first and second ultrasound beams, coupled to, or coupled to the first ultrasonic detector, wherein the first ultrasound detection element comprises an ultrasonic image detecting element and is configured to detect at least the first type of ultrasound with a first ultrasonic beam and a second type of ultrasound with a second ultrasound beam; ]	[ a second ultrasonic detector configured to receive at least one of the different ultrasound beams, and ]
0.9999924	1453	[ wherein, in the first plurality of ultrasound beams received by the first ultrasonic detector, the different levels of movement of the different kinds of ultrasound beams are detected by each of the different ultrasound detectors, and ]	[ set an ultrasonic energy for detecting the first and second ultrasound beams, coupled to, or coupled to the first ultrasonic detector, wherein the first ultrasound detection element comprises an ultrasonic image detecting element and is configured to detect at least the first type of ultrasound with a first ultrasonic beam and a second type of ultrasound with a second ultrasound beam; ]
0.99999213	1454	[ wherein, in the second plurality of ultrasound beams received by the second ultrasonic detector, the different levels of movement of the different kinds of ultrasound beams are detected by each of the different ultrasound detectors without any overlap between the different types of ultrasound beams. ]	[ wherein, in the first plurality of ultrasound beams received by the first ultrasonic detector, the different levels of movement of the different kinds of ultrasound beams are detected by each of the different ultrasound detectors, and ]
0.999987	1455	[ providing first and second ultrasound imaging devices, one of said first and second ultrasound imaging devices being mounted to a distal end of a subject; ]	[ A method for providing an ultrasound imaging image of a subject comprising: ]
0.9999919	1456	[ supplying a first ultrasound imaging device with image data representing the subject; and ]	[ providing first and second ultrasound imaging devices, one of said first and second ultrasound imaging devices being mounted to a distal end of a subject; ]
0.99999225	1457	[ supplying a second ultrasound imaging device with image data representing the subject at different points in time when the first ultrasound imaging device is in a first position when it images the subject and opposite first positions when it images the subject and when the second ultrasound imaging device is in a second position when it images the subject in time-dispersed images with only those parts of the subject that are not in a subject. ]	[ supplying a first ultrasound imaging device with image data representing the subject; and ]
0.99999166	1458	[ i) determining that the ovuloplasty of the ovary is not in need of in vitro fertilization, said determining being based on a determined probability that a tubular ovary of the ovary was capable of producing a human egg without in vitro fertilization; ]	[ A process for reducing or eliminating the need for in vitro fertilization performed by a human female having a tubular ovary, said process comprising the steps of: ]
0.9999684	1459	[ ii) administering to said non-ovulate ovary a composition comprising: ]	[ i) determining that the ovuloplasty of the ovary is not in need of in vitro fertilization, said determining being based on a determined probability that a tubular ovary of the ovary was capable of producing a human egg without in vitro fertilization; ]
0.99964964	1460	[ a) a drug of sufficient efficacy to eliminate the need for in vitro fertilization; ]	[ ii) administering to said non-ovulate ovary a composition comprising: ]
0.9996861	1461	[ b) a nucleic acid encoding a human progenitor; and ]	[ a) a drug of sufficient efficacy to eliminate the need for in vitro fertilization; ]
0.000300441	1462	[ c) no more than 0.005% by weight of said composition; and ]	[ b) a nucleic acid encoding a human progenitor; and ]
0.0053961994	1463	[ iii) exposing said non-ovulate ovary for an amount which does not inhibit or delay the proliferation of said human egg. ]	[ c) no more than 0.005% by weight of said composition; and ]
0.9999906	1464	[ providing said external device with a charging module, the charging module comprising a processor, a memory, and ]	[ A method for increasing power to a power source provided in an external device, including one or more electronics, such that power can be supplied, the method comprising: ]
0.99998593	1465	[ a sensing module configured to detect a user state of said charging module and to adjust the power supplied to said external device based on the detected user state of said charging module, wherein the sensing module is capable of sensing at least one parameter indicative of at least one function of said computing device, the at least one parameter being one or more sensors adapted to acquire detected and sensed data from the one or more sensors, such that the sensed of said one or more sensors can be correlated with the sensed of said one or more sensors in a non-linear manner. ]	[ providing said external device with a charging module, the charging module comprising a processor, a memory, and ]
0.9930675	1466	[ a) providing an interior membrane having a first layer and a second layer and an outer membrane, the exterior surface of the inner portion of the container being adjacent to the first and second layer of the interior membrane; ]	[ A method for producing an antimicrobial compound in a microfiber in a tubular container sized and configured to retain, at a first end thereof, a fluid comprising a biological material comprising a first biological component and at least one second biological component having a composition of a biological composition comprising bioactive agents, the method comprising the steps of: ]
0.9999919	1467	[ b) providing an outer coating which contains at least one active agent to provide an antimicrobial coating, the exterior surface of the inner compartment being adjacent to the outer coating, the outward surface of the first and second layers being exposed to a water-dispersive system so as to provide an antimicrobial surface of the outer membrane which contains a substantial amount of biocompatible material; and ]	[ a) providing an interior membrane having a first layer and a second layer and an outer membrane, the exterior surface of the inner portion of the container being adjacent to the first and second layer of the interior membrane; ]
0.99968505	1468	[ c) drying the interior membrane at an ambient temperature of at least 120&#xb0; C. to allow for the presence of hydrophilic, bioactive fluids to the fluid in the interior, wherein the composition is selected from the group consisting of: ]	[ b) providing an outer coating which contains at least one active agent to provide an antimicrobial coating, the exterior surface of the inner compartment being adjacent to the outer coating, the outward surface of the first and second layers being exposed to a water-dispersive system so as to provide an antimicrobial surface of the outer membrane which contains a substantial amount of biocompatible material; and ]
0.9993131	1469	[ 1) cellulose or cornstarch, ]	[ c) drying the interior membrane at an ambient temperature of at least 120&#xb0; C. to allow for the presence of hydrophilic, bioactive fluids to the fluid in the interior, wherein the composition is selected from the group consisting of: ]
0.9999527	1470	[ 2) polyvinyl alcohol, ]	[ 1) cellulose or cornstarch, ]
0.99927753	1471	[ 3) pectooligosaccharides, ]	[ 2) polyvinyl alcohol, ]
0.9999887	1472	[ 4) propylene glycol and polysaccharides, ]	[ 3) pectooligosaccharides, ]
0.99995387	1473	[ 5) lactic acid or hydrolyzed carbohydrates, ]	[ 4) propylene glycol and polysaccharides, ]
0.99996924	1474	[ 6) gelatinous starch, ]	[ 5) lactic acid or hydrolyzed carbohydrates, ]
0.999938	1475	[ 7) cellulose binder oil or polyurethane binder, and ]	[ 6) gelatinous starch, ]
0.9998559	1476	[ 8) a combination of these products. ]	[ 7) cellulose binder oil or polyurethane binder, and ]
0.99965453	1477	[ (a) administering to a subject in need thereof an effective amount of a biocompatible compound, wherein said biocompatible compound is an antibody or antibody component capable of binding to an immunogenic ligand thereof; and ]	[ A method for treating skin cancer comprising: ]
0.99998784	1478	[ (b) detecting an antibody or antibody component against a surface antigen of the skin cancer by using an immunoglobulin. ]	[ (a) administering to a subject in need thereof an effective amount of a biocompatible compound, wherein said biocompatible compound is an antibody or antibody component capable of binding to an immunogenic ligand thereof; and ]
0.99998736	1479	[ (a) providing the heart with a current flow of pulsed pulse energy within the heart; and ]	[ A method for providing a high-intensity pulse to the heart comprising: ]
0.9998839	1480	[ (b) providing an electric pressure source having a first discharge port, a second discharge port and an electric pressure sensing device to cause an electric current to flow therethrough to a first location adjacent the first discharge port of said current source and a second location adjacent the second discharge port of said current source, the electric pressure sensing device determining a low pressure of tissue based on an electrical current flowing along a length of the path and sensing whether the tissue is substantially covered by the electric current. ]	[ (a) providing the heart with a current flow of pulsed pulse energy within the heart; and ]
0.99999225	1481	[ an auxiliary side, said auxiliary side comprising at least one end and, with the auxiliary side defined such that the upper edge is disposed outside the inewheel end of the conduit and the inewheel end of a catheter comprises a proximal end, wherein said inewheel ends of the conduit are interconnected by a channel of material into which the lower edge of the catheter is inserted when in use, wherein said conduit is secured to an inner surface of the catheter in order to allow passage of one end of the auxiliary side of the catheter into and out of a body cavity of the patient via the inewheel end of the conduit. ]	[ A catheter comprising a conduit which has an inewheel end, a distal end and an upper edge, and ]
0.99998605	1482	[ a second portion comprising an amino acid substitution wherein the substituent is located upstream of the first portion of the protein, wherein the two amino acids in the second portion are adjacent one another, wherein the substituent in the first portion is selected from the group consisting of a polynucleotide in amino acid sequence 1 through 19 of SEQ ID SEQ ID NO: 2 or a polynucleotide in polynucleotide 1 through 19 of SEQ ID SEQ ID NO: 2 or a polynucleotide in polynucleotide 1 through 19 of SEQ ID SEQ ID NO: 2; and ]	[ A method for treating a subject in need thereof, comprising providing an isolated polynucleotide encoding a protein that specifically binds to a peptide of the class of polypeptides, the protein comprising: a first portion for binding to the class-specific peptide, and ]
0.9995023	1483	[ a compound that binds to the class-specific peptide. ]	[ a second portion comprising an amino acid substitution wherein the substituent is located upstream of the first portion of the protein, wherein the two amino acids in the second portion are adjacent one another, wherein the substituent in the first portion is selected from the group consisting of a polynucleotide in amino acid sequence 1 through 19 of SEQ ID SEQ ID NO: 2 or a polynucleotide in polynucleotide 1 through 19 of SEQ ID SEQ ID NO: 2 or a polynucleotide in polynucleotide 1 through 19 of SEQ ID SEQ ID NO: 2; and ]
0.99999213	1484	[ wherein said antigen, when isolated from a human, expresses a polypeptide having the structure that is: ]	[ A method for identifying an antigen that has the properties of a polypeptide having the structure that is: ]
0.9999691	1485	[ wherein said polypeptide has a binding activity that is at least 30% (1) at 1-15&#xb0; C., the binding activity being between 7.1&#xb0; C. and 10&#xb0; C., and ]	[ wherein said antigen, when isolated from a human, expresses a polypeptide having the structure that is: ]
0.9996995	1486	[ (2) at 1&#xb0; C. and less than 10&#xb0; C. and less than 20&#xb0; C. ]	[ wherein said polypeptide has a binding activity that is at least 30% (1) at 1-15&#xb0; C., the binding activity being between 7.1&#xb0; C. and 10&#xb0; C., and ]
0.9883046	1487	[ a housing; ]	[ A food storage device, comprising: ]
0.04131714	1488	[ a tray having a first end and a second end; ]	[ a housing; ]
0.9999919	1489	[ a lid disposed at the first end of the tray; ]	[ a tray having a first end and a second end; ]
0.9999299	1490	[ a lid portion defining an exit opening at the second end of the lid portion; and ]	[ a lid disposed at the first end of the tray; ]
0.9714136	1491	[ a valve comprising: ]	[ a lid portion defining an exit opening at the second end of the lid portion; and ]
0.9977519	1492	[ an exit opening positioned between a first lumen extending from the exit opening to a second lumen extending from the exit opening to a receptacle, the receptacle having a length therebetween relative to the receptacle length; and ]	[ a valve comprising: ]
0.99997985	1493	[ an inside opening configured for sealing communication channels for feeding food from the lid through the receptacle, wherein the valve is configured to open from the receptacle when at least one of a first contact or a second contact with a food is made to move the lid from the first end of the housing to the second end of the housing, thereby enabling the exit opening to direct a portion of the first contact to flow through the opening and the inside opening to direct a portion of the second contact, ]	[ an exit opening positioned between a first lumen extending from the exit opening to a second lumen extending from the exit opening to a receptacle, the receptacle having a length therebetween relative to the receptacle length; and ]
0.99998975	1494	[ a second contact configured to release a portion of the lid when the second contact moves from an open status to a closed status, wherein each of the first, second and third contacts are formed from a resilient member having an inner wall; and ]	[ an inside opening configured for sealing communication channels for feeding food from the lid through the receptacle, wherein the valve is configured to open from the receptacle when at least one of a first contact or a second contact with a food is made to move the lid from the first end of the housing to the second end of the housing, thereby enabling the exit opening to direct a portion of the first contact to flow through the opening and the inside opening to direct a portion of the second contact, ]
0.9790592	1495	[ an exterior surface defined by an edge portion. ]	[ a second contact configured to release a portion of the lid when the second contact moves from an open status to a closed status, wherein each of the first, second and third contacts are formed from a resilient member having an inner wall; and ]
0.9993512	1496	[ light emitting members (LEDs) which are disposed on a surface of a frame; ]	[ A portable light emitting diode (LED) comprising: ]
0.9999732	1497	[ a circuit (LCD) disposed in the light emitting members; ]	[ light emitting members (LEDs) which are disposed on a surface of a frame; ]
0.99974245	1498	[ at least one transistor (T-LED) disposed within the circuit, the at least one transistor (T-LED) being a transistor having an output circuit, an output voltage source, and ]	[ a circuit (LCD) disposed in the light emitting members; ]
0.03385722	1499	[ an exit circuit; and ]	[ at least one transistor (T-LED) disposed within the circuit, the at least one transistor (T-LED) being a transistor having an output circuit, an output voltage source, and ]
0.99680054	1500	[ a battery compartment having a terminal circuit in communication with a battery, which can be powered by the output voltage source and the output voltage of the output circuit. ]	[ an exit circuit; and ]
0.9999838	1501	[ a) administering to a subject a composition to enable cardiac stents to penetrate within the heart of the subject; ]	[ A method of preventing cardiac stent implantation from having an impact on cardiac rhythm, comprising the steps of: ]
0.99935824	1502	[ b) administering an antibody, at least one antibody specificity group, or an antibody specificity fragment thereof, or a non-specific antibody fragment thereof, the antibody specificity group or antibody specificity fragment, or antibody specificity fragment thereof specifically binding to the amino acid sequence of SEQ ID NO. 12. ]	[ a) administering to a subject a composition to enable cardiac stents to penetrate within the heart of the subject; ]
0.9981369	1503	[ receive an input from an external device, the input comprising coordinates of a space; ]	[ A system for creating a set of one or more objects, comprising: said system in communication with at least one object of said set of one or more objects in the form, having the apparatus being configured to: ]
0.9998248	1504	[ determine, in response to said input, an orientation of the at least one object based upon the input; ]	[ receive an input from an external device, the input comprising coordinates of a space; ]
0.9999918	1505	[ set, in response to set of the at least one object being oriented, a portion of said external device as a position for placing said at least one object; ]	[ determine, in response to said input, an orientation of the at least one object based upon the input; ]
0.99999225	1506	[ move said portion of said external device in response to said position being set as the at least one object having a respective orientation when said apparatus receives a first change in said space, wherein said first change in said space comprises a move of said external device from at least one of the positions determined as the at least one object having the respective orientation. ]	[ set, in response to set of the at least one object being oriented, a portion of said external device as a position for placing said at least one object; ]
0.99055964	1507	[ (a) a first delivery device; ]	[ An apparatus for administering a drug and for administering a therapeutic agent at a dosage rate exceeding or not exceeding a preset dosage level in a patient, the apparatus comprising: ]
0.9999902	1508	[ (b) a second delivery device, each capable of being inserted within an insertion space of a patient and of being moved at a time and for a set timing relative to a predetermined time interval from the first delivery device into an insertion space adjacent to the patient to which the second delivery device is attached, wherein the second delivery device is configured for the insertion of a plurality of different drugs, wherein each of the different drugs comprises a drug of less drug effect than the drug of the first delivery device; ]	[ (a) a first delivery device; ]
0.9999919	1509	[ (c) a data transfer station at a center of the first delivery device; and ]	[ (b) a second delivery device, each capable of being inserted within an insertion space of a patient and of being moved at a time and for a set timing relative to a predetermined time interval from the first delivery device into an insertion space adjacent to the patient to which the second delivery device is attached, wherein the second delivery device is configured for the insertion of a plurality of different drugs, wherein each of the different drugs comprises a drug of less drug effect than the drug of the first delivery device; ]
0.99999225	1510	[ (d) a data transfer station at a center of the second delivery device. ]	[ (c) a data transfer station at a center of the first delivery device; and ]
0.99999225	1511	[ rearranging the amino acid sequence for a different cytotoxic peptide which inhibits or reversibly inhibits cytotoxic T cell function by a mutation or substituting units in a polynucleotide when compared to a polypeptide of a polypeptide having the same amino acid sequence, characterized in that the cytotoxic peptide is the heavy chain moiety. ]	[ A method for inhibiting apoptosis in cells in which a cytotoxic peptide which inhibits or reversibly inhibits cytotoxic T cell function is formed from a polypeptide which is a polypeptide selected from the group consisting of; polypeptides having at least 80 amino acids, or a variant thereof, having at least 25 contiguous residues and no more than two mutations, wherein each mutation is associated with a different function and is selected from the group consisting of modifying the amino acid sequence by one or more substituting units, substituting an residues selected from the group consisting of modifying the amino acid sequence by a polynucleotide, changing the nucleotide sequence by a polynucleotide, changing one or more of the residues selected from the group consisting of modifying the amino acid sequence by a polynucleotide, or any mixture thereof, and ]
0.9854951	1512	[ a support; ]	[ An apparatus comprising: ]
0.9999095	1513	[ a first portion on which the support and the first portion are connected by a first connection device; ]	[ a support; ]
0.999954	1514	[ a plurality of gaming elements formed of an input element, an input component, and ]	[ A system for a gaming machine at a gaming machine, comprising: ]
0.99999213	1515	[ a controller coupled to theinput element, the input component and the controller being connected in parallel to form a plurality of gaming elements, each of the plurality of gaming elements comprising a plurality of input elements, each of the input elements being connected to the input component and configured to control a player, the user and respective controllable inputs; and ]	[ a plurality of gaming elements formed of an input element, an input component, and ]
0.99999225	1516	[ a processor coupled to a data communication device for receiving a first set of controller inputs in response to input of a first controller of the plurality of gaming elements, wherein the processor controls the input component to control the player, the user and respective controllable inputs in a manner that is different from that in which the first controller controls the user, the controller being connected to the information receiving device via a data line and configured for being programmed by a user and being stored in a storage. ]	[ a controller coupled to theinput element, the input component and the controller being connected in parallel to form a plurality of gaming elements, each of the plurality of gaming elements comprising a plurality of input elements, each of the input elements being connected to the input component and configured to control a player, the user and respective controllable inputs; and ]
0.9999919	1517	[ (a) inserting a surgical device into an extracorporeal space between a first intervertebral disc and a second intervertebral disc, the tissue of the second intervertebral disc extending below a surface of the intervertebral disc; ]	[ A method for treating an intervertebral disc, the method comprising: ]
0.99999225	1518	[ (b) inserting a spacer material between the first intervertebral disc and the second intervertebral disc extending below the surface of the intervertebral disc and the spacer material being provided in a generally horizontal manner; and ]	[ (a) inserting a surgical device into an extracorporeal space between a first intervertebral disc and a second intervertebral disc, the tissue of the second intervertebral disc extending below a surface of the intervertebral disc; ]
0.99999225	1519	[ (c) treating the second intervertebral disc with a non-invasive, non-surgical spacer material having a volume that is less than that of the tissue of the first intervertebral disc, where the non-invasive, non-surgical spacer material provides the greatest compression in a location near a distal end of the first intervertebral disc relative to a location near a distal end of the second intervertebral disc. ]	[ (b) inserting a spacer material between the first intervertebral disc and the second intervertebral disc extending below the surface of the intervertebral disc and the spacer material being provided in a generally horizontal manner; and ]
0.9999857	1520	[ a catheter body having a proximal end and a distal end, the stent comprising at least one sleeve configured to be insertable into the catheter, the at least one sleeve being configured to be disposed in a space between a distal end of the distal end of the catheter and a distal end of a proximal end of the proximal end of the catheter and configured to receive a head of the catheter, and ]	[ A stent for insertion into a distal end of a catheter, the stent comprising: ]
0.99999154	1521	[ to be separated from the at least one sleeve by an opening of the catheter body; ]	[ a catheter body having a proximal end and a distal end, the stent comprising at least one sleeve configured to be insertable into the catheter, the at least one sleeve being configured to be disposed in a space between a distal end of the distal end of the catheter and a distal end of a proximal end of the proximal end of the catheter and configured to receive a head of the catheter, and ]
0.9999914	1522	[ an inlet port configured in the catheter body, and ]	[ to be separated from the at least one sleeve by an opening of the catheter body; ]
0.9999906	1523	[ configured for insertion into the space between the distal end of the distal end and the opening in the catheter body in a proximal position, the stent being configured to further define a distal end, each of the at least one sleeve or the openings within the stent including an opening of a different width, to permit a first distance between the inlet port and a laterally positioned end of the catheter in the catheter body to be smaller than to allow a different diameter of the distal end of the stent relative to the opening in the catheter body to be a greater distance than two opposing diametrically opposed diametrically opposed diametrically opposed portions of the at least one sleeve, wherein each of the diametrically opposed diametrically opposed portions of at least one sleeve includes at least one of a central, center, front side, inner side and a side wall; and ]	[ an inlet port configured in the catheter body, and ]
0.99999034	1524	[ a first fluid channel configured to receive water through the distal end of the stent and configured to flow through the opening in the catheter body. ]	[ configured for insertion into the space between the distal end of the distal end and the opening in the catheter body in a proximal position, the stent being configured to further define a distal end, each of the at least one sleeve or the openings within the stent including an opening of a different width, to permit a first distance between the inlet port and a laterally positioned end of the catheter in the catheter body to be smaller than to allow a different diameter of the distal end of the stent relative to the opening in the catheter body to be a greater distance than two opposing diametrically opposed diametrically opposed diametrically opposed portions of the at least one sleeve, wherein each of the diametrically opposed diametrically opposed portions of at least one sleeve includes at least one of a central, center, front side, inner side and a side wall; and ]
0.9991524	1525	[ (a) a container body having a top end portion, a second end portion, and ]	[ A container for retaining pharmaceuticals, the container comprising: ]
0.999943	1526	[ a bottom portion, said top end portion having an aperture to receive an upper end portion of a pharmaceutical; ]	[ (a) a container body having a top end portion, a second end portion, and ]
0.99998736	1527	[ (b) a cover comprising a plurality of cover openings, said cover having a first sidewall disposed in a first position and a second sidewall disposed in a second position parallel to the first position, said first sidewall being configured to receive said upper end portion thereof in said aperture; ]	[ a bottom portion, said top end portion having an aperture to receive an upper end portion of a pharmaceutical; ]
0.99998283	1528	[ (c) a plurality of lids positioned at least partially on and in communication with said opening of each said cover opening; ]	[ (b) a cover comprising a plurality of cover openings, said cover having a first sidewall disposed in a first position and a second sidewall disposed in a second position parallel to the first position, said first sidewall being configured to receive said upper end portion thereof in said aperture; ]
0.9999554	1529	[ (d) a closure assembly coupled to each seal and arranged to close and lock said aperture to the container body to secure said pharmaceuticals in said container; and ]	[ (c) a plurality of lids positioned at least partially on and in communication with said opening of each said cover opening; ]
0.9999813	1530	[ (e) at least one cover clamp member movably coupled to said at least one cover opening of each said cover to clamp on said lid. ]	[ (d) a closure assembly coupled to each seal and arranged to close and lock said aperture to the container body to secure said pharmaceuticals in said container; and ]
0.99999213	1531	[ treating or preventing the development or severity of neurodegenerative disorder in the subject. ]	[ A method of treating or preventing the development of a neurodegenerative disorder in a subject with neurodegenerative impairment, the method comprising administering to the subject an agent that reduces the rate of proliferation of cell bodies and cells in the brain of the subject, a pharmacologic mechanism whereby the agent decreases the proliferation of the cells so as to reduce neurodegenerative impairment, and ]
0.9747661	1532	[ a housing having an upper surface and a lower surface; ]	[ An apparatus for an implant comprisingan endoscope comprising: ]
0.99998784	1533	[ a body mounted to the upper surface; ]	[ a housing having an upper surface and a lower surface; ]
0.0048403423	1534	[ two proximal ends of the endoscope, each having a distal end opposite to its proximal portion; ]	[ a body mounted to the upper surface; ]
0.99999106	1535	[ at least two distal ends of the opposite distal ends of each respective distal end of the first and second distal ends of the second distal end of the endoscope relative to each other; and ]	[ two proximal ends of the endoscope, each having a distal end opposite to its proximal portion; ]
0.999959	1536	[ a first mounting portion on the lower surface of the at least two distal ends; ]	[ at least two distal ends of the opposite distal ends of each respective distal end of the first and second distal ends of the second distal end of the endoscope relative to each other; and ]
0.9999913	1537	[ a second mounting portion mounted to the upper surface. ]	[ a first mounting portion on the lower surface of the at least two distal ends; ]
0.99696463	1538	[ a frame; ]	[ An exercise machine comprising: ]
0.9998841	1539	[ a handle on said frame; ]	[ a frame; ]
0.999956	1540	[ a rotatable chair mount coupled to said frame; ]	[ a handle on said frame; ]
0.9999918	1541	[ a drive device disposed on said chair mount; ]	[ a rotatable chair mount coupled to said frame; ]
0.99999225	1542	[ an acceleration sensor disposed on said chair mount for sensing acceleration, said acceleration sensor being coupled to an actuator of a pedal motor; ]	[ a drive device disposed on said chair mount; ]
0.99998987	1543	[ a motor driven by an motor of said pedal motor and coupled to said drive device; ]	[ an acceleration sensor disposed on said chair mount for sensing acceleration, said acceleration sensor being coupled to an actuator of a pedal motor; ]
0.99999154	1544	[ a power supply device coupled to said drive device; ]	[ a motor driven by an motor of said pedal motor and coupled to said drive device; ]
0.99999213	1545	[ a drive force transmitter coupled to an electrical lead of said power supply device; ]	[ a power supply device coupled to said drive device; ]
0.99999225	1546	[ a motor drive generator for generating a drive force transmitted through said electrical lead through means of said power supply device and said drive force transmitter; ]	[ a drive force transmitter coupled to an electrical lead of said power supply device; ]
0.9997402	1547	[ an output control device and a switching means coupled to said output control device for switching an operation of said drive device from a first operation to a second operation, said position of said switching means in said switching means is chosen based on said position of said output control device in said switching means; and ]	[ a motor drive generator for generating a drive force transmitted through said electrical lead through means of said power supply device and said drive force transmitter; ]
0.9999908	1548	[ a control signal transmitter to receive said output control device; ]	[ an output control device and a switching means coupled to said output control device for switching an operation of said drive device from a first operation to a second operation, said position of said switching means in said switching means is chosen based on said position of said output control device in said switching means; and ]
0.99968755	1549	[ an acceleration actuator being disposed on said rotatable chair mount for generating an actuation signal, said acceleration actuator being coupled to a control signal and a drive controller, said control signal including acceleration values, said acceleration value from said acceleration actuator being generated by said driving motor and said driving force generator respectively, said control signal including acceleration values being transmitted from said transmission means to a control module of said power supply device and said switching means respectively and said actuator being disposed on said rotatable chair mount for generating an output signal, said output signal being transmitted on said output control device, said control signal and said output signal being delivered to said output control device, said control module receiving said output signal based on said acceleration value transmitted to said control module, said output signal indicating a force and an acceleration. ]	[ a control signal transmitter to receive said output control device; ]
0.9999907	1550	[ a) administering to the heart failure a single dose of a drug having at least one of: (a) a high affinity &#x3b1; ]	[ A method for treating a heart failure within a subject in need thereof, wherein the heart failure is related to a cardiac disorder and wherein said method comprises the steps of: ]
0.99983597	1551	[ -4(R)3-deoxy-D-glucopyranoside; (b) an isolated nucleic acid encoding a nucleic acid ligand that specifically binds the drug; and ]	[ a) administering to the heart failure a single dose of a drug having at least one of: (a) a high affinity &#x3b1; ]
0.99997115	1552	[ (c) an isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: ]	[ -4(R)3-deoxy-D-glucopyranoside; (b) an isolated nucleic acid encoding a nucleic acid ligand that specifically binds the drug; and ]
0.9995097	1553	[ 3, SEQ ID NO: ]	[ (c) an isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: ]
0.99998844	1554	[ 5, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998975	1555	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.99998677	1556	[ 8, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.9999889	1557	[ 11, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.9999887	1558	[ 12, SEQ ID NO: ]	[ 11, SEQ ID NO: ]
0.9999893	1559	[ 13, SEQ ID NO: ]	[ 12, SEQ ID NO: ]
0.99998903	1560	[ 14, SEQ ID NO: ]	[ 13, SEQ ID NO: ]
0.9999882	1561	[ 15, SEQ ID NO: ]	[ 14, SEQ ID NO: ]
0.99998534	1562	[ 16 and SEQ ID NO: ]	[ 15, SEQ ID NO: ]
0.99985504	1563	[ 17. ]	[ 16 and SEQ ID NO: ]
0.9949884	1564	[ or an aryl, heteroaryl or heterocycle group, in which R1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, acyl, cationic or carboxy, and ]	[ A compound of formula I: ]
0.9978666	1565	[ R2 is hydroxyl, is not a monodimethylene or pentylmorpholine. ]	[ or an aryl, heteroaryl or heterocycle group, in which R1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, acyl, cationic or carboxy, and ]
0.0235613	1566	[ a frame; ]	[ A patient support, comprising: ]
0.98004305	1567	[ a support frame having an end to be fixedly received within a patient's body, and ]	[ a frame; ]
0.997017	1568	[ having a plurality of rigid leg joints having substantially the same relative movement pattern; and ]	[ a support frame having an end to be fixedly received within a patient's body, and ]
0.99187285	1569	[ at least a first and a second support leg having a length of less than about 50, ]	[ having a plurality of rigid leg joints having substantially the same relative movement pattern; and ]
0.99993825	1570	[ 000mm and about 100, ]	[ at least a first and a second support leg having a length of less than about 50, ]
0.99993634	1571	[ 000mm, the first support leg extending from the first support frame into a portion of the patient's body and being fixedly attached to a lateral side of the frame; ]	[ 000mm and about 100, ]
0.99631065	1572	[ a first flexible member disposed in a first of the plurality of rigid leg joints extending therefrom, and ]	[ 000mm, the first support leg extending from the first support frame into a portion of the patient's body and being fixedly attached to a lateral side of the frame; ]
0.99999213	1573	[ a second flexible member disposed in a second of the plurality of rigid leg joints extending therefrom, ]	[ a first flexible member disposed in a first of the plurality of rigid leg joints extending therefrom, and ]
0.9999896	1574	[ wherein the first flexible member and the second flexible member define a first leg pivot mechanism that can be slid between each other with the first side of the frame being in position at the first leg pivot mechanism, the second leg pivot mechanism, when in the configuration of the frame, moves the first support leg in a vertical plane to an intermediate position with respect to the patient's body along the distal region of the lateral side of the frame, and ]	[ a second flexible member disposed in a second of the plurality of rigid leg joints extending therefrom, ]
0.9999908	1575	[ each flexed leg element of the first and second flexible members being a different one of a series of three or more leg elements. ]	[ wherein the first flexible member and the second flexible member define a first leg pivot mechanism that can be slid between each other with the first side of the frame being in position at the first leg pivot mechanism, the second leg pivot mechanism, when in the configuration of the frame, moves the first support leg in a vertical plane to an intermediate position with respect to the patient's body along the distal region of the lateral side of the frame, and ]
0.39096394	1576	[ a first shaft side portion defining a first longitudinal axis and having an outer diameter of between about 0.1 to about 1.0 inches, and ]	[ A golf club head comprising: ]
0.9940686	1577	[ a first center line defining a first centerline direction; ]	[ a first shaft side portion defining a first longitudinal axis and having an outer diameter of between about 0.1 to about 1.0 inches, and ]
0.99584264	1578	[ a first first shaft side section defined along an outer diameter of at least about 0.1 inches; ]	[ a first center line defining a first centerline direction; ]
0.99999154	1579	[ a first second shaft side section defined along one of said first longitudinal axis and said one of said first longitudinal axis, respectively; and ]	[ a first first shaft side section defined along an outer diameter of at least about 0.1 inches; ]
0.99999	1580	[ a second first shaft side section defined along an outer diameter of about 0.1 inches, whereinthe first and second center lines define a first centerline direction, the first centerline direction is perpendicular to the second centerline direction, or the first centerline direction and the second centerline direction intersect, wherein the outer diameter of the first shaft side section and the outer diameter of the first first first shaft side section are opposite; and ]	[ a first second shaft side section defined along one of said first longitudinal axis and said one of said first longitudinal axis, respectively; and ]
0.99999213	1581	[ the first centerline direction defines a first centerline end zone. ]	[ a second first shaft side section defined along an outer diameter of about 0.1 inches, whereinthe first and second center lines define a first centerline direction, the first centerline direction is perpendicular to the second centerline direction, or the first centerline direction and the second centerline direction intersect, wherein the outer diameter of the first shaft side section and the outer diameter of the first first first shaft side section are opposite; and ]
0.99943525	1582	[ a support member for supporting a patient; ]	[ A medical apparatus comprising: ]
0.99998105	1583	[ a patient medical system disposed below said support member and configured to support a patient and move about a patient patient's limbs; ]	[ a support member for supporting a patient; ]
0.99999034	1584	[ a control system configured to control said patient medical system to perform an operation under conditions that are appropriate to a desired medical procedure, said operation comprising a medical procedure performed by the patient. ]	[ a patient medical system disposed below said support member and configured to support a patient and move about a patient patient's limbs; ]
0.99988806	1585	[ detecting a heat wave with respect to a detection electrode located between an exterior surface of the vehicle and two sensors disposed on the vehicle, wherein the detected heat wave is within a predetermined intensity range, wherein the detected heat wave is not sensed after the detected heat wave is detected; ]	[ A method of determining an initial energy density at a body heat sensor of a vehicle, comprising: ]
0.99999225	1586	[ determining a first energy density of the detected heat wave based on at least one of the two sensors, and ]	[ detecting a heat wave with respect to a detection electrode located between an exterior surface of the vehicle and two sensors disposed on the vehicle, wherein the detected heat wave is within a predetermined intensity range, wherein the detected heat wave is not sensed after the detected heat wave is detected; ]
0.99999225	1587	[ for at least a portion of the time it is outside the defined initial energy density, determining a second energy density of the detected heat wave based on at least one of the two sensors and by measuring a temperature at both the detector and at one or more sensors spaced between the detection electrodes; ]	[ determining a first energy density of the detected heat wave based on at least one of the two sensors, and ]
0.9999578	1588	[ measuring a first temperature variation based on the sensor temperature measurements; ]	[ for at least a portion of the time it is outside the defined initial energy density, determining a second energy density of the detected heat wave based on at least one of the two sensors and by measuring a temperature at both the detector and at one or more sensors spaced between the detection electrodes; ]
0.99999225	1589	[ measuring a second temperature variation based on the sensor temperature measurements and based on the body heat sensor's response thereto; ]	[ measuring a first temperature variation based on the sensor temperature measurements; ]
0.9999924	1590	[ combining the first temperature variation for the first amount of time and the second temperature variation for the first amount of time to produce a data set in which a data set indicative of the first and second temperatures is representative of the detection electrode of the body heat sensor, wherein at least a portion of the first temperature variation for the first amount of time is less than the at least one of the two sensors for the same duration and less than the a subset of the second temperature variation for the first amount of time is less than the at least one of the two sensors for the same duration for a selected type of sensor of the vehicle. ]	[ measuring a second temperature variation based on the sensor temperature measurements and based on the body heat sensor's response thereto; ]
0.9999914	1591	[ a distal end of said body members is configured to move in a first direction in relation to said cylindrical and flat end, said proximal portion having a second direction, said proximal portion being configured to be selectively engaging a distal portion of said cylindrical and flat end. ]	[ A catheter for delivering an endoscope, said catheter having a cylindrical and substantially flat end, a proximal end for insertion into an artery and a distal end for removal of the endoscope, said catheter having one or more elongate body members arranged along said cylindrical and flat end, said body members being configured to be selectively inserted or removably disengaged from said cylindrical and flat end, said distal end having a proximal portion and a distal end proximal portion, two outer ends of said body members extending in opposite direction relative to said cylindrical and flat end; a first end of said body members is configured to move in a first direction relative to said cylindrical and flat end, said first end of said body members being configured to engage a first end of an endoscope for insertion into an artery when said cylindrical and flat end is inserted into an artery of a patient, a second end of said body members being configured to move in a second direction relative to said cylindrical and flat end, said second end of said body members being configured to engage a second end of the endoscope for removal; and ]
0.9998847	1592	[ obtaining blood samples from a body of the individual; ]	[ A method of treating a heart condition or blood vessel disease of an individual, the method comprising: ]
0.9999858	1593	[ determining a difference in blood oxygenation characteristic (CO2) values between the blood samples; ]	[ obtaining blood samples from a body of the individual; ]
0.9999924	1594	[ analyzing a difference in blood oxygenation characteristic (CO2) value between the body of an individual and a control blood sample from a control blood sample taken at least three minutes prior to sampling, wherein the analyze step determines the differences in CO2 values by combining the obtained blood samples; ]	[ determining a difference in blood oxygenation characteristic (CO2) values between the blood samples; ]
0.9999919	1595	[ comparing the blood samples to the compare CO2 value; and ]	[ analyzing a difference in blood oxygenation characteristic (CO2) value between the body of an individual and a control blood sample from a control blood sample taken at least three minutes prior to sampling, wherein the analyze step determines the differences in CO2 values by combining the obtained blood samples; ]
0.9999924	1596	[ treating a condition wherein the blood samples contain a difference in CO2 values from within a predetermined range that is different from or equal to a difference value within the predetermined range. ]	[ comparing the blood samples to the compare CO2 value; and ]
0.99998045	1597	[ a power source that allows the operation of the electronic apparatus by electrical power; ]	[ An electronic apparatus including: ]
0.9993284	1598	[ a first switch for setting the power source to an off position, the first switch associated with the power source; ]	[ a power source that allows the operation of the electronic apparatus by electrical power; ]
0.999992	1599	[ a second switch, the second switch associated with the power source; ]	[ a first switch for setting the power source to an off position, the first switch associated with the power source; ]
0.9995913	1600	[ a control unit that provides signals to a first signal source and an image sensor that detects image information associated with a first object to be displayed on the first image display area on that first switch; ]	[ a second switch, the second switch associated with the power source; ]
0.98660165	1601	[ a memory that stores the received signals; ]	[ a control unit that provides signals to a first signal source and an image sensor that detects image information associated with a first object to be displayed on the first image display area on that first switch; ]
0.9997727	1602	[ a first controller that controls the operation of the power source, the first switch, the two signal sources, the memory, and ]	[ a memory that stores the received signals; ]
0.9999398	1603	[ the first controller in dependence on the received signals. ]	[ a first controller that controls the operation of the power source, the first switch, the two signal sources, the memory, and ]
0.022929087	1604	[ receiving a user's position from a wireless remote device; ]	[ A method comprising: ]
0.9999914	1605	[ calculating at least two positional coordinates of the user from the user's own position within a range of a first wireless remote device; ]	[ receiving a user's position from a wireless remote device; ]
0.99999225	1606	[ determining a location of the first wirelessly remote device relative to the user's position via a second wireless remote device; and ]	[ calculating at least two positional coordinates of the user from the user's own position within a range of a first wireless remote device; ]
0.99999166	1607	[ generating at least one virtual signal for use while the user is moving within the user's location within the range of the first wireless remote device, the user being an operator of either the first device or the second, based on: ]	[ determining a location of the first wirelessly remote device relative to the user's position via a second wireless remote device; and ]
0.9916802	1608	[ a. the user having configured: ]	[ generating at least one virtual signal for use while the user is moving within the user's location within the range of the first wireless remote device, the user being an operator of either the first device or the second, based on: ]
0.011960782	1609	[ (a) a first navigation button including at least one buttons to: ]	[ a. the user having configured: ]
0.9996191	1610	[ (i) select a new virtual state; ]	[ (a) a first navigation button including at least one buttons to: ]
0.9999914	1611	[ (ii) select a new virtual location; and ]	[ (i) select a new virtual state; ]
0.99996746	1612	[ (iii) select an icon when the icon is displayed in the second wireless remote device; and ]	[ (ii) select a new virtual location; and ]
0.99990165	1613	[ (b) a second navigation button for: ]	[ (iii) select an icon when the icon is displayed in the second wireless remote device; and ]
0.9997198	1614	[ (i) selecting a new virtual location; and ]	[ (b) a second navigation button for: ]
0.99999225	1615	[ (ii) selecting a new virtual location in response to an instruction received by the first navigation button, ]	[ (i) selecting a new virtual location; and ]
0.9999924	1616	[ the second navigation button having been configured in a manner that it can activate the second wireless remote device when the virtual location is in the user's current virtual location. ]	[ (ii) selecting a new virtual location in response to an instruction received by the first navigation button, ]
0.99999225	1617	[ establishing a plurality of predetermined time intervals and a plurality of first-off-start intervals within said plurality of seconds between the time of surgery and the time of release of at least one first organ system; and ]	[ A method for managing the availability of at least one organ system in a human during surgery comprising: ]
0.005474454	1618	[ administering to said human: ]	[ establishing a plurality of predetermined time intervals and a plurality of first-off-start intervals within said plurality of seconds between the time of surgery and the time of release of at least one first organ system; and ]
0.98615056	1619	[ (i) at least one first substance for the at least one organ system in said plurality of seconds, ]	[ administering to said human: ]
0.99999213	1620	[ (ii) at least one second substance for the at least one organ system in said plurality of seconds, and ]	[ (i) at least one first substance for the at least one organ system in said plurality of seconds, ]
0.999992	1621	[ (iii) at least one third substance at least at first and second time intervals from said first-off-start intervals. ]	[ (ii) at least one second substance for the at least one organ system in said plurality of seconds, and ]
0.99996233	1622	[ 2 and wherein it comprises at least one amino acid sequence that is at a position 7-15 of SEQ ID NO: ]	[ An isolated polypeptide or recombinant polypeptide comprising a protein, wherein the protein comprising said polynucleotide and said protein is representative of a polypeptide, or a polynucleotide that binds to a polypeptide comprising said polypeptide, in particular an epitope, comprising:A) an amino acid sequence of SEQ ID NO: ]
0.99999106	1623	[ 2 and wherein said position 7-15 comprises at least one of: ]	[ 2 and wherein it comprises at least one amino acid sequence that is at a position 7-15 of SEQ ID NO: ]
0.9999807	1624	[ a) a position between positions 4-18 of SEQ ID NO: ]	[ 2 and wherein said position 7-15 comprises at least one of: ]
0.00028505255	1625	[ 2, ]	[ a) a position between positions 4-18 of SEQ ID NO: ]
3.1101557e-05	1626	[ b) a position between positions 4-21 of SEQ ID NO: ]	[ 2, ]
0.00025709713	1627	[ 2, ]	[ b) a position between positions 4-21 of SEQ ID NO: ]
3.9151557e-05	1628	[ c) a position between positions 4- 26 of SEQ ID NO: ]	[ 2, ]
0.00028849888	1629	[ 2, ]	[ c) a position between positions 4- 26 of SEQ ID NO: ]
3.3605378e-05	1630	[ d) a position between positions 4- 25 of SEQ ID NO: ]	[ 2, ]
0.00025834216	1631	[ 2, ]	[ d) a position between positions 4- 25 of SEQ ID NO: ]
2.6995289e-05	1632	[ e) a position between positions 4-29 of SEQ ID NO: ]	[ 2, ]
0.013438612	1633	[ 2, and, ]	[ e) a position between positions 4-29 of SEQ ID NO: ]
0.9956585	1634	[ f) at least one amino acid sequence that includes nucleotide sequence 1 to 30 of SEQ ID NO: ]	[ 2, and, ]
0.997552	1635	[ 2. ]	[ f) at least one amino acid sequence that includes nucleotide sequence 1 to 30 of SEQ ID NO: ]
0.997355	1636	[ , whereinO&#x2014; ]	[ A compound of formula (I)whereineach group is H, CN, COOH, COOZ, CNZH, CNZO, CNZ2O,CNZ2Z, CNZ6O, or O&#x2014; ]
0.99200165	1637	[ comprises R&#x2014; ]	[ , whereinO&#x2014; ]
0.981937	1638	[ CH2&#x2032; ]	[ comprises R&#x2014; ]
0.99964285	1639	[ R, H, O, CH2&#x2032; ]	[ CH2&#x2032; ]
0.99970216	1640	[ CH2, CO, or CO&#x2032; ]	[ R, H, O, CH2&#x2032; ]
0.9659421	1641	[ , and ]	[ CH2, CO, or CO&#x2032; ]
0.9932782	1642	[ R&#x2014; ]	[ , and ]
0.032025527	1643	[ D&#x2032; ]	[ R&#x2014; ]
0.0016736039	1644	[ , where the nitrogen atom represents the oxygen atom, the carbon atom comprises the carbon atom of Formula (1)1R1, wherein R1 has a ring-bound or ring-unbound linker, ]	[ D&#x2032; ]
0.99772364	1645	[ wherein R2 is &#x2014; ]	[ , where the nitrogen atom represents the oxygen atom, the carbon atom comprises the carbon atom of Formula (1)1R1, wherein R1 has a ring-bound or ring-unbound linker, ]
0.108177476	1646	[ H, ]	[ wherein R2 is &#x2014; ]
0.97737175	1647	[ and R1 does not have the ring-bound or ring-unbound linker. ]	[ H, ]
0.986712	1648	[ providing a bag that includes at least one cover and a first opening associated with said at least one cover, wherein said first opening has a first opening diameter and a first opening circumference, wherein said at least one cover has a first sealing portion that is configured to seal said first opening, wherein said first opening is substantially rectangular in shape when viewed from at least a first side of said bag. ]	[ A method for dispensing food, the method comprising: ]
0.02770112	1649	[ a housing having a main body; ]	[ A fluid flow control device for fluid delivery, comprising: ]
0.9999788	1650	[ a reservoir configured to receive fluid in fluid communication with the main body; ]	[ a housing having a main body; ]
0.99999046	1651	[ a fluid delivery tube configured to facilitate the fluid delivery, the transport and delivery of a fluid in fluid communication therewith; the fluid delivery tube having a first flow path that extends from the main body to one end of the fluid delivery device, the first flow path configured for fluid communication with the port at an associated port of the main body; ]	[ a reservoir configured to receive fluid in fluid communication with the main body; ]
0.99999225	1652	[ a dispenser configured for dispensing a first amount of a fluid, the dispenser configured to be disposed adjacent to the fluid delivery tube adjacent one of the main body and at an associated first flow path to facilitate dispensing the fluid; ]	[ a fluid delivery tube configured to facilitate the fluid delivery, the transport and delivery of a fluid in fluid communication therewith; the fluid delivery tube having a first flow path that extends from the main body to one end of the fluid delivery device, the first flow path configured for fluid communication with the port at an associated port of the main body; ]
0.9999913	1653	[ a controller configured for being positioned in fluid communication with the fluid delivery tube and configured to: ]	[ a dispenser configured for dispensing a first amount of a fluid, the dispenser configured to be disposed adjacent to the fluid delivery tube adjacent one of the main body and at an associated first flow path to facilitate dispensing the fluid; ]
0.99898285	1654	[ receive a signal from the port; ]	[ a controller configured for being positioned in fluid communication with the fluid delivery tube and configured to: ]
0.9983693	1655	[ determine the maximum amount of fluid transported via the first flow path; and ]	[ receive a signal from the port; ]
0.99971074	1656	[ determine, from the signal received by the controller, whether or not to continue liquid delivery by contacting a fluid in fluid communication between the fluid delivery tube and the central fluid infusion system. ]	[ determine the maximum amount of fluid transported via the first flow path; and ]
0.99994564	1657	[ providing a graft material having a first surface and one or more second surface surfaces; ]	[ A method of forming a bone graft comprising the steps of: ]
0.99999225	1658	[ introducing a second material into the graft material so as to cover at least one of the first surface or the second surface; and ]	[ providing a graft material having a first surface and one or more second surface surfaces; ]
0.99999225	1659	[ forming a graft structure of the graft material around the second surface so each surface of the graft material has a face to support the graft structure in situ. ]	[ introducing a second material into the graft material so as to cover at least one of the first surface or the second surface; and ]
0.9998454	1660	[ a medical system operable to provide first and second devices for a surgical procedure; ]	[ A system for a cardiac surgery, comprising: ]
0.009358627	1661	[ a patient support having an exterior surface having fixed positioning and a longitudinal axis; ]	[ a medical system operable to provide first and second devices for a surgical procedure; ]
0.9913436	1662	[ one of the devices comprising a first actuator operable to provide an impulse for positioning said device; ]	[ a patient support having an exterior surface having fixed positioning and a longitudinal axis; ]
0.9999919	1663	[ a second actuator operable to provide an acceleration to said device to generate an energy wavefront in said device; ]	[ one of the devices comprising a first actuator operable to provide an impulse for positioning said device; ]
0.9999877	1664	[ a controller operable to control said first and second actuators to cause the first and second devices to move along the longitudinal axis in a trajectory that is perpendicular to the longitudinal axis, wherein the velocity vector (V), the velocity vector (V&#xd7; ]	[ a second actuator operable to provide an acceleration to said device to generate an energy wavefront in said device; ]
0.9993037	1665	[ , V&#x2212; ]	[ a controller operable to control said first and second actuators to cause the first and second devices to move along the longitudinal axis in a trajectory that is perpendicular to the longitudinal axis, wherein the velocity vector (V), the velocity vector (V&#xd7; ]
0.99152243	1666	[ ) and the direction of movement of the device (D&#x3c; ]	[ , V&#x2212; ]
0.9916243	1667	[ V&#x2212; ]	[ ) and the direction of movement of the device (D&#x3c; ]
0.9999645	1668	[ = (V&#x2212; ]	[ V&#x2212; ]
0.9999783	1669	[ )V&#x2212; ]	[ = (V&#x2212; ]
0.94536877	1670	[ , ]	[ )V&#x2212; ]
0.0024620583	1671	[ ) are aligned with a transverse-span direction, respectively, of the device, thereby providing a fixed position for said device, the velocity and direction in response to a user intervention in the mode of operation of the device; ]	[ , ]
9.235919e-05	1672	[ wherein the first actuator includes a first spring; and ]	[ ) are aligned with a transverse-span direction, respectively, of the device, thereby providing a fixed position for said device, the velocity and direction in response to a user intervention in the mode of operation of the device; ]
0.99999213	1673	[ wherein the second actuator includes a second spring. ]	[ wherein the first actuator includes a first spring; and ]
0.99773765	1674	[ an active agent that inhibits a function of a ligand; ]	[ A device for generating or treating inflammatory bowel disease comprising: ]
0.00012847225	1675	[ a delivery container configured to receive a first agent into the delivery container and a second agent disposed inside a delivery container and configured to release said first agent into the delivery container; ]	[ an active agent that inhibits a function of a ligand; ]
0.99999154	1676	[ a first release device for release of the first agent from the delivery container wherein the first release device is a first release device to be coupled to at least one of first and second sides or first and second sides of the delivery container, wherein the first release device is a first release device configured to release a first agent into the delivery container, wherein the first release device is configured to release a second agent into the delivery container and wherein the first release device is configured to release a second agent into the delivery container when the delivery container is in a first state; ]	[ a delivery container configured to receive a first agent into the delivery container and a second agent disposed inside a delivery container and configured to release said first agent into the delivery container; ]
0.99999225	1677	[ a first release device coupling member positioned adjacent to the delivery container configured to couple at least one of the first and second agents; and ]	[ a first release device for release of the first agent from the delivery container wherein the first release device is a first release device to be coupled to at least one of first and second sides or first and second sides of the delivery container, wherein the first release device is a first release device configured to release a first agent into the delivery container, wherein the first release device is configured to release a second agent into the delivery container and wherein the first release device is configured to release a second agent into the delivery container when the delivery container is in a first state; ]
0.99999225	1678	[ a second release device coupling member positioned adjacent to the delivery container including at least one of its side and a side opposite said first release device. ]	[ a first release device coupling member positioned adjacent to the delivery container configured to couple at least one of the first and second agents; and ]
0.9986375	1679	[ a) producing a dry oil from a composition comprising at least one water-based acid or salt, and ]	[ A method of preparing an oil, comprising: ]
0.9999919	1680	[ at least one salt of a water-based acid or salt; ]	[ a) producing a dry oil from a composition comprising at least one water-based acid or salt, and ]
0.020302331	1681	[ b) producing a liquid from said dry oil or liquid by mixing a mixture of the dry oil and the liquid; and ]	[ at least one salt of a water-based acid or salt; ]
0.99998665	1682	[ c) using said liquid to remove water from the oil. ]	[ b) producing a liquid from said dry oil or liquid by mixing a mixture of the dry oil and the liquid; and ]
0.99999225	1683	[ inserting a prosthetic prosthesis to form a gait space and extending from a first prostosis, said gait space comprising a pair of lateral sides and a pair of lateral sides, wherein: ]	[ A method for performing orthotic closure of a gait space comprising: ]
0.99998736	1684	[ the prosthetic prosthesis is a hollow prosthesis comprising a proximal end and a distal surface; ]	[ inserting a prosthetic prosthesis to form a gait space and extending from a first prostosis, said gait space comprising a pair of lateral sides and a pair of lateral sides, wherein: ]
0.9999857	1685	[ the proximal end of the prosthesis is attached to at least one end of the pair of lateral sides defining said gait space during the insertion; and ]	[ the prosthetic prosthesis is a hollow prosthesis comprising a proximal end and a distal surface; ]
0.99999213	1686	[ the prosthesis has a flexible interface with the prosthetic prosthesis defining the lateral sides, wherein when the prosthesis is inserted during the gait space, the distal end of the hollow prosthesis engages the distal surface of the prosthesis for the closure of the gait space for orthotic closure of the gait space; and ]	[ the proximal end of the prosthesis is attached to at least one end of the pair of lateral sides defining said gait space during the insertion; and ]
0.99999225	1687	[ positioning at least one of the pair of lateral sides of the distal end of the prosthesis to be positioned within a gait space while maintaining a diameter-independent, vertical width of at least one of said lateral sides. ]	[ the prosthesis has a flexible interface with the prosthetic prosthesis defining the lateral sides, wherein when the prosthesis is inserted during the gait space, the distal end of the hollow prosthesis engages the distal surface of the prosthesis for the closure of the gait space for orthotic closure of the gait space; and ]
0.99997735	1688	[ (iii) at least one of the grooves includes an aperture in the posterior end; (c) a first and a second guide which are mounted on opposing ends of the circumferential channel; (d) at least one second guide mounted to a front surface of the longitudinal groove; (e) a pair of substantially vertical, circumferential guides which are mounted on a front surface of the longitudinal groove and are substantially horizontal; and ]	[ A surgical catheter being formed and adapted for insertion into a surgical instrument, wherein the catheter comprises: (a) a longitudinal groove having a proximal end which is connected to an elongated section having a distal end and a posterior end, wherein the proximal end of the groove defines a circumferential channel; (b) a first and a second groove which is attached to the circumferential channel, wherein (i) the first groove extends between the proximal end of the circumferential channel to the distal end, (ii) each groove has a diameter greater than the diameter of the longitudinal groove, both grooves having a diameter of less than 1 mm, and ]
0.99999225	1689	[ (f) at least one catheter guide mounted on a front surface of the longitudinal groove. ]	[ (iii) at least one of the grooves includes an aperture in the posterior end; (c) a first and a second guide which are mounted on opposing ends of the circumferential channel; (d) at least one second guide mounted to a front surface of the longitudinal groove; (e) a pair of substantially vertical, circumferential guides which are mounted on a front surface of the longitudinal groove and are substantially horizontal; and ]
0.9998498	1690	[ scanning a medical device for a device identifier including at least one medical device identifier code and at least one device identifier, wherein said mobile device defines at least one communication protocol defined by one of said at least one medical device identifiers and said at least one device identifier, wherein said scanning comprises at least one scan in which said mobile device has multiple scan positions; ]	[ An automated method for selecting medical devices for medical treatment comprising the steps of: ]
0.99999225	1691	[ receiving a medical device selection request for a medical device from one or more of said different scan positions; ]	[ scanning a medical device for a device identifier including at least one medical device identifier code and at least one device identifier, wherein said mobile device defines at least one communication protocol defined by one of said at least one medical device identifiers and said at least one device identifier, wherein said scanning comprises at least one scan in which said mobile device has multiple scan positions; ]
0.9999901	1692	[ selecting said medical device identifier code from said device identifier code list; ]	[ receiving a medical device selection request for a medical device from one or more of said different scan positions; ]
0.99891865	1693	[ receiving a health care device identifier from a health care device; ]	[ selecting said medical device identifier code from said device identifier code list; ]
0.9999051	1694	[ determining a device identifier based on the device identifier and information contained in at least one of said medical device identifiers; and ]	[ receiving a health care device identifier from a health care device; ]
0.99999225	1695	[ transmitting said device identifier and medical device selected from said device identifier code list to the health care device during a medical procedure. ]	[ determining a device identifier based on the device identifier and information contained in at least one of said medical device identifiers; and ]
0.9999888	1696	[ providing a bovine breast comprising a tubular, thick tissue wall at a proximal end and a lumen extending from said tubular, thick tissue wall to a distal end, said distal end of said bovine breast connected with said tubular, thickness tissue wall and comprising a spherically aligned, open-end portion, said spherically aligned, open-end portion being formed with the thickness tissue wall in substantially a single region extending from said proximal end to said distal end of said bovine breast, said distal end of said bovine breast comprising: ]	[ A method for promoting growth of a bovine breast, said method comprising the steps of: ]
0.9999912	1697	[ a lumen comprising an upper, narrower section that has a substantially constant width between the first end of said tubular, thicker tissue wall and the first end of said lumen which is substantially parallel to said tubular, thicker tissue wall and extending into the tubular, thick tissue wall, wherein said lumen is formed by a second, narrower, narrow section from the distal end to an end portion of said lumen that is substantially straight and generally substantially parallel to the second end of said tubular, thicker tissue wall; and ]	[ providing a bovine breast comprising a tubular, thick tissue wall at a proximal end and a lumen extending from said tubular, thick tissue wall to a distal end, said distal end of said bovine breast connected with said tubular, thickness tissue wall and comprising a spherically aligned, open-end portion, said spherically aligned, open-end portion being formed with the thickness tissue wall in substantially a single region extending from said proximal end to said distal end of said bovine breast, said distal end of said bovine breast comprising: ]
0.99997044	1698	[ a lumen, wherein one end of the lumen is formed by a transverse region between the second end of said lumen and the side wall, and ]	[ a lumen comprising an upper, narrower section that has a substantially constant width between the first end of said tubular, thicker tissue wall and the first end of said lumen which is substantially parallel to said tubular, thicker tissue wall and extending into the tubular, thick tissue wall, wherein said lumen is formed by a second, narrower, narrow section from the distal end to an end portion of said lumen that is substantially straight and generally substantially parallel to the second end of said tubular, thicker tissue wall; and ]
0.99999225	1699	[ the other end of the lumen is formed by a transverse region between the lower end of said lumen and the side wall. ]	[ a lumen, wherein one end of the lumen is formed by a transverse region between the second end of said lumen and the side wall, and ]
0.9999913	1700	[ receiving via a first user-controlled user device an instruction to enable a first user-controlled user control through the first display at a first time to a first application to perform actions of a first type on a first application, wherein the first user-controlled user control is an application-specific and/or virtual user control; and ]	[ A method of controlling a computer to execute a first computer program to provide a first user-controlled user control to a first device that comprises a first display and a second device that comprises a second display, the method comprising: ]
0.99999225	1701	[ automatically causing, by the first user-controlled user device, the first user-controlled user control to perform actions of the second type on the first application at a second time different from the first time, wherein the second time is determined from the first time or from predetermined values associated with events in the first time. ]	[ receiving via a first user-controlled user device an instruction to enable a first user-controlled user control through the first display at a first time to a first application to perform actions of a first type on a first application, wherein the first user-controlled user control is an application-specific and/or virtual user control; and ]
0.9929133	1702	[ a) preparing a material of a composition having a first particle having a particle diameter of more than about 1000 &#x3bc; ]	[ A method of forming nanoparticles, comprising the steps of: ]
0.9967963	1703	[ m; ]	[ a) preparing a material of a composition having a first particle having a particle diameter of more than about 1000 &#x3bc; ]
0.98022616	1704	[ b) exposing the prepared material to an electro-absorbent coating which has a particle diameter of fewer than about 500 &#x3bc; ]	[ m; ]
0.99953926	1705	[ m and a viscosity less than about 16 g/cm3, ]	[ b) exposing the prepared material to an electro-absorbent coating which has a particle diameter of fewer than about 500 &#x3bc; ]
0.9845472	1706	[ in order to form nanoparticles having a particle diameter in the range of about 1000&#xb0; ]	[ m and a viscosity less than about 16 g/cm3, ]
0.99804014	1707	[ m to about 1300&#xb0; ]	[ in order to form nanoparticles having a particle diameter in the range of about 1000&#xb0; ]
0.99753463	1708	[ m; ]	[ m to about 1300&#xb0; ]
0.026563771	1709	[ c) providing an energy source comprising at least one of electrodes, an inductance conductor for contacting a substance between the electrodes and a power source, wherein the energy source comprises a plurality of discretely electrically connected and electrically-active semiconductor parts, wherein the semiconductor parts are arranged such that the semiconductor parts are electrically conductable and electrically-free. ]	[ m; ]
0.99998903	1710	[ a conveyor disposed within said housing between said housing and said dispenser and mounted over said housing; ]	[ A body assembly for dispensing water having a dispenser disposed therein and a distal end having a substantially vertical port, said body assembly comprising: <|span|>a housing having an outer bottom surface substantially perpendicular to a longitudinal length of said housing and being sized to be disposed within said dispenser; ]
0.9996599	1711	[ an adjustable nozzle assembly disposed in said housing and adapted to be adjusted between a first position which discharges a fluid to be dispensed from said nozzle and a second position which is in communication with one side of said distal end; ]	[ a conveyor disposed within said housing between said housing and said dispenser and mounted over said housing; ]
0.99967885	1712	[ a base portion formed in said housing from which the housing defines an elongated aperture that is generally horizontal; and ]	[ an adjustable nozzle assembly disposed in said housing and adapted to be adjusted between a first position which discharges a fluid to be dispensed from said nozzle and a second position which is in communication with one side of said distal end; ]
0.9998621	1713	[ at least one guide member mounted on an external surface of the hollow base portion and extending in said distal direction from an underside of said distal end. ]	[ a base portion formed in said housing from which the housing defines an elongated aperture that is generally horizontal; and ]
0.0011435972	1714	[ (i) a peptide, or a nucleic acid variant thereof, with a peptide-based structure comprising an amino acid sequence, wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 3, and ]	[ A method for treating a human or animal subject having a coronary artery, said method comprising administering to said individual an amount of a composition comprising at least one active ingredient selected from the group consisting of at least one active ingredient selected from: ]
0.99989486	1715	[ wherein the peptide has a length of between about 200 &#x3b2; ]	[ (i) a peptide, or a nucleic acid variant thereof, with a peptide-based structure comprising an amino acid sequence, wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 3, and ]
0.9989754	1716	[ m and about 300 &#x3b2; ]	[ wherein the peptide has a length of between about 200 &#x3b2; ]
0.9961591	1717	[ m, ]	[ m and about 300 &#x3b2; ]
0.0033843028	1718	[ (ii) at least one peptide having SEQ ID NO: 1, and ]	[ m, ]
0.9999889	1719	[ (iii) a non-peptide comprising at least one of SEQ ID NO: 3 and SEQ ID NO: 4, wherein at least one of the peptides does not form a polypeptide. ]	[ (ii) at least one peptide having SEQ ID NO: 1, and ]
0.004605981	1720	[ a) at least one rod having proximal and distal ends, and ]	[ A surgical instrument for insertion in or on a blood vessel comprising: ]
0.99031913	1721	[ wherein the proximal end is pivotable about a center axis at a distance of about 0.01 inches from the axial longitudinal direction; and ]	[ a) at least one rod having proximal and distal ends, and ]
0.01798477	1722	[ b) at least one surgical tool which, when held by a proximal end of the rod, extends between the intermediate ends of the rod and extends to an interior of the vessel, wherein for at least one of the proximal end and distal end of said surgical tool, a proximal end of the rod protrudes outwardly from the distal end of said tool to thereby define a distal end of a cutting edge of said tool or and wherein at least one hole is cut through at least one side of the knife. ]	[ wherein the proximal end is pivotable about a center axis at a distance of about 0.01 inches from the axial longitudinal direction; and ]
0.9990865	1723	[ a needle including a central section adapted to mate with a tip portion; ]	[ A self-contained assembly for an injection needle, comprising: ]
0.99498355	1724	[ a base having a distal end, a proximal end, and ]	[ a needle including a central section adapted to mate with a tip portion; ]
0.9980323	1725	[ a proximal portion, and ]	[ a base having a distal end, a proximal end, and ]
0.9955367	1726	[ a bore therein, adapted to mate, with the central section on the tip portion; ]	[ a proximal portion, and ]
0.9995171	1727	[ a mounting cap adapted to engage with the distal end of the base; ]	[ a bore therein, adapted to mate, with the central section on the tip portion; ]
0.99579155	1728	[ a retaining member extending from the central section of the needle; ]	[ a mounting cap adapted to engage with the distal end of the base; ]
0.9991943	1729	[ a cover of the distal section, adapted to engage the cover of the base; and ]	[ a retaining member extending from the central section of the needle; ]
0.99993074	1730	[ a closure member movably positioned in the bore of the needle, whereby the closure member extends from the base to the central section on the needle. ]	[ a cover of the distal section, adapted to engage the cover of the base; and ]
0.9998079	1731	[ an imaging system that generates images of at least an part of a patient; and ]	[ An ultrasound system, the system comprising: ]
0.9976712	1732	[ a processor that: ]	[ an imaging system that generates images of at least an part of a patient; and ]
0.9982362	1733	[ receives a set of images of the patient, ]	[ a processor that: ]
0.99999166	1734	[ determines to generate at least one imaging image of the patient associated with an image of a reference image taken of the patient based on the set of images of the patient, and ]	[ receives a set of images of the patient, ]
0.99999213	1735	[ determines, from the determined image of the patient, to display one or more reference images. ]	[ determines to generate at least one imaging image of the patient associated with an image of a reference image taken of the patient based on the set of images of the patient, and ]
0.99999	1736	[ identifying, by the processor, at least one of the patient's conditions corresponding to at least one diagnostic criterion; ]	[ A method at least partially carried out by a processor for providing a patient with a diagnosis or treatment plan that is customized based at least in part on diagnostic criteria, comprising: ]
0.99999166	1737	[ assigning an algorithm to a set of code points to identify a condition associated with the patient based at least in part on the identified condition; ]	[ identifying, by the processor, at least one of the patient's conditions corresponding to at least one diagnostic criterion; ]
0.9999924	1738	[ identifying a condition in addition to the identified condition based at least in part on a set of code points to assign the algorithm to each of the code points from: each identified code point being assigned an identity with respect to the identified condition to specify the assigned identity, wherein each assigned identity corresponds to a code point for which the algorithm applies, a code point that has at least one associated code point that corresponds to the identified condition and an identity corresponding to the code point that has the associated code point associated with it being assigned; ]	[ assigning an algorithm to a set of code points to identify a condition associated with the patient based at least in part on the identified condition; ]
0.99999225	1739	[ associating the assigned identity with a code point for the identified condition based at least in part on the identified code point that has the associated identity; ]	[ identifying a condition in addition to the identified condition based at least in part on a set of code points to assign the algorithm to each of the code points from: each identified code point being assigned an identity with respect to the identified condition to specify the assigned identity, wherein each assigned identity corresponds to a code point for which the algorithm applies, a code point that has at least one associated code point that corresponds to the identified condition and an identity corresponding to the code point that has the associated code point associated with it being assigned; ]
0.99999213	1740	[ storing a diagnostic code for the identified condition in memory; ]	[ associating the assigned identity with a code point for the identified condition based at least in part on the identified code point that has the associated identity; ]
0.99991894	1741	[ receiving information indicative of a user's condition; and ]	[ storing a diagnostic code for the identified condition in memory; ]
0.9999907	1742	[ automatically performing the associated code for the identified condition based at least in part on the information, wherein the associated code is stored in accordance with the user's condition and further wherein performing the associated code is based on a specific condition associated with the identified condition and wherein the processor performs the associated code for the identified condition based on a unique identifier associated with the identified condition. ]	[ receiving information indicative of a user's condition; and ]
0.99999034	1743	[ detecting an abnormality in a medical implant on an individual; ]	[ A method for operating a medical implant system, the method comprising: ]
0.99998903	1744	[ processing an analyte monitoring signal output by the implant using a first analyte monitoring circuit for detecting an abnormality in the device, the first analyte monitoring circuit generating an input signal with a first output signal, the input signal comprising a difference between a first sensor signal and a first analyte sensor signal; ]	[ detecting an abnormality in a medical implant on an individual; ]
0.9999826	1745	[ detecting a medical condition upon receipt of the input signal; ]	[ processing an analyte monitoring signal output by the implant using a first analyte monitoring circuit for detecting an abnormality in the device, the first analyte monitoring circuit generating an input signal with a first output signal, the input signal comprising a difference between a first sensor signal and a first analyte sensor signal; ]
0.9999833	1746	[ determining, based on a difference between a first output signal and a first analyte sensor signal, whether the first signal is suitable to be used for operation by the medical implant system in response to the determining, receiving and processing the medical condition; and ]	[ detecting a medical condition upon receipt of the input signal; ]
0.9999924	1747	[ activating for operational use the medical implant system based on the determined medical condition and in response to the first output signal having at least a positive value or a positive signal with a first indication if the medical condition is determined to be present. ]	[ determining, based on a difference between a first output signal and a first analyte sensor signal, whether the first signal is suitable to be used for operation by the medical implant system in response to the determining, receiving and processing the medical condition; and ]
0.011313551	1748	[ an anti-human tumor drug comprising a monoclonal antibody recognizing a monoclonal antibody that exhibits antibody fusion activity in a human IgG epitope selected from the group consisting of human IgG 2, human IgG 6, human IgG 10, human IgG 11, and ]	[ A method for reducing an inflammatory disease, said method comprising treating a subject in need of such treatment with: ]
0.99998903	1749	[ human IgG 14; and ]	[ an anti-human tumor drug comprising a monoclonal antibody recognizing a monoclonal antibody that exhibits antibody fusion activity in a human IgG epitope selected from the group consisting of human IgG 2, human IgG 6, human IgG 10, human IgG 11, and ]
0.9997687	1750	[ one or more anti-cancer drugs comprising a monoclonal antibody recognizeably reacting with a target human antibody. ]	[ human IgG 14; and ]
0.99971384	1751	[ administering to the mouse a nonionic peptide comprising the amino acid sequence of SEQ ID NO: ]	[ A method for treating osteoarthritis in a mouse in need thereof, said method comprising: ]
0.9992731	1752	[ 1 or SEQ ID NO: ]	[ administering to the mouse a nonionic peptide comprising the amino acid sequence of SEQ ID NO: ]
0.9975228	1753	[ 3. ]	[ 1 or SEQ ID NO: ]
0.99990106	1754	[ 1, (b) an amino acid sequence of sequence E8-E12 of SEQ ID NO: ]	[ A non-transgenic plant, comprising a sequence encoding at least one cpeptide selected from the group consisting of (a) an amino acid sequence of sequence A16-A27 of SEQ ID NO: ]
0.99999094	1755	[ 2, or (c) an amino acid sequence of sequence SEQ ID NO: ]	[ 1, (b) an amino acid sequence of sequence E8-E12 of SEQ ID NO: ]
0.9999572	1756	[ 5 or a corresponding SEQ ID NO: ]	[ 2, or (c) an amino acid sequence of sequence SEQ ID NO: ]
0.9973889	1757	[ 2. ]	[ 5 or a corresponding SEQ ID NO: ]
0.9999913	1758	[ inserting a probe into said uterus; ]	[ A method for treating an endometriosis-containing uterus when said uterus is in an intrauterine state, comprising: ]
0.9999863	1759	[ inserting a stent into the uterus through an inlet end; and ]	[ inserting a probe into said uterus; ]
0.0038171748	1760	[ distal-initiating lysosomal degradation of a target nucleic acid encoding a cell line comprising a first sequence and a second sequence, wherein the first and second sequences are different than each other. ]	[ inserting a stent into the uterus through an inlet end; and ]
0.9861996	1761	[ a) depositing a liquid metal film in a first substrate that comprises: ]	[ A method of manufacturing a flexible film comprising the steps of: ]
0.99801767	1762	[ i) an upper layer, ]	[ a) depositing a liquid metal film in a first substrate that comprises: ]
0.9999907	1763	[ ii) an upper-lying layer, and ]	[ i) an upper layer, ]
0.99984396	1764	[ iii) an open top layer of a thin film-to-tint-coat system, the thin film-to-tint-coat system comprising a first, intermediate step and a second, lower step; and ]	[ ii) an upper-lying layer, and ]
0.99998	1765	[ b) contacting the liquid metal film with a first substrate material, wherein the first substrate is formed as a combination of the upper-lying layer and the open top layer; ]	[ iii) an open top layer of a thin film-to-tint-coat system, the thin film-to-tint-coat system comprising a first, intermediate step and a second, lower step; and ]
0.999992	1766	[ c) forming the liquid metal film, wherein a second substrate material is applied to the liquid metal film; and ]	[ b) contacting the liquid metal film with a first substrate material, wherein the first substrate is formed as a combination of the upper-lying layer and the open top layer; ]
0.9999919	1767	[ d) exposing the liquid metal film to light, where the first and second substrate material are exposed such that the film may be stretched or broken. ]	[ c) forming the liquid metal film, wherein a second substrate material is applied to the liquid metal film; and ]
0.99264514	1768	[ a container disposed therein; ]	[ An infusion device, comprising: ]
0.99958104	1769	[ a reservoir of fluid therein; ]	[ a container disposed therein; ]
0.9999918	1770	[ at least one electrode disposed in the reservoir of fluid; ]	[ a reservoir of fluid therein; ]
0.99998426	1771	[ a source of electrical stimulation located at a remote location and disposed in communication with the at least one electrode; ]	[ at least one electrode disposed in the reservoir of fluid; ]
0.9999913	1772	[ at least one electrical conduit for directing electric energy to the at least one electrical stimulation source; ]	[ a source of electrical stimulation located at a remote location and disposed in communication with the at least one electrode; ]
0.99998987	1773	[ a control unit in charge of controlling electrical signal delivery from the at least one electrical conduit; ]	[ at least one electrical conduit for directing electric energy to the at least one electrical stimulation source; ]
0.99978036	1774	[ a switch connected to the source of electrical stimulation and the at least one electrode; ]	[ a control unit in charge of controlling electrical signal delivery from the at least one electrical conduit; ]
0.9999882	1775	[ a switch removably connected to the control unit, wherein a current flowing from said switch to the control unit indicates that the at least one stimulation source is to be energized; and ]	[ a switch connected to the source of electrical stimulation and the at least one electrode; ]
0.9999895	1776	[ an alarm signal connected to the switch, if there is any electrical signal delivery from said source of electrical stimulation from a time prior to the switch being switched from current control to active control of electrical stimulation, thereby causing the alarm signal to be programmed. ]	[ a switch removably connected to the control unit, wherein a current flowing from said switch to the control unit indicates that the at least one stimulation source is to be energized; and ]
0.99694306	1777	[ providing a first segment of a movement track, the first segment of the movement track having a first dimension that is smaller than a second dimension; ]	[ A method of determining a maximum potential value to be obtained during a first portion of a movement of a plurality of legs of a running apparatus, comprising the steps of: ]
0.9999918	1778	[ supplying a first control to the movement control, the first control, configured such that a first movement of a plurality of legs between a first position and a second position on a surface of the movement track is used for determining a current potential value for the plurality of legs, the first movement being made at a first speed and in a first direction, the control configured to use the starting position, when a first surface is at first distance from an end of the movement track, as a starting direction for the first movement; ]	[ providing a first segment of a movement track, the first segment of the movement track having a first dimension that is smaller than a second dimension; ]
0.999992	1779	[ providing a first control to the track control, the first control configured so that a first motion of the plurality of legs between the first position and the second position is used for determining the potential value determined at the first position; ]	[ supplying a first control to the movement control, the first control, configured such that a first movement of a plurality of legs between a first position and a second position on a surface of the movement track is used for determining a current potential value for the plurality of legs, the first movement being made at a first speed and in a first direction, the control configured to use the starting position, when a first surface is at first distance from an end of the movement track, as a starting direction for the first movement; ]
0.9998542	1780	[ providing a second segment of the movement track, the second segment having a second dimension that is smaller than the first dimension; ]	[ providing a first control to the track control, the first control configured so that a first motion of the plurality of legs between the first position and the second position is used for determining the potential value determined at the first position; ]
0.9999902	1781	[ supplying a second control to the track control, the second control configured such that a next movement of the plurality of legs between a second position and a third position on the surface of the movement track is used for determining a current potential value, the second control configured to use the starting position, when a next surface of the movement track is at a second distance from the end of the movement track, as the starting direction for the second action; ]	[ providing a second segment of the movement track, the second segment having a second dimension that is smaller than the first dimension; ]
0.9999919	1782	[ providing a third segment of the movement track, the third segment having a third dimension that is smaller than the first dimension. ]	[ supplying a second control to the track control, the second control configured such that a next movement of the plurality of legs between a second position and a third position on the surface of the movement track is used for determining a current potential value, the second control configured to use the starting position, when a next surface of the movement track is at a second distance from the end of the movement track, as the starting direction for the second action; ]
0.015343405	1783	[ an insertable support surface defining a hollow cylinder; ]	[ A medical instrument apparatus for positioning and retracting a plurality of medical instruments disposed within an anatomical structure to a desired orientation to be used for medical treatment in an operator, the medical instrument apparatus comprising: ]
0.9999893	1784	[ at least one handle and at least one handle-receive side surface, with at least one of the handles extending away from the insertable support surface, each of the at least one handle and each at least one handle-receive side surface comprising a hollow chamber containing a plurality of the plurality of the medical instruments disposed within the anatomical structure, ]	[ an insertable support surface defining a hollow cylinder; ]
0.99999225	1785	[ wherein at least one of at least one handle and at least one handle-receive side surface has a plurality of longitudinal axis elements extending therealong, with each longitudinal axis element having a first end and a second end, the first end of the first end and the second end of the second end of the second end defining an interior portion of the cylinder; ]	[ at least one handle and at least one handle-receive side surface, with at least one of the handles extending away from the insertable support surface, each of the at least one handle and each at least one handle-receive side surface comprising a hollow chamber containing a plurality of the plurality of the medical instruments disposed within the anatomical structure, ]
0.9999914	1786	[ a first member extending from at least one of the handle and at least one side surface of the insertable support surface and capable of being pivotably engaged with at least one of the handle and at least one handle-receive side surface, said first member defining at least one open longitudinal passage for receiving the medical instruments. ]	[ wherein at least one of at least one handle and at least one handle-receive side surface has a plurality of longitudinal axis elements extending therealong, with each longitudinal axis element having a first end and a second end, the first end of the first end and the second end of the second end of the second end defining an interior portion of the cylinder; ]
0.999974	1787	[ inserting an endoscope into a breast; ]	[ A method for treating a disease of the breast, the method comprising: ]
0.9999833	1788	[ providing a plurality of probes which are configured such that they can travel between the breast and a probe attachment, wherein each of the plurality of probes is configured to be a different size and shape, and ]	[ inserting an endoscope into a breast; ]
0.99999225	1789	[ wherein each of the plurality of probes comprises a bone surface along which the breast is inserted and through which fluid flows; ]	[ providing a plurality of probes which are configured such that they can travel between the breast and a probe attachment, wherein each of the plurality of probes is configured to be a different size and shape, and ]
0.99999225	1790	[ placing the bone surface on the bone of the probe so that fluid can flow through the bone surface to the breast through the bone surface; ]	[ wherein each of the plurality of probes comprises a bone surface along which the breast is inserted and through which fluid flows; ]
0.99998677	1791	[ heating a medical fluid in a conduit in fluid communication with the bone surface so that the material can absorb and expand the medical fluid to make the medical fluid heat transferable across the bone surface such that the medical fluid is heated to a certain heat to generate a thermal pulse from wherein blood vessels are expanded, and ]	[ placing the bone surface on the bone of the probe so that fluid can flow through the bone surface to the breast through the bone surface; ]
0.9999913	1792	[ wherein the thermal pulse is different for each of the types of bone; and ]	[ heating a medical fluid in a conduit in fluid communication with the bone surface so that the material can absorb and expand the medical fluid to make the medical fluid heat transferable across the bone surface such that the medical fluid is heated to a certain heat to generate a thermal pulse from wherein blood vessels are expanded, and ]
0.99999225	1793	[ injecting a biological fluid into the bone with the thermal pulse from the breast which is not absorbed into the bone, in a manner comprising: ]	[ wherein the thermal pulse is different for each of the types of bone; and ]
0.99999213	1794	[ injecting the biological fluid through the conduit, through the bone and into the breast, ]	[ injecting a biological fluid into the bone with the thermal pulse from the breast which is not absorbed into the bone, in a manner comprising: ]
0.9999906	1795	[ receiving an energy released energy from the breast, and ]	[ injecting the biological fluid through the conduit, through the bone and into the breast, ]
0.9999112	1796	[ then injecting the energy into or through the probe. ]	[ receiving an energy released energy from the breast, and ]
0.9991285	1797	[ a) an implant body; ]	[ A stent implant for use in one or more vertebral bodies, comprising: ]
0.9999919	1798	[ b) at least one segment extending from the implant body, wherein at least one segment is movable from a first shape into a second shape; ]	[ a) an implant body; ]
0.99998665	1799	[ c) at least two segments that extend between the first and second segments, wherein each of the segments has a thickness; ]	[ b) at least one segment extending from the implant body, wherein at least one segment is movable from a first shape into a second shape; ]
0.99979836	1800	[ d) two stent structures arranged on the body, wherein: ]	[ c) at least two segments that extend between the first and second segments, wherein each of the segments has a thickness; ]
0.9999908	1801	[ e) each segment does not extend beyond a first section of the stent structure; and ]	[ d) two stent structures arranged on the body, wherein: ]
0.9999889	1802	[ f) wherein the at least two segments are formed by a separate segment of the stent. ]	[ e) each segment does not extend beyond a first section of the stent structure; and ]
0.99974674	1803	[ human hematopoietic stem cell, and ]	[ A method of inhibiting immune response of cancer cells to antigens comprising administering to a mammalian subject a therapeutically effective amount of a therapeutically effective amount of an immunogenic antigen to elicit a immune response in the cancer cells, wherein the immunogenic antigen is selected from the group consisting of: human epidermal growth factor, and ]
0.99985135	1804	[ wherein the immune response is prevented by administration of an antigens suppressing agent, wherein any one or more of the immunogenic antigen, antigens, and ]	[ human hematopoietic stem cell, and ]
0.99998045	1805	[ antigens suppressants are selected from the group consisting of a human antigens and a human skin immunoglobulin. ]	[ wherein the immune response is prevented by administration of an antigens suppressing agent, wherein any one or more of the immunogenic antigen, antigens, and ]
0.99931073	1806	[ (i) SEQ ID NO: 3; ]	[ A method of inhibiting the expression of a protein having the sequence selected from the group consisting of: ]
0.9999882	1807	[ (ii) SEQ ID NO: 4; and ]	[ (i) SEQ ID NO: 3; ]
0.9999888	1808	[ (iii) SEQ ID NO: 5. ]	[ (ii) SEQ ID NO: 4; and ]
0.9995059	1809	[ or any combination thereof and which can be administered by oral dosage forms to a patient to be treated in a pharmaceutically effective amount. ]	[ An apparatus for the preparation of an effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a pharmaceutically active pharmaceutical agent, said pharmaceutical agent containing a pharmaceutically active compound of formula1: ]
0.9886149	1810	[ a data storage unit; ]	[ A computer implemented data storage system for storing computer-executable program code, wherein said computer implemented data storage system comprises: ]
0.99998176	1811	[ each said data storing unit including a first and a second level of storage; ]	[ a data storage unit; ]
0.99993825	1812	[ at least one processor connected to said storage unit to apply commands in response to a command; ]	[ each said data storing unit including a first and a second level of storage; ]
0.99997735	1813	[ a memory of said memory that stores software coded by said said at least one processor for the application of an operation to said at least one processor when said said at least one processor is subjected to a predetermined command; and ]	[ at least one processor connected to said storage unit to apply commands in response to a command; ]
0.9999862	1814	[ a computer-executable program that executes when said command is applied and stored in said memory, said computer executable program having a data type assigned to a specific computer system, and ]	[ a memory of said memory that stores software coded by said said at least one processor for the application of an operation to said at least one processor when said said at least one processor is subjected to a predetermined command; and ]
0.036661398	1815	[ wherein: ]	[ a computer-executable program that executes when said command is applied and stored in said memory, said computer executable program having a data type assigned to a specific computer system, and ]
0.018134436	1816	[ said executable program corresponds to computer program code stored in said second level of storage; and ]	[ wherein: ]
0.9999913	1817	[ said executable program is executable in a computer, ]	[ said executable program corresponds to computer program code stored in said second level of storage; and ]
0.99999213	1818	[ wherein said executable program stores a plurality of data files, each of said data files being stored in the computer, and ]	[ said executable program is executable in a computer, ]
0.99999213	1819	[ wherein the commands stored in respective computer-executable program files of said executable program are applied. ]	[ wherein said executable program stores a plurality of data files, each of said data files being stored in the computer, and ]
0.9999869	1820	[ 3 wherein the nucleic acid sequence is encoded by an amino acid sequence of SEQ ID NO: 3. ]	[ A system for the treatment of a malignant tumor in a subject in need thereof comprising an isolated nuclear locus comprising at least one DNA-binding locus, the isolated nucleic acid comprising a nucleotide sequence of at least 95% sequence identity to a nucleic acid sequence of SEQ ID NO: ]
0.9999924	1821	[ providing a first composition, in an oral interface, having: ]	[ A method for delivering a first composition to a subject by an oral interface, comprising: ]
0.9986596	1822	[ at least one active ingredient; and ]	[ providing a first composition, in an oral interface, having: ]
0.9996327	1823	[ at least one bioactive agent; and ]	[ at least one active ingredient; and ]
0.9901736	1824	[ providing at least a proximal end of a device for receiving the first composition, wherein the proximal end of the device are adapted to fit in a mouth of the subject, ]	[ at least one bioactive agent; and ]
0.99900013	1825	[ wherein the device provides access to an internal fluid, wherein the device comprises: ]	[ providing at least a proximal end of a device for receiving the first composition, wherein the proximal end of the device are adapted to fit in a mouth of the subject, ]
0.017163342	1826	[ an airtight seal for containing and sealing the at least one active ingredient, wherein the airtight seal includes an opening for an exit air intake port, wherein the airtight cap includes a sealing opening on a side opposite the airtight seal to seal the air opening, whereby a flow of the at least one active ingredient through the opening can be delivered into and out of the seal, and ]	[ wherein the device provides access to an internal fluid, wherein the device comprises: ]
0.99999213	1827	[ wherein access to and the flow of the at least one active ingredient through the opening can be accessed via a passage in the airtight seal that is at least partially contained within the sealed air opening of the airtight seal so that the flow of the at least one active ingredient may be delivered through the closure of the opening through the passage. ]	[ an airtight seal for containing and sealing the at least one active ingredient, wherein the airtight seal includes an opening for an exit air intake port, wherein the airtight cap includes a sealing opening on a side opposite the airtight seal to seal the air opening, whereby a flow of the at least one active ingredient through the opening can be delivered into and out of the seal, and ]
0.9984811	1828	[ (a) positioning an object to be used as a base; ]	[ An object-orbiting method comprising: ]
0.9999658	1829	[ (b) positioning a second target for acquiring information about a region of interest in the object's structure; ]	[ (a) positioning an object to be used as a base; ]
0.99999213	1830	[ (c) acquiring information from the second target, the information about the region of interest being obtained by evaluating information provided by at least one of the first target and the second target and by observing the second target interacting with the object; and ]	[ (b) positioning a second target for acquiring information about a region of interest in the object's structure; ]
0.99999094	1831	[ (d) displaying a display device including a plurality of virtual objects for representing an image from the second target, wherein each of the plurality of virtual objects includes one of the plurality of object-orbiting methods. ]	[ (c) acquiring information from the second target, the information about the region of interest being obtained by evaluating information provided by at least one of the first target and the second target and by observing the second target interacting with the object; and ]
0.99138945	1832	[ a housing; and ]	[ A container for storing a therapeutic liquid, comprising: ]
0.96379083	1833	[ an internal container configured as a cylindrical housing when in a closed state and a flexible container when in a open state, and ]	[ a housing; and ]
0.99999106	1834	[ configured to fit within the interior of the internal container, wherein the internal container is formed of an open interior cavity, wherein the internal container houses a first part and a second part, the first part being larger in diameter than the second part and the internal container being shaped to accommodate the first part between the first part and the second part when in the closed state and to accommodate the first part between the internal container between the first part and the external container, and ]	[ an internal container configured as a cylindrical housing when in a closed state and a flexible container when in a open state, and ]
0.999992	1835	[ wherein the first part and the second part are disposed in the open interior cavity. ]	[ configured to fit within the interior of the internal container, wherein the internal container is formed of an open interior cavity, wherein the internal container houses a first part and a second part, the first part being larger in diameter than the second part and the internal container being shaped to accommodate the first part between the first part and the second part when in the closed state and to accommodate the first part between the internal container between the first part and the external container, and ]
0.99999034	1836	[ a) providing a first medical or other device for treatment or diagnosis; ]	[ A method for making a medical or other device for treatment or diagnosis with a drug or medicine that is effective and non-toxic and has high potential of becoming active on a user's skin in a controlled manner during the treatment or diagnosis, the method including: ]
0.99999094	1837	[ b) providing a delivery device for delivering drug or medicine from the first medical or other device to a user, whereby the delivery device is configured such that the drug or medicine has a higher concentration of at least one of the one or more of the four drug or medicine metabolically active metabolites in the delivery device than has been in the delivery device previously as a function of time, which makes at least a portion of the drug or medicine active but that has a greater concentration of the at least one of the the one or more drug metabolically active metabolite in the delivery device than at least a portion of the drug or medicine effective. ]	[ a) providing a first medical or other device for treatment or diagnosis; ]
0.99910754	1838	[ 1 and an amino acid sequence having a homology &#x3b2; ]	[ A method for preparing a polypeptide, comprising the steps of a) providing an isolated polypeptide comprising the sequence of SEQ ID NO: 0 &#x3bc; ]
0.9999708	1839	[ 11&#x3bc; with SEQ ID NO: 6 or 7, c) creating a compound of the polypeptide having the homology, or, e) forming a polypeptide having the compound at a level sufficient to enhance the activity of the polypeptide in vitro to improve an effect of the polypeptide when tested in an assay. ]	[ 1 and an amino acid sequence having a homology &#x3b2; ]
0.99999225	1840	[ wherein the composition acts to inhibit the effect of the intervertebral disc. ]	[ A method of inhibiting inflammation in patients with chronic inflammatory bowel disease in which an intervertebral disc is present in the abdominal wall proximal to a distal end of an intervertebral disc which is proximal to a distal end of the intervertebral disc, the method comprising administering to said patients a composition which comprises an anti-inflammatory antibody which specifically binds to and/or stimulates the cell-signalling molecule that is the precursor for inflammation, wherein the antibody is anti-CD14, and ]
0.99999166	1841	[ (a) providing a bone graft; ]	[ A method of treating a patient suffering from a bone graft-induced syndrome including a patient with osteoarthritis of the femoral condyle comprising the following steps: ]
0.0019381441	1842	[ (b) administering a compound of the formula: ]	[ (a) providing a bone graft; ]
0.9929595	1843	[ or a pharmaceutically acceptable salt thereof, in an amount effective to treat or alleviate the severity of the treated bone graft-induced syndrome, that is effective to treat or alleviate the severity of osteoarthritis of the femoral condyle; ]	[ (b) administering a compound of the formula: ]
0.99999166	1844	[ (c) obtaining a second dose of the compounds which is effective to treat or alleviate the severity of osteoarthritis of the femoral condyle. ]	[ or a pharmaceutically acceptable salt thereof, in an amount effective to treat or alleviate the severity of the treated bone graft-induced syndrome, that is effective to treat or alleviate the severity of osteoarthritis of the femoral condyle; ]
0.9994436	1845	[ an electrode including a body portion and a cover; ]	[ A device for the insertion of an electrode into a body, comprising: ]
0.9999894	1846	[ a first portion of the electrode and a second portion of the electrode adjacent to the body portion, the first and second portions of the electrode comprising the cover portion and one another being disposed in fluid communication such that the cover portion is capable of being folded and the other portion of the electrode is configured to be inserted into body tissue; ]	[ an electrode including a body portion and a cover; ]
0.99999213	1847	[ a flexible conductive member inserted into the body portion between the first portion of the electrode and the cover portion; wherein the conductive member is adapted to be selectively attached to the cover portion and at least one end of the conductive member is disposed within the cover portion to be selectively secured to the cover portion; and ]	[ a first portion of the electrode and a second portion of the electrode adjacent to the body portion, the first and second portions of the electrode comprising the cover portion and one another being disposed in fluid communication such that the cover portion is capable of being folded and the other portion of the electrode is configured to be inserted into body tissue; ]
0.999992	1848	[ a sealing element disposed between the conductive member and the cover portion, the sealing element being flexible and in fluid communication with the conductive member and the seal element. ]	[ a flexible conductive member inserted into the body portion between the first portion of the electrode and the cover portion; wherein the conductive member is adapted to be selectively attached to the cover portion and at least one end of the conductive member is disposed within the cover portion to be selectively secured to the cover portion; and ]
0.9999913	1849	[ 2, the polypeptide sequence being the amino acid sequence of SEQ ID NO: ]	[ A method of inhibiting the tumor growth of a cancer in a patient, the method comprising administering to the patient a drug having a molecular structure having the structure of one or more polynucleotide sequences encoding polypeptide sequences having an amino acid sequence having a sequence having at least 90% sequence identity to SEQ ID NO: ]
0.9990256	1850	[ 2. ]	[ 2, the polypeptide sequence being the amino acid sequence of SEQ ID NO: ]
0.97866595	1851	[ a first layer constructed of a plurality of components, the first layer comprising an air-dispersible material that is transparent and that is generally rigid and not flexible; and ]	[ An implantable device comprising: ]
0.99999225	1852	[ a second layer constructed of a plurality of components, the second layer comprising water-dispersible material that is transparent and that is generally rigid and not flexible, wherein the second layer comprises a first side and a second side and wherein the first side and the second side are provided within the first layer. ]	[ a first layer constructed of a plurality of components, the first layer comprising an air-dispersible material that is transparent and that is generally rigid and not flexible; and ]
0.026719995	1853	[ capturing a target image using an imaging device including: ]	[ A method comprising: ]
0.9999751	1854	[ imaging an object such that a first set of reference points located at any of a plurality of reference positions located in relation with said target object are visible to said imaging device; and ]	[ capturing a target image using an imaging device including: ]
0.9999924	1855	[ generating a second set of reference points based on said imaging device, said second set of reference points being located in a relation with a first reference point, said second reference point being located in a relation with a second reference point; ]	[ imaging an object such that a first set of reference points located at any of a plurality of reference positions located in relation with said target object are visible to said imaging device; and ]
0.99930143	1856	[ wherein said object includes a plurality of different angles; ]	[ generating a second set of reference points based on said imaging device, said second set of reference points being located in a relation with a first reference point, said second reference point being located in a relation with a second reference point; ]
0.99996245	1857	[ acquiring an image of said object using said imaging device using an imaging device with an image generating device having at least one image source; ]	[ wherein said object includes a plurality of different angles; ]
0.99998915	1858	[ generating at least one digital signal associated with said at least one image source; and ]	[ acquiring an image of said object using said imaging device using an imaging device with an image generating device having at least one image source; ]
0.99999213	1859	[ processing said digital signal to generate at least one digital image based on said at least one digital signal. ]	[ generating at least one digital signal associated with said at least one image source; and ]
0.9995553	1860	[ a tooth; ]	[ An instrument for performing a dental procedure comprising: ]
0.99997985	1861	[ a lumen defined within the tooth; ]	[ a tooth; ]
0.9998512	1862	[ an operating end comprising a piston having a first piston aperture proximal to the tooth and a second piston aperture proximal to the operation end; ]	[ a lumen defined within the tooth; ]
0.9999671	1863	[ a drive shaft configured for movement with the tooth; ]	[ an operating end comprising a piston having a first piston aperture proximal to the tooth and a second piston aperture proximal to the operation end; ]
0.999908	1864	[ a second end of the operating end disposed at one end of the lumen, wherein the second end of the operating end is configured to be displaced by a portion of the tooth when the operating end is moved to the operating end by an actuator; and ]	[ a drive shaft configured for movement with the tooth; ]
0.9999862	1865	[ a connection element between at least one valve disposed at or in the mouth of the patient and at least one valve member disposed on the tooth, wherein a predetermined distance is defined for the operation end of the operation end to be received and removed from and inserted into a socket of the socket for removal of the at least one valve from the operating end; ]	[ a second end of the operating end disposed at one end of the lumen, wherein the second end of the operating end is configured to be displaced by a portion of the tooth when the operating end is moved to the operating end by an actuator; and ]
0.9999883	1866	[ wherein the connection element is configured to detachably attach the connection element at a first location, wherein the first location is within the first piston aperture, and ]	[ a connection element between at least one valve disposed at or in the mouth of the patient and at least one valve member disposed on the tooth, wherein a predetermined distance is defined for the operation end of the operation end to be received and removed from and inserted into a socket of the socket for removal of the at least one valve from the operating end; ]
0.99999225	1867	[ wherein the first piston aperture is spaced substantially equal distance apart from, and ]	[ wherein the connection element is configured to detachably attach the connection element at a first location, wherein the first location is within the first piston aperture, and ]
0.99999225	1868	[ spaced from, a second piston aperture configured to receive a screw member in a location that is spaced substantially greater than the predetermined distance, and ]	[ wherein the first piston aperture is spaced substantially equal distance apart from, and ]
0.99999213	1869	[ wherein the screw member is defined between the second piston aperture and the first piston aperture, and ]	[ spaced from, a second piston aperture configured to receive a screw member in a location that is spaced substantially greater than the predetermined distance, and ]
0.97373295	1870	[ having a substantially larger length than the predetermined distance in each of a first and a second configuration, the first and second configurations being different from each other, wherein the drive shaft is configured to move the operation end relative to the teeth while the connection element and the connection element member is detached from the teeth. ]	[ wherein the screw member is defined between the second piston aperture and the first piston aperture, and ]
0.99540615	1871	[ (a) at least one monofluoromethylmethylene sulfonate (MSMFS) monomer; and ]	[ A composition comprising: ]
0.9999906	1872	[ (b) at least one monofluorescent organic solvent such as a polyethylene glycol solvent, a solvate and a monolayer of which at least one monomer is present in the solvate portion, so as to allow the MSMFS monomer to react with the at least one monofluorescent organic solvent. ]	[ (a) at least one monofluoromethylmethylene sulfonate (MSMFS) monomer; and ]
0.9999908	1873	[ higher than the pH of the emulsified form, wherein a pharmaceutically acceptable ester that is effective against bacterial infection having been prepared by reacting a pharmaceutically acceptable salts and organic esters of said salt and hydrophobic agent with a polymerized polymer formed by polymerization of the substance which comprises the pharmaceutically acceptable salt and hydrophobic agent to form a solid having a molecular weight of about 300 or more, wherein the polymerization has occurred by the use of a heat treating method. ]	[ A method for preparing a mixture including an emulsion comprising an emulsified form of a pharmaceutical ingredient and a water-soluble salt comprising water and a hydrophobic agent at a pH ]
0.99958915	1874	[ composition of a patient to measure the concentration of a fluid contained in the patient, comprising the steps of: ]	[ A method of monitoring the temperature, and ]
0.99999166	1875	[ measuring the concentration of the fluid; ]	[ composition of a patient to measure the concentration of a fluid contained in the patient, comprising the steps of: ]
0.9999906	1876	[ computing the concentration of the fluid from an output on an ultrasound probe, providing the ultrasound probe for a patient whose presence is to be monitored; ]	[ measuring the concentration of the fluid; ]
0.99999154	1877	[ monitoring the concentration of the fluid using: ]	[ computing the concentration of the fluid from an output on an ultrasound probe, providing the ultrasound probe for a patient whose presence is to be monitored; ]
0.9883851	1878	[ an ultrasonic imaging method for the patient; ]	[ monitoring the concentration of the fluid using: ]
0.99999225	1879	[ a plurality of sensor devices for measuring one or more of the characteristics of the fluid, wherein each sensor device is individually connected to one or more ultrasound transmitters and is coupled to a different processing unit, wherein in response to determining that the patient is not present by the temperature, the ultrasonic imaging method for the patient is delayed, and ]	[ an ultrasonic imaging method for the patient; ]
0.9999907	1880	[ a temperature change to a temperature of the patient is sensed using the one or more sensor devices; ]	[ a plurality of sensor devices for measuring one or more of the characteristics of the fluid, wherein each sensor device is individually connected to one or more ultrasound transmitters and is coupled to a different processing unit, wherein in response to determining that the patient is not present by the temperature, the ultrasonic imaging method for the patient is delayed, and ]
0.99998534	1881	[ measuring and calculating a heat transfer rate for the patient, wherein the heat transfer rate is measured using at least a first sensing step and a second sensing step; ]	[ a temperature change to a temperature of the patient is sensed using the one or more sensor devices; ]
0.999972	1882	[ analyzing the concentration of the fluid from the patient to determine the composition of the fluid; and ]	[ measuring and calculating a heat transfer rate for the patient, wherein the heat transfer rate is measured using at least a first sensing step and a second sensing step; ]
0.99999225	1883	[ processing the concentration of the fluid from the patient to determine the composition of the fluid based on the temperature change using at least a third sensing step and a fourth sensing step, wherein the third sensing step includes a control step for the monitoring of the concentration of the fluid based on a calculation based on the concentration of the fluid. ]	[ analyzing the concentration of the fluid from the patient to determine the composition of the fluid; and ]
0.9993837	1884	[ providing a flexible assembly; ]	[ A method for manufacturing a disposable medical imaging device comprising: ]
0.9999875	1885	[ forming the flexible assembly into a first part having a first curved surface, the first part including a plurality of channels of fluid for receiving the plurality of cells of the first cell; and ]	[ providing a flexible assembly; ]
0.99999213	1886	[ forming the flexible assembly into a second part having a second curved surface, the second part including a plurality of channels of fluid for receiving the plurality of cells of the second cell, wherein when the flexible assembly is disposed in the first part, the assembly contacts the first curved surface of the first part to form a first flexible assembly assembly with a first plurality of channels of fluid for receiving the plurality of cells of the first cell and a second plurality of channels of fluid for receiving the plurality of cells of the second cell. ]	[ forming the flexible assembly into a first part having a first curved surface, the first part including a plurality of channels of fluid for receiving the plurality of cells of the first cell; and ]
0.010383668	1887	[ a first structure having a first structure portion and a second structure portion; ]	[ An implantable medical device for providing pain care, comprising: ]
0.9749536	1888	[ a pressure transducer and a first electrode; and ]	[ a first structure having a first structure portion and a second structure portion; ]
0.9808311	1889	[ a second structure component, ]	[ a pressure transducer and a first electrode; and ]
0.9999385	1890	[ wherein the first structure portion is shaped substantially to the shape of an ear canal and the second structure portion is shaped substantially to the shape of a tooth. ]	[ a second structure component, ]
0.9999701	1891	[ a first housing arranged to be disposed on a body part and having an interior surface; ]	[ A body part assembly, comprising: ]
0.9999913	1892	[ a second housing opposite the first housing arranged to be disposed on the interior surface of the second housing to enclose the first housing and including: ]	[ a first housing arranged to be disposed on a body part and having an interior surface; ]
0.9717944	1893	[ a first port; ]	[ a second housing opposite the first housing arranged to be disposed on the interior surface of the second housing to enclose the first housing and including: ]
0.9999759	1894	[ a second port connected to the first port and extending through a wall of the second housing; and ]	[ a first port; ]
0.9999906	1895	[ a first surface disposed adjacent to one of the two ports arranged to be disposed on the interior surface of the first housing and configured to support a first weight having a first weight value, the first surface of the first port being positioned proximate the interior surface of the second housing; and ]	[ a second port connected to the first port and extending through a wall of the second housing; and ]
0.99999225	1896	[ a second surface disposed adjacent to one of the two ports arranged to be disposed on the interior surface of the second housing and configured to support a second weight having a second weight value that is less than the first weight value, the second surface of the second port being positioned proximate and opposite the first surface of the second housing such that a plurality of weights that are located proximate and distant from each other and proximate the first surface of the second housing when the housing is in a first position are substantially parallel to each other. ]	[ a first surface disposed adjacent to one of the two ports arranged to be disposed on the interior surface of the first housing and configured to support a first weight having a first weight value, the first surface of the first port being positioned proximate the interior surface of the second housing; and ]
0.9993783	1897	[ having a front portion, a distal portion, a front side and a rear side; ]	[ An optical fiber for the implantation of radiation imaging device, comprising: a lens mounted on a rear portion of a tube, and ]
0.99918264	1898	[ a first optic fiber being selectively located at a first orientation, for the imaging device, with the front portion of the lens at a first end point; ]	[ having a front portion, a distal portion, a front side and a rear side; ]
0.9996462	1899	[ a filter mounted on the mounting portion, for the optical fiber, for receiving a filter from a first light source, and ]	[ a first optic fiber being selectively located at a first orientation, for the imaging device, with the front portion of the lens at a first end point; ]
0.99996877	1900	[ for receiving at least a portion of the light from the light source, the filtering configured to filter the transmitted light; ]	[ a filter mounted on the mounting portion, for the optical fiber, for receiving a filter from a first light source, and ]
0.012834921	1901	[ (a) a lens-to-recoil optical coupling configured to form a connection between the optical fiber and the first lens; and ]	[ for receiving at least a portion of the light from the light source, the filtering configured to filter the transmitted light; ]
0.9999907	1902	[ (b) a lens-to-recoil optical portion, having a first end, configured to be secured to the front portion of the tube and a second end, positioned in communication with the distal portion of the lens, and ]	[ (a) a lens-to-recoil optical coupling configured to form a connection between the optical fiber and the first lens; and ]
0.99999166	1903	[ configured to removably attach the optical fiber to the imaging device, the first end of the lens-to-recoil optical portion of the lens-to-recoil optical coupling of the lens-to-recoil optical coupling being configured to receive the first optic fiber; ]	[ (b) a lens-to-recoil optical portion, having a first end, configured to be secured to the front portion of the tube and a second end, positioned in communication with the distal portion of the lens, and ]
0.9999918	1904	[ wherein the lens is configured so as to maintain axial alignment between the front portion of the lens and said lens-to-recoil optical member of the optical fiber. ]	[ configured to removably attach the optical fiber to the imaging device, the first end of the lens-to-recoil optical portion of the lens-to-recoil optical coupling of the lens-to-recoil optical coupling being configured to receive the first optic fiber; ]
0.0060269693	1905	[ B&#x2014; ]	[ A method for treating inflammation, comprising administering an anti-inflammatory composition in combination with a therapy that, after a first exposure to an inflammatory environment, induces a release of inflammatory molecules, such as TNF(R)(R), IL-1&#x2014; ]
0.0010800883	1906	[ , TNF(S)(R) and IL-1&#x2014; ]	[ B&#x2014; ]
0.9990288	1907	[ R&#x2014; (SEQ ID NO: 24), to a patient suffering from a chronic inflammation, wherein the therapy is administered before or after applying therapy to a subject with chronic inflammation, wherein the method comprising administering the composition to the patient in combination with the said therapy. ]	[ , TNF(S)(R) and IL-1&#x2014; ]
0.99435425	1908	[ at least one controller; and ]	[ A system for providing fluid services in accordance with a plan for providing a service and for supplying a fluid in a first manner and a fluid in a second manner, characterized in that the system comprising: ]
0.99999034	1909	[ at least one communication module communicating with at least one network interface of said controller for controlling at least one of said at least one controller, said at least one controller, said communication module, and ]	[ at least one controller; and ]
0.9999602	1910	[ said communication interface, ]	[ at least one communication module communicating with at least one network interface of said controller for controlling at least one of said at least one controller, said at least one controller, said communication module, and ]
0.99928975	1911	[ wherein in communication with the communication module, operation of operation of communication between said at least one controller and at least one communication module, operation of reception of fluid from said at least one communication module, operation of distribution of said fluid service from said method of a first manner to said method of second manner, determination of when one or both of said two method of said first manner and said one or both of said two method of said second manner is not available, and ]	[ said communication interface, ]
0.016712984	1912	[ communication of information between at least one first user and one or both first network administrators of said device. ]	[ wherein in communication with the communication module, operation of operation of communication between said at least one controller and at least one communication module, operation of reception of fluid from said at least one communication module, operation of distribution of said fluid service from said method of a first manner to said method of second manner, determination of when one or both of said two method of said first manner and said one or both of said two method of said second manner is not available, and ]
0.98405737	1913	[ (a) providing a substrate; ]	[ A method for manufacturing a dental crown comprising: ]
0.9999136	1914	[ (b) forming a hollow cavity with the substrate. ]	[ (a) providing a substrate; ]
0.90999717	1915	[ m and 99.6 &#x3bc; ]	[ A medical device comprising: at least one biocompatible material having an average molecular weight of between 2.2 &#x3bc; ]
0.99879324	1916	[ m; and ]	[ m and 99.6 &#x3bc; ]
0.010392207	1917	[ at least one transgenic material having an average molecular weight of between 2.0 &#x3bc; ]	[ m; and ]
0.012365392	1918	[ m and 99.6 &#x3bc; ]	[ at least one transgenic material having an average molecular weight of between 2.0 &#x3bc; ]
0.99749184	1919	[ m, wherein the at least one biocompatible material is selected from the group consisting of the polyethylene glycol and polyester, and ]	[ m and 99.6 &#x3bc; ]
0.9935913	1920	[ non-polymers comprising polyvinyl alcohol, polyether, polyethermethacrylate, and ]	[ m, wherein the at least one biocompatible material is selected from the group consisting of the polyethylene glycol and polyester, and ]
0.9994831	1921	[ poly(vinyl alcohol) polymer; ]	[ non-polymers comprising polyvinyl alcohol, polyether, polyethermethacrylate, and ]
1.14995755e-05	1922	[ wherein the at least onetransgenic material, wherein the transgenic material is encoded in the at least one biocompatible material and comprises a DNA that includes the DNA sequence of SEQ ID NO: ]	[ poly(vinyl alcohol) polymer; ]
0.99084723	1923	[ 2. ]	[ wherein the at least onetransgenic material, wherein the transgenic material is encoded in the at least one biocompatible material and comprises a DNA that includes the DNA sequence of SEQ ID NO: ]
0.99958533	1924	[ (a) SEQ ID NO: 1; ]	[ A single component compound having an isolated monoclonal antibody, wherein the antibody consists of: ]
0.9999373	1925	[ (b) its SEQ ID NO: 1 wherein the monoclonal antibody binds to SEQ ID NO: 1; and ]	[ (a) SEQ ID NO: 1; ]
0.9999361	1926	[ (c) an antibody fragment selected from SEQ ID NO: 2, SEQ ID NO: 4, and ]	[ (b) its SEQ ID NO: 1 wherein the monoclonal antibody binds to SEQ ID NO: 1; and ]
0.99969494	1927	[ SEQ ID NO: 5. ]	[ (c) an antibody fragment selected from SEQ ID NO: 2, SEQ ID NO: 4, and ]
0.0070163775	1928	[ a first patient access connector including a connection portion provided at a forward end of said patient access connector for use in connection with an exterior wall of a patient entrance to an examination section of said exterior wall of said patient entrance; ]	[ An apparatus for performing pre-puncture procedures for the treatment of a subject, comprising: ]
0.9999924	1929	[ a second patient access connector including a connection portion provided at a rear end of said first patient access connector for use in connection with an exterior wall of said patient access connector; ]	[ a first patient access connector including a connection portion provided at a forward end of said patient access connector for use in connection with an exterior wall of a patient entrance to an examination section of said exterior wall of said patient entrance; ]
0.999992	1930	[ an access control device connected to said first patient access connector; and ]	[ a second patient access connector including a connection portion provided at a rear end of said first patient access connector for use in connection with an exterior wall of said patient access connector; ]
0.00011752977	1931	[ a pre-puncture portion comprising: ]	[ an access control device connected to said first patient access connector; and ]
0.0028865188	1932	[ a first medical device, which comprises a handle and an opening to receive and retain said exterior wall, and ]	[ a pre-puncture portion comprising: ]
0.999992	1933	[ a second medical device, which comprises a head and is operatively connected to said second patient access connector via a first connecting device and a connector wire, ]	[ a first medical device, which comprises a handle and an opening to receive and retain said exterior wall, and ]
0.99999213	1934	[ wherein said connector wire is a cable that is provided between said first and second medical devices, and ]	[ a second medical device, which comprises a head and is operatively connected to said second patient access connector via a first connecting device and a connector wire, ]
0.99999213	1935	[ wherein said connector wire is configured to be disposed on one of said first and second medical devices with its inner ends coupled with said opening so as to be capable of retaining in an un-closed position said exterior wall when said connection portion is in a closed position, and ]	[ wherein said connector wire is a cable that is provided between said first and second medical devices, and ]
0.99999213	1936	[ wherein said opening is positioned at the bottom of said second medical device when the connection portion is in a closed position, such that when said opening is positioned at the bottom of the second medical device, when said second medical device is in a closed position, said connecting device is operably attached to said first patient access connector and said end of said cable is connected to said opening so that when said second medical device is in an open position, said connector wire is coupled to the end of said connector wire and the locking device is located on the outside of each of said first and second medical devices. ]	[ wherein said connector wire is configured to be disposed on one of said first and second medical devices with its inner ends coupled with said opening so as to be capable of retaining in an un-closed position said exterior wall when said connection portion is in a closed position, and ]
0.999244	1937	[ (a) providing biocompatible tissue or an implant containing biocompatible tissue for being implanted in a subject; and ]	[ A method of treating an inflammatory disease, comprising: ]
0.9999609	1938	[ (b) treating the subject in a manner that prevents a progression of the inflammatory disease; ]	[ (a) providing biocompatible tissue or an implant containing biocompatible tissue for being implanted in a subject; and ]
0.99992836	1939	[ the biocompatible tissue or implant that is used in the method of treating said inflammatory disease comprising cells containing cells that cause cell growth and/or proliferation to a level that is substantially normal for normal biological tissue; a compound selected from the group consisting of: the polypeptides of SEQ ID NO: ]	[ (b) treating the subject in a manner that prevents a progression of the inflammatory disease; ]
0.9887749	1940	[ 7, 10, 12, 15, 17, 18, 21, 22, 23, 24, 25, or 26. ]	[ the biocompatible tissue or implant that is used in the method of treating said inflammatory disease comprising cells containing cells that cause cell growth and/or proliferation to a level that is substantially normal for normal biological tissue; a compound selected from the group consisting of: the polypeptides of SEQ ID NO: ]
0.99925154	1941	[ a head protection body comprising: ]	[ A non-surgical head wound treatment system comprising; ]
0.9987031	1942	[ a first face plate and a second face plate, the first face plate pivotally coupled to a substantially horizontal headplate, the second face plate configured to engage a side surface of a first head; ]	[ a head protection body comprising: ]
0.99998796	1943	[ a first and a second medical device, each medical device being located proximally of one of the first face plate and the second face plate, wherein the first and the second medical device are configured to be positioned within a first range from a medical instrument; ]	[ a first face plate and a second face plate, the first face plate pivotally coupled to a substantially horizontal headplate, the second face plate configured to engage a side surface of a first head; ]
0.02446519	1944	[ a pressure sensor to sense a pressure of the head; ]	[ a first and a second medical device, each medical device being located proximally of one of the first face plate and the second face plate, wherein the first and the second medical device are configured to be positioned within a first range from a medical instrument; ]
0.9993407	1945	[ a second medical device configured to be positioned proximally of the first medical device and coupled to a first medical device, wherein the medical device is configured to transmit an output of an operation and to receive an output from the operation, wherein the second medical device is configured to transmit an output of an operation to the medical device and not to transmit the output of the operation to the headprotection body; ]	[ a pressure sensor to sense a pressure of the head; ]
0.99998164	1946	[ first and second means, wherein the first means is configured to connect to the medical device, and ]	[ a second medical device configured to be positioned proximally of the first medical device and coupled to a first medical device, wherein the medical device is configured to transmit an output of an operation and to receive an output from the operation, wherein the second medical device is configured to transmit an output of an operation to the medical device and not to transmit the output of the operation to the headprotection body; ]
0.9999914	1947	[ the second means is configured to connect to the medical device after the second medical device is attached to the head; and ]	[ first and second means, wherein the first means is configured to connect to the medical device, and ]
0.99992275	1948	[ a flexible body configured to support the head and a patient's head; ]	[ the second means is configured to connect to the medical device after the second medical device is attached to the head; and ]
0.99987483	1949	[ a second medical device configured to connect to the first medical device and coupled via the first medical device to the pressure sensor, after the second medical device is attached to the head protection body, and ]	[ a flexible body configured to support the head and a patient's head; ]
0.9999919	1950	[ configured to transmit output of the operation when it is activated by the head protection body, the output of the operation including ultrasound sound. ]	[ a second medical device configured to connect to the first medical device and coupled via the first medical device to the pressure sensor, after the second medical device is attached to the head protection body, and ]
0.9999417	1951	[ at least one liquid container having a lid, with at least first and second interior walls, and ]	[ A liquid pharmaceutical container, comprising: ]
0.9999902	1952	[ first and second openings extending therebetween that are generally sealed against the liquid container; ]	[ at least one liquid container having a lid, with at least first and second interior walls, and ]
0.99997294	1953	[ an expandable dispenser mounted on the lid of the at least one liquid container, such the expandable dispenser is configured to be pushed into a fluid volume; and ]	[ first and second openings extending therebetween that are generally sealed against the liquid container; ]
0.99999225	1954	[ at least one liquid-insulated conduit being coupled at least in part to the at least one liquid container so as to provide a fluid transfer pathway from at least the expandable dispenser to the liquid container; ]	[ an expandable dispenser mounted on the lid of the at least one liquid container, such the expandable dispenser is configured to be pushed into a fluid volume; and ]
0.9999919	1955	[ wherein the expandable dispenser is further configured to expand when contacted with fluids in the fluid volume; ]	[ at least one liquid-insulated conduit being coupled at least in part to the at least one liquid container so as to provide a fluid transfer pathway from at least the expandable dispenser to the liquid container; ]
0.99999225	1956	[ wherein the expandable dispenser further comprises at least one expandable housing, disposed on the expandable dispenser, and ]	[ wherein the expandable dispenser is further configured to expand when contacted with fluids in the fluid volume; ]
0.99999225	1957	[ at least one interior barrier layer that has an outer wall and a plurality of openings extending therethrough that, when closed, is configured such that when the expandable dispenser is pushed into the fluid volume, the openings are blocked by the outer wall of the at least one expandable housing. ]	[ wherein the expandable dispenser further comprises at least one expandable housing, disposed on the expandable dispenser, and ]
0.9998877	1958	[ applying an adhesive to each end of a first axon, the first axon located proximate a bone; ]	[ A method for improving the ability of the skin to support an axon, said method comprising: ]
0.99999225	1959	[ applying a second adhesive to each end of a second axon, the second axon located in a bone, wherein the adhesive on said first axon and the second adhesive on said second axon are both applied along a substantially straight surface that extends substantially parallel to the bone, the adhesive of the first and second axons being applied at a thickness greater than that between and at the distal end of the first and second axons; ]	[ applying an adhesive to each end of a first axon, the first axon located proximate a bone; ]
0.99999225	1960	[ applying a coating to each of the two axons between the proximal and distal ends of the first and second axons, wherein the coating, at least in part, includes a layer of a surfactant; and ]	[ applying a second adhesive to each end of a second axon, the second axon located in a bone, wherein the adhesive on said first axon and the second adhesive on said second axon are both applied along a substantially straight surface that extends substantially parallel to the bone, the adhesive of the first and second axons being applied at a thickness greater than that between and at the distal end of the first and second axons; ]
0.99999225	1961	[ selectively positioning the first and second axons along a straight surface and removing the coating, wherein the coating is applied a distance between the proximal and distal ends of the first and second axons that is smaller than the distance between each of the proximal axons and the distal axon. ]	[ applying a coating to each of the two axons between the proximal and distal ends of the first and second axons, wherein the coating, at least in part, includes a layer of a surfactant; and ]
0.9999896	1962	[ applying a first composition to a lumen of the esophagus; ]	[ A method of delivering a humanized agent between the esophageal or esophageal trachea, the method comprising: ]
0.9999795	1963	[ receiving a first, preselected amount of the humanized agent through the esophageal or esophageal trachea; ]	[ applying a first composition to a lumen of the esophagus; ]
0.9999924	1964	[ applying a second composition to a distal area of the esophagus adjacent to and located beyond the first, preselected amount of the humanized agent; and ]	[ receiving a first, preselected amount of the humanized agent through the esophageal or esophageal trachea; ]
0.99999225	1965	[ receiving a second, preselected amount of the humanized agent through the proximal or distal area of the esophagus. ]	[ applying a second composition to a distal area of the esophagus adjacent to and located beyond the first, preselected amount of the humanized agent; and ]
0.99995255	1966	[ at least one tube including a plurality of tubes, the tubes adapted to be disposed in the body of a patient when medicating; and ]	[ An apparatus for delivering a medicament, the apparatus comprising: ]
0.020342974	1967	[ further comprising: ]	[ at least one tube including a plurality of tubes, the tubes adapted to be disposed in the body of a patient when medicating; and ]
0.059715267	1968	[ a medicament supply member; ]	[ further comprising: ]
0.99996233	1969	[ a medicament delivery system for delivering the medicament to the at least one tube; and ]	[ a medicament supply member; ]
0.9999397	1970	[ an insertion shaft configured to be received in the body within the patient and to be engaged at end portions of the transport tubes and the medicament supply member, and ]	[ a medicament delivery system for delivering the medicament to the at least one tube; and ]
0.9999924	1971	[ at each end portion of the transport tubes, a connector configured to engage to a connector of an external device for attaching the supply member to a medicament delivery system, and ]	[ an insertion shaft configured to be received in the body within the patient and to be engaged at end portions of the transport tubes and the medicament supply member, and ]
0.9999895	1972	[ wherein said external device at each end portion is adapted to receive a medicament, and ]	[ at each end portion of the transport tubes, a connector configured to engage to a connector of an external device for attaching the supply member to a medicament delivery system, and ]
0.9998542	1973	[ wherein said medicament supply member is configured to deliver one or more medicaments to the one or more tubes located in the interior of the patient. ]	[ wherein said external device at each end portion is adapted to receive a medicament, and ]
0.999907	1974	[ an injection into a body tissue, wherein the injection is provided in an uncoated state so as to deliver the therapeutic agent to the body tissue and is delivered via at least one injectable drug delivery device comprising a needle having a first body portion which is configured to be implanted on the body tissue and an outer surface disposed between two outer surfaces; and ]	[ A method for delivering a therapeutic agent to a subject in need thereof comprising: ]
0.99999225	1975	[ an injection into a body cavity surrounding the skin surface, wherein the injection is delivered via the needle and the needle has a second body portion which includes a plurality of channels wherein said channel is configured to receive an elastomeric polymeric material and for receiving the therapeutic agent from an outlet from the drug delivery device when the needle is injected within a first tube and is injected at a second tube where the first tube terminates at a distal end of the channel in the second body portion when the drug delivery device is inserted into a body cavity, wherein the second tube is configured to be located within the body tissue, wherein said second body portion includes a hollow portion of the second body portion defining a transverse path such as extends proximally and ends within the body cavity. ]	[ an injection into a body tissue, wherein the injection is provided in an uncoated state so as to deliver the therapeutic agent to the body tissue and is delivered via at least one injectable drug delivery device comprising a needle having a first body portion which is configured to be implanted on the body tissue and an outer surface disposed between two outer surfaces; and ]
0.01898631	1976	[ an opening having an opening channel; ]	[ A medical device comprising: ]
0.9657922	1977	[ an elongate segment having a first end and a second end; and ]	[ an opening having an opening channel; ]
0.99998	1978	[ a compression housing having a first outer chamber for receiving and holding an object, the compression housing including a second outer chamber and at least two longitudinal channels for passing an external air in the first open channel, an end of the first outer chamber extending through the first channel, the elongate segment being at least partially enclosed by the at least two channels, the compression housing further including a pair of fastening means which are movable around the elastic portion of the elongate segment such that the at least two channels overlap at one of the forward surfaces, the second outer chamber having a first opening for receiving the object, the elongate segment having a first seal to seal the end of the first opening; and ]	[ an elongate segment having a first end and a second end; and ]
0.98466545	1979	[ at least one pressure sensor for detecting an environment pressure at the opening. ]	[ a compression housing having a first outer chamber for receiving and holding an object, the compression housing including a second outer chamber and at least two longitudinal channels for passing an external air in the first open channel, an end of the first outer chamber extending through the first channel, the elongate segment being at least partially enclosed by the at least two channels, the compression housing further including a pair of fastening means which are movable around the elastic portion of the elongate segment such that the at least two channels overlap at one of the forward surfaces, the second outer chamber having a first opening for receiving the object, the elongate segment having a first seal to seal the end of the first opening; and ]
0.99999154	1980	[ at least one sensor for measuring a surface area of a surface of a body component and for outputting a set of values associated with a condition or function of the surface of the body component; ]	[ A system for monitoring and controlling the motion of a plurality of body components, wherein the system comprises: ]
0.99999213	1981	[ an algorithm unit configured to perform a simulation of the body component that comprises the movement of the body component between a pre-determined location and a desired location; ]	[ at least one sensor for measuring a surface area of a surface of a body component and for outputting a set of values associated with a condition or function of the surface of the body component; ]
0.99999225	1982	[ an output unit configured to convert the simulated surface area of the body component into a series of real values and output a series of actual values associated with a state of function of the simulated surface of the body component; ]	[ an algorithm unit configured to perform a simulation of the body component that comprises the movement of the body component between a pre-determined location and a desired location; ]
0.9999912	1983	[ a feedback unit configured to receive the actual values and to alert a user via a user interface associated with the feedback unit; and ]	[ an output unit configured to convert the simulated surface area of the body component into a series of real values and output a series of actual values associated with a state of function of the simulated surface of the body component; ]
0.9993722	1984	[ a control unit configured at least in part to control the body component from the desired location, ]	[ a feedback unit configured to receive the actual values and to alert a user via a user interface associated with the feedback unit; and ]
0.9988771	1985	[ wherein the feedback unit is configured to receive an alert to alert the user, and ]	[ a control unit configured at least in part to control the body component from the desired location, ]
0.999992	1986	[ wherein the control unit is configured to instruct the user via the feedback unit to change the simulated surface area of the body component to a desired surface area based on the real values of the simulated surface of the body component. ]	[ wherein the feedback unit is configured to receive an alert to alert the user, and ]
0.999897	1987	[ a) attaching a catheter to a patient, ]	[ A method for making of a catheter having a first end and a second end, comprising: ]
0.99999106	1988	[ b) removing the catheter from the patient, and ]	[ a) attaching a catheter to a patient, ]
0.99993384	1989	[ c) connecting a first catheter tip to an end of the second end; ]	[ b) removing the catheter from the patient, and ]
0.99999034	1990	[ d) placing the second end at the beginning of a catheter body, where said end of said catheter body ends in a catheter body pocket and where a first end of a second catheter tip is in the pocket; and ]	[ c) connecting a first catheter tip to an end of the second end; ]
0.99999213	1991	[ e) placing the second end at the end of a catheter tip end. ]	[ d) placing the second end at the beginning of a catheter body, where said end of said catheter body ends in a catheter body pocket and where a first end of a second catheter tip is in the pocket; and ]
0.99993944	1992	[ administering to a patient having arthritis an effective amount of an effective amount of a compound of formula (I): ]	[ A method of treating arthritis comprising: ]
0.9995271	1993	[ whereinR is hydrogen, C1-6 alkyl or C1-6 alkynyl; ]	[ administering to a patient having arthritis an effective amount of an effective amount of a compound of formula (I): ]
0.99905056	1994	[ X is hydrogen; ]	[ whereinR is hydrogen, C1-6 alkyl or C1-6 alkynyl; ]
0.99957913	1995	[ A is hydrogen; or a pharmaceutically acceptable salt thereof. ]	[ X is hydrogen; ]
0.021397494	1996	[ 4.10 &#x3bb; ]	[ A compound having an aromatic ring having a length equal to or greater than 20&#xb0; ]
0.0093487725	1997	[ m and comprising 1) a hydrazine ring; 2) a hydroxyalkyl ring, and ]	[ 4.10 &#x3bb; ]
0.99994504	1998	[ 3) a hydroxyl ring; in which the hydrazine and the hydroxyl ring together form a cross-linked monomer, wherein the cross-linked monomer is a salt of the polyurethane moiety; wherein the cross-linked monomer is present with the amount of polyurethane being greater than 0.01.5 &#x3bc; ]	[ m and comprising 1) a hydrazine ring; 2) a hydroxyalkyl ring, and ]
0.99999225	1999	[ m, wherein the cross-linked monomer is in a monomeric state, wherein the cross-linked monomer is a cross-linked form of a polyurethane moiety and less than 0.1.0 &#x3bc; ]	[ 3) a hydroxyl ring; in which the hydrazine and the hydroxyl ring together form a cross-linked monomer, wherein the cross-linked monomer is a salt of the polyurethane moiety; wherein the cross-linked monomer is present with the amount of polyurethane being greater than 0.01.5 &#x3bc; ]
0.99999213	2000	[ m, wherein a ratio of the cross-linked monomer between the polyurethane moiety and the cross-linked polyurethane moiety is 6.50: ]	[ m, wherein the cross-linked monomer is in a monomeric state, wherein the cross-linked monomer is a cross-linked form of a polyurethane moiety and less than 0.1.0 &#x3bc; ]
0.9625765	2001	[ 1, and ]	[ m, wherein a ratio of the cross-linked monomer between the polyurethane moiety and the cross-linked polyurethane moiety is 6.50: ]
0.9913277	2002	[ wherein the cross-linked monomer forms a cross-linked component in water and less than the maximum amount of the cross-linked monomer of 2: ]	[ 1, and ]
0.984962	2003	[ 1. ]	[ wherein the cross-linked monomer forms a cross-linked component in water and less than the maximum amount of the cross-linked monomer of 2: ]
0.00037047733	2004	[ (a) depositing, in a porous-type polymer material, a high frequency vibration and magnetization wave in a phase-change region of a polymer structure of such that said high frequency vibration and the magnetization wave are at least partially transverse to the phase-change region; ]	[ A method for the production of high purity, pure titanium dioxide in a sterilized state, comprising: ]
0.9999924	2005	[ (b) irradiating in a single magnetic particle beam such that a high-energy particle beam has to pass through at least one of said high frequency vibration and magnetic beam and the magnetization wave on its way to said at least one of said high frequency vibration and magnetic beam; ]	[ (a) depositing, in a porous-type polymer material, a high frequency vibration and magnetization wave in a phase-change region of a polymer structure of such that said high frequency vibration and the magnetization wave are at least partially transverse to the phase-change region; ]
0.99998665	2006	[ (c) exposing a polymer surface of at least 20 microns in thickness to said particle beam by ion beam treatment, thereby causing said particle beam to contact said polymer surface; ]	[ (b) irradiating in a single magnetic particle beam such that a high-energy particle beam has to pass through at least one of said high frequency vibration and magnetic beam and the magnetization wave on its way to said at least one of said high frequency vibration and magnetic beam; ]
0.99955744	2007	[ (d) irradiating in a non-woven textile or a garment fiber such that said high frequencies remain transverse to said phase-change region. ]	[ (c) exposing a polymer surface of at least 20 microns in thickness to said particle beam by ion beam treatment, thereby causing said particle beam to contact said polymer surface; ]
0.97305566	2008	[ executing a process comprising: ]	[ A method of using a microprocessor comprising: ]
0.98111045	2009	[ receiving an input from a first user through a display, the input relating to a user input to a first application; ]	[ executing a process comprising: ]
0.9931954	2010	[ retrieving software code stored in a memory including a software application code and a user control code from a storage device of a computer for execution when the application is executing; and ]	[ receiving an input from a first user through a display, the input relating to a user input to a first application; ]
0.9999919	2011	[ executing the software code to control a first user operation, wherein the user control is based on at least the software code retrieved from the storage device, wherein the process comprises: ]	[ retrieving software code stored in a memory including a software application code and a user control code from a storage device of a computer for execution when the application is executing; and ]
0.99999213	2012	[ determining whether the software code has been stored in the storage device; and ]	[ executing the software code to control a first user operation, wherein the user control is based on at least the software code retrieved from the storage device, wherein the process comprises: ]
0.9252594	2013	[ when so determined: ]	[ determining whether the software code has been stored in the storage device; and ]
0.017091572	2014	[ reading the software code from the storage device; ]	[ when so determined: ]
0.9999913	2015	[ reading the user control code from the storage device; and ]	[ reading the software code from the storage device; ]
0.9999924	2016	[ transmitting the code and the user control code to a microprocessor controller for execution; and ]	[ reading the user control code from the storage device; and ]
0.99999225	2017	[ after determining that the software code has been stored in the storage device and in the memory, retrieving the software code from the storage device and the user control code from the computer; ]	[ transmitting the code and the user control code to a microprocessor controller for execution; and ]
0.9999852	2018	[ sending the retrieved software code to the microprocessor controller for execution; ]	[ after determining that the software code has been stored in the storage device and in the memory, retrieving the software code from the storage device and the user control code from the computer; ]
0.9999924	2019	[ receiving a response to a request to send the retrieved code to the microprocessor controller; and ]	[ sending the retrieved software code to the microprocessor controller for execution; ]
0.99999225	2020	[ after determining that the retrieved software code has been stored in the memory and in the memory, transmitting the retrieved code to the microprocessor controller for execution. ]	[ receiving a response to a request to send the retrieved code to the microprocessor controller; and ]
0.9999813	2021	[ a sensor system configured to detect a location of a patient to be placed into or on a medical instrument; ]	[ A system for a medical instrument, comprising: ]
0.9999856	2022	[ a data processor configured to provide real time signal processing with the sensor system, the data processor configured to: ]	[ a sensor system configured to detect a location of a patient to be placed into or on a medical instrument; ]
0.99935037	2023	[ identify a medical device associated with the patient based on detected location of the patient; and ]	[ a data processor configured to provide real time signal processing with the sensor system, the data processor configured to: ]
0.9999906	2024	[ determine an operating parameter of the medical instrument based on the identified medical device; ]	[ identify a medical device associated with the patient based on detected location of the patient; and ]
0.99888736	2025	[ a processing device configured to provide real time signal processing with the sensor system, the processing device further configured to: ]	[ determine an operating parameter of the medical instrument based on the identified medical device; ]
0.9992723	2026	[ identify a patient to be placed into or on the medical instrument based on the location of the target patient, the patient being placed into or on the medical instrument by a medical operator; ]	[ a processing device configured to provide real time signal processing with the sensor system, the processing device further configured to: ]
0.9999895	2027	[ determine a location of the patient using at least one of the patient location information and the operating parameter and using the processing device; ]	[ identify a patient to be placed into or on the medical instrument based on the location of the target patient, the patient being placed into or on the medical instrument by a medical operator; ]
0.99999166	2028	[ store the location of the patient in a database; ]	[ determine a location of the patient using at least one of the patient location information and the operating parameter and using the processing device; ]
0.99997663	2029	[ determine an operating parameter of said patient based on said location of the patient, said operating parameter including a target location to be performed by said patient; ]	[ store the location of the patient in a database; ]
0.999845	2030	[ determine a location of the patient's physical body based on a first location of the patient identified by the processor and a second location of the patient identified by the processor, the first location of the patient identified by the processor being less than the second location of the patient identified by the processor; ]	[ determine an operating parameter of said patient based on said location of the patient, said operating parameter including a target location to be performed by said patient; ]
0.99999225	2031	[ determine a second location of the patient's physical body based on the location of the patient; and ]	[ determine a location of the patient's physical body based on a first location of the patient identified by the processor and a second location of the patient identified by the processor, the first location of the patient identified by the processor being less than the second location of the patient identified by the processor; ]
0.99992776	2032	[ display an operator's input on the medical instrument. ]	[ determine a second location of the patient's physical body based on the location of the patient; and ]
0.9987984	2033	[ a) a monoclonal antibody or an antigen-binding fragment that specifically binds and comprises SEQ ID NO: 27; and ]	[ A method for treating or preventing a disorder wherein said method comprising administering to an animal, an immune stimulating agent comprising: ]
0.99990594	2034	[ b) a polypeptide selected from the group consisting of SEQ ID NO: 33, 37 and 39. ]	[ a) a monoclonal antibody or an antigen-binding fragment that specifically binds and comprises SEQ ID NO: 27; and ]
0.99881774	2035	[ 6. ]	[ An isolated nucleic acid comprising a nucleic acid sequence having at least 99% sequence identity to SEQ ID NO: ]
0.025443796	2036	[ a body portion having a distal tip opening; and ]	[ A surgical lancet which comprises: ]
0.99998355	2037	[ a lancet shaft extending from said body portion, said lancet and said shaft being disposed in a generally axial relationship, ]	[ a body portion having a distal tip opening; and ]
0.9999918	2038	[ wherein at least one of said shaft and lancet bodies is disposed adjacent to at least one of a first bone and a second bone in at least one of an osteochondral or vertebral joint, respectively, and ]	[ a lancet shaft extending from said body portion, said lancet and said shaft being disposed in a generally axial relationship, ]
0.9999908	2039	[ wherein a first lancet tooth which is disposed adjacent to a lancet bone is disposed in contact with a lancet tip that is disposed in contact with said at least one other lancet bone, and ]	[ wherein at least one of said shaft and lancet bodies is disposed adjacent to at least one of a first bone and a second bone in at least one of an osteochondral or vertebral joint, respectively, and ]
0.99999225	2040	[ wherein a first lancet bone is positioned within a second lancet tooth that is positioned adjacent to a second bone, wherein after said first and first lancet tooth are received within at least said second and second bones, a lancet shaft and said first and second teeth respectively move to engage each other at a later time by way of an elastic force between said teeth. ]	[ wherein a first lancet tooth which is disposed adjacent to a lancet bone is disposed in contact with a lancet tip that is disposed in contact with said at least one other lancet bone, and ]
0.9999069	2041	[ a cylindrically-shaped body having an axial end portion adapted for receiving a catheter; ]	[ A catheter, comprising: ]
0.996079	2042	[ a first portion for transmitting a medical fluid to the tubular body, said fluid having a first fluid rate and having a second fluid rate different than the first fluid rate; ]	[ a cylindrically-shaped body having an axial end portion adapted for receiving a catheter; ]
0.9999894	2043	[ a third portion for fluid flow through the tubular body, said third portion having a longitudinal axis having an oblong shape, a curved portion including an upper and lower edge opposite the upper and lower edge of the cylindrically-shaped body, therebetween are two opposing lower portions, wherein the first section is connected to the third portion at an end of the elongate portion, wherein said straight-line arrangement of the first portions defines a circular area and at least one hole therethrough, and ]	[ a first portion for transmitting a medical fluid to the tubular body, said fluid having a first fluid rate and having a second fluid rate different than the first fluid rate; ]
0.9999901	2044	[ wherein a portion thereof extends from the curved portion to the circular area from a first tip to a second tip; and ]	[ a third portion for fluid flow through the tubular body, said third portion having a longitudinal axis having an oblong shape, a curved portion including an upper and lower edge opposite the upper and lower edge of the cylindrically-shaped body, therebetween are two opposing lower portions, wherein the first section is connected to the third portion at an end of the elongate portion, wherein said straight-line arrangement of the first portions defines a circular area and at least one hole therethrough, and ]
0.015063493	2045	[ an elongate portion disposed between said cylindrically-shaped body and said first and third portions to facilitate passage between the cylindrically-shaped body and the straight-line arrangement of the first and third portions; ]	[ wherein a portion thereof extends from the curved portion to the circular area from a first tip to a second tip; and ]
0.99999166	2046	[ wherein a catheter catheter is a catheter having a first port and a second port operatively coupled to the first port of the cylindrically-shaped body, the cylindrically-shaped body having a first diameter and a second diameter, the elongate portion of the catheter catheter being generally cylindrically-shaped. ]	[ an elongate portion disposed between said cylindrically-shaped body and said first and third portions to facilitate passage between the cylindrically-shaped body and the straight-line arrangement of the first and third portions; ]
0.9999814	2047	[ contacting the tissue with a non-ionic fluid having a specific strength and specific energy; ]	[ A method for forming an implant in a body having tissue, the method comprising: ]
0.9999919	2048	[ introducing the non-ionic fluid in the body; and ]	[ contacting the tissue with a non-ionic fluid having a specific strength and specific energy; ]
0.99999225	2049	[ detecting the specific energy of the non-ionic fluid when the non-ionic fluid is introduced into the body. ]	[ introducing the non-ionic fluid in the body; and ]
0.9999081	2050	[ 1) a single nucleotide polymorphism is found at position 17 of the amino acid sequence of SEQ ID NO. 1 or an isolated polypeptide of at least 70 contiguous amino acids in the amino acid sequences of SEQ ID NO. 1 or its SEQ ID NO. 1. ]	[ An isolated molecule, comprising a sequence defined by the amino acid sequence of SEQ ID NO. 1 where: ]
0.9906198	2051	[ the method comprising the steps of: ]	[ A method of preparing a protein component that consists of a first and second group of amino acids, said first group comprising at least 50% arginine, ]
0.98667103	2052	[ providing an isolated enzyme comprising a peptide ligand and at least one variable region having a length which is a function of its length, the amino acid sequence (SEQ ID NO: 21) of SEQ ID NO: 21 corresponding to an amino acid sequence of SEQ ID NO: 22 of the protein component selected from SEQ ID NO: 22, SEQ ID NO: 23, and ]	[ the method comprising the steps of: ]
0.99985933	2053	[ SEQ ID NO: 24 of SEQ ID NO: 23; ]	[ providing an isolated enzyme comprising a peptide ligand and at least one variable region having a length which is a function of its length, the amino acid sequence (SEQ ID NO: 21) of SEQ ID NO: 21 corresponding to an amino acid sequence of SEQ ID NO: 22 of the protein component selected from SEQ ID NO: 22, SEQ ID NO: 23, and ]
0.004098578	2054	[ preparing an isolated protein component prepared from the isolated enzyme obtained in accordance with step (a) of the method; and ]	[ SEQ ID NO: 24 of SEQ ID NO: 23; ]
0.999992	2055	[ removing and depositing the isolated enzyme from a composition selected from a first composition having an active component comprising 10 to 50% arginine, a second composition comprising 10 to 50% arginine, and ]	[ preparing an isolated protein component prepared from the isolated enzyme obtained in accordance with step (a) of the method; and ]
0.9999913	2056	[ a third composition comprising 10 to 50% arginine, ]	[ removing and depositing the isolated enzyme from a composition selected from a first composition having an active component comprising 10 to 50% arginine, a second composition comprising 10 to 50% arginine, and ]
0.9999788	2057	[ wherein said first composition is formed by incubating a purified reaction product of the first preparation of the first group of amino acids on a purified reaction product of the second preparation of one of the first group of amino acids, and ]	[ a third composition comprising 10 to 50% arginine, ]
0.99999225	2058	[ wherein said third composition is formed by incubating a purified reaction product of the fourth preparation of the first group of amino acids on a purified reaction product of the second preparation of one of the second group of amino acids. ]	[ wherein said first composition is formed by incubating a purified reaction product of the first preparation of the first group of amino acids on a purified reaction product of the second preparation of one of the first group of amino acids, and ]
0.9999641	2059	[ a top and bottom edge extending away from said top layer, wherein said bottom and top edges are bonded together by a material including a porous polyamide; ]	[ A machine for making a moldable polypropylene plastic, said moldable polypropylene plastic comprising a top layer, a bottom layer, and ]
0.99999225	2060	[ wherein said bottom edge is a hollow polyester polymeric material formed from a porous polyamide in substantially equal portions on said top layer. ]	[ a top and bottom edge extending away from said top layer, wherein said bottom and top edges are bonded together by a material including a porous polyamide; ]
0.9736631	2061	[ a flexible substrate including at least one first side, wherein the at least one first side is disposed at a first orientation; and ]	[ A device comprising: ]
0.99999106	2062	[ a first contact member disposed and extending radially outwardly, wherein the at least one first side and at least one adjacent side are spaced along a first dimension; ]	[ a flexible substrate including at least one first side, wherein the at least one first side is disposed at a first orientation; and ]
0.9702959	2063	[ wherein the elongate member comprising: ]	[ a first contact member disposed and extending radially outwardly, wherein the at least one first side and at least one adjacent side are spaced along a first dimension; ]
0.98466057	2064	[ a first end that is substantially conical and has a first substantially convex end; ]	[ wherein the elongate member comprising: ]
0.98885787	2065	[ a first elongate groove disposed generally along the second side of the first side such that the first elongate groove is located between a first and an opposite side of the first elongate groove; ]	[ a first end that is substantially conical and has a first substantially convex end; ]
0.9672919	2066	[ a second end that is substantially conical and has a second substantially convex end; ]	[ a first elongate groove disposed generally along the second side of the first side such that the first elongate groove is located between a first and an opposite side of the first elongate groove; ]
0.99987566	2067	[ a third elongate groove disposed generally along the second side of the second end such that the third elongate groove is located between a second and a opposite side of the third elongate groove; ]	[ a second end that is substantially conical and has a second substantially convex end; ]
0.9999924	2068	[ a first elongate groove disposed within the third elongate groove; and ]	[ a third elongate groove disposed generally along the second side of the second end such that the third elongate groove is located between a second and a opposite side of the third elongate groove; ]
0.99999225	2069	[ a second elongate groove disposed generally along the second side of the second elongate groove; ]	[ a first elongate groove disposed within the third elongate groove; and ]
0.9999858	2070	[ wherein the elongate support is substantially convex and the first and second elongate grooves of the elongate member, respectively, extend inwardly to and along an outwardly extended length of the first, fifth, sixth, ninth, eleventh, thirteenth, and ]	[ a second elongate groove disposed generally along the second side of the second elongate groove; ]
0.9999919	2071	[ sixteenth elongate grooves. ]	[ wherein the elongate support is substantially convex and the first and second elongate grooves of the elongate member, respectively, extend inwardly to and along an outwardly extended length of the first, fifth, sixth, ninth, eleventh, thirteenth, and ]
0.99784493	2072	[ A1 of SEQ ID NO: ]	[ A method for inhibiting the growth and advancement of a cystic fibrosis protein-containing tumor in an animal, comprising administering a therapeutically effective amount of an antibody formed on antigen-binding protein (Ab-BP) and/or antigen-binding fragment (AbF) to the animal, wherein the antibody is made from a nucleic acid comprising at least one of the nucleotides: ]
0.99999166	2073	[ 1 or A2 of SEQ ID NO: ]	[ A1 of SEQ ID NO: ]
0.0006603105	2074	[ 1 that is an F2 region, and ]	[ 1 or A2 of SEQ ID NO: ]
0.99979	2075	[ is non-specific for either C1-F5 or A2 region, wherein the antibody inhibits the growth and advancement of a cystic fibrosis (CF) protein-containing tumor in the animal. ]	[ 1 that is an F2 region, and ]
0.9959955	2076	[ 5 or 5. ]	[ An isolated antibody or antigen-binding fragment thereof, comprising three or more amino acids of SEQ ID NO: ]
0.99998593	2077	[ (a) contacting a corn or soybean with corn binder; ]	[ A process for producing a seed of corn or soybean varieties that have greater resistance to corn rotworm (H. arifilis), wherein the seed is selected from the group consisting of corn, soybean, hickory, tobacco, corn corn, cotton, rice, pea, potato, buckwheat or rye, comprising the steps of: ]
0.99999166	2078	[ (b) forming a polymerized coating that is formed on the surface of the corn or soybean. ]	[ (a) contacting a corn or soybean with corn binder; ]
0.99916077	2079	[ an X-ray source having a beam source; ]	[ A system for use in a diagnostic imaging apparatus, comprising: ]
0.9999908	2080	[ an X-ray detector that detects X-ray radiation that has passed from said beam source; and ]	[ an X-ray source having a beam source; ]
0.99999225	2081	[ a signal generation circuit that generates and stores a signal indicative of said radiation detected by said X-ray detector and outputs a signal based on said detected radiation based on said beam source; ]	[ an X-ray detector that detects X-ray radiation that has passed from said beam source; and ]
0.9999896	2082	[ a first image display device and a second image display device, each of said first and second image display devices providing an image of part of a selected tissue in a patient's body to be scanned, each of said first and second image display devices being independently connected to said X-ray source, said X-ray source including an imaging tube; ]	[ a signal generation circuit that generates and stores a signal indicative of said radiation detected by said X-ray detector and outputs a signal based on said detected radiation based on said beam source; ]
0.99998915	2083	[ an X-ray detector for detecting said detected X-ray; and ]	[ a first image display device and a second image display device, each of said first and second image display devices providing an image of part of a selected tissue in a patient's body to be scanned, each of said first and second image display devices being independently connected to said X-ray source, said X-ray source including an imaging tube; ]
0.99998856	2084	[ a processor that, with input from said signal generation circuit, executes processing steps corresponding to one or more of said image displays, such that a selected target organ in said selected tissue is represented on said first or second image display device from said output of said signal generation circuit, the processing steps causing a change of a scan path of the X-ray beam according to said changed scan path, and ]	[ an X-ray detector for detecting said detected X-ray; and ]
0.99999213	2085	[ an image in said scanned tissue is displayed on said first or second image display device. ]	[ a processor that, with input from said signal generation circuit, executes processing steps corresponding to one or more of said image displays, such that a selected target organ in said selected tissue is represented on said first or second image display device from said output of said signal generation circuit, the processing steps causing a change of a scan path of the X-ray beam according to said changed scan path, and ]
0.99329776	2086	[ a housing having a proximal end and a distal end; ]	[ A medical device, comprising: ]
0.9999001	2087	[ a proximal surface of said proximal end of said housing configured to receive an arm of a player; ]	[ a housing having a proximal end and a distal end; ]
0.9999306	2088	[ a distal surface of said proximal end of said housing configured to communicate with a patient in a controlled operation, wherein said distal surface has an adjustable angle of rotation for accommodating a patient's arm when said distal surface is in said adjustable angle of rotation; and ]	[ a proximal surface of said proximal end of said housing configured to receive an arm of a player; ]
0.9997899	2089	[ a base configured to securely fit an orthopedic insert, wherein at least a portion of said base has been constructed to fit a portion of said device when said fixed angle of rotation is at the prescribed angle for each of the plurality of light sources. ]	[ a distal surface of said proximal end of said housing configured to communicate with a patient in a controlled operation, wherein said distal surface has an adjustable angle of rotation for accommodating a patient's arm when said distal surface is in said adjustable angle of rotation; and ]
0.91791254	2090	[ a plurality of segments, each segment having an upper end, an opposite lower end, and ]	[ A medical device adapted to fit over a lumen of a coronary vessel, the device comprising: ]
0.9999517	2091	[ a distal end positioned at a bottom region of the lumen for being secured between both the upper and lower ends, the devices further comprising a distal segment which includes a support portion configured for affixing a surgical instrument to the medical device, the support portion being positioned at a lower end of the segment at an angle of 50&#xb0; relative to a longitudinal axis of the medical device, and ]	[ a plurality of segments, each segment having an upper end, an opposite lower end, and ]
0.99789184	2092	[ an inner surface, wherein the inner surface defines at least one lumen for an artery; ]	[ a distal end positioned at a bottom region of the lumen for being secured between both the upper and lower ends, the devices further comprising a distal segment which includes a support portion configured for affixing a surgical instrument to the medical device, the support portion being positioned at a lower end of the segment at an angle of 50&#xb0; relative to a longitudinal axis of the medical device, and ]
0.99856454	2093	[ the distal segment further including a pair of slots for receiving and securing a connector; ]	[ an inner surface, wherein the inner surface defines at least one lumen for an artery; ]
0.98045486	2094	[ a screw member disposed between either the proximal end of the support portion or a proximal end of the inner surface; ]	[ the distal segment further including a pair of slots for receiving and securing a connector; ]
0.023836758	2095	[ and a proximal portion of the upper end of the distal segment having a first engagement portion with respect to the connecting section or the connector, wherein the lower end of the platform is configured to engage the distal portion of the upper end of the distal segment; ]	[ a screw member disposed between either the proximal end of the support portion or a proximal end of the inner surface; ]
0.9967055	2096	[ wherein the plurality of segments are aligned along a proximal long axis that extends from the upper end of the projection to a bottom of the lumen. ]	[ and a proximal portion of the upper end of the distal segment having a first engagement portion with respect to the connecting section or the connector, wherein the lower end of the platform is configured to engage the distal portion of the upper end of the distal segment; ]
0.9999907	2097	[ a base, defining an internal surface of which are arranged a plurality of medical devices; ]	[ A medical device from which a plurality of medical devices is arranged, comprising: ]
0.99998105	2098	[ a plurality of support members connected to the internal surface of the base; ]	[ a base, defining an internal surface of which are arranged a plurality of medical devices; ]
0.9999522	2099	[ at least two support members disposed in each of the plurality of support members, said at least two support members being adapted to move along a path of a rotation of the support members; and ]	[ a plurality of support members connected to the internal surface of the base; ]
0.9916359	2100	[ at least one power source and a power control circuit configured to operate at least one portion of the plurality of medical devices while simultaneously operating a substantially parallel power supply to the at least one portion. ]	[ at least two support members disposed in each of the plurality of support members, said at least two support members being adapted to move along a path of a rotation of the support members; and ]
0.023806276	2101	[ a plurality of processor components comprising a memory and a communication protocol capable of accessing the memory; ]	[ An electronic device which enables a user to select a method of acquiring information, the device consisting of: ]
0.9999918	2102	[ a processor in communication with the communication protocol; ]	[ a plurality of processor components comprising a memory and a communication protocol capable of accessing the memory; ]
0.99680173	2103	[ an image processing unit in communication with the plurality of processor components and the memory that processes an image which is acquired by the image processing unit; ]	[ a processor in communication with the communication protocol; ]
0.9999918	2104	[ a selection device in communication with the memory and in communication with the processor components; ]	[ an image processing unit in communication with the plurality of processor components and the memory that processes an image which is acquired by the image processing unit; ]
0.99997234	2105	[ a controller in communications with the control components; and ]	[ a selection device in communication with the memory and in communication with the processor components; ]
0.9987999	2106	[ a memory in communication with an image storing unit, wherein the processing system receives image data from the image storing unit, and ]	[ a controller in communications with the control components; and ]
0.99997675	2107	[ controls the memory to store image data, wherein a selection, at least one of acquisition, selection, and ]	[ a memory in communication with an image storing unit, wherein the processing system receives image data from the image storing unit, and ]
0.9993362	2108	[ selection is made by the user, and ]	[ controls the memory to store image data, wherein a selection, at least one of acquisition, selection, and ]
0.99993694	2109	[ wherein, in real time, the processor components are in communication with the processing system and, in real time, the selection is sent to the selection device. ]	[ selection is made by the user, and ]
0.9999057	2110	[ a. administering an intravenous fluid into the subject; and ]	[ A method of providing a fluid delivery system for a subject comprising: ]
0.99999094	2111	[ b. moving a fluid delivery device from fluid delivery to at least one of a first or second fluid delivery mechanism through a fluid pump when the intravenous fluid passes through blood. ]	[ a. administering an intravenous fluid into the subject; and ]
0.0068336274	2112	[ a) an implanted body or body part comprising a surgical instrument for surgical insertion in an environment comprising a human body, a vertebra, a connective tissue, a skin, and ]	[ A system comprising: ]
0.9909376	2113	[ a blood vessel; ]	[ a) an implanted body or body part comprising a surgical instrument for surgical insertion in an environment comprising a human body, a vertebra, a connective tissue, a skin, and ]
0.012927169	2114	[ b) a device for providing cardiac stimulation in the human body in a heart via the bone and an electrical interface in the human body; ]	[ a blood vessel; ]
0.99999225	2115	[ c) a cardiac stimulation sensor coupled to the apparatus for providing cardiac stimulation in the human body via the device; and ]	[ b) a device for providing cardiac stimulation in the human body in a heart via the bone and an electrical interface in the human body; ]
0.99999225	2116	[ d) a controller, coupled to the controller, adapted to change from having cardiac stimulation by the cardiac stimulation sensor based on the cardiac stimulation by the cardiac stimulation sensor, to having cardiac stimulation by means of the device via the electrical interface when a cardiac signal exceeds at least a predetermined threshold power when the surgical instrument is placed in the human body. ]	[ c) a cardiac stimulation sensor coupled to the apparatus for providing cardiac stimulation in the human body via the device; and ]
0.9999895	2117	[ an in-vivo ultrasound-processing unit that processes ultrasound signals, including ultrasound signals associated with the first patient, to produce a first ultrasound image using said ultrasound signals produced by said processing unit; ]	[ An in-vivo ultrasound imaging apparatus configured to image a tissue volume between a first patient and a second patient, said imaging apparatus comprising: ]
0.999992	2118	[ a control unit that controls, via a control unit control circuit, a time period to be used for processing said first ultrasound image; and ]	[ an in-vivo ultrasound-processing unit that processes ultrasound signals, including ultrasound signals associated with the first patient, to produce a first ultrasound image using said ultrasound signals produced by said processing unit; ]
0.9999641	2119	[ an output control circuit that provides an output control signal corresponding to said processing time period, wherein said control unit control circuit determines from the output control signal whether said time period is a closed period in which the time period is open, a closed time period in which the time period is closed and a closed time period in which the time period is continuous, then said control unit control circuit provides an output control signal to said output control circuit corresponding to said closed time period, said closed period in which the time period isopen, and ]	[ a control unit that controls, via a control unit control circuit, a time period to be used for processing said first ultrasound image; and ]
0.99999094	2120	[ said continuous of the time period, and ]	[ an output control circuit that provides an output control signal corresponding to said processing time period, wherein said control unit control circuit determines from the output control signal whether said time period is a closed period in which the time period is open, a closed time period in which the time period is closed and a closed time period in which the time period is continuous, then said control unit control circuit provides an output control signal to said output control circuit corresponding to said closed time period, said closed period in which the time period isopen, and ]
0.9999871	2121	[ when said time period is open, said control unit provides an output control signal to said output control circuit corresponding to said closed time period, said closed time period in which the time period is continuous. ]	[ said continuous of the time period, and ]
0.4219177	2122	[ analyzing and mapping a first image of a first object to a second image comprising a plurality of images, each image comprising a set of different image content; ]	[ A method comprising: ]
0.9999918	2123	[ generating a first set of image metadata defining at least one image attribute of a first object; ]	[ analyzing and mapping a first image of a first object to a second image comprising a plurality of images, each image comprising a set of different image content; ]
0.99999225	2124	[ generating a second set of image metadata defining at least one image attribute of a second object, wherein: ]	[ generating a first set of image metadata defining at least one image attribute of a first object; ]
0.99999154	2125	[ the first set of images defines at least one spatial position defined as a second image by the second object; ]	[ generating a second set of image metadata defining at least one image attribute of a second object, wherein: ]
0.9999924	2126	[ the second set of images defines at least one spatial position defined as a first object by the first object; and ]	[ the first set of images defines at least one spatial position defined as a second image by the second object; ]
0.99998987	2127	[ at least one of the first and second sets of image metadata is stored at a time in the first set of images. ]	[ the second set of images defines at least one spatial position defined as a first object by the first object; and ]
0.9971642	2128	[ wherein the variable nitrogen atom is replaced with a single nitrogen atom in the formula: ]	[ A compound of formula (I) or an pharmaceutically acceptable salt thereof: ]
0.98189247	2129	[ wherein R1 is H, is Cl, is O, is Cl2 and is (C1-C4 alkyl) or (C1-C4 cyano), is O, is 2-isopropyl, is 1, 2, 3-dihydro-3-chloro-1-butyl, is 1-butyl, is O or is C1-C4 alkyl; ]	[ wherein the variable nitrogen atom is replaced with a single nitrogen atom in the formula: ]
0.99894696	2130	[ R2 is a hydrogen atom, or is N, H or is a nitrogen atom; and ]	[ wherein R1 is H, is Cl, is O, is Cl2 and is (C1-C4 alkyl) or (C1-C4 cyano), is O, is 2-isopropyl, is 1, 2, 3-dihydro-3-chloro-1-butyl, is 1-butyl, is O or is C1-C4 alkyl; ]
0.9993205	2131	[ Z indicates a hydrogen atom. ]	[ R2 is a hydrogen atom, or is N, H or is a nitrogen atom; and ]
0.9986426	2132	[ a body having a main surface to be grasped; ]	[ A device for securing a handle, comprising: ]
0.99998844	2133	[ a first gripping bar mounted on the body and having a first end portion with an obliquely directed pivot pivot mechanism arranged on one side of the first end portion with an edge of the edge extending from a surface of the first end portion towards an adjacent surface of the main surface; ]	[ a body having a main surface to be grasped; ]
0.99999225	2134	[ a second gripping bar mounted on the body and having a second end portion with a second obliquely directed pivoting mechanism arranged on another side of the second end portion with an edge of the edge extending from a surface of the second end portion towards an adjacent surface of the main surface; and ]	[ a first gripping bar mounted on the body and having a first end portion with an obliquely directed pivot pivot mechanism arranged on one side of the first end portion with an edge of the edge extending from a surface of the first end portion towards an adjacent surface of the main surface; ]
0.999992	2135	[ a first locking member mounted on the body and having a first locking mechanism that is rotatably mounted on the main surface, and ]	[ a second gripping bar mounted on the body and having a second end portion with a second obliquely directed pivoting mechanism arranged on another side of the second end portion with an edge of the edge extending from a surface of the second end portion towards an adjacent surface of the main surface; and ]
0.9999908	2136	[ having a second locking mechanism that is rotatable with respect to the first locking member via a sliding connection and comprises a hinge that is rotatable with respect to the locking mechanism via a locking mechanism that pivots with respect to the sliding connection such that when the locking member is moved thereupon, the first locking mechanism is rotated to the second locking mechanism to lock the body against removal of the first gripping bar from the body. ]	[ a first locking member mounted on the body and having a first locking mechanism that is rotatably mounted on the main surface, and ]
0.99999213	2137	[ providing a transgenic animal having a genome containing nucleic acid sequence of said N-terminal gene, the genetic gene set contained within the genetic gene set of nucleic acid sequence of said N-terminal gene; and ]	[ A method to select an animal whose DNA is modified by an amino acid in a genetic gene set containing only the N-terminal gene of the genetic gene set in a transgenic animal having a genome consisting of said N-terminal gene in a cell, the method comprising: ]
0.99999225	2138	[ providing said transgenic animal with a transgenic cell having a DNA sequence that is at least 80% identical to a genome of said transgenic animal and that is capable of inducing expression of said N-terminal gene of the genetic gene set, wherein said transgenic cell is capable of initiating production of DNA from said N-terminal gene of the genetic gene set in said transgenic animal. ]	[ providing a transgenic animal having a genome containing nucleic acid sequence of said N-terminal gene, the genetic gene set contained within the genetic gene set of nucleic acid sequence of said N-terminal gene; and ]
0.744419	2139	[ or a salt thereof. ]	[ S-phase acidophthalmic compound comprising the formula (I): ]
0.99515295	2140	[ a bone rod support frame having first and second ends defined by a wall, ]	[ A surgical implement, comprising: ]
0.99999213	2141	[ an elongate tubular member having first and second ends provided upon and extending axially from the wall of the bone rod support frame, each of the first and second ends provided with an attachment structure having a plurality of teeth arranged about, or embedded in, respective portions thereof, the attachment structures configured to be releasably secured through an interior of the frame. ]	[ a bone rod support frame having first and second ends defined by a wall, ]
0.999713	2142	[ a) providing a single-agent product solution comprising at least one pharmaceutically acceptable carrier; and ]	[ A method for the preparation of a pharmaceutical composition for a pharmaceutical delivery system comprising: ]
0.99997914	2143	[ b) preparing a pharmaceutical composition, including a pharmaceutically acceptable carrier; and ]	[ a) providing a single-agent product solution comprising at least one pharmaceutically acceptable carrier; and ]
0.99995816	2144	[ combining the pharmaceutical composition in a single-agent delivery system to form a single-agent composition. ]	[ b) preparing a pharmaceutical composition, including a pharmaceutically acceptable carrier; and ]
0.99998903	2145	[ (a) administering a hydrogel to an eye, the hydrogel providing an effective amount of a polymeric film; and ]	[ A method for preparing a hydrogel for use in an implant in an eye, the method comprising the steps of: ]
0.9999813	2146	[ (b) adding an adjuvanted polymeric film comprising a water molecule, said adjuvanted polymeric film having a viscosity to exceed the viscosity of water by at least 1.5% such that the polymeric film has a reduced ability to contact a viscoelastic membrane. ]	[ (a) administering a hydrogel to an eye, the hydrogel providing an effective amount of a polymeric film; and ]
0.00010721433	2147	[ 8-yl)-2-(3-dihydroxyethyl)pyridin-2-yl)-acetamide. ]	[ A method of treating a tumor comprising administering to an individual a therapeutically effective amount of a first active ingredient of poly(ethylene glycol, ]
0.99999034	2148	[ an applicator including a housing; ]	[ An applicator assembly comprising: ]
0.99995434	2149	[ a housing member defining a cylindrical housing, wherein the cylindrical housing is adapted to receive an applicator assembly therein; ]	[ an applicator including a housing; ]
0.9999831	2150	[ an applicator plunger including a plunger assembly; ]	[ a housing member defining a cylindrical housing, wherein the cylindrical housing is adapted to receive an applicator assembly therein; ]
0.9999894	2151	[ an applicator member receiving the applicator assembly; and ]	[ an applicator plunger including a plunger assembly; ]
0.99824286	2152	[ a housing and plunger body engaging surfaces configured to permit the plunger assembly to movement while the housing and plunger body are in fluid communication, the housing and plunger body including a first and a second engaging configuration, respectively, the first engaging configuration including a proximal coupling portion that provides fluid connection between the housing member and the plunger assembly; ]	[ an applicator member receiving the applicator assembly; and ]
0.9978223	2153	[ wherein said first coupling portion includes at least two slots, and ]	[ a housing and plunger body engaging surfaces configured to permit the plunger assembly to movement while the housing and plunger body are in fluid communication, the housing and plunger body including a first and a second engaging configuration, respectively, the first engaging configuration including a proximal coupling portion that provides fluid connection between the housing member and the plunger assembly; ]
0.015309172	2154	[ wherein said housing member is configured to provide an engagement surface of the applicator member when the applicator member is positioned within the first and second engaging configurations and when the housing member is in the engagement position for receiving the applicator assembly. ]	[ wherein said first coupling portion includes at least two slots, and ]
0.99744874	2155	[ a head formed from a soft or rubber material and having a head sole; ]	[ A golf club shaft, comprising: ]
0.99999034	2156	[ an offset portion and a striking portion, the offset portion being received in an inner surface of the outer surface of the head sole and adapted to contact a surface of the outer surface of the head sole at an angle relative to a longitudinal axis of the club; ]	[ a head formed from a soft or rubber material and having a head sole; ]
0.9999918	2157	[ a tip protruding from the head sole of the club head, wherein the tip is adapted for direct hitting by a golfer and for a strike by non-golfer; ]	[ an offset portion and a striking portion, the offset portion being received in an inner surface of the outer surface of the head sole and adapted to contact a surface of the outer surface of the head sole at an angle relative to a longitudinal axis of the club; ]
0.9998988	2158	[ a drive mechanism provided with a shaft housing, the shaft housing comprising a bore, an opening to the shaft interior, a drive assembly mounted in the hole to produce a swing direction in a direction away from the swing direction of the golf club, and ]	[ a tip protruding from the head sole of the club head, wherein the tip is adapted for direct hitting by a golfer and for a strike by non-golfer; ]
0.99999213	2159	[ a locking assembly mounted in the shaft interior, the locking assembly having an open hole on a side of said shaft housing, the locking assembly adapted to receive a shaft from the shaft housing, which is driven to be engaged with a groove in an inner surface of the head sole and to be locked in a swing direction by a rotation of the drive assembly, ]	[ a drive mechanism provided with a shaft housing, the shaft housing comprising a bore, an opening to the shaft interior, a drive assembly mounted in the hole to produce a swing direction in a direction away from the swing direction of the golf club, and ]
0.99999225	2160	[ wherein, as the head is driven on the club head, the outer surface of the head sole and the surface of the outer surface are displaced, the shaft being secured to said swing direction relative to the swing direction of the golf club. ]	[ a locking assembly mounted in the shaft interior, the locking assembly having an open hole on a side of said shaft housing, the locking assembly adapted to receive a shaft from the shaft housing, which is driven to be engaged with a groove in an inner surface of the head sole and to be locked in a swing direction by a rotation of the drive assembly, ]
0.0016858139	2161	[ a base that supports a body including a longitudinal axis extending through a longitudinal opening in the body; ]	[ An implantable medical device comprising: ]
0.016704492	2162	[ a first head having at least one outer face configured to receive a proximal end of a central shaft, the first head having a front surface configured to align with at least a portion of a proximal portion of a central shaft of the central shaft. ]	[ a base that supports a body including a longitudinal axis extending through a longitudinal opening in the body; ]
0.99997485	2163	[ non-woven, non-woven-like, non-woven-like-like, and ]	[ A tool for providing a non-retractable, removable, non-woven, resilient, non-stretch-like, and ]
0.9946955	2164	[ flexible garment, the tool being designed such that the tool can be selectively releasably attached to at least at one of: a first part of a garment, or a second part of the garment on which the tool is to be mounted, the tool to be detachably attachable to said first part of the garment, and <|span|>/or an interior of the garment comprising a first area of the garment and a second area of the garment, whereupon the garment that is to be detached from said first part of the garment moves from said first area to said second area and, when the tool is attached to said first part of the garment, the tool becomes resiliently attached to said first part of the garment and is releasably attachable to at least one surface in said first interior or second interior of said first area of the garment to enable the tool to be detached from said second part of the garment by removal of the tool from said first interior or second interior of said first area of the garment. ]	[ non-woven, non-woven-like, non-woven-like-like, and ]
0.008581573	2165	[ (a) providing a first non-magnetic flexible material; ]	[ A method for manufacturing a single-point attachment to a single-point body-worn surgical instrument, comprising the steps of: ]
0.9999918	2166	[ (b) supplying a second single-point attachment member to be disposed in, or releasably attached to, the first non-magnetic flexible material and a plurality of first attachment members from another type of nonmagnetic flexible material, further comprising: ]	[ (a) providing a first non-magnetic flexible material; ]
0.99999213	2167	[ (i) providing a magnetic coupling element to be connected between the plurality of first attachment members; and ]	[ (b) supplying a second single-point attachment member to be disposed in, or releasably attached to, the first non-magnetic flexible material and a plurality of first attachment members from another type of nonmagnetic flexible material, further comprising: ]
0.99996793	2168	[ (ii) attaching the first non-magnetic flexible material to a single-point body-worn surgical instrument having a plurality of different single-point attachment members; ]	[ (i) providing a magnetic coupling element to be connected between the plurality of first attachment members; and ]
0.9999924	2169	[ (c) disposing each of the plurality of single-point attachment members on at least one of the plurality of attachment members of the other type of nonmagnetic flexible material; and ]	[ (ii) attaching the first non-magnetic flexible material to a single-point body-worn surgical instrument having a plurality of different single-point attachment members; ]
0.99999225	2170	[ (d) mounting the plurality of single-point attachment members over the plurality of attachment members, ]	[ (c) disposing each of the plurality of single-point attachment members on at least one of the plurality of attachment members of the other type of nonmagnetic flexible material; and ]
0.99999225	2171	[ wherein the plurality of single-point attachment members are arranged to be disposed inside of an interior cavity of an exterior surgical instrument, ]	[ (d) mounting the plurality of single-point attachment members over the plurality of attachment members, ]
0.99998343	2172	[ wherein there is first and second interior surfaces of the interior cavities that are formed by at least a part of at least one of the plurality of attachment members of the other type of nonmagnetic flexible material, and ]	[ wherein the plurality of single-point attachment members are arranged to be disposed inside of an interior cavity of an exterior surgical instrument, ]
0.99999225	2173	[ wherein both at least a part of at least one of the plurality of attachment members has been disposed on an exterior surface of the interior cavity. ]	[ wherein there is first and second interior surfaces of the interior cavities that are formed by at least a part of at least one of the plurality of attachment members of the other type of nonmagnetic flexible material, and ]
0.99718827	2174	[ a) a cannula configured as a balloon-shaped balloon and having an upper and lower surface, a distal end, and ]	[ A catheter for a medical device comprising: ]
0.99509877	2175	[ a head portion, the catheter being adapted to be inserted through a body site; ]	[ a) a cannula configured as a balloon-shaped balloon and having an upper and lower surface, a distal end, and ]
0.9999788	2176	[ b) an elongated rod extending along an upper length of the catheter, said elongated rod configured for insertion into said body site and operable to deliver an injection into said body site; ]	[ a head portion, the catheter being adapted to be inserted through a body site; ]
0.99999034	2177	[ c) at least one distal sleeve extending along a lower length of the catheter; ]	[ b) an elongated rod extending along an upper length of the catheter, said elongated rod configured for insertion into said body site and operable to deliver an injection into said body site; ]
0.99997556	2178	[ d) at least one outer sleeve terminating at said head portion to releasably anchor said catheter against a lumen of said body site; ]	[ c) at least one distal sleeve extending along a lower length of the catheter; ]
0.9998203	2179	[ e) a pair of flexible rods extending from a proximal end of the tube, said tubes forming a substantially vertical body extending into an annular structure about a central diameter and with a thickness in the order of 25&#xb0; to 50&#xb0; in order to cover the diameter of said lumen; and ]	[ d) at least one outer sleeve terminating at said head portion to releasably anchor said catheter against a lumen of said body site; ]
0.9999764	2180	[ f) a tubular body having at least two ends adapted to be mounted in contact with the outer sleeve and a tubular body elongated shaft adapted to engage the inner walls of said tubes to engage the body site of the catheter when being inserted, said tubular body having a height in the order of 25&#xb0; and ]	[ e) a pair of flexible rods extending from a proximal end of the tube, said tubes forming a substantially vertical body extending into an annular structure about a central diameter and with a thickness in the order of 25&#xb0; to 50&#xb0; in order to cover the diameter of said lumen; and ]
0.9987613	2181	[ 50&#xb0; above the surface of the lumen. ]	[ f) a tubular body having at least two ends adapted to be mounted in contact with the outer sleeve and a tubular body elongated shaft adapted to engage the inner walls of said tubes to engage the body site of the catheter when being inserted, said tubular body having a height in the order of 25&#xb0; and ]
0.9999678	2182	[ (a) lymph node tumor or lymph node tumor, wherein said tumor includes in its outermost periphery at least one tumor cell; ]	[ A method for the treatment of a subject having a malignant tumor and a circulating platelet-derived growth factor (PDGF) in a lymph node region, wherein said tumor is characterized by: ]
0.9999355	2183	[ (b) a surface of the tumor having an increased probability of infection by a pathogenic organism; ]	[ (a) lymph node tumor or lymph node tumor, wherein said tumor includes in its outermost periphery at least one tumor cell; ]
0.9999658	2184	[ (c) blood in response to infection and having greater than 0.5 mmHg DGF with a value ]	[ (b) a surface of the tumor having an increased probability of infection by a pathogenic organism; ]
0.99993443	2185	[ 8.0 to 9.0 ng/ml, wherein said PDGF is associated with an increased concentration of plasma PDGF between 0.1 to 10 nanograms/liter during the course of infection; and ]	[ (c) blood in response to infection and having greater than 0.5 mmHg DGF with a value ]
0.999979	2186	[ (d) a subject having a plasma PDGF value of 2.0. ]	[ 8.0 to 9.0 ng/ml, wherein said PDGF is associated with an increased concentration of plasma PDGF between 0.1 to 10 nanograms/liter during the course of infection; and ]
0.970438	2187	[ providing and managing a collection of virtual objects within and in space; ]	[ A method, comprising: ]
0.999982	2188	[ determining, based on a virtual object's presence in a field of view of a virtual camera, that the virtual object is currently in a given field of view; and ]	[ providing and managing a collection of virtual objects within and in space; ]
0.9999918	2189	[ using, in response to said determined presence of said virtual object, determining one or more virtual objects, ]	[ determining, based on a virtual object's presence in a field of view of a virtual camera, that the virtual object is currently in a given field of view; and ]
0.9999907	2190	[ wherein a plurality of virtual objects are determined by having said virtual cameras produce a series of images of a virtual object and to receive a user input to automatically adjust the camera in response to the image data of the camera, and ]	[ using, in response to said determined presence of said virtual object, determining one or more virtual objects, ]
0.99999225	2191	[ wherein each of said plurality of virtual objects is determined as an object which is currently in a given field of view of said camera by a set of camera rules (12) including a set of image conditions, wherein, in a case where a virtual object is not currently in said given field of view, each of said set of image conditions comprises a respective set of image conditions that is selected from one of the image conditions defined by one of said image conditions defined by the first set of image conditions associated with said virtual object, or wherein a virtual object is defined as a virtual object in one of said set of image conditions based one or more of their respective set of image conditions. ]	[ wherein a plurality of virtual objects are determined by having said virtual cameras produce a series of images of a virtual object and to receive a user input to automatically adjust the camera in response to the image data of the camera, and ]
0.99909353	2192	[ (a) a base, the base comprising a radiation source having an exterior surface and an interior surface, the exterior surface including a first irradiation radiation source having an endoscopic beam port in communication with the interior surface of the radiation source and defining a first open aperture, the exterior surface of the radiation source having an inner surface defining an area having a depth of less than one millimeter and configured to be substantially confined therebetween and for receiving and irradiating radiation from the interior surface of the radiation source; ]	[ A device for delivering therapeutic radiation, comprising: ]
0.999992	2193	[ (b) at least one radiotherapy beam port in communication with the interior surface of the radiation source, and ]	[ (a) a base, the base comprising a radiation source having an exterior surface and an interior surface, the exterior surface including a first irradiation radiation source having an endoscopic beam port in communication with the interior surface of the radiation source and defining a first open aperture, the exterior surface of the radiation source having an inner surface defining an area having a depth of less than one millimeter and configured to be substantially confined therebetween and for receiving and irradiating radiation from the interior surface of the radiation source; ]
0.99994135	2194	[ being configured for receiving a range of radiological parameters including radiation dose, temperature, depth and flow through said radiation port; and ]	[ (b) at least one radiotherapy beam port in communication with the interior surface of the radiation source, and ]
0.99809414	2195	[ (c) at least one radiation therapy source in communication with the interior surface of the radiation source; ]	[ being configured for receiving a range of radiological parameters including radiation dose, temperature, depth and flow through said radiation port; and ]
0.9999083	2196	[ wherein the radium source has an exterior surface having a first surface surface defining a first radiation surface; and ]	[ (c) at least one radiation therapy source in communication with the interior surface of the radiation source; ]
0.99999213	2197	[ wherein the radiation source is in contact with the radium source through the first surface surface. ]	[ wherein the radium source has an exterior surface having a first surface surface defining a first radiation surface; and ]
0.999992	2198	[ administering to a subject with the condition such that the respiratory tract is impaired; ]	[ A method of diagnosing a condition that causes impairment of a respiratory tract comprising the steps of: ]
0.99998844	2199	[ detecting a change in respiratory tract motion in the patient; ]	[ administering to a subject with the condition such that the respiratory tract is impaired; ]
0.99999225	2200	[ analyzing the change in respiratory tract motion, after a first monitoring period, for a determination of a condition that caused impairment of the respiratory tract; and ]	[ detecting a change in respiratory tract motion in the patient; ]
0.99999225	2201	[ determining a condition that caused impairment that required medication, wherein the determination comprises determining at least one symptom of impaired respiratory tract motion for the determination of the condition that caused impairment of the respiratory tract, for the following second monitoring period: ]	[ analyzing the change in respiratory tract motion, after a first monitoring period, for a determination of a condition that caused impairment of the respiratory tract; and ]
0.99999166	2202	[ wherein the determined condition for the subsequent second monitoring period (i.e. the first monitoring period) is indicative of that condition. ]	[ determining a condition that caused impairment that required medication, wherein the determination comprises determining at least one symptom of impaired respiratory tract motion for the determination of the condition that caused impairment of the respiratory tract, for the following second monitoring period: ]
0.9985858	2203	[ an elongate body having a first member adapted to extend proximally from a distal end, a first distal end, and ]	[ A surgical blade, comprising: ]
0.99942386	2204	[ a first distal passage on an exterior thereof; ]	[ an elongate body having a first member adapted to extend proximally from a distal end, a first distal end, and ]
0.99762875	2205	[ a second member having a second member end adapted to extend proximally from a proximal end of the elongate body and adapted to mate with the second member end; and ]	[ a first distal passage on an exterior thereof; ]
0.99904674	2206	[ a blade body having a first member disposed axially above and abutting the first member body on a longitudinal axis, and ]	[ a second member having a second member end adapted to extend proximally from a proximal end of the elongate body and adapted to mate with the second member end; and ]
0.99999225	2207	[ a second member disposed axially above and abutting the second member body on a longitudinal axis; ]	[ a blade body having a first member disposed axially above and abutting the first member body on a longitudinal axis, and ]
0.999845	2208	[ wherein the second member and the elongate body are formed of a compound consisting of (1) H Cl(O)N(O)R(O)N(O)R(O)N(OH)m and (2) H Cl(OH)N(O)F(O)F, whereinR is Cl(C) or Cl(O) and NH is O. ]	[ a second member disposed axially above and abutting the second member body on a longitudinal axis; ]
0.00036548823	2209	[ a. a main support; ]	[ An apparatus for delivering a bioregenerative agent or a therapeutically effective amount of an alkali metal to a subject, wherein the apparatus comprises: ]
0.9985672	2210	[ b. a catheter; and, ]	[ a. a main support; ]
0.99998283	2211	[ c. a delivery device having a proximal end and a distal end, the delivery device being coupled with the main support and the catheter. ]	[ b. a catheter; and, ]
0.9999881	2212	[ a conduit element configured to receive or hold the conduit element in a position extending across the first opening from at least the proximal end to the distal end. ]	[ An elongate tubular apparatus comprising a first opening, a conduit therein with a first side, a second open end, a conduit body having a proximal end and a distal end, and ]
0.9997043	2213	[ a vessel for delivery of blood; ]	[ An apparatus for reducing the volume of blood flowing through the heart, comprising: ]
0.9999089	2214	[ a catheter extending within the vessel and extending between proximal and distal ends thereof, a first end configured to be within fluid communication with an intraluminal space and a second end, proximal of the first end, configured to be substantially in fluid communication with an outside of the heart; and ]	[ a vessel for delivery of blood; ]
0.9999858	2215	[ an implant positioned within the catheter. ]	[ a catheter extending within the vessel and extending between proximal and distal ends thereof, a first end configured to be within fluid communication with an intraluminal space and a second end, proximal of the first end, configured to be substantially in fluid communication with an outside of the heart; and ]
0.9982052	2216	[ at least one sensor for sensing at least first and second physical parameters; ]	[ An apparatus for controlling the direction of a body, comprising: ]
0.9894912	2217	[ a processor for executing control logic that includes: ]	[ at least one sensor for sensing at least first and second physical parameters; ]
0.016624901	2218	[ determining a predetermined predetermined physical parameter for a first physical parameter and determining a predetermined predetermined physical parameter for a second physical parameter; ]	[ a processor for executing control logic that includes: ]
0.9999924	2219	[ in accordance with the predetermined predetermined physical parameter set, determining a predetermined physical parameter for the predetermined predetermined physical parameter; and ]	[ determining a predetermined predetermined physical parameter for a first physical parameter and determining a predetermined predetermined physical parameter for a second physical parameter; ]
0.9999924	2220	[ in response to said determining, comparing the predetermined physical parameter set to a reference physical parameter; and ]	[ in accordance with the predetermined predetermined physical parameter set, determining a predetermined physical parameter for the predetermined predetermined physical parameter; and ]
0.99999225	2221	[ in response to said comparing the predetermined physical parameter set to the reference physical parameter, correcting the specified physical parameters in accordance with an information based on the specified physical parameter set. ]	[ in response to said determining, comparing the predetermined physical parameter set to a reference physical parameter; and ]
0.99994624	2222	[ a flexible stent comprising a head having a cavity; ]	[ A stent delivery system for preventing post-partum depression of a baby, comprising: ]
0.99694294	2223	[ an elongate member disposed within the elongate member; and ]	[ a flexible stent comprising a head having a cavity; ]
0.99998784	2224	[ a flexible anchor disposed in the elongate member, the anchor configured to be selectively removably attached to an end of the stent when the stent is attached to the elongate member, the anchor further configured to hold the anchor in a neutral position. ]	[ an elongate member disposed within the elongate member; and ]
0.999992	2225	[ a) allowing the anionic solution to flow to form a liquid containing solution; ]	[ A method of dispensing a liquid containing solution comprising an anionic solution and a hydroxyl salt comprising: ]
0.9999908	2226	[ b) forming a first solution in a first flow path of the liquid containing solution by passing the first solution; and ]	[ a) allowing the anionic solution to flow to form a liquid containing solution; ]
0.99998355	2227	[ c) allowing the hydroxyl salt and the first solution to flow together and at a greater amount than the volume of the hydroxyl salt and the first solution so that the anionic solution is suspended in the hydroxyl salt until the hydroxyl salt is in full contact with one or more of the liquid forming solvents comprising at least one of a hydroxyl acid, a hydroxypropylbutyric acid and a glycerol derivative as a hydroxyl acid with the hydroxypropylbutyric acid and glycerol derivative forming at least one of the solution or the hydroxyl acid or the hydroxyl acid and glycerol derivative forming the at least one solution when the hydroxyl acid is partially dissolved. ]	[ b) forming a first solution in a first flow path of the liquid containing solution by passing the first solution; and ]
0.99853873	2228	[ (a) depositing a therapeutic agent into at least a portion of a subject's skin; ]	[ A method for providing a patient with a pharmaceutical active ingredient, the method comprising: ]
0.9997074	2229	[ (b) providing at least two electrodes comprising: ]	[ (a) depositing a therapeutic agent into at least a portion of a subject's skin; ]
0.99849904	2230	[ (i) at least one electrode configured to receive a therapeutic agent; and ]	[ (b) providing at least two electrodes comprising: ]
0.999894	2231	[ (ii) a first non-stimulatory electrode having an electrode structure configured to deliver a first pharmacologically active agent to the subject; and ]	[ (i) at least one electrode configured to receive a therapeutic agent; and ]
0.99999225	2232	[ (c) activating the non-stimulatory electrode so as to provide a second pharmically active agent to the subject. ]	[ (ii) a first non-stimulatory electrode having an electrode structure configured to deliver a first pharmacologically active agent to the subject; and ]
0.99998426	2233	[ b. attaching said tubular member to a second body, ]	[ A method for producing a prosthetic prosthesis comprisinga. inserting into said implant a device comprising a tubular member that encircles an interior body surface of the implant, said tubular member including a plurality of ribs joined by a first channel, ]
0.99992514	2234	[ c. removing an outer surface of said implant from said body surface, and ]	[ b. attaching said tubular member to a second body, ]
0.99999213	2235	[ d. removing an outer surface of said prosthesis from said body surface of said implant. ]	[ c. removing an outer surface of said implant from said body surface, and ]
0.9998516	2236	[ an intermingling of cutting elements and surfaces of a cutting sheet in a mixing, comprising mixing a mixture of cutting elements with surfaces of a cutting sheet to form a coating; and ]	[ A method of manufacturing a medical instrument with a cutting element having a substantially circular cross-section of and having a longitudinal axis, comprising: ]
0.9999912	2237	[ processing using an energy emitter the coating of the cutting sheet, which comprises at least two layers, wherein: ]	[ an intermingling of cutting elements and surfaces of a cutting sheet in a mixing, comprising mixing a mixture of cutting elements with surfaces of a cutting sheet to form a coating; and ]
0.9997682	2238	[ (a) the layers comprise a single, rigid, flat layer that is at least one-third of thickness in a predetermined direction, and ]	[ processing using an energy emitter the coating of the cutting sheet, which comprises at least two layers, wherein: ]
0.9999924	2239	[ comprises at least one thin layer that is at least three-quarters of thickness in the predetermined direction; and ]	[ (a) the layers comprise a single, rigid, flat layer that is at least one-third of thickness in a predetermined direction, and ]
0.99590695	2240	[ (b) the thickness of each layer is substantially equal to a width of an interior of the coating. ]	[ comprises at least one thin layer that is at least three-quarters of thickness in the predetermined direction; and ]
0.9959078	2241	[ an image pickup assembly; ]	[ An imaging apparatus comprising: ]
0.99843484	2242	[ a first image sensor; ]	[ an image pickup assembly; ]
0.9999912	2243	[ a second image sensor adapted to be coupled to the first image sensor, the second image sensor adapted to receive image data associated with a first area of an object and a second area of the object, wherein imaging comprises: ]	[ a first image sensor; ]
0.9990908	2244	[ a first image capture; ]	[ a second image sensor adapted to be coupled to the first image sensor, the second image sensor adapted to receive image data associated with a first area of an object and a second area of the object, wherein imaging comprises: ]
0.99999213	2245	[ a third image capture; and ]	[ a first image capture; ]
0.99999225	2246	[ a fourth image capture; and ]	[ a third image capture; and ]
0.99998236	2247	[ an interface for receiving data associated with a display device and for providing a second image capture; ]	[ a fourth image capture; and ]
0.9974806	2248	[ an adjustment module for adjusting image signals received by the image pickup assembly by first and second portions of the image data and for adjusting an image signal received by the image pickup assembly by a third portion of the image data; and ]	[ an interface for receiving data associated with a display device and for providing a second image capture; ]
0.9999907	2249	[ a display controller adapted for displaying a first image of the second image from a first position in the second image data from the interface having the first image sensor disposed proximate to the image pickupassembly and for displaying a second image of the first image from a second position in the second image data from the interface having the first image sensor disposed proximate to the image pickupassembly without the first image signal being adjusted. ]	[ an adjustment module for adjusting image signals received by the image pickup assembly by first and second portions of the image data and for adjusting an image signal received by the image pickup assembly by a third portion of the image data; and ]
0.9939843	2250	[ receiving input at the front end of a controller, the controller configured to receive input of data; ]	[ A method of managing a game in which one or more rules of a game are to be activated, comprising: ]
0.9987016	2251	[ determining whether a character selected for operation or placement in a game scene is in a play state of the game; and ]	[ receiving input at the front end of a controller, the controller configured to receive input of data; ]
0.9999279	2252	[ activating a rule in accordance with the character position. ]	[ determining whether a character selected for operation or placement in a game scene is in a play state of the game; and ]
0.9930935	2253	[ wherein X is an alkylene having an optical intensity of at least 25&#xb0; &#x3bc; ]	[ A method for manufacturing or manufacturing a composite material comprising a polymer of Formula (I): ]
0.96546036	2254	[ s; ]	[ wherein X is an alkylene having an optical intensity of at least 25&#xb0; &#x3bc; ]
0.9783986	2255	[ or a polyethylene having an optical efficiency of at least 6 cm/hour and a refractive index of less than 2; and ]	[ s; ]
0.99547887	2256	[ Y is at least one selected from the group consisting of nitro, sulfur, alkenyl or alkenylsulfonyl compounds. ]	[ or a polyethylene having an optical efficiency of at least 6 cm/hour and a refractive index of less than 2; and ]
0.9867929	2257	[ an imaging source; and ]	[ A magnetic resonance imaging apparatus, comprising: ]
0.9999907	2258	[ a magnetic resonance imaging device attached to said imaging source, ]	[ an imaging source; and ]
0.99999046	2259	[ said magnetic resonance imaging device including means for providing high frequency magnetic resonance (MR) data and means for processing, via a processor, low frequency MR data to obtain low-frequency MR data. ]	[ a magnetic resonance imaging device attached to said imaging source, ]
0.99999166	2260	[ providing, upon movement of the image pickup and the object, an image pickup device having an angular velocity and having an angle of rotation; ]	[ A method of determining a location on an object for an image pickup, comprising: ]
0.99999225	2261	[ providing, upon movement of the image pickup device and the object, a detection unit; ]	[ providing, upon movement of the image pickup and the object, an image pickup device having an angular velocity and having an angle of rotation; ]
0.999992	2262	[ receiving, by the image pickup device, an interference information signal from the detection unit, wherein the interference information signal includes at least one of (a) a measurement reference and (b) a data reference; ]	[ providing, upon movement of the image pickup device and the object, a detection unit; ]
0.99999225	2263	[ calculating, by the detection unit, an angle of rotation of the location of the image pickup device on the object with respect to the object using the data reference; and ]	[ receiving, by the image pickup device, an interference information signal from the detection unit, wherein the interference information signal includes at least one of (a) a measurement reference and (b) a data reference; ]
0.9994728	2264	[ producing, by the detector, an error signal that is an error result of the calculation; ]	[ calculating, by the detection unit, an angle of rotation of the location of the image pickup device on the object with respect to the object using the data reference; and ]
0.004729332	2265	[ wherein the detecting unit calculates the angle of rotation using a measurement reference that is located at a first angle of rotation on the object and a measurement reference that is located at a second angle of rotation on the object; ]	[ producing, by the detector, an error signal that is an error result of the calculation; ]
0.99998534	2266	[ generating a first predetermined value by applying a first constant to the first measurement reference and a second predetermined value by applying a second constant to the first measurement reference of the data reference in the angular velocity of the detection unit, such that the first and second predetermined values of the error signal correspond to the position of the image pickup device on the object. ]	[ wherein the detecting unit calculates the angle of rotation using a measurement reference that is located at a first angle of rotation on the object and a measurement reference that is located at a second angle of rotation on the object; ]
0.99998987	2267	[ providing a first dental restoration material and a third dental restoration material; ]	[ A method for performing a dental restoration procedure, comprising: ]
0.99999225	2268	[ providing a method of removing a tooth, said restoration material comprising a first tooth restoration material having a first surface, wherein said first surface is aligned with said at least one first surface and wherein said first dental restoration material has a second surface opposed to said at least one first surface and wherein said second dental restoration material has a lower edge which faces said first surface; ]	[ providing a first dental restoration material and a third dental restoration material; ]
0.99999225	2269	[ inserting the third dental restoration material into an adjacent and non-spatially contiguous space and distally extending an opening at least on at least one surface of said third dental restoration material such that the lower edge of said third dental restoration material faces away from said second surface; ]	[ providing a method of removing a tooth, said restoration material comprising a first tooth restoration material having a first surface, wherein said first surface is aligned with said at least one first surface and wherein said first dental restoration material has a second surface opposed to said at least one first surface and wherein said second dental restoration material has a lower edge which faces said first surface; ]
0.99999225	2270	[ cutting the dental restoration material over the dental restoration material to create a cut, wherein the dentin is inserted over the dental restoration material to create a cavity; and ]	[ inserting the third dental restoration material into an adjacent and non-spatially contiguous space and distally extending an opening at least on at least one surface of said third dental restoration material such that the lower edge of said third dental restoration material faces away from said second surface; ]
0.9999924	2271	[ removing the dental restoration material from the cavity by removing said cut. ]	[ cutting the dental restoration material over the dental restoration material to create a cut, wherein the dentin is inserted over the dental restoration material to create a cavity; and ]
0.9990134	2272	[ measuring a tissue site from a patient; ]	[ A method of treating osteosarcoma treatment in a patient, comprising: ]
0.99997675	2273	[ determining a site level using a computed tomography scanner; and ]	[ measuring a tissue site from a patient; ]
0.99996436	2274	[ using a computer, determining tissue function for the tissue site. ]	[ determining a site level using a computed tomography scanner; and ]
0.99300355	2275	[ an insert member defining a body; ]	[ An apparatus for the placement of an implantable medical device, comprising: ]
0.015415437	2276	[ an adhesive comprising a plurality of discrete adhesive components, at least one of the discrete components selected from the group consisting of a resin, a polymer, an ester, a glycol, and ]	[ an insert member defining a body; ]
0.0049308133	2277	[ a salt; ]	[ an adhesive comprising a plurality of discrete adhesive components, at least one of the discrete components selected from the group consisting of a resin, a polymer, an ester, a glycol, and ]
1.6586362e-05	2278	[ a first adhesive positioned within a first recess within an outer surface of the insert member, wherein the first recess is located closer to an inner surface of the insert member than a second recess located at least partially within the insert member; ]	[ a salt; ]
0.99999225	2279	[ a second adhesive positioned within a second recess located closer to the body and the insert member, wherein the second recess does not extend beyond the first recess; ]	[ a first adhesive positioned within a first recess within an outer surface of the insert member, wherein the first recess is located closer to an inner surface of the insert member than a second recess located at least partially within the insert member; ]
0.9997093	2280	[ wherein the first and second recesses are positioned adjacent each other, and ]	[ a second adhesive positioned within a second recess located closer to the body and the insert member, wherein the second recess does not extend beyond the first recess; ]
0.99999154	2281	[ the second and third recesses are positioned adjacent each other, to minimize flexural stress to the second and third recesses; ]	[ wherein the first and second recesses are positioned adjacent each other, and ]
0.9999894	2282	[ wherein the first and the other second recesses are positioned adjacent each other, from the interior of the insert member to the outside of the insert member, the outer surface of the insert member and the outer surface of the insert member being substantially parallel; and ]	[ the second and third recesses are positioned adjacent each other, to minimize flexural stress to the second and third recesses; ]
0.9999844	2283	[ wherein at least one recess is positioned at a length of the insertion member from said first and second recesses when the second and third recesses are positioned adjacent each other. ]	[ wherein the first and the other second recesses are positioned adjacent each other, from the interior of the insert member to the outside of the insert member, the outer surface of the insert member and the outer surface of the insert member being substantially parallel; and ]
0.99988806	2284	[ a first ring having an outer face and a substantially unaltered inner surface arranged to define a ball-surface region adjacent to the outer face opposite a center region; ]	[ A golf ball comprising: ]
0.99999225	2285	[ a second ring having an outer face and a substantially unaltered inner surface arranged to define a ball-surface region adjacent to the outer face opposing the center region; and ]	[ a first ring having an outer face and a substantially unaltered inner surface arranged to define a ball-surface region adjacent to the outer face opposite a center region; ]
0.99995744	2286	[ a portion of a front face having proximal and distal ends formed from an elongated, generally cylindrical material having cross-sectional dimensions, the elongated material having substantially identical cross-sectional dimensions with respect to a portion of the portion of the outer face. ]	[ a second ring having an outer face and a substantially unaltered inner surface arranged to define a ball-surface region adjacent to the outer face opposing the center region; and ]
0.99842924	2287	[ a core comprising a core structure having a plurality of holes within the core structure; ]	[ A golf ball comprising: ]
0.9949726	2288	[ a ball liner forming a ball and having a hole with a diameter smaller than that of the ball, the ball liner having a central portion; ]	[ a core comprising a core structure having a plurality of holes within the core structure; ]
0.0012448119	2289	[ a first layer surrounding: ]	[ a ball liner forming a ball and having a hole with a diameter smaller than that of the ball, the ball liner having a central portion; ]
0.004171777	2290	[ the hole of the ball liner; and ]	[ a first layer surrounding: ]
0.0008458312	2291	[ a second layer surrounded by the first layer; ]	[ the hole of the ball liner; and ]
0.0023263677	2292	[ wherein the hole in the ball liner comprises one or more holes, all of the holes in the ball liner being larger than and parallel to each other and having different shapes, ]	[ a second layer surrounded by the first layer; ]
0.99999225	2293	[ wherein the holes in the first layer, the second layer and the hole in the core structure have different dimensions in respect to the circumference of the core structure, the ball liner being sized so that the one or more holes of the ball within the core structure conform to the dimensions of the hole in the ball liner. ]	[ wherein the hole in the ball liner comprises one or more holes, all of the holes in the ball liner being larger than and parallel to each other and having different shapes, ]
0.99985874	2294	[ a plurality of therapeutic implantable devices, each therapeutic implantable device having a proximal end including a plurality of implantable therapeutic elements and a distal end including a plurality of device elements, wherein each device element configured for engagement with an appropriate element of a body site within the therapeutic implantable device; ]	[ A therapeutic device comprising: ]
0.99999106	2295	[ wherein the device elements are configured for use during an operation, and ]	[ a plurality of therapeutic implantable devices, each therapeutic implantable device having a proximal end including a plurality of implantable therapeutic elements and a distal end including a plurality of device elements, wherein each device element configured for engagement with an appropriate element of a body site within the therapeutic implantable device; ]
0.9999913	2296	[ wherein the device elements comprise a plurality of the devices configured for engagement with the device sites within the physical body site. ]	[ wherein the device elements are configured for use during an operation, and ]
0.99999213	2297	[ imaging a region of interest of the intravascular object with a detection imaging apparatus; ]	[ A method for detecting an intravascular object, comprising: ]
0.9999924	2298	[ obtaining an image based on the imaging of the region of interest in response to data received from the detection imaging apparatus; ]	[ imaging a region of interest of the intravascular object with a detection imaging apparatus; ]
0.99998903	2299	[ defining a first set of values for intensity based on a detection pattern obtained by applying a first signal and a second signal on the image in response to the imaging; ]	[ obtaining an image based on the imaging of the region of interest in response to data received from the detection imaging apparatus; ]
0.99999213	2300	[ setting a first threshold value for the processing of the intensity based on the detection pattern; ]	[ defining a first set of values for intensity based on a detection pattern obtained by applying a first signal and a second signal on the image in response to the imaging; ]
0.99999225	2301	[ estimating intensity of the detection pattern by using a first parameter for the first set of values; and ]	[ setting a first threshold value for the processing of the intensity based on the detection pattern; ]
0.99999225	2302	[ determining by computing the first threshold value from the first set of values an intensity of the detection pattern based on the estimating parameter, having a second set of values for intensity with corresponding parameters for the second threshold value. ]	[ estimating intensity of the detection pattern by using a first parameter for the first set of values; and ]
0.99905664	2303	[ a shaft having a proximal end with an open end and a distal end; ]	[ A surgical instrument comprising: ]
0.99998474	2304	[ a handle coupled to the proximal end of the shaft and having a guide and a pair of pivotally spaced legs that rotate with respect to the handle between a first position in which the guide includes a longitudinal axis and a second position in which the guide does not include a longitudinal axis; ]	[ a shaft having a proximal end with an open end and a distal end; ]
0.9999888	2305	[ a proximal end, the shaft in the first position; ]	[ a handle coupled to the proximal end of the shaft and having a guide and a pair of pivotally spaced legs that rotate with respect to the handle between a first position in which the guide includes a longitudinal axis and a second position in which the guide does not include a longitudinal axis; ]
0.9999896	2306	[ a distal end, the handle in the second position; and ]	[ a proximal end, the shaft in the first position; ]
0.99974614	2307	[ a screw coupled to the shaft, the screw being arranged to pivot on the shaft, but when the handle is in the first position in a first position in which the first legs of the guide are arranged relative to the handle, the handle rotatably coupled to the shaft to rotate the screw about the shaft, the handle further including a pair of arms coupled to the pivotally spaced legs of the guide; ]	[ a distal end, the handle in the second position; and ]
0.99999166	2308	[ wherein the shaft includes a longitudinal axis defining a length of the shaft when coupled to the handle and the handle includes a pair of pivotally spaced legs. ]	[ a screw coupled to the shaft, the screw being arranged to pivot on the shaft, but when the handle is in the first position in a first position in which the first legs of the guide are arranged relative to the handle, the handle rotatably coupled to the shaft to rotate the screw about the shaft, the handle further including a pair of arms coupled to the pivotally spaced legs of the guide; ]
0.9916707	2309	[ storing in a computer; ]	[ A method of selecting a first product from a second product in a combination or combined product collection comprising: ]
0.9849569	2310	[ analyzing a first set of measurements of a first product; ]	[ storing in a computer; ]
0.9999924	2311	[ evaluating a second set of measurements of a second product and providing a first rating for the first product and a second rating for the second product based on said analyzed first set of measurements and said evaluated second set of measurements to be added to the combined product collection; ]	[ analyzing a first set of measurements of a first product; ]
0.99999225	2312	[ evaluating the combined product collection; and ]	[ evaluating a second set of measurements of a second product and providing a first rating for the first product and a second rating for the second product based on said analyzed first set of measurements and said evaluated second set of measurements to be added to the combined product collection; ]
0.9999924	2313	[ selecting the first product from the combined product collection; ]	[ evaluating the combined product collection; and ]
0.9999924	2314	[ wherein said evaluating includes: identifying a first or second problem area in the combined product collection; ]	[ selecting the first product from the combined product collection; ]
0.9999924	2315	[ selecting a first or second product based on each of the identified first or second problem areas; ]	[ wherein said evaluating includes: identifying a first or second problem area in the combined product collection; ]
0.99999225	2316	[ selecting a second or third solution to said identified first or second issue area in the combined product collection; ]	[ selecting a first or second product based on each of the identified first or second problem areas; ]
0.9999789	2317	[ assigning a first or second rating for each of said selectable products; and ]	[ selecting a second or third solution to said identified first or second issue area in the combined product collection; ]
0.9999703	2318	[ providing at least one feature in use the selected product. ]	[ assigning a first or second rating for each of said selectable products; and ]
